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Summary 
In recent years, cyclic dinucleotides have been discovered in many important signalling pathways 
forming a highly interesting field in the research topic of second messengers. They exist in 
prokaryotes, regulating key functions of the cell, and in eukaryotes, as signalling molecule in the 
mammalian innate immune system. The main part of the present work focuses on the degradation 
of the prokaryotic second messenger c-di-AMP, while a minor section deals with applications for 
the eukaryotic 2′3′-cGAMP. 
The recently discovered dinucleotide second messenger c-di-AMP plays an important role in 
bacteria and was found to be essential in most species including many pathogens, such as 
Staphylococcus aureus, Listeria monocytogenes or Streptococcus pneumoniae. In the past 
10 years, a new research field developed to characterize the functions of c-di-AMP. It is involved 
in DNA integrity, sporulation, growth, cell wall metabolism, antibiotic resistance, potassium 
homeostasis, osmolyte uptake, biofilm formation, virulence and gene regulation. Although several 
c-di-AMP-binding proteins have been discovered, many of the pathways are not understood in 
detail. Recent studies identified the regulation of osmolyte homeostasis, in particular potassium 
ion transport, to be a major function of c-di-AMP. For accurate signal transduction in the cell, the 
levels of c-di-AMP have to be tightly regulated. This can be achieved either by controlling rates 
of synthesis or degradation of the second messenger. The synthesis from two ATP molecules is 
catalyzed by diadenylate cyclase domain (DACs) containing proteins, whereas the degradation is 
performed by specific phosphodiesterases (PDEs). In view of the fact that c-di-AMP has crucial 
functions in many pathogens, the signalling pathway represents an interesting research field for 
drug discovery. 
The hydrolysis pathways of c-di-AMP are not understood in detail yet. PgpH, GdpP and DhhP 
represent prototypes of the three major classes of c-di-AMP specific PDEs that have been 
identified so far. The multi domain membrane PDE GdpP and the single domain soluble DhhP 
PDE use the same catalytic DHH domain for c-di-AMP hydrolysis. Both DHH-domain containing 
PDEs are present in parallel in many species, which raises several questions regarding the 
degradation pathway of c-di-AMP. For a better understanding of c-di-AMP hydrolysis by 
DHH-type PDEs, a homologue from Thermotoga maritima (TmPDE) was analyzed 
biochemically and structurally. The results include six high-resolution structures of TmPDE in 
different reaction steps and thus provide a detailed insight into the reaction mechanism. 
Furthermore, the substrate specificity was described extensively, supporting a two-step 
degradation pathway for c-di-AMP. However, in some species such as Streptomyces that lack all 
of the so far described PDEs, c-di-AMP hydrolysis has to be performed differently. In 
Streptomyces venezuelae, recently a novel PDE class was identified, which is distinct from all 
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known c-di-AMP specific PDEs. In a collaboration project with the Tschowri group (Humboldt-
Universität Berlin), the present work reveals that this enzyme specifically hydrolyzes c-di-AMP. 
It is mainly present in Actinobacteria and therefore described as AtaC (Actinobacterial PDE 
targeting c-di-AMP). Based on a combination of structure predictions and mutational analysis, the 
results indicate a manganese ion-dependent hydrolysis mechanism. In contrast to DHH-type 
PDEs, AtaC was shown to be a monomer. In conclusion, the findings on the two PDEs TmPDE 
and AtaC described in the present work contribute substantially on the degradation pathway of 
c-di-AMP. 
Apart from the prokaryotic CDNs, the recently identified eukaryotic 2′3′-cGAMP moved into 
focus of scientific research. 2′3′-cGAMP is a signalling molecule in the cGAS-STING pathway, 
which is an important innate immune component. Since modifications in this pathway were found 
to be potential approaches for cancer immunotherapy, it not only raised scientific interest in 
academia but also in industry. Therefore, methods to describe this pathway are highly required. In 
the present work, a fluorescent analogue of 2′3′-cGAMP, named fGAMP, was characterized and 
analyzed in regard to novel applications. It was shown to bind STING in vitro and induce its 
activation cells. Binding to STING decreases the fluorescence of fGAMP, which provides the 
possibility to develop a fluorescent STING binding assay that could be commercially applied as 
screening technology to identify therapeutic molecules for STING.  
2
 Introduction 
For proper environmental adaption, every organism has to sense external signals that derive from 
changes in temperature, light, nutrients or pH. Subsequently, the information can be transduced to 
multiple targets by using second messenger molecules, often connected in complex signalling 
pathways. A major class of these molecules are nucleotide-derived second messengers, which 
have key functions in a variety of signal pathways in eukaryotes, prokaryotes and archaea. As 
these signal pathways are often required for many important cellular processes, they display 
possible targets for the treatment of diseases. The increasing number of antibiotic resistant 
pathogens is a worldwide concern and alternatives for treatment of bacterial diseases are highly 
required. A better understanding of the nucleotide second messenger signalling pathways can give 
important insights for novel drug development [1–3]. 
1. Cyclic dinucleotide second messengers 
Nucleotide second messenger were discovered in many important signalling pathways of 
eukaryotes and prokaryotes. So far, all physiological types consist of an adenosine 
monophosphate (AMP) or a guanosine monophosphate (GMP) component. The cyclic nucleotides 
cyclic 3′,5′-AMP (cAMP) and cyclic 3′,5′-GMP (cGMP) were first identified in eukaryotes in 
1957 and 1963 by the group of Sutherland, who reported an important role in mammalian 
hormone regulation [4–6]. Later, both molecules were also described in prokaryotic signalling 
pathways. In 1970, (p)ppGpp (GDP 3′-diphosphate and GTP 3′-diphosphate) was found in 
Escherichia coli, representing the first prokaryotic nucleotide second messenger that has been 
hitherto described [7]. It is produced upon nutrient starvation and coordinates survival in 
stationary phases, which is termed stringent response [1]. Another type of nucleotide second 
messengers are cyclic dinucleotides (CDNs), including cyclic di-GMP (c-di-GMP), 
cyclic di-AMP (c-di-AMP) and two cyclic GMP-AMP types (3′3′-cGAMP and 2′3′-cGAMP). The 
prokaryotic CDNs are key signalling molecules for a variety of functions in bacterial cells. 
Particularly c-di-AMP is essential many species. All known prokaryotic CDNs are linked by two 
3′5′ phosphodiester bonds between the ribose components. However, in eukaryotes a non-
canonical version of cGAMP was discovered as signalling molecule in the innate immune 
system [8,9]. It is linked by one 3′5′ and one 2′5′ phosphodiester bond and is therefore 
distinguished as 2′3′-cGAMP [10–12] (described in chapter 4 in more detail).  
Besides the characterized CDNs, a series of novel CDNs and one trinucleotide have been 
discovered as products of nucleotidyltransferases (CD-NTases) in a recent study. These 
CD-NTases are widely distributed in bacterial genomes and share a high structural homology to 
well characterized CD-NTases, like OAS1, cGAS or DncV. The analysis comprises major 
product formation of cyclic di-UMP, cyclic UMP-AMP and cyclic AMP-AMP-GMP. Although 
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they all have been shown to bind and activate mammalian CDN-receptors of the innate immune 
system, their physiological existence and function in prokaryotes have not been elucidated 
yet [13]. 
The best-characterized CDN is c-di-GMP, which was already discovered in 1987 by the group of 
Benziman [14]. The major role of c-di-GMP is to switch between motility and biofilm formation 
of many species, such as Vibrio cholerae, Pseudomonas aeruginosa, E. coli or Klebsiella 
pneumoniae [15–19]. It is synthesised by diguanylate cyclases (DGCs) and degraded by specific 
phosphodiesterases (PDEs), containing either EAL or HD-GYP domains, which are described in 
chapter 3.2 in more detail. DGCs synthesize c-di-GMP from two molecules of GTP. Their 
conserved motif is present in the catalytic active site (A-site) of GGDEF or GGEEF domains, 
which function as homodimers. The active site is located in the dimer interface with each unit 
coordinating one GTP. In the first step, the intermediate 5′-pppGpG is formed prior to cyclization 
to c-di-GMP. In addition to the active site, many GGDEF domains also contain an inhibitory site 
(I-site), which binds c-di-GMP and leads to allosteric auto-inhibition. Furthermore, GGDEF 
domains are often linked to regulatory domains, which can activate or inhibit catalysis of 
c-di-GMP. It is noteworthy that a significant number of GGDEF domains are connected to EAL 
or HD-GYP domains, thus the respective proteins can contain both synthase and 
phosphodiesterase at the same time (discussed in more detail in chapter 3.2). The signal 
transduction of c-di-GMP was described for several receptors, including PiLZ domains, I-sites in 
catalytic enzymes and degenerate GGDEF, EAL or HD-GYP domains. In addition, c-di-GMP is 
signalling by gene regulation through binding to transcription factors, repressors or riboswitches. 
This regulation pathway mainly correlates with biofilm formation. However, some studies also 
report effects on virulence, regulation of the cell cycle and other processes [1,20]. 
The prokaryotic 3′3′-cGAMP was discovered in 2012 in V. cholerae [21]. It is synthesized from 
ATP and GTP by the dinucleotide cyclase DncV, which also produces c-di-AMP and c-di-GMP 
as byproducts. DncV is required for chemotaxis repression in V. cholerae. Interestingly, the 
repression of chemotaxis leads to enhanced intestinal colonialization indicating an important role 
of DncV on this function [21]. The V. cholerae phospholipase CapV was shown to be directly 
activated by 3′3′-cGAMP and to modify the cell membrane [22]. Besides, 3′3′-cGAMP can also 
bind to riboswitches, as observed for electrophysiology genes in Geobacter sulfurreducens and 
the control of exoelectrogenesis in Deltaproteobacteria [23,24]. Apart from V. cholerae, the 
production of 3′3′-cGAMP by DncV was also described in E. coli, where it correlates with 
biofilm formation and motility [25]. Although DncV is distinct from other prokaryotic 
CD-NTases, its structure and binding mode are highly similar to the eukaryotic 2′3′-cGAMP 
synthase cGAS [26]. Recently, 3′3′-cGAMP was also shown to be synthesized by hybrid 
promiscuous (Hypr) GGDEF enzymes, that can produce all three prokaryotic CDNs [27]. For the 
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degradation of 3′3′-cGAMP, three specific PDEs have been identified so far [28] (described in 
chapter 3.2). 
In 2008, c-di-AMP was discovered in the crystal structure of the DNA integrity scanning protein 
DisA by Witte et al. [29]. As it is essential for most bacteria, including many pathogens, 
c-di-AMP expanded the research field of bacterial CDNs significantly. The synthesis, function 
and degradation of c-di-AMP will be the main topic of the following chapters. 
2. The essential second messenger: c-di-AMP 
Since the discovery of c-di-AMP, several targets and functions of this second messenger have 
been reported. It is mainly produced in gram-positive bacteria but also found in a few 
gram-negative species. The signalling pathway of c-di-AMP has been analyzed intensively in 
many pathogens, including S. aureus, L. monocytogenes or Mycobacterium tuberculosis and 
model organisms like B. subtilis. The research topic raised particular interest as c-di-AMP was 
found to be essential under normal growth conditions in almost all tested species, including 
B. subtilis, S. aureus, L. monocytogenes, S. pneumoniae and Mycoplasma pneumoniae [30–37]. 
On the other hand, accumulation of c-di-AMP inhibits growth. In addition, c-di-AMP is secreted 
from pathogens during infection and induces innate immune response. In bacterial cells, c-di-
AMP is involved in DNA integrity, sporulation, growth, cell wall metabolism, antibiotic 
resistance, potassium homeostasis, osmolyte uptake, biofilm formation, virulence and gene 
regulation. The synthesis of c-di-AMP from two ATP molecules is catalyzed by diadenylate 
cyclases (DACs). Specific phosphodiesterases (PDEs) hydrolyze c-di-AMP to avoid accumulation 
of the second messenger (Figure 1). The synthesis, degradation and the most important functions 
of c-di-AMP from recent studies are described in the following chapters. 
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 Figure 1: Signalling pathway of c-di-AMP divided into synthesis, functions and degradation. DAC domains, found in 
different proteins, synthesise c-di-AMP from two molecules of ATP. Receptors bind c-di-AMP for signalling functions. 
The degradation of c-di-AMP is performed by HD- or DHH- domain containing PDEs, producing AMP via the 
intermediate 5′-pApA. 
2.1. Synthesis 
The synthesis of c-di-AMP from two molecules of ATP is catalyzed by diadenylate cyclase 
domains (DACs). DAC domains are present in all so far analyzed c-di-AMP-producing species, 
annotated in the Pfam database [38] in 4053 protein sequences from 4909 organisms (Pfam 
accession PF02457). Five different major classes of proteins containing DAC domains have been 
characterized so far, classified as DisA, CdaA (also DacA), CdaS (also DacB), CdaM and CdaZ 
(also DacZ) [29,35–37,39–41]. In some species, these enzymes occur in parallel, as for example 
DisA, CdaA and CdaS in B. subtilis, while most bacteria only possess a single c-di-AMP 
synthase [42]. Although the single protein classes can differ in additional domains and oligomeric 
assembly, all DAC domains contain conserved motifs, in particular the DGA (Asp-Gly-Ala) and 
RHR (Arg-His-Arg) motif (Figure 2B). 
The first DAC domain was characterized from the crystal structure of the DNA integrity scanning 
protein A (DisA) from T. maritima [29]. Prior to this study, DisA was reported to trigger a 
sporulation DNA damage checkpoint response [43]. After the identification of its diadenylate 
activity, DisA proteins were also described to synthesize c-di-AMP in other species, such as 
B. subtilis, Mycobacterium smegmatis or M. tuberculosis [29,44,45]. In addition, the 
determination of crystal structures of DisA in different reaction states allowed the precise 
characterization of DAC domains [29,39]. DisA consists of an N-terminal DAC domain and a 
C-terminal DNA-binding helix-hairpin-helix (HhH) domain connected by a helical spine. Two 
DisA tetramers form an octamer with the DAC domains facing each other, comprising the active 
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sites (Figure 2A), which is highly specific for adenosine through hydrophobic interactions and 
steric properties. The synthesis of c-di-AMP is dependent on magnesium or manganese ions, 
which are coordinated by Asp 75 of the DGA motif of the opposite monomer. The triphosphate of 
ATP is bent around the metal ion and the conserved RHR motif is additionally coordinating the β- 
and γ-phosphate. A highly conserved serine is polarizing the γ-phosphate, resulting in a suitable 
arrangement of the α-phosphate for nucleophilic attack from the 3′-OH group of the ATP located 
opposite to form c-di-AMP. DisA is constitutively active unless it binds branched DNA, such as 
holiday junctions, which reduces c-di-AMP synthesis [29,39]. In B. subtilis, the induction of DNA 
damage was shown to result in arrested sporulation dependent on DisA. In addition, the deletion 
of DisA leads to lower c-di-AMP levels and reduced sporulation [46]. In conclusion, the function 
of DisA is to scan the DNA for integrity and signal DNA damage via reduced levels of 
c-di-AMP [29,46]. Additionally, DisA is part of a conserved operon also encoding for RadA 
(SMS), an ATPase associated to DNA damage repair. RadA inhibits DisA activity in B. subtilis 
and M. smegmatis and the interplay of DisA and RadA was shown to be crucial for homologous 
recombination (HR) [47,48]. A recent study reports the interaction of DisA with Mfd and Uvr in 
correlation with nucleotide excision repair (NER) [49]. Although further investigation is required 
to characterize the regulation of DisA, an important function for c-di-AMP in DNA maintenance 
is evident. 
 
Figure 2: Crystal structure of T. maritima DisA. (A) Octameric assembly of T. maritima DisA in complex with 
c-di-AMP; DAC domain (purple), linker domain (green) and HhH DNA-binding domain (blue) (PDB 3C1Y [29]). (B) 
Close up view on a DAC domain dimer of T. maritima DisA in complex with 3′-dATP and Mn2+ (purple, PDB 4YVZ 
[39]). Conserved motifs are annotated (cyan). 
Another DAC domain containing protein is the c-di-AMP synthase A (CdaA or DacA), which is 
the most prominent among bacteria. In many pathogenic species like S. aureus or 
L. monocytogenes it is the only DAC domain protein. CdaA consists of a cytosolic DAC domain 
flanked by coiled coils and is associated to the membrane via three transmembrane helices at the 
N-terminus. The single DAC domains of CdaA from L. monocytogenes and S. aureus are 
structurally highly similar to the DAC domain of DisA (Figure 3). Although some crystal 
structures are lacking the head-to-head conformation [50,51], the active DAC dimer could be 
analyzed in a recent crystal structure of L. monocytogenes CdaA [52]. Consistent with the DAC 
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reaction mechanism, multiple dimers of DacA from S. aureus have to interact for enzymatic 
activity [50]. CdaA is part of a conserved operon containing genes for the regulatory protein ybbR 
and the phosphoglucosamine mutase glmM. The transmembrane region of CdaA interacts with 
YbbR (also CdaR) while the cytosolic part of CdaA binds to GlmM. YbbR consists of one 
transmembrane region and four YbbR domains which are predicted to be extracellular [53]. 
Although the precise function is unclear, YbbR was shown to negatively regulate CdaA activity in 
L. monocytogenes and to be involved in acid stress resistance in S. aureus [54,55]. GlmM is 
essential for cell wall integrity being required in the synthesis pathway of peptidoglycan [56]. It 
was shown to inhibit CdaA activity in Lactococcus lactis and S. aureus most likely by preventing 
CdaA to form dimers [50,57]. These observations depict an important role of CdaA in cell wall 
metabolism in agreement with the phenotypes of CdaA mutant strains addressed in chapter 2.3. 
 
Figure 3: Crystal structure of L. monocytogenes CdaA (blue, PDB 6HVL [52]) in superimposition with a DAC domain 
dimer of T. maritima DisA (red, PDB 3C1Y [29]). 
A third class of diadenylate cyclases, which is only present in Bacillus species, is exclusively 
expressed during sporulation and is referred to as cyclic di-AMP synthase S (CdaS). As the levels 
of c-di-AMP are important for spore germination, CdaS is assumed to control these locally in 
forespores. The deletion of CdaS in B. subtilis spores results in disturbed germination. However, 
the precise regulation of CdaS can only be suggested based on the structural information. In 
addition to the DAC domain, CdaS contains a YojJ domain, consisting of two α-helices. The 
crystal structure and SEC experiments indicate a possible hexameric assembly of CdaS, without 
the DAC domains facing each other as required for enzymatic activity. A mutation in the 
α-helices leads to a dramatic increase in activity, which indicates an autoinhibitory role of the 
YojJ domain by holding CdaS in the inactive hexameric form. It is assumed that a signal activates 
CdaS by disrupting the hexameric assembly to promote spore germination [58,59]. 
Another DAC domain containing protein is CdaM, which consists of an additional 
transmembrane helix and is present in species of the Mycoplasma genus. The synthesis of c-di-
AMP was observed for CdaM from M. pneumoniae [37]. DAC domains were identified in several 
further hypothetical proteins by sequence homology, including CdaZ, which is present in archaea. 
The analysis of a homologue from Haloferax volcanii confirms the existence of c-di-AMP in 
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archaea. CdaZ is essential in H. volcanii, whereas its overexpression leads to cell death [41]. 
Besides, the production of c-di-AMP was also observed for a CdaZ homologue from 
Methanocaldococcus jannaschii [40].  
2.2. DNA integrity and sporulation 
Some bacterial species react to nutritional stress by forming highly environmentally resistant 
dormant cells, called endospores. The spores return to vegetative growth by a process named 
germination if nutrients become available again [60,61]. Sporulation is mainly observed and 
characterized in Bacillus species but was more recently also detected in Mycobacteria [62]. The 
correlation to c-di-AMP is reported for B. subtilis in several studies. During sporulation, the levels 
of c-di-AMP are increased and reduced levels cause a delay. The DNA integrity scanning protein 
DisA has an important regulatory function for this process. DisA produces c-di-AMP dependent 
on an intact DNA, which is required for spore formation. The deletion of DisA results in delayed 
sporulation. In addition, DNA damaging agents lead to reduced levels of c-di-AMP in a 
DisA-dependent manner in B. subtilis [29,46]. Another correlation is observed for the c-di-AMP 
synthase CdaS, which is required for spore germination and is only expressed during 
sporulation [58,59]. However, the targets of c-di-AMP which regulate this process are not yet 
identified. 
2.3. Growth, cell wall metabolism and antibiotic resistance 
As c-di-AMP is essential for most bacterial species, basic cell functions are expected to be 
associated to this second messenger. Several studies report that altered c-di-AMP levels induce 
growth defects as observed in many species, such as B. subtilis, S. aureus, L. monocytogenes, 
M. smegmatis, M. tuberculosis, M. pneumoniae, Streptococcus pyogenes and Streptococcus 
suis [2,35,37,47,54,63–65]. 
A direct correlation between c-di-AMP levels and cell wall biosynthesis has been shown in 
S. aureus. The cell wall of such gram-positive bacteria is composed of highly cross-linked 
peptidoglycan (PG) polymers, wall teichoic acid (WTA) and lipoteichoic acid (LTA). As shown 
for LTA deficient mutant strains in S. aureus, lack of LTA results in growth defects. This 
phenotype can be compensated by increased PG cross-linking, which correlates with elevated 
c-di-AMP levels [63]. Accordingly, c-di-AMP has an effect on PG in B. subtilis. The deletion of 
c-di-AMP results in cell lysis and reduced cell growth. This phenotype can be can be supressed by 
addition of SMM (Spizizen minimal medium), which is known to restore growth of PG deficient 
cells [35]. A direct link of c-di-AMP to cell wall metabolism was identified for the membrane-
associated c-di-AMP synthase CdaA (DacA). The activity of CdaA is inhibited by the 
phosphoglucosamine mutase GlmM, which is an essential component in the synthesis pathway of 
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PG [50,57]. Deletion of CdaA in L. monocytogenes affects cell wall integrity, cell division and 
growth and leads to higher sensitivity to cell wall active antibiotics [54]. 
The role of c-di-AMP in cell wall metabolism is particularly interesting in regard to resistance 
against cell wall targeting antibiotics. The absence of c-di-AMP in B. subtilis results in increased 
susceptibility to cefixime, aztreonam and moenomycine. The opposite effect, a higher resistance 
against these antibiotics, is observed at increased levels of c-di-AMP [35]. The correlation 
between c-di-AMP and antibiotic resistance has also been shown for pathogenic species, such as 
S. aureus, S. pyogenes or L. monocytogenes [2,54,63,66]. For example, the deletion of c-di-AMP 
in L. monocytogenes results in decreased growth rates and increased susceptibility to cefuroxime, 
ampicillin and penicillin [67]. A higher sensitivity to antibiotics was also shown for c-di-AMP 
deficient strains of methicillin resistant S. aureus (MRSA) [66]. 
2.4. Osmolyte homeostasis 
In recent years, the regulation of osmolyte transport, in particular potassium ion (K+) transport has 
been described as a major role of c-di-AMP in bacteria. K+ is one of the most important and 
abundant cations in a cell. It buffers the negative charge of DNA, maintains the turgor and is 
required for the activity of various enzymes. Bacterial cells possess K+ concentrations between 
200 – 400 mM and have to respond to changes in K+ levels, as an accumulation is toxic [68]. 
Recent studies revealed several K+ transport systems that are regulated by c-di-AMP. These can 
be either controlled directly by c-di-AMP binding, as it is the case for proteins of the 
Trk/Ktr/HTK superfamily and proteins of the KupA/B class, or by c-di-AMP dependent gene 
regulation as described for KimA and Kdp(F)ABC [69–73] (Figure 4). For all these transport 
systems, the import of K+ was shown to be inhibited by c-di-AMP. In addition, the cation/proton 
antiporter CpaA, which exports K+ and Na+ in S. aureus is more active when bound to 
c-di-AMP [74]. 
The direct interaction with c-di-AMP is best described for RCK_C (regulator of conductance of 
K+) domains, which are present in the two Ktr family transport systems KtrA/B and KtrC/D, the 
antiporter CpaA and the transcription factor BusR. Ktr transport systems consist of two 
components, a dimeric membrane channel (KtrB or KtrD) and a cytoplasmic regulatory octamer 
(KtrA or KtrC), which is required for activity. The cytoplasmic component consists of one 
ATP-binding N-terminal RCK_N domain and one C-terminal RCK_C domain, which binds 
c-di-AMP. ATP induces higher activity while the interaction with c-di-AMP inhibits complex 
formation of the two channel components and leads to inhibition of K+ import [69,73,75–77]. The 
crystal structures of KtrA (Figure 5) and CpaA in complex with c-di-AMP reveal a common 
dimeric overall fold with c-di-AMP bound in the dimer interface of the RCK_C domain. As both 
structures are lacking their N-terminal part, it remains unclear what conformational changes from 
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binding c-di-AMP modulate the activity of the ion channel [74,78]. Further proteins of the 
Ktr/Trk family that were shown to bind c-di-AMP, are the KtrAB orthologues CabP/SPD_0076 
from S. pneumoniae and TrkH from Streptococcus agalactiae [71,79]. In L. lactis, a different 
K+ transporter system has been discovered recently. Some strains contain a two-copy operon of 
the K+ transporters KupA and KupB, which are both inhibited by binding c-di-AMP [72]. 
A different way of controlling K+ transport by c-di-AMP occurs via gene regulation. In S. aureus, 
the expression of the K+ transport system Kdp(F)ABC is activated by the two component system 
KdpDE. This activation is inhibited by c-di-AMP binding to the sensor kinase component 
KdpD [70]. However, for Kdp expressing species that lack the KdpDE component, a different 
pathway of regulation is required. In Bacillus thuringiensis, a riboswitch at the 5′-UTR of the Kdp 
transcript interacts with c-di-AMP and subsequently blocks Kdp(F)ABC transcription [80]. This 
riboswitch-mediated regulation by c-di-AMP is also observed for other K+ transport systems. 
Particularly, the B. subtilis genome contains two copies of ydaO, a riboswitch located upstream of 
KimA and KtrA/B, respectively [73]. Binding of c-di-AMP to ydaO was shown to inhibit 
downstream gene expression [81]. Interestingly, both high affinity K+ transporters are expressed 
at lower levels during high external K+ concentrations. This coincides with a higher expression of 
CdaA and elevated c-di-AMP levels under these conditions. However, the mechanism how 
K+ levels affect CdaA expression is not yet understood [73]. 
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 Figure 4: Schematic overview of c-di-AMP (black symbol) mediated osmolyte regulation identified in different species. 
Inhibition and activation processes are indicated by red arrows. Enzymes involved in K+ uptake (green), K+ export 
(red), glycine betaine uptake (orange) and carnitine uptake (purple) are depicted. Operon structures are shown as blue 
arrow boxes and expression pathways by waved lines. Adapted from F. M. Commichau, J. Gibhardt, S. Halbedel, J. 
Gundlach, and J. Stülke, “A Delicate Connection: c-di-AMP Affects Cell Integrity by Controlling Osmolyte Transport,” 
Trends Microbiol., vol. 26, no. 3, pp. 175–185, 2018 with permission from Elsevier [82]. 
Besides the regulation of K+ transport, also other osmolyte transport systems are presumably 
regulated by c-di-AMP. A common feature of these systems is the cystathionine‐β‐synthase 
domain (CBS), which in some proteins specifically binds c-di-AMP. For example, the ATPase 
subunit OpuCA of the carnitine transporter OpuC contains two CBS domains, which bind 
c-di-AMP. It was shown that c-di-AMP inhibits the osmolyte uptake of OpuC for 
L. monocytogenes and S. aureus homologues [83,84]. The crystal structure of the 
L. monocytogenes OpuCA CBS domain reveals a dimeric assembly with c-di-AMP located in the 
dimeric interface (Figure 5). It is assumed that c-di-AMP inhibits the ATPase activity of OpuCA, 
which is required for the osmolyte transport [84,85]. Another osmolyte transport system 
containing a CBS domain is the glycine betaine transporter BusAB. In contrast to OpuCA, the 
CBS domain of the BusA subunit cannot interact with c-di-AMP. In this case, the regulation by 
c-di-AMP is bridged by the transcription factor BusR. It binds c-di-AMP with its RCK_C domain 
and targets a sequence upstream of the BusAB operon. Elevated c-di-AMP levels were shown to 
reduce BusA/B expression and result in lower glycine betaine levels in L. lactis and 
S. agalactiae [79,86]. Nevertheless, the precise molecular mechanisms of BusR regulation by 
c-di-AMP remain elusive. 
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 Figure 5: Crystal structures of two common c-di-AMP-binding domains. (A) RCK_C dimer of S. aureus KtrA (PDB 
4XTT [78]). (B) CBS dimer of L. monocytogenes OpuCA in complex with c-di-AMP (PDB 5KS7 [84]). 
The signalling and the regulation of K+ import and other osmolytes is crucial for cell growth and 
osmoprotection and is most likely a major function of c-di-AMP. This leads to the suggestion that 
most of the phenotypes in c-di-AMP deficient cells, like perturbations in cell wall, cell growth 
and survival, could be caused by changes in the cellular turgor [73,82].  
2.5. Biofilm formation and virulence 
The formation of biofilms is an important ability of many bacteria to colonize on a surface and it 
often correlates with virulence of pathogens. The switch between motility and biofilm formation 
is a major function of c-di-GMP [87]. However, several studies have also reported a crucial role 
of c-di-AMP in this process [63,65,88–90]. For example, S. aureus cells with elevated c-di-AMP 
levels showed 3-fold higher biofilm amounts [63]. Similar phenotypes were observed in 
S. mutans, whereas the accumulation of c-di-AMP reduces biofilm formation in B. subtilis and 
S. suis [65,89,90]. Whether these functions are directly regulated by c-di-AMP or result from 
other cellular defects in c-di-AMP-altered cells, is not fully explored. Only for S. mutans, a recent 
study was able to propose a direct link to c-di-AMP [89]. During the formation of a biofilm, the 
cells synthesise extracellular polysaccharides (EPS) which are required for adhesion, protection 
and structure of the matrix [91]. A major polysaccharide synthase of S. mutans is GtfB. PDE 
deletion strains of S. mutans show a correlation between increased c-di-AMP levels and higher 
expression of GtfB. The gtfB gene regulator VicR is assumed to interact with the c-di-AMP 
receptor CabPA. According to the proposed pathway, increased levels of c-di-AMP stimulate the 
expression of GtfB via CabPA and VicR to induce biofilm formation [89].  
In addition, increased levels of c-di-AMP lead to reduced virulence in the pathogens 
L. monocytogenes, M. tuberculosis, S. pneumoniae, S. pyogenes and S. suis [32,65,92–94]. Mice, 
infected with a PDE deletion strain of L. monocytogenes (ΔpdeA ΔpgpH) result in 3-log reduced 
bacterial growth in the analysed organs compared to wild type infections [94]. Similarly, the 
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respective M. tuberculosis PDE deletion (ΔcnpB) strain results in less infection phenotypes and 
extended survival rates in mouse models [93]. These observations highlight the relevance of the 
c-di-AMP signalling pathway as a target for antibacterial treatment. 
2.6. Other functions 
Besides the major pathways of c-di-AMP that have been described in the previous chapters, the 
second messenger is also found to bind targets, which have hitherto been less characterized. 
The first discovered c-di-AMP receptor regulator was the TetR family transcription factor DarR 
from M. smegmatis. TetR family regulators are described to change their target DNA affinity 
dependent on small molecule binding. The negative gene expression regulator DarR was shown to 
bind c-di-AMP specifically, thereby increasing the affinity to its palindromic 14 bp target DNA. 
This sequence is present in three promotor regions, including the genes encoding for one cold 
shock protein and two proteins involved in fatty acid metabolism and transportation. Deletion of 
DarR leads to an increased cell length in M. smegmatis while overexpression results in inhibited 
cell growth [95]. However, the precise regulation of DarR by c-di-AMP is not well understood as 
an independent study and more detailed structural and biochemical investigations are missing. 
The pyruvate carboxylase homologues LmPC from L. monocytogenes, EfPC from Enterococcus 
faecalis and LlPC from L. lactis were also shown to specifically bind c-di-AMP. These enzymes 
catalyze the carboxylation of pyruvate to oxaloacetate, an important component in the citric acid 
cycle. They form a tetramer with each monomer consisting of a biotin carboxyl carrier protein 
(BCCP), a biotin carboxylase domain (BC), a carboxyltransferase domain (CT) and a PC 
tetramerization domain (PT). In the first step, biotin is carboxylated by the BC. Consequently, the 
carboxyl group is transferred to pyruvate by the CT. This reaction requires large conformational 
changes, which are suggested to be inhibited by c-di-AMP. The crystal structures of LmPC and 
LlPC reveal the binding site of c-di-AMP in the dimer interface of two CT domains distinct from 
the pyruvate binding site. Compared to the apo structure, the single domains are twisted in the 
c-di-AMP bound structure, which is assumed to be an inactive conformation. The deletion of 
c-di-AMP in L. monocytogenes strains results in metabolic imbalance, increased synthesis of 
glutamine and disturbed intracellular growth. Thus, the regulation of PC by c-di-AMP seems to be 
important for the virulence of L. monocytogenes [96,97]. 
Another class of c-di-AMP-binding proteins are the PII-like signal transduction proteins (PstA or 
DarA). PII proteins are widely distributed among bacteria, archaea and plants and have a variety of 
functions and interaction partners. In bacteria, they often bind ATP/ADP and 2-oxoglutarate and 
are mainly associated with nitrogen metabolism. They share high sequence homology and have a 
common trimeric structure with a ferredoxin-like fold core domain and two flexible regions, 
called B-loop and T-loop [98]. The interaction with other proteins is diverse, as direct binding is 
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reported for the T-loop but also for the core domain [99,100]. The interaction of PstA with 
c-di-AMP was biochemically and structurally characterized for homologues from S. aureus, 
L. monocytogenes and B. subtilis. Although PstA has a low sequence homology, the conserved 
structure and assembly is highly similar to PII proteins. However, a major difference is the 
swapped length of the B-loop and the T-loop, which are both flexible in the apo structure. The 
interface between the single monomers represents the binding site for c-di-AMP. Although there 
are no major conformational changes between the ligand-free and c-di-AMP bound structure, 
c-di-AMP binding is supposed to stabilize the T-loop. The highly flexible B-loop is not resolved 
in the structures, wherefore no information on influences from c-di-AMP binding is available. 
Presumably, a rearrangement of one or both loops is important for association with a downstream 
interaction partner, which has not been identified. So far, no phenotypes of PstA deletion strains 
were observed and further investigation is required to elucidate the function of these 
proteins [101–104]. 
During the search for c-di-AMP interaction partners, further c-di-AMP-binding proteins were 
identified but have not been characterized. In particular, a DRaCALA (differential radial capillary 
action of ligand assay) screening assay with proteins from B. subtilis containing either a RCK_C 
or a CBS domain revealed binding of c-di-AMP for the K+/H+ antiporter KhtT, the primary 
Mg2+ transporter MgtE and a protein of unknown function, called DarB [105]. Furthermore, a 
proteomics search for c-di-AMP-binding proteins in L. monocytogenes identified the transcription 
factor Nrd as potential interaction partner, but so far no characterization except for c-di-AMP 
binding has been performed [96]. 
Several functions of c-di-AMP have been identified but the precise signalling pathway and the 
connection to different phenotypes is still not yet fully understood. The roles of c-di-AMP differ 
among bacteria and the search for further interaction partners will be a crucial part in future 
investigations. 
3. Degradation of bacterial cyclic dinucleotides 
In addition to synthesis, the levels of a second messenger in the cell can be regulated by 
degradation or export. Cyclic dinucleotides are degraded by cleavage of their phosphodiester 
linkages by phosphodiesterases (PDEs). The hydrolysis of phosphodiester linkages is an 
important enzymatic reaction in all kingdoms for the degradation of DNA, RNA or small 
molecules. In case of second messengers, degradation is crucial to regulate their levels precisely. 
Therefore, the hydrolyzing PDEs have to be very specific. Cyclic dinucleotide specific PDEs 
share a two metal ion-dependent hydrolysis mechanism, as common for the cleavage of 
phosphodiester linkages [106] (Figure 6). However, cyclic dinucleotides are hydrolyzed by 
different PDE classes, which are described in the following chapters. 
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 Figure 6: The two metal ion-dependent hydrolysis of 5′-pApA by Rv2837c. The two highly coordinated Mn2+ ions 
bring a water molecule in position for a nucleophilic attack on the phosphate of the phosphodiester linkage of 5′-pApA. 
Originally published by He et al. [107] 
3.1. Degradation of c-di-AMP 
Two major catalytic domains have been discovered to hydrolyze c-di-AMP specifically. They are 
classified according to their conserved active site motifs into DHH-type (Asp-His-His) or 
HD-type (His-Asp) PDEs. DHH domains can be part of the membrane-coupled multidomain 
PDEs of the GdpP-type or occur as cytosolic standalone domains termed DhhP-type PDEs. 
However, it was also shown that c-di-AMP can be secreted from L. monocytogenes and 
M. tuberculosis during infection, which represents another possibility to regulate c-di-AMP 
levels [93,108]. More recently, an extracellular c-di-AMP specific ectonucleotidase named CdnP 
has been discovered in S. agalactiae, which is responsible for the hydrolysis of secreted 
c-di-AMP to reduce innate immune response from the infected host [109]. 
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 Figure 7: Schematic overview of the degradation pathways of c-di-AMP. The membrane-coupled PDEs PgpH and 
GdpP catalyse the hydrolysis of c-di-AMP to 5′-pApA. The soluble DhhP PDE hydrolyses the hydrolysis of c-di-AMP 
to AMP or exclusively the hydrolysis of 5′-pApA to AMP, depending on the species homologue. The MdrMTAC 
transport systems were are required for secretion of c-di-AMP. CdnP hydrolyses secreted c-di-AMP to AMP. Adapted 
from T. A. N. Huynh and J. J. Woodward, “Too much of a good thing: Regulated depletion of c-di-AMP in the bacterial 
cytoplasm,” Curr. Opin. Microbiol., vol. 30, pp. 22–29, 2016, with permission from Elsevier [110]. 
3.1.1. DHH-type PDEs 
DHH-type PDEs are members of the DHH-DHHA1 domain superfamily, which comprises 
exonucleases (RecJ) [111], oligoribonucleases (NrnA) [112] and PDEs (GdpP and 
DhhP) [113,114]. They share a highly similar structure and a two metal ion-dependent reaction 
mechanism, which was described for DHH-type PDEs [107,112,113,115,116], RecJ-like 
proteins [117] and the nanoRNAse NrnA [118]. The c-di-AMP specific DHH-type PDEs occur in 
two different versions, referred to as GdpP or DhhP, according to their domain architecture and 
substrate specificity.  
The GdpP (GGDEF domain protein containing phosphodiesterase) consists of a transmembrane 
part, a Per-Arnt-Sim (PAS) domain, a degenerated GGDEF domain and the catalytic 
DHH-DHHA1 domain. It was the first c-di-AMP specific PDE to be discovered in 2010 by 
Rao et al. [113]. The hydrolysis of c-di-AMP is catalyzed by the DHH-DHHA1 domain and 
results exclusively in the linear dinucleotide intermediate 5′-pApA. The reaction is metal ion-
dependent with the highest activity observed for Mn2+ or Co2+ ions [113]. The additional domains 
PAS and GGDEF are supposed to possess a regulatory function. PAS domains occur as small 
molecule binders with different functions including redox-sensing with O2 or CO as ligands. For 
B. subtilis and Geobacillus thermodenitrificans GdpP, the PAS domains were shown to bind 
b-type heme and thereby strongly inhibit c-di-AMP hydrolysis [119]. Although lacking the typical 
PAS-conserved histidine or cysteine residues for heme-binding, the NMR structure of the PAS 
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domain from G. thermodenitrificans GdpP reveals a suitable binding pocket for heme [120]. In 
addition, the complex with ferrous heme is able to coordinate carbon monoxide (CO), 
cyanide (CN-) and nitric oxide (NO), however, reactivation of c-di-AMP hydrolysis was only 
observed for NO binding. NO is known to be involved in antibacterial host immune response 
leading to the suggestion that GdpP PDEs are sensing NO [119]. Another possible regulation of 
GdpP PDEs might be mediated by the degenerate GGDEF domain. The majority of GGDEF 
homologues catalyse the synthesis of c-di-GMP. On the other hand, several degenerate GGDEF 
domains that lack the conserved motif residues can only bind or hydrolyse GTP without 
producing c-di-GMP. They are often present as additional domains in c-di-GMP-degrading 
proteins. In Caulobacter crescentus, a correlation between stimulation of the c-di-GMP 
hydrolysing EAL domain and binding of GTP by the GGDEF has been observed [121,122]. It is 
tempting to speculate about an analogous function for the GGDEF domain of GdpP. On the 
contrary, only weak ATPase activity was observed for B. subtilis GdpP (YybT) and no difference 
in c-di-AMP hydrolysis could be shown [113]. Furthermore, no full-length structure of GdpP is 
available yet to describe the mechanism of signal transduction between PAS or GGDEF to the 
catalytic DHH-DHHA1 domain. The precise membrane association and domain organization of 
these proteins is not characterized either. 
The DhhP (also Pde2) PDE is a soluble stand-alone DHH-DHHA1 domain, first described from 
S. pneumoniae by Bai et al. in 2013 [32]. In contrast to GdpP, the DhhP PDEs can accept 
different substrates depending on the species homologue. The DhhP homologues of Borrelia 
burgdorferi, M. tuberculosis and M. smegmatis hydrolyse c-di-AMP into both, 5′-pApA and the 
single nucleotide AMP as final product [45,107,114]. On the other hand, DhhP analogues from 
S. pneumoniae, S. aureus, T. maritima and S. mutans have a clear preference for linear 
dinucleotide substrates, like 5′-pApA, while the hydrolysis of c-di-AMP could not be shown 
under physiological conditions [32,55,115,123]. As DhhP PDEs can occur in addition to GdpP 
PDEs, a two-step degradation pathway for c-di-AMP is suggested for these species. In the first 
step, GdpP hydrolyses c-di-AMP to the linear intermediate 5′-pApA and a DhhP catalyses the 
second step from 5′-pApA to AMP [115]. 
Structural information of the DHH-DHHA1 domain is available from different species 
homologues (Figure 8). Crystal structures were obtained from the DhhP homologues Rv2837c 
from M. tuberculosis, MsPDE (or NrnA) from M. smegmatis and TmPDE from 
T. maritima [107,115]. A full-length structure of GdpP is not solved yet but the separate 
DHH-DHHA1 construct from S. aureus could be crystallized in a recent study [116]. 
DHH-DHHA1 domains form butterfly shaped dimers with each monomer consisting of the two 
subunits DHH and DHHA1 connected by a flexible loop (Figure 8A and 8C). A cleft between the 
two subunits represents the active site, including the DHH motif from the DHH part and a 
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conserved GGG(H) stretch in the DHHA1 part [107,112,115,116,118] (Figure 8B). The highly 
conserved aspartate and histidine residues of the DHH motif coordinate the metal ions, which are 
required for activity [107,113,115,118]. In addition to the DHH motif, two aspartate residues 
(D420 and D499 in B. subtilis GdpP, D80 and D154 in T. maritima TmPDE) were shown to be 
crucial for metal ion binding as a mutation to alanine or asparagine resulted in catalytic 
inactivation [113,115]. For TmPDE it could be shown that these residues do not affect substrate 
binding [115]. The substrate coordination depends on the dinucleotide ligand and the species 
homologue. The active site can be divided into 3 nucleoside binding subsites C, R and G. The C 
site contains a conserved GGG(H) stretch, which is responsible for the main interactions to one of 
the nucleotide residues. The second nucleotide residue of c-di-AMP and 5′-pApA is coordinated 
differently (Figure 8D). The catalytic DHH domain of S. aureus GdpP binds and hydrolyses 
c-di-AMP in GC position. In contrast, 5′-pApA is coordinated in the RC site of Rv2837c and 
TmPDE. It is assumed that the smaller R-site of GdpP does not allow 5′-pApA to enter the RC 
position and thus prevents its hydrolysis [116]. 
 
Figure 8: Crystal structures of the DHH domain from different species. (A) Rv2837c from M. tuberculosis in complex 
with 5′-pApA (orange) and two Mn2+ ions (purple), divided into the DHH domain (green) and the DHHA1 domain 
(blue) (PDB 5JJU [107]) (B) Close up view on the active site of Rv2837c in complex with 5′-pApA with depicted 
conserved motifs (red) (PDB 5JJU [107]). (C) Superimposition of Rv2837c in complex with 5′-pApA (gray, PDB 5JJU 
[107]), TmPDE in complex with 5′-pApA (red, PDB 5O4Z [115]) and the DHH-DHHA1 domain from S. aureus GdpP 
in complex with c-di-AMP (blue, PDB 5XSN [116]). (D) Superimposition of the conformation of 5′-pApA in Rv2837c 
(gray, PDB 5JJU [107]) and c-di-AMP in the active site of S. aureus GdpP (blue, PDB 5XSN [116]). 
DHH-type PDEs have a significant role in the degradation of c-di-AMP. The deletion of these 
PDEs results in accumulation of c-di-AMP and defective cell functions. For example, the deletion 
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of the GdpP homologue in S. aureus leads to a smaller cell size and an increased PG cross-linking 
in the cell wall. In addition, a higher resistance against cell wall targeting antibiotics [63]. 
Furthermore reduced virulence was observed in PDE deficient strains of many pathogens, such as 
M. tuberculosis, S. pneumoniae, S. suis or S. pyogenes [32,65,92,93,124]. The deletion of the 
DhhP homologue Rv2837 in M. tuberculosis results in increased levels of secreted c-di-AMP and 
a higher innate immune response from the host cell in infection mouse models [93]. In 
S. pneumoniae, the homologues of DhhP and GdpP are important for growth and essential for 
virulence in infection models [32]. Similar effects have also been observed in GdpP deletion 
strains of S. suis [65]. In conclusion, the DHH-type PDEs play a crucial role for growth and 
virulence of many bacterial species, as they contribute significantly to the regulation of c-di-AMP 
levels. 
3.1.2. HD-type PDEs 
HD-type PDEs belong to a superfamily of phosphohydrolases with different substrates, including 
HD-GYP domain proteins for hydrolysis of c-di-GMP and 3′3′-cGAMP. One class of HD-type 
PDEs was also shown to be specific for c-di-AMP hydrolysis. These proteins are widely 
distributed in many c-di-AMP producing species and are referred to as PgpH, after the first 
described homologue from L. monocytogenes. PgpH PDEs are membrane-associated via seven 
transmembrane helices and consist of an N-terminal extracellular domain and a C-terminal 
cytoplasmic HD-domain [94]. This domain architecture is referred to as 7TMR-HD family, which 
consists of mainly uncharacterized prokaryotic surface receptors [125]. While the structure and 
the role of the extracellular domain have not been described yet, the single HD domain, 
containing the conserved His-Asp motif, has been identified to hydrolyze c-di-AMP. Similar to 
GdpP, PgpH hydrolyses c-di-AMP exclusively to 5′-pApA and has significantly lower activity for 
c-di-GMP. PgpH is dependent on Mn2+ ions, while Fe2+ ions inhibit the activity. The crystal 
structure reveals a similar reaction mechanism to the previously described DHH-type hydrolysis. 
Two metal ions coordinate the oxygens from one phosphodiester bond and activate a water 
molecule to perform a nucleophilic attack on the phosphate. At this, the histidine and aspartate 
residues of the highly conserved HD motif are essential for coordinating the metal ions and thus 
for hydrolysis activity. The activity of PgpH was shown to be inhibited by ppGpp with an 
IC50 value of approximately 200 – 400 µM. The all-helical overall structure of PgpH (Figure 9) is 
similar to HD-GYP PDE structures although they only share <20% sequence homology [94]. 
Homologues of PgpH can be found in many c-di-AMP producing species and are assumed to 
contribute significantly to the degradation of c-di-AMP. They can exist in parallel to GdpP and 
DhhP PDEs as found in L. monocytogenes. Interestingly, the activity of GdpP and PgpH was 
shown to be dependent on the cellular state of L. monocytogenes. During broth growth, the impact 
on c-di-AMP is higher for PdeA (GdpP homologue) and during intracellular growth inside host 
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cells, c-di-AMP levels are affected particularly by PgpH [94]. For B. subtilis, a deletion of PgpH 
results in a 2-fold higher c-di-AMP concentration compared to the deletion of GdpP [126]. This 
indicates an important role for PgpH in the degradation of c-di-AMP, although more 
investigations are required to characterize the activity and the role of the extracellular domain.  
 
Figure 9: Crystal structure of L. monocytogenes PgpH in complex with two Fe2+ ions (orange) and c-di-AMP (PDB 
4S1B [94]). 
3.1.3. Export of c-di-AMP and detection by the host cell 
In addition to the hydrolysis by PDEs, the intracellular c-di-AMP levels can also be regulated by 
export. The secretion of c-di-AMP has been observed in several species including the pathogens 
M. tuberculosis and L. monocytogenes [64,108,127–129]. The mechanism of c-di-AMP secretion 
was described to be dependent on multidrug efflux pumps (MDRs) of the MFS superfamily, as 
first described by Woodward et al. for L. monocytogenes [108]. MDRs are important transport 
systems for a variety of unspecific and structurally unrelated molecules in all kingdoms. Their 
function in drug export from bacteria makes them particularly interesting in regard to antibiotic 
resistance [130]. In L. monocytogenes, the four MDRs MdrM, MdrT, MdrA and MdrC 
(MdrMTAC) have been identified to secrete c-di-AMP [108,127,131,132]. This secretion 
contributes significantly to the degradation of c-di-AMP levels. Increased c-di-AMP levels in 
ΔMdrMTAC knockout strains result in altered peptidoglycan production and increased 
susceptibility to vancomycine [127]. Besides, the secretion of c-di-AMP by MDRs was also 
described in other species. Llmg1210 from L. lactis shares 45% sequence homology to MdrT and 
36% to MdrM and is involved in c-di-AMP export as well. Accordingly, the overexpression of 
Llmg1210 together with the membrane protein Llmg1211 results in a complementation of 
osmoprotection in ΔGdpP strains [86]. Furthermore, the two putative c-di-AMP transporters ycnB 
and yhcA from B. subtilis share over 30% sequence homology to MdrM and MdrT and a double 
knockout strain leads to a significant decrease in secreted c-di-AMP. In B. subtilis, the secretion 
of c-di-AMP correlates with biofilm formation and plant attachment [88]. MdrMTAC transporters 
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are also involved in the response to lipoteichoic acid (LTA) stress [132]. LTAs are associated to 
membrane glycolipids and have important functions for the cell wall of gram positive 
bacteria [133]. The synthesis of LTAs is dependent on the described MDR pumps and a reduced 
synthesis of LTAs results in increased IFN-β response in infected cells. Although a link to 
c-di-AMP is tempting, there is no experimental evidence for a correlation yet [132]. 
Apart from the contribution to c-di-AMP degradation, the secretion of c-di-AMP has effects in 
infected host cells. Secreted c-di-AMP can be detected by the mammalian innate immune system, 
as shown in infection models with M. tuberculosis, L. monocytogenes or Chlamydia 
trachomatis [64,108,134]. So far, the three different host receptors STING, RECON and ERAdP 
have been identified to sense c-di-AMP. The ER membrane-coupled adaptor protein STING 
(stimulator of interferon genes) plays a key role in the mammalian innate immune system (in 
more detail in chapter 4.3.). Although the major function is signalling of the endogenous second 
messenger 2′3′-cGAMP, STING can also detect invading bacterial CDNs, such as c-di-AMP, 
resulting in the induction of a type I IFN response [128,129,134,135]. In a more recent study, the 
aldo-keto reductase RECON (reductase controlling NF-κB) was shown to have a significantly 
higher affinity for c-di-AMP than STING. The activity of RECON is dependent on NAD-binding, 
which is inhibited competitively by c-di-AMP. This inhibition results in the production of 
pro-inflammatory cytokines and bactericidal gene expression as observed in L. monocytogenes 
infection models of murine macrophages. In addition, the induction of a type I interferon response 
is diminished by overexpression of RECON, leading to the suggestion of reduced STING 
activation by c-di-AMP under these conditions [136]. Another ER-located receptor, termed 
ERAdP (Endoplasmatic Reticulum Adaptor Protein), was also shown to bind c-di-AMP with a 
higher affinity compared to STING [137]. This adaptor protein is found in the two transcript 
isoforms Eradp, which is mainly expressed in NK cells and cytotoxic T cells, and Cnep1r1, which 
is also present in monocytes and macrophages. Specific binding of c-di-AMP leads to 
dimerization of ERAdP and association to the kinase TAK1. This results in activation of NF-κB 
and subsequently expression of pro-inflammatory cytokines. The role of ERAdP for immune 
response was confirmed in infection models of mice with L. monocytogenes [137]. However, 
more investigations are highly required to elucidate, whether one of these pathways is mainly 
activated or whether these receptors are abundant in specific cell types. Besides, it was shown that 
the detection of c-di-AMP can also be prevented by the bacterial cell. In S. agalactiae, the 
secreted c-di-AMP  is hydrolyzed by the extracellular ectonucleotidase CdnP to inhibit an innate 
immune response [109]. 
3.1.4. The ectonucleotidase CdnP 
In a recent study from Andrade et al., the ectonucleotidase CdnP has been discovered to 
hydrolyse extracellular c-di-AMP in S. agalactiae (Group B Streptococcus) [109]. CdnP consists 
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of a metallophosphatase domain including a conserved NHE motif, a 5′-nucleotide-binding site 
and a transmembrane part at each terminus, one of them containing an LPxTG cell wall anchoring 
motif. Amongst bacterial nucleotide second messengers, CdnP has a clear preference for 
hydrolysis of c-di-AMP to AMP. However, also weak activity for c-di-GMP and 3′3′-cGAMP 
have been observed. The histidine from the conserved NHE motif is essential for hydrolysis 
activity as a mutation leads to full inactivation. CdnP acts in concert with the ectonucleotidase 
NudP, which further hydrolyzes AMP to adenosine and phosphate. Inactivation of CdnP in 
S. agalactiae does not affect c-di-AMP related intracellular functions but the levels of 
extracellular c-di-AMP are increased significantly [109]. The secretion of c-di-AMP is assumed 
to be an important additional regulatory mechanism of intracellular c-di-AMP levels. However, 
bacterial nucleotide second messenger are detected by the host and activate innate immune 
response [64,108,134,135]. CdnP is therefore suggested to be a regulator of extracellular c-di-
AMP levels to prevent an innate immune response [109]. 
3.2. Degradation of c-di-GMP and 3′3′-cGAMP 
The degradation of c-di-GMP is catalyzed by EAL (Glu-Ala-Leu) domains or by HD-GYP 
(His-Asp-Gly-Tyr-Pro) domains [20]. Although both can occur as stand-alone domains, they are 
often N-terminally linked to various sensory input domains as part of multidomain 
proteins [20,87,138]. Therefore, the levels of c-di-GMP are suggested to be regulated through 
synthesis and degradation by different environmental and cellular signals [87]. 
The major role of c-di-GMP in bacteria is the switch between motility and biofilm formation [20]. 
In order to ensure a correct signalling, the levels of c-di-GMP have to be regulated by 
degradation. The first characterized hydrolysis of c-di-GMP was described for EAL 
domains [139]. In vitro experiments confirmed hydrolysis of c-di-GMP to 5′-pGpG whereas no 
activity for c-di-AMP was observed. The second step of hydrolysis, the conversion of 5′-pGpG to 
the final product 5′-GMP, is very slow and probably performed by other enzymes [20]. At this, 
enzymatic activity is dependent on Mn2+ or Mg2+ ions and is inhibited by Ca2+ ions [140]. 
Structural approaches revealed a dimeric assembly for EAL domains, which appears to be 
required for activation. The glutamate residue of the conserved EAL motif coordinates one metal 
ion and is essential for activity, as a mutation to glutamine leads to inactivation. The hydrolysis of 
c-di-GMP is catalyzed by two metal ions activating a water molecule, which performs a 
nucleophilic attack on the phosphodiester linkage, which is a common mechanism for metal 
ion-dependent PDEs. In contrast to the bent conformation in DGCs and other receptors, c-di-GMP 
is bound in a stretched conformation in the EAL domain to facilitate the nucleophilic attack on the 
phosphate [20,141,142]. EAL domains are often found in combination with regulatory domains. 
In particular, ~2/3 of all EAL domains are coupled to GGDEF domains of which ~40% are 
predicted to lack DGC activity [20,143]. However, the majority of such proteins contain one or 
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both domains in a catalytically inactive state. Only a small number was shown to be 
bifunctional [20]. One possible reason for the coexistence of two domains with opposite functions 
is the possibility to activate only one of them at a time. For example, the membrane-bound 
regulator MorA from P. aeruginosa contains both, GGDEF and EAL domains, in a functional 
state [144]. In Vibrio parahaemolyticus, the activities of GGDEF and EAL of ScrC are suggested 
to be regulated by the interaction partners SrcA and SrcB [145]. The structure of another 
bifunctional protein, RbdA from P. aeruginosa is available with GGDEF bound to GTP and EAL 
bound to c-di-GMP (Figure 10). Each monomer of the RbdA dimer consists of two 
transmembrane helices, a PAS domain, a GGDEF domain and an EAL domain. The crystal 
structure reveals an autoinhibited state, as the active sites of GGDEF and EAL face each other 
and are not accessible for substrates. Activity assays and SAXS analysis indicate a conformational 
change upon GTP-binding and allosteric activation of the EAL domain [146,147]. 
 
Figure 10: Crystal structure of P. aeruginosa RbdA in complex with c-di-GMP, PAS domain dimer (light and dark 
blue), GGDEF domains (light and dark yellow) and EAL domain dimer (light and dark red) are depicted (PDB 
5XGE [147]). 
The second type of c-di-GMP-degrading domains are HD-GYP domains, which are a subgroup of 
the HD-domain family. HD-GYP domains are present in different proteins with structural and 
functional varieties [148]. The first hydrolysis of c-di-GMP by an HD-GYP domain was 
characterized for the regulatory protein RpfG from Xanthomonas campestris. In contrast to EAL 
domains, which produce mainly 5′-pGpG, the analyzed reaction product of RpfG was solely 
GMP [149]. The HD-GYP domain proteins PA4781 and PA4108 from P. aeruginosa show 
5′-pGpG as intermediate product, which is bound with higher affinity and has a lower turnover 
compared to c-di-GMP [150]. Deletion of these two proteins leads to increased c-di-GMP levels, 
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reduced swarming motility and altered virulence [151]. However, HD-GYP domains can also be 
inactive for c-di-GMP hydrolysis, like the homologue in Bd1817 from Bdellovibrio 
bacteriovorus, which is lacking the conserved tyrosine residue [152]. Structural information is 
available from crystal structures of B. bacteriovorus Bd1817, Persephonella marina PmGH and 
P. aeruginosa PA4781. They all share an all helical fold and a comparable active site, which is 
distinct from EAL domains (Figure 11). However, differences between the HD-GYP domains can 
be observed in the active site and the metal ion coordination. While Bd1817 and PA4781 
coordinate the metal ions in two positions, PmGH has a trinuclear metal active site 
(M1, M2, M3). The positions M1 and M2 are occupied in Bd1817 whereas M1 and M3 are 
occupied in PA4781 [148,152–154]. PmGH is the only protein, for which a structure with 
complexed c-di-GMP could be solved. The dinucleotide is coordinated in a bent conformation to 
locate the phosphodiester linkage in close proximity to the metal-binding site for hydrolysis [153]. 
The conserved GYP loop in PmGH and PA4781 creates a kink in a helix (helix 3), which leads to 
an open conformation of a “lid” loop on top of the active site [148,153]. In Bd1817, this lid is 
closed, restricting the access to the active site [152]. HD-GYP proteins were also shown to be 
regulated by their N-terminal domain. For example, the REC domain of PA4781 has to be 
phosphorylated for activity [150]. In addition, HD-GYP domains are proposed to directly interact 
with other proteins for regulation of their activity [148,152,153]. For many HD-GYP domains, it 
remains elusive whether they are degenerated or have to be activated by so far unknown 
interaction partners. 
 
Figure 11: Crystal structure of P. marina PmGH in complex with c-di-GMP (blue) and Fe2+ ions (orange). HD-GYP 
domain (red) is depicted (PDB 4MDZ [153]). 
In addition to c-di-GMP degradation, HD-GYP domains were also found to hydrolyze 
3′3′-cGAMP. Three HD-GYP domain PDEs from V. cholerae were shown to be specific for 
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3′3′-cGAMP and were thus designated as V-cGAP1/2/3. V-cGAP2 and V-cGAP3 are converting 
3′3′-cGAMP to the linear intermediate 5′-pApG. V-cGAP1 is additionally cleaving the linkage to 
the 5′-phosphate in a second step resulting in ApG as final product. All three PDEs are specific 
for a 3′3′-phosphodiester linkage as they are not able to hydrolyze 2′3′-cGAMP. It was shown that 
mutations in the HD or the GYP motif abolish activity and the deletion of V-cGAPs in vivo 
results in enhanced bacterial infectivity [28]. 
4. Cyclic dinucleotide second messengers in eukaryotes 
4.1. 2′3′-cGAMP 
Besides prokaryotes, signal transduction by a cyclic dinucleotide second messenger was also 
discovered in the mammalian innate immune system, which raised particular scientific 
interest [8,9]. The cyclic GMP-AMP synthase (cGAS) produces an isomer of cGAMP that is 
distinct from bacterial dinucleotide second messengers through its non-canonical phosphodiester 
linkage. Whereas all known bacterial CDNs are all linked by two 3′5′-phosphodiester bonds, the 
mammalian cGAMP is connected by one 2′5′ and one 3′5′-phosphodiester linkage and is therefore 
distinguished as 2′3′-cGAMP [10–12] (Figure 12). 
 
Figure 12: Structure comparison of the prokaryotic 3′3′-cGAMP and the eukaryotic 2′3′-cGAMP. 
The innate immune system has to deal with continuous threats. Therefore, several pathways for 
recognition, signal transduction and response to pathogens have evolved. A crucial step in this 
system is the detection of foreign molecules, which are described as pathogen-associated 
molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). This is 
performed by pattern recognition receptors (PRRs) located on the cell membrane, including 
toll-like receptors (TLRs) or C-type lectin receptors (CLRs), or by cytosolic receptors, such as 
NOD-like receptors (NLR) or RIG-I-like receptors (RLR) [155]. Another type of pathogen 
detection and signalling is the cGAS-STING pathway [8]. The synthesis of 2′3′-cGAMP by cGAS 
is the first step in recognition of foreign DNA or damage induced leakage of self-DNA in the 
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cytosol. The stimulator of interferon genes (STING) binds 2′3′-cGAMP and induces further signal 
transduction resulting in antiviral and pro-inflammatory gene expression [10–12]. The 
cGAS-STING pathway represents an extensive research field (reviewed in e.g. [156,157]), thus 
the following chapters focus on the structure and function of cGAS and STING. 
4.2. Synthesis of 2′3′-cGAMP 
The cyclic GMP-AMP synthase cGAS is a member of nucleotidyltransferase (NTase) family 
proteins, which are involved in diverse mechanisms, including RNA modification, DNA repair or 
signal transduction [158]. It consists of an unstructured N-terminal part and a C-terminal catalytic 
male abnormal 21 (Mab21) domain, which contains the NTase fold [8]. Although it has a 
different signalling pathway, cGAS is structurally and mechanistically highly similar to the 
2′-5′-oligoadenylate synthase OAS1 [8,159,160]. OAS proteins sense dsRNA and produce 
2′-5′-oligoadenylates to activate RNA degradation by RNase L and thus inhibit virus 
proliferation [161–163]. In a similar manner, cGAS senses double-stranded DNA (dsDNA) in the 
cytosol and synthesizes 2′3′-cGAMP from ATP and GTP to signal innate immune response to 
pathogens. Independent of the sequence, cGAS binds DNA and dimerizes. In addition, the 
activity of cGAS increases with DNA length. The current model proposes that binding of one 
cGAS dimer facilitates binding of further cGAS dimers, which is indicated by higher affinities for 
longer DNA. The crystal structure of a cGAS4:DNA2 complex supports this model and reveals a 
slightly bend DNA, which is assumed to be a crucial factor for oligomerization. It was also shown 
that this orientation of the DNA can be induced by other DNA interacting proteins, like bacterial 
nucleoid HU proteins, mitochondrial transcription factor A (TFAM) or the high mobility group 
box 1 protein (HMGB1) [164–166]. 
The catalytic Mab21 domain of cGAS consists of two lobes connected by a long “spine” helix. 
DNA interaction occurs on two sites of each cGAS monomer (Figure 13A). The spine helix and a 
zinc-thumb form “site A” and the second DNA-binding site is referred to as “site B”. Binding to 
DNA induces a “kink” in the spine helix that closes the lobes and makes the active site accessible 
for the substrates (Figure 13B). A loop rearrangement in the active site facilitates coordination of 
Mg2+,  ATP and GTP [11,167]. One nucleoside-binding site is highly specific for GTP. The other 
site coordinates the ATP base mainly through stacking interactions, thus it can also be occupied 
by GTP. Two Mg2+ ions coordinate the triphosphate of ATP to position the α-phosphate for a 
nucleophilic attack by the 2′-OH group of GTP, which results in the linear intermediate pppGpA. 
As this reaction can only be catalyzed on one site of the catalytic core, the linear intermediate has 
to flip or dissociate from the active site and rebind for cyclization. In the flipped position, the 
triphosphate of the guanosine is coordinated by the two Mg2+ ions to facilitate a nucleophilic 
attack of the 3′-OH group of the adenosine ribose. Since both binding pockets can be occupied by 
GTP, formation of c-di-GMP is observed as byproduct [10,11,167]. 
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Figure 13: Structure of the Mab21 domain of cGAS. (A) Dimeric assembly of the Mab21 domain of mouse cGAS in 
complex with 18 bp DNA and 2′3′-cGAMP (PDB 4LEZ [166]). (B) Mab21 domain of mouse cGAS in complex with 
16 bp DNA and ATP (PDB 4K97 [11]).  
The N-terminus of cGAS (aa 1-161) is unstructured, poorly conserved and controversially 
described in recent studies. Despite the poor sequence homology, it shares a predominantly 
positive charge among cGAS homologues [168]. This enables the N-terminus to bind DNA 
unspecifically and independently from the Mab21 domain [8]. According to electromobility shift 
assays (EMSAs), cGAS constructs containing the N-terminus have a significantly higher affinity 
to DNA and have higher enzymatic activity compared to truncated constructs [169]. A recent 
study reports an accumulation of cGAS 161-522 (ΔN-terminus) and cGAS 1-161 (only 
N-terminus) in the nucleus, whereas a cGAS 1-212 construct is mainly located in the cytosol. In 
addition, it was shown that the N-terminus is required for centromeric DNA sensing [170]. 
Another indicated function of the N-terminus is the localization of cGAS at the plasma 
membrane. The N-terminus of cGAS binds to PI(4,5)P2 (phosphatidylinositol 4,5-biphosphate) 
which is a component of cell membranes. Full-length cGAS expressed in THP1 cells is mainly 
present at the plasma membrane whereas the N-terminally truncated version accumulates in the 
cytosol and the nucleus [171]. Although these observations give possible suggestions about the 
function of the cGAS N-terminus, it remains not fully understood and a structural analysis is 
missing. 
4.3. cGAS-STING signalling 
Prior to the discovery of 2′3′-cGAMP, it was suggested that one type of innate immune pathway 
is mediated through direct sensing of invading bacterial CDNs by the adaptor protein STING. In 
recent years, several studies have revealed the cGAS-STING pathway and discovered STING 
activation by endogenous 2′3′-cGAMP. The central role of STING is the activation of the 
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interferon regulatory factor 3 (IRF3) and NF-κB transcription factors, resulting in the production 
of type I interferons and other cytokines. Binding of 2′3′-cGAMP induces oligomerization of 
STING, which is subsequently phosphorylated by the tank-binding kinase I (TBK1). This enables 
phosphorylation of IRF3 by STING [172] (Figure 14). 
 
Figure 14: The cGAS-STING signalling pathway. DNA in the cytosol can originate from bacteria, retroviruses, DNA 
viruses, dead cells, damaged mitochondria or genome instability. The cGAMP synthase cGAS detects DNA in the 
cytosol and starts producing 2′3′-cGAMP from ATP and GTP. The ER coupled receptor STING can bind 2′3′-cGAMP 
or bacterial derived CDNs. Subsequently, STING translocates to the Golgi apparatus and phosphorylates IRF3 via 
TBK1 to induce a type I IFN response. ENPP1 regulates the 2′3′-cGAMP levels by hydrolysis. Reprinted by permission 
from Springer Nature Customer Service Centre GmbH: Springer Nature, Nature Immunology, Regulation and function 
of the cGAS-STING pathway of cytosolic DNA sensing, Q. Chen, L. Sun, and Z. J. Chen, Copr. 2016 [157]. 
STING is a 42 kDa protein located at the endoplasmatic reticulum (ER) membrane. It consists of 
four N-terminal transmembrane helices, a cytosolic ligand-binding domain (LBD) and a 
C-terminal TBK1-binding motif (TBM). STING forms a dimer, which is twisted between the 
transmembrane part and the LBD in the inactive state (Figure 15A). The ligand-binding pocket is 
located between two “wings” of a V-shaped dimer of the LBDs. Binding to 2′3′-cGAMP induces 
a 180° rotation of the LBDs to the transmembrane part, resulting in a parallel orientation of the 
dimer (Figure 15B). This conformational change is assumed to be required for STING 
oligomerization. A cryo-EM structure of a chicken STING tetramer supports this model and 
reveals possible oligomerization interactions in a LBD loop. In addition, it was shown that STING 
phosphorylation by TBK1 requires an oligomeric assembly of STING. Independent of 
2′3′-cGAMP activation, the TBK1 dimer binds to a C-terminal β-strand like motif of STING, 
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which is connected to the LBD by a flexible linker. The available complex structure of STING 
and TBK1 has two kinase domain active sites of TBK1 located too distant from the STING 
phosphorylation motif pLxIS (p for hydrophobic residue, x for any residue and S for the 
phosphorylation site). Thus, the current model proposes, that TBK1 phosphorylates this motif on 
the tail of a neighbouring STING dimer [173,174]. The phosphorylated pLxIS motif is 
subsequently bound by IRF3, as has also been observed for other adaptor proteins, like MAVS 
(mitochondrial antiviral signalling) or TRIF (TIR domain containing adapter inducing 
interferon β) [175]. This brings IRF3 and TBK1 in close proximity for IRF3 
phosphorylation [173]. 
 
Figure 15: Full-length structure of chicken STING in (A) ligand-free state (PDB 6NT6 [174]) and (B) in complex with 
2′3′-cGAMP, LBD = ligand-binding domain. TM = transmembrane part (PDB 6NT7 [174]). 
Apart from these major orientational rearrangements, some minor conformational changes can be 
observed in the LBD upon ligand binding. The V-shaped LBD structure of STING closes upon 
2′3′-cGAMP binding and a four stranded β-sheet forms a “lid” covering the binding pocket 
(Figure 15B). It is assumed that this closure correlates with the activation of STING for different 
ligands [176]. In addition to 2′3′-cGAMP, the bacterial dinucleotides c-di-AMP, c-di-GMP and 
3′3′-cGAMP were also shown to bind and activate STING. However, the binding affinity and 
activation is significantly higher for 2′3′-cGAMP [177,178]. Mainly open lid conformations are 
observed in crystal structures of the human STING LBD in complex with c-di-GMP [179–181], 
except for one structure with a closed lid [182]. In contrast to human STING structures, mouse 
STING LBD structures share a closed conformation in complex with different CDNs and possess 
less ligand specificity [183,184]. Furthermore, STING exists in two allele variants, having a R232 
or a H232 residue in the LBD that determines CDN binding specificity. According to a human 
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genome DNA screen for STING from over 1000 individuals, the R232 variant is 
predominant [185]. Interestingly, it was shown that both STING variants are selective for 
2′3′-cGAMP, whereas only STING R232 also responds to bacterial CDNs [12]. Unfortunately, no 
structure of full-length STING bound by a bacterial CDN is available to elucidate major 
conformational changes upon bacterial CDN binding. Thus, further investigations are important to 
get a better understanding of the selective STING activation and its role in CDN sensing. 
4.4. Therapeutic potential of the cGAS-STING pathway 
In recent years, the cGAS-STING pathway was discovered to be a highly promising target for 
anti-cancer therapy. One important strategy to treat cancer is immunotherapy, which represents an 
emerging research field. Immunotherapy uses the body’s own immune system to fight tumor 
cells, in particular by inducing adaptive anti tumor immunity. This can be achieved by different 
antibody-based approaches, such as bispecific antibodies or immune checkpoint inhibitors (ICI) 
or modified immune cells, including chimeric antigen receptor T cells (CAR-T). The 
cGAS-STING pathway has an important role in innate immunity and represents an additional 
target for immunotherapy. Cytosolic DNA is sensed by cGAS and induces a type I IFN response 
via STING. This pathway can also be induced by DNA leakage in tumor cells or tumor cell 
derived DNA in dendritic cells (DCs). The expression of type I IFN in DCs contributes to the 
induction of tumor specific cytotoxic T cell priming and results in a specific anti tumor immune 
response to tumor cells [186,187] (Figure 16). 
 
Figure 16: Schematic representation of the role of cGAS-STING pathway in anti-cancer treatment. Tumor cell-derived 
DNA can enter the cytosol of DCs. Upon detection, cGAS produces 2′3′-cGAMP, which activates STING resulting in 
type I IFN production. This induces priming of cytotoxic T cells that specifically attack the tumor cells. Adapted from 
D. Bose, “CGAS/STING pathway in cancer: Jekyll and hyde story of cancer immune response,” Int. J. Mol. Sci., vol. 
18, no. 11, 2017 [187] 
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In order to manipulate the induction of type I IFN production for tumor cell treatment, the 
cGAS-STING pathway could be activated artificially. This approach raised the search for STING 
agonists, with 5,6-dimethyllxanthenone-4-acetic acid (DMXAA, also Vadimezan or ASA404) 
(Novartis) as most prominent example. DMXAA was shown to bind and activate mouse STING 
and possess a high anti-tumor potential in mouse models [188–190]. However, it failed in phase 
III clinical trials [191] as it does not bind and activate the human homologue of 
STING [184,190,192]. A similar specificity was observed for the type I interferon inducer 
10-carboxymethyl-9-acridanone (CMA) [193], which binds and activates mouse STING but fails 
to bind human STING [184]. Besides synthesized small molecule binders, also CDNs represent 
potential agonists. For example, c-di-GMP was shown to enhance anti-tumor effects as adjuvant 
in several approaches or directly attack tumor cells by activation of caspase-3. STING was shown 
to discriminate between canonical 3′3′-CDNs and noncanonical 2′3′-CDNs by higher binding 
affinity for the latter version. Therefore, STING agonists have been developed based on the 
noncanonical 2′3′-phosphodiester linkage. Noncanonical linked dithio 2′3′-CDNs were shown to 
bind STING and have a potential in anti-cancer immune response, as for example the derivative 
ML RR-S2 CDA (also ADU-S100), which was developed by Aduro Biotech [190]. The efficacy 
of ADU-S100 is currently investigated in phase I clinical trials. One major disadvantage of CDNs 
is the incapability to cross the cellular membrane. Therefore a carrier molecule is required [186]. 
 
Figure 17: Structures of the STING agonists DMXAA (Novartis), c-di-GMP and ADU-S100 (Aduro Biotech).  
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 Objectives 
In recent years, cyclic dinucleotides have been discovered to play a role as second messengers in 
many important signalling pathways in both, prokaryotes and eukaryotes.  
In prokaryotes, c-di-AMP is an important second messenger as it is essential in most species. 
Since it was discovered only recently, many functions of the c-di-AMP signalling pathway are not 
yet fully understood. In particular, the degradation pathway raises many open questions and thus 
represents the major topic of this work. Two of the so far discovered PDE types, GdpP and DhhP, 
use the same highly conserved DHH-DHHA1 domain for catalysis although they occur in parallel 
in many species. While GdpP hydrolyzes c-di-AMP exclusively to 5′-pApA, the substrate 
specificity of DhhP homologues varies in literature. One major aim of this work was to 
characterize the structure and function of DhhP PDEs based on the homologue TmPDE from 
T. maritima. In order to determine the substrate specificity of TmPDE, activity assays and binding 
experiments were performed. Different cyclic dinucleotides, linear dinucleotides or short RNAs 
were tested as possible substrates. Crystallization, small-angle x-ray scattering (SAXS) and 
right-angle light scattering (RALS) were used for structural characterization. Based on the 
structural information, an inactive TmPDE D80N D154N was designed for binding experiments. 
The results were compared to DhhP homologues from other species, such as SpPde2 and 
Rv2837c, to describe the function of these enzymes. Although these findings contribute to a better 
understanding of c-di-AMP degradation, the hydrolysis pathway remains unclear in some species, 
such as Streptomyces, that do not contain any of the known PDEs. The discovery of a novel PDE 
for c-di-AMP hydrolysis in S. venezuelae by the group of Natalia Tschowri (Humboldt-
Universität Berlin) gives important insights to unravel this unknown degradation pathway. In a 
collaborative project with the Tschowri group the precise function of this enzyme should be 
elucidated. Therefore, the second major part of this work was the biochemical characterization of 
this novel PDE, named AtaC. The substrate specificity was analyzed using different dinucleotide 
ligands in activity assays. In addition, several approaches to gain structural information were 
tested. 
Cyclic dinucleotides also play an important role in eukaryotes. The recently discovered 
2′3′-cGAMP functions as a second messenger in the cGAS-STING pathway of the innate immune 
system. It is involved in the detection of pathogens and represents the first signal for cytosolic 
DNA recognition. The pathway raised particular scientific interest, since it was found to be a 
potential target for cancer immunotherapy. Therefore, an extensive research on the activity of 
cGAS or STING is highly interesting. One part of the present work was the characterization of a 
fluorescent 2′3′-cGAMP analogue, named fGAMP, in regard to a novel application for STING 
analysis. Thus, it was tested for STING binding by ITC experiments. Furthermore, the fluorescent 
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properties of fGAMP were analyzed using a fluorescence plate reader. A change of fluorescence 
intensity upon STING binding is required for the establishment of a fluorescence-based assay. 
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1. Structural and Biophysical Analysis of the Soluble DHH/DHHA1-Type 
Phosphodiesterase TM1595 from Thermotoga maritima 
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This publication provides a detailed insight in the degradation of c-di-AMP by DHH-type PDEs, 
based on the homologue TmPDE from T. maritima. TmPDE was characterized structurally and 
biophysically to elucidate its function. The substrate specificity was determined using HPLC-
based ion exchange chromatography activity assays and by binding analysis using surface 
plasmon resonance spectroscopy and isothermal titration calorimetry. These experiments show a 
high activity and binding affinity for linear dinucleotides, such as 5′-pApA, 5′-pApG and 
5′-pGpG, whereas cyclic dinucleotides are not hydrolyzed and bound under physiological 
conditions. Furthermore, six high-resolution crystal structures of TmPDE in different reaction 
states were obtained, allowing a detailed description of the hydrolysis mechanism. In addition, 
right-angle light scattering and small-angle x-ray scattering data reveal a dimer in solution. In 
conclusion, the structural and biophysical characterization of TmPDE indicates a clear preference 
for linear dinucleotides, supporting a two-step degradation pathway for c-di-AMP. 
 
Author contribution 
The author of the present thesis expressed and purified TmPDE for structural and biophysical 
analysis. Together with M. Müller, the substrate specificity and binding was analyzed using ion 
exchange chromatography activity assays and surface plasmon resonance spectroscopy. 
Furthermore, the author of this thesis characterized substrate binding affinity by isothermal 
titration calorimetry. In addition, he crystallized TmPDE in complex with 5′-pApA, 5′-pApG and 
GMP and performed data collection and evaluation with support of G. Witte. He wrote the 
manuscript together with G. Witte. 
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The concentration of messenger molecules in bacte-
rial cells needs to be tightly regulated. This can be
achieved by either controlling the synthesis rate,
degradation, or export by specific transporters,
respectively. The regulation of the essential second
messenger c-di-AMP is achieved by modulation of
the diadenylate cyclase activity as well as by specific
phosphodiesterases that hydrolyze c-di-AMP in the
cell. We provide here structural and biochemical
data on the DHH-type phosphodiesterase TmPDE
(TM1595) from Thermotoga maritima. Our analysis
shows that TmPDE is preferentially degrading
linear dinucleotides, such as 50-pApA, 50-pGpG, and
50-pApG, compared with cyclic dinucleotide sub-
strates. The high-resolution structural data provided
here describe all steps of the PDE reaction: the
ligand-free enzyme, two substrate-bound states,
and three post-reaction states. We can furthermore
show that Pde2 from Streptococcus pneumoniae
shares both structural features and substrate speci-
ficity based on small-angle X-ray scattering data and
biochemical assays.
INTRODUCTION
Nucleotide second messengers are key components in cellular
signaling that link signals to cellular responses. To achieve
robust signaling that allows fast reaction to environmental or
metabolic changes, the cellular levels of the messenger mole-
cules are often regulated in both their synthesis and degradation,
or they are even exported from the cell. In the case of the bacte-
rial second messenger 30,50-cyclic di-adenosine monophos-
phate (c-di-AMP), the synthesis of the messenger molecule is
carried out by DAC (di-adenylate cyclase) domain proteins that
selectively synthesize c-di-AMP from two molecules of ATP
(Witte et al., 2008). c-di-AMP is involved in a variety of processes
in the cell, most of them related to potassium homeostasis or cellStru3wall biogenesis, reviewed for example in Corrigan and Gr€undling
(2013). Remarkably, c-di-AMP is the first secondmessenger that
has been described to be essential for the bacteria synthesizing
it, as total knockouts of DAC domain proteins are for example le-
thal in Bacillus subtilis (Mehne et al., 2013), Staphylococcus
aureus (Corrigan et al., 2013), and Listeria monocytogenes (Witte
et al., 2013). In vivo experiments in different organisms showed
that the cellular level of c-di-AMP needs to be tightly regulated,
as even small changes lead to drastic effects in the viability of
the cells. For quite some time the essentiality of c-di-AMP could
not be pinpointed, but a recent study in B. subtilis showed that
c-di-AMP is, in fact, a key component in controlling potassium
homeostasis (Gundlach et al., 2017). The c-di-AMP pathway is
also an interesting target for antimicrobial therapies (M€uller
et al., 2015a), because the pathway influences sensitivity to anti-
biotic treatment (Dengler et al., 2013; Whiteley et al., 2017) and is
found in many pathogenic bacteria such as L. monocytogenes
(Woodward et al., 2010), Mycobacterium tuberculosis (Bai
et al., 2012), Streptococcus pneumoniae (Kamegaya et al.,
2011), and S. aureus, including methicillin-resistant S. aureus.
The regulation of c-di-AMP synthesis is controlled by expression
levels or activity of the respective proteins. For example,
B. subtilis CdaS is expressed prior to sporulation (Nicolas
et al., 2012), and also direct regulation of the DAC domains via
ligand interactions was observed, as described for the DAC pro-
totype DNA-integrity scanning protein A (DisA) from Thermotoga
maritima andB. subtilis.DisA switches off its c-di-AMP synthesis
upon binding to recombination intermediate DNA structures and
likely acts as a checkpoint protein that ensures genome integrity
prior to sporulation of the bacteria (Bejerano-Sagie et al., 2006;
Oppenheimer-Shaanan et al., 2011; Witte et al., 2008). Another
example is the regulation of the membrane protein CdaA by
CdaR (Mehne et al., 2013). In addition to limited synthesis, a
decrease in the total cellular c-di-AMP levels can also be
achieved by selective degradation of the messenger molecule
by c-di-AMP-specific phosphodiesterases (PDE) that degrade
c-di-AMP to AMP and/or 50-pApA. In bacteria, two types of
c-di-AMP PDEs have been identified so far.
The first PDE that was characterized in detail is the multido-
main membrane-associated DHH/DHHA1-type phosphodies-
terase GdpP, which is encoded by YybT in B. subtilis (Figure 1A)
(Rao et al., 2010). GdpP carries two additional regulatorycture 25, 1887–1897, December 5, 2017 ª 2017 Elsevier Ltd. 18877
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domains in addition to the two active PDE domains DHH and
DHHA1; a sensory PAS (Per-Arnt-Sim) domain and a degener-
ated GGDEF domain. Whereas the former has been shown to
bind Heme and nitric oxide, thereby affecting the PDE activity
(Rao et al., 2011), the latter motif originally derives from proteins
involved in c-di-GMP signaling but in this case binds and hydro-
lyzes ATP. GdpP has been shown to specifically hydrolyze c-di-
AMP to 50-pApA in presence of Mn2+ but also shows c-di-GMP
phosphodiesterase activity resulting in 50-pGpG (Rao et al.,
2010). DHH/DHHA1-type PDEs also occur as soluble proteins
comprising just the DHH/DHHA1 domains without the regulato-
ry domains (Figure 1A), such as in S. pneumoniae (Pde2) (Bai
et al., 2013), M. tuberculosis (CnpB/PDE/Rv2837c) (He et al.,
2016), M. smegmatis (PDE) (Tang et al., 2015), and S. aureus
(Pde2) (Bowman et al., 2016). Although these proteins belong
to the DHH/DHH1A group, they have interestingly been re-
ported to possess altered product specificity as they degrade
c-di-AMP as well as 50-pApA to AMP. Even though it was
shown that S. aureus Pde2 might degrade c-di-AMP to
50-pApA, it has a clear preference for the hydrolysis of the sec-
ond step, i.e., 50-pApA to 2 AMP (Bowman et al., 2016). In
contrast, the biochemistry of the other PDEs mentioned above
remains somewhat uncertain. In addition to the DHH/DHHA1-
type PDEs, a second class of c-di-AMP-specific phosphodies-
terases has been identified in L. monocytogenes (Huynh et al.,
2015). L. monocytogenes PgpH is a member of the HD super-
family, named after the His-Asp residues that are functionally
important as they coordinate the catalytically essential metal
ions. PgpH and homologs are integral membrane proteins
that belong to the 7TM-7TMR_HD family and consist of a seven
transmembrane helix domain and a cytoplasmatic HD domain
and (Huynh and Woodward, 2016). PgpH-type PDEs also
show preferential hydrolysis of one of the 30-50-phosphodiester
bonds in c-di-AMP, resulting in the linear product 50-pApA. Of
note, both DHH- and HD-type phosphodiesterases occur in
bacteria with c-di-AMP pathways; some species have both of
them (e.g., L. monocytogenes), whereas others have only one
representative, most commonly DHH-type enzymes (Huynh
and Woodward, 2016). As PgpH and GdpP are obviously
responsible for the first step in c-di-AMP hydrolysis (its lineari-
zation to 50-pApA), it is tempting to speculate that the soluble
DHH-type PDEs carry out its subsequent hydrolysis from
50-pApA to 2 AMP. Structural studies of the intracellular domain
of the L. monocytogenes PgpH HD domain PDE (Huynh et al.,
2015) and the soluble DHH domain phosphodiesterases from
M. tuberculosis (He et al., 2016) suggest a similar mechanismFigure 1. Multiple Sequence Alignment and Overall Structural Charact
(A) Sequence alignment of PDEs from different species. Secondary structure ele
DHHA1 domain in gray. Nucleotide-binding residues are marked by asterisks a
C-terminal DHH/DHHA1 domain is shown, the other sequences represent the fu
(B) Buffer-corrected SAXS curve of a 7 mg/mL TmPDE wild-type sample shown a
apo state, inset) obtained using CRYSOL (Svergun et al., 1995) (c2 = 2.3).
(C) Guinier plot analysis ln I(s) versus s2 of the SAXS-data from (C). The radius of g
(s*RG < 1.3), RG = 2.67 nm. The lower panel shows the residuals of the linear regr
aggregating.
(D) Crystal structure of the biological dimer of TmPDE D80N D154N mutant in the
domains of one monomer are colored light blue and gray, respectively, whereas
(E) Surface representation of the TmPDE D80 D154N mutant in 50-pApG-bound
(F) Surface representation of the TmPDE apo structure in the same orientation a
3of hydrolysis in which the two-metal-ion catalytic center facili-
tates the attack of the phosphodiester by an activated water
molecule. To gain a more detailed view on the mechanism
and biophysical properties of the second step in c-di-AMP
degradation, we solved crystal structures of the soluble DHH-
type PDE from T. maritima (TM1595) in different nucleotide-
bound states and performed biochemical and biophysical as-
says to determine the kinetic and thermodynamic properties
of nucleotide binding.
RESULTS AND DISCUSSION
Protein Characterization
Based on sequence homology searches we identified a putative
c-di-AMP phosphodiesterase in T. maritima. The 37.5 kDa pro-
tein encoded by TM_1595 is highly similar to known DHH/
DHHA1-PDEs and thus will be referred to as TmPDE (Figure 1A).
We recombinantly expressed TmPDE in Escherichia coli and
purified it to homogeneity. For comparative reasons we also pu-
rified the Pde2 protein from S. pneumoniae (SpPde2), which has
been described to possess c-di-AMP phosphodiesterase activ-
ity (Bai et al., 2013). Both purified PDEs elute as single peaks in
size-exclusion chromatography (SEC) with a hydrodynamic
radius corresponding to a dimeric form of the PDEs. To unam-
biguously determine the molecular weight in solution we also
performed analytical SEC coupled right-angle laser light scat-
tering (SEC-RALS) and small-angle X-ray scattering (SAXS).
The respective molecular weights derived from these methods
indicate that TmPDE forms a dimeric assembly in solution (Fig-
ures 1B, 1C, and S1).
Product Specificity and Phosphodiesterase Activity
To analyze the phosphodiesterase activity of both TmPDE and
SpPde2, we individually incubated the proteins with c-di-AMP,
50-pApA, 50-pApG, or 50-pGpG, and analyzed the products by
liquid chromatography (LC; see the STAR Methods). The reac-
tion partners showed well-separated peaks, allowing their
integration and Michaelis-Menten-like kinetic evaluation. Inter-
estingly, we could detect robust and fast phosphodiesterase
activity of both PDEs when using the linear substrates 50-pApA
(KM = 204 ± 10 mM; kcat = 0.14 s
1), 50-pApG (KM = 355 ±
36 mM, kcat = 0.26 ± 0.02 s
1), and 50-pGpG (similar activity,
but no detectable saturation in the KM assays). The cyclic dinu-
cleotide c-di-AMP, however, was only degraded to a small
extent under the various conditions tested, and only the use of
1,000-fold higher protein concentration yielded detectableerization of TmPDE
ments from TmPDE are shown above, with the DHH domain in light blue and
nd the highly conserved active site is outlined. For B. subtilis GdpP only the
ll-length proteins.
s black circles with the theoretical scattering curve shown in red of TmPDE (in
yration was determined from linear regression (red) of data in the Guinier region
ession. The linearity of the Guinier plot indicates that the TmPDE sample is not
50-pApG-bound state shown in cartoon representation. The DHH and DHHA1
the other monomer is colored orange. 50-pApG is shown as black sticks.
state in which both binding sites are closed.
s shown in (E) with one open binding site.
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Figure 2. Binding and Activity of TmPDE with Different Ligands
(A) ITC measurement of 20 mM TmPDE D80N D154N mutant titrated with 200 mM c-di-AMP and the respective binding curve fit (KD = 4.58 ± 1.93 mM).
(B) ITC measurement raw data of 20 mM TmPDE D80N D154N mutant titrated with 250 mM ligand: 50-pGpG (black), 50-pApG (red), and 50-pApA (blue).
(C) Binding curves and fits of ITC titrations of the TmPDE D80N D154N mutant with 50-pGpG (KD = 247 ± 59 nM) (black), 50-pApG (KD = 191 ± 36 nM) (red), and
50-pApA (KD = 860 ± 94 nM) (blue). The inset shows a representative signature plot of the ITC measurement with 50-pApA with DG = 8.26 kcal/mol,
DH = 12.8 kcal/mol, and –TDS = 4.55 kcal/mol (similar values were observed for the other linear 50-pNpNs).
(D) SPR measurement of the TmPDE D80N D154N mutant (on chip) with injections of 8–1,000 mM c-di-AMP.
(E) SPR measurement of the TmPDE D80N D154N mutant (on chip) with injections of 8–1,000 mM 50-pApA.
(F) Steady-state affinity fits for SPR measurements of the TmPDE D80N D154N mutant titrated with 50-pGpG (KD = 86 ± 3 nM) (black), 50-pApG (KD = 76 ± 4 nM)
(red), and 50-pApA (KD = 584 ± 26 nM) (blue).
(legend continued on next page)
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amounts of AMP (Figures 2 and S2). This extremely low turnover
did not allow for reliable determination of kinetic parameters for
either TmPDE or SpPde2. This finding is in agreement with data
from Bowman et al. (2016) showing that soluble DHH/DHHA1-
type PDEs prefer the hydrolysis of 50-pApA over the direct
hydrolysis of c-di-AMP. Indeed, the turnover of c-di-AMP for
both TmPDE and SpPde2 is almost negligible in comparison
with the 50-pApA substrate. In contrast, the DHH/DHHA1-type
GdpP-type protein from B. subtilis (Figure 2J) and
S. pneumoniae SpPde1 (not shown) clearly show degradation
of c-di-AMP to 50-pApA, despite the homologous catalytic do-
mains. A truncated B. subtilis GdpP construct lacking the regu-
latory domains (GdpP-DHH/DHHA1) also hydrolyzes c-di-AMP
to 50-pApA, thus excluding the regulatory domains of GdpP as
a reason for the ligand specificity (Figure 2J). To elucidate differ-
ences between PDE and GdpP phosphodiesterases, we
modeled B. subtilis GdpP based on sequence alignment and
our TmPDE structure using SWISS-MODEL (Biasini et al.,
2014). As expected, the GdpP model shows a similar overall
structure (Figure S3E), whereas analysis of the active site reveals
that the modeled ligand 50-pApA does not fit into the GdpP
model structure due to steric hindrance of residues L191 and
N314 (Figure S3F). This could be a reason for the incomplete
hydrolysis of c-di-AMP to 50-pApA in GdpP-like phosphodiester-
ases, although this assumption is only based on a structure
prediction and remains to be verified.
To be able to monitor substrate binding to the protein, we pro-
duced an inactive mutant of TmPDE that can bind the sub-
strate(s) but lacks catalytic activity. Site-directed mutagenesis
of two acidic residues abolished binding of the catalytically
essential active site Mn2+ ions in the active site, which are neces-
sary for activating the water molecule that performs the nucleo-
philic attack on the 30-50-phosphodiester (Rao et al., 2010).
These respective aspartate residues were identified by homol-
ogy analysis and mutated to asparagine (i.e., D80N D154N; Fig-
ures 3A and 3B) instead of alanine, as described previously (Rao
et al., 2010), to have a more conservative mutation. The resulting
mutant and wild-type proteins showed identical elution profiles
and molecular weight in SEC-RALS, and also show similar
SAXS curves, suggesting that the mutations did not alter overall
protein conformation or oligomeric state (Figures S1A, S1G, and
S1H). In the LC-based assays we were not able to detect any
turnover of 50-pApA or c-di-AMP by TmPDE D80N D154N, con-
firming that this mutant is completely inactive under the assay
conditions used.(G) Ion-exchange chromatography runs onMonoQ5/50GL column of the reaction
250 mM 50-pApA (red) and 250 mM c-di-AMP (black).
(H) Representative chromatograms of the activity assays of TmPDE (10 nM) with
change chromatography with a Mono Q 5/50 GL column.
(I) Michaelis-Menten kinetics of the reactions from TmPDE (10 nM) with substrates
at 20C. 50-pApA, KM = 204 ± 10 mM; 50-pApG, KM = 355 ± 36 mM. Also shown are
three independent experiments.
(J) Ion-exchange chromatography runs on Resource Q column of the reaction pro
c-di-AMP (red) and 1 mM B. subtilisGdpP-DHH/DHHA1 + 250 mM c-di-AMP (blac
and c-di-AMP (orange).
(K) Ion-exchange chromatography runs on Mono Q 5/50 GL column of the rea
50-pApApA (red) after 1 hr at 20C and the respective standard 50-pApApA (show
(L) Michaelis-Menten kinetics of the reactions from SpPde2 with 50-pApA (62.5–2,
the data points for c-di-AMP (black). Shown are mean values with errors from th
4We performed surface plasmon resonance (SPR) experiments
to rule out mechanistic differences in c-di-AMP or 50-pApA hy-
drolysis, which might lead to the apparent inactivity in vitro and
to further characterize the product binding of TmPDE. The inac-
tive mutant TmPDE D80N D154N was immobilized on the SPR
chip, and different concentrations of the respective cyclic and
linear nucleotides were injected over the chip’s surface. The re-
sulting binding curves determined from the sensorgrams (Fig-
ures 2D–2F and S2E–S2G) indicate that TmPDE D80N D154N
is not capable of binding c-di-AMP or c-di-GMP under the con-
ditions tested. In contrast, linear products were bound with KD
values in the nanomolar range (Figures 2D–2F and 4B), some
of them with high on-off rates beyond the resolution of the SPR
instrument, as indicated by the abrupt rise and fall in the respec-
tive sensorgrams (Figure 2E). To further determine thermody-
namic parameters of the substrate binding, we also performed
isothermal titration calorimetry (ITC). Using c-di-AMP as a ligand,
the integrated heat curves only showed a low-affinity binding
(KD = 4.58 ± 1.93 mM) in an endothermic reaction. In contrast,
the linear substrates clearly show high-affinity binding and pa-
rameters indicative of enthalpy-driven substrate binding with
50-pGpG (KD = 247 ± 59 nM), 50-pApG (KD = 191 ± 36 nM), and
50-pApA (KD = 860 ± 94 nM) (Figures 2A–2C and 4B).
These biophysical data, in combination with the in vitro activity
assays, strongly argue that the native substrate of TmPDE (and
SpPde2) is in fact a linear dinucleotide (e.g., 50-pApA, 50-pApG,
and 50-pGpG as tested here), and that cyclic derivatives are
bound only to a much lower extent. The fast on-off kinetics sug-
gest that the active site is readily accessible by diffusion from the
bulk solvent. Because there is only one active site in the DHH-
DHHA1 domain phosphodiesterase, the full degradation of
c-di-AMP to two molecules of AMP would require either reorien-
tation (rotation) of the intermediate 50-pApA within the active site
or its release and rebinding. With respect to the previously
described hydrolysis of c-di-AMP by SpPde2 and Rv2837c,
and the binding affinities determined here, we can confirm
that, for c-di-AMP hydrolysis, orders of magnitude higher con-
centrations are needed in the assays. Using higher concentra-
tions of c-di-AMP certainly increases the probability of c-di-
AMP binding to TmDPE/SpPde2 and might potentially lead to
the linearized product 50-pApA, which is then degraded much
more rapidly to two molecules of AMP due to the higher affinity
to the DHH active site as seen in Figure S2A. This might explain
why c-di-AMP PDE activity has been described for some of the
soluble DHH-type PDEs in literature. To rule out that TmPDE hasproducts after 1 hr incubation from 100 mL reactions containing 2 mMTmPDE +
substrate 50-pApG (62.5–2000 mM) after 25 min at 20C analyzed by ion-ex-
50-pApA (62.5–2,000 mM) (blue) and 50-pApG (62.5–2,000 mM) (red) after 25min
the data points for c-di-AMP (black). Shown are mean values with errors from
ducts from 100 mL reactions containing 1 mM B. subtilis GdpP-DTM + 250 mM
k) after 1 hr at 20C. Also shown are the standards AMP (green), 50-pApA (blue),
ction products from a 100 mL reaction containing 100 nM TmPDE + 250 mM
n in black).
000 mM) (blue). KM = 97 ± 8 mM after 25 min incubation at 20
C. Also shown are
ree independent experiments.
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Figure 3. Active Site of TmPDE in Different Ligand-Bound (Reaction Intermediate) States
(A) Detailed view on the empty active site of TmPDE. Substrate-binding residues are shown as sticks and manganese ions are shown as purple spheres.
(B) Detailed view of the active site of TmPDE D80N D154N crystallized with 50-pApG. The bound ligand and the interacting residues are shown as sticks and the
manganese ions (modeled, see main text) as purple spheres.
(C) TmPDE D80N D154N with 50-pApA in the nucleotide binding cleft. The positions for the 50- and 30-nucleotides are labeled with A and B in the sugar ring.
(D) TmPDED80ND154Nwith twomolecules of AMP in site A and site B resulting from 50-pApA cleavage. The phosphate of nucleotide in position B hasmoved up,
in agreement with the SN2-mechanism.
(E) Wild-type TmPDE with AMP and Mn2+ ions at site A. The second AMP, c.f., D has already left site B.
(F) TmPDE D80N D154N after hydrolysis of 50-pGpG and only one GMP (site A) left in the active site.even higher specificity for longer RNAs, such that it might serve
as nanoRNase, we also tested 50-pApApA as a substrate (Fig-
ure 2K). TmPDE showed almost no cleavage of the trinucleotide,
despite a doubled reaction time and a ten times higher protein
concentration compared with the 50-pApA experiment.
Structural Determination of TmPDE in Different Ligand-
Bound States
To obtain structural information that allows a description of the
putative substrate recognition and PDE mechanism, we crystal-
lized wild-type TmPDE in absence of ligands (apo-) and in the
product-bound form II (AMP/Mn2+). We also crystallized the
mutant TmPDE D80N D154N in the presence of different linear
dinucleotides, trapping the enzyme in different reaction interme-
diate states (substrates I and II, products I–III).
We used datasets collected from TmPDE product state crys-
tals (containing Mn2+, AMP, or GMP) diffracting to 1.9 A˚ to phase1892 Structure 25, 1887–1897, December 5, 2017 42the data by single-wavelength anomalous diffraction. The ob-
tained map showed readily interpretable electron density for
the two molecules in the asymmetric unit. This allowed us to
build the almost complete structure of TmPDE with good valida-
tion statistics, and the final model comprises residues 1–319 for
both chains in the asymmetric unit, 501 water molecules and
6 Mn2+ ions (numbers for TmPDE/AMP-Mn2+, i.e., product II)
(Table 1). The refined model was subsequently used to deter-
mine the structures of apo TmPDE and the substrate and prod-
uct complexes by molecular replacement. These structures
were then refined and yielded similar statistics (Table 1).
Overall Structural Properties of TmPDE
One chain of TmPDE consists of the two clearly separated do-
mains DHH (residues 1–190) and DHHA1 (residues 194–end),
connected by a linker between helices a8 and a9 (Figure 1 and
Movie S1). Monomeric TmPDE has overall dimensions of
Figure 4. Schematic Representation of the
Hydrolysis Reaction of TmPDE
(A) The reaction cycle based on available struc-
tures: The pre-reaction state of TmPDE shows one
open active site in the dimer. 50-pNpN ligands bind
tightly to TmPDE, whereas c-di-NMPs bind much
weaker. The bound ligand is hydrolyzed resulting in
two NMP molecules in the active site. The two
NMPs are then released separately (30 nucleotide
followed by the 50 nucleotide) prior to binding of the
next substrate.
(B) The table summarizes all results of binding
experiments and activity assays. KD values are
calculated from ITC and SPR experiments, kon and
koff from SPRmeasurements. The errors represent
the error of the individual fit of the binding model to
the experimental data. KM and kcat values from
Mono Q activity assays are mean values and errors
of three independent experiments. Please note
that 50-pGpG is hydrolyzed with approximately
similar activity, but the assay does not allow for
determination of parameters.approximately 55 3 35 3 30 A˚. The eponymous active site con-
taining the highly conserved DHHmotif is located in the cleft be-
tween DHH and DHHA1. The two domains share high structural
similarity with the DHH/DHHA1 structures of nanoRNases (Sri-
vastav et al., 2014; Uemura et al., 2013) and also the PDE from
M. tuberculosis Rv2837c (He et al., 2016). The DHH domain
comprising residues 1–192 consists of a five-stranded parallel
b sheet domain flanked by helices (a1–a8). It harbors the catalyt-
ically active residues (see below) and is responsible for metal ion
coordination. The smaller C-terminal DHHA1 domain (residues
195–end) is connected to the DHH domain via a flexible linker
domain and has a DHH similar fold comprising a central mixed
b sheet domain (b6–b11) surrounded by helices (a9–a13). The
dimeric assembly is mainly achieved by a large number of con-
tacts between the a helices, creating a continuous helical central
part in the dimer whereas the b sheet domains face outward.
The crystal packing (50-pApA-structure with one molecule per
asymmetric unit in C2221) and the arrangement of the molecules
in the asymmetric units of the other structures suggest that
TmPDE forms a butterfly-shaped dimer with overall dimensions
of 803 553 40 A˚. The interactions of the DHH/DHHA1 domains
and the linker region, with many hydrophobic interactions medi-
ated by, e.g., helices a7–a9, results in outward facing clefts ofStructu43the active sites, with the monomers hav-
ing an approximately 60 tilt with respect
to each other. This arrangement creates
a large buried surface area of approxi-
mately 2,050 A˚2. In contrast, the only
other possible dimeric assembly has in-
ward facing active sites and a much lower
buried surface area of approximately
800 A˚2. To experimentally validate the
biological assembly, we collected solu-
tion scattering data of wild-type TmPDE
and also of the D54N D180N mutant.
The shapes of the averaged scattering
curves are only compatible with the theo-retical scattering curves of the respective butterfly-shaped
dimers (Figures 1B, S1G, and S1H). We also collected SAXS
data from the homologous S. pneumoniae Pde2 (Figures
S1C–S1F), which we also used as a reference in our biochemical
assays. Lacking a high-resolution structure of SpPde2, we per-
formed ab initiomodeling using the SpPde2 SAXS data. All ab in-
itio models of independent runs (n = 20) were highly similar, and
the final averaged shape shows a good fit and similarity to our
crystallographic TmPDE dimer (description below, Figure S1E).
Because the linker between DHH and DHHA1 domains allows
the cleft to open and consequently change its accessibility to the
bulk solvent, the active site of TmPDE is certainly able to harbor
and degrade more substrates than tested here. This is in agree-
ment with data on the mycobacterial phosphodiesterase
Rv2837c (He et al., 2016) and nanoRNases (Srivastav et al.,
2014), which show that these enzymes can degrade various
small nucleic acid substrates.
Substrate Coordination and Mn2+-Activated 30-50-
Phosphodiester Bond Cleavage
To characterize substrate binding, cleavage, and release, we
determined the structures of the nucleotide-free state, two sub-
strate-bound, and three product-bound states of TmPDE. There 25, 1887–1897, December 5, 2017 1893
Table 1. Crystallographic Data and Refinement Statistics
Unbound State
(Apo)
Substrate I
50-pApA
Substrate II
50-pApG
Product I
pApA
Product II
AMP/Mn2+
Product III
GMP/Mn2+
Protein wild-type D80N D154N D80N D154N D80N D154N wild-type D80N D154N
Data Collection
Beamline EMBL P14 ESRF ID30A
MASSIF-1
EMBL P13 EMBL P13 EMBL P14 SLS X06SA
Wavelength (A˚) 0.9763 0.9660 1.1999 1.1999 1.5498 (SAD) 1.2999 (SAD)
Space group C 2 C 2 2 21 C 2 2 21 C 2 2 21 P 21 21 21 P 21 21 21
Cell dimensions
a, b, c (A˚) 132.7, 54.9,
108.6
71.7, 87.8,
122.4
70.4, 88.3,
124.3
71.4, 87.6,
121.9
55.3, 106.8,
134.1
55.9, 105.6,
134.5
a, b, g () 90, 118, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Resolution 95–1.7
(1.74–1.70)
50–1.7
(1.74–1.70)
62–1.55
(1.59–1.55)
60.9–1.55
(1.59–1.50)
50–1.9
(1.95–1.90)
50–1.9
(1.95–1.90)
CC1/2 99.8 (65.9) 99.9 (75.0) 100 (75.5) 100 (75.8) 99.9 (66.1) 99.9 (74.6)
Rmeas 11.7 (101) 5.5 (76.6) 3.7 (82.8) 4.5 (121) 10 (85.5) 7.2 (130.5)
I/sI 13.3 (2.0) 21.4 (2.25) 19.2 (1.87) 19.7 (1.67) 14.3 (2.5) 17.4 (1.9)
Completeness (%) 96.5 (95.9) 98.8 (97.8) 98.4 (95.4) 99.5 (98.3) 95.2 (92.1) 99.7 (99.9)
Redundancy 6.9 (6.8) 9.9 (4.5) 4.5 (4.3) 6.6 (6.3) 6.7 (6.6) 6.9 (6.9)
Refinement
Resolution 20–1.75 44–1.7 50–1.55 41–1.55 49–1.9 46–1.9
No. of reflections 67,550 42,286 106,907 106,661 115,140 62,479
Rwork/Rfree 16.4/19.0 17.3/19.6 15.8/18.3 16.8/19.5 16.4/20.4 16.3/20.3
Molecules (asu) 2 1 1 1 2 2
No. of atoms
Protein 5,118 2,606 2,620 2,639 5,130 5,144
Nucleotides/ligands -/87 45/44 46/94 46/62 46/11 48/28
Water 527 249 279 295 501 551
RMSD
Bond lengths (A˚) 0.004 0.006 0.006 0.006 0.007 0.010
Bond angles () 0.691 0.763 0.811 0.849 0.821 1.004
Ramachandran plot (%)
Favored 98 99 97 98 98 99
Allowed 2 1 3 2 2 1
Outliers – – – – – –
PDB ID 5O25 5O4Z 5O58 5O70 5O1U 5O7F
RMSD, root-mean-square deviation; asu, asymmetric unit.mutant TmPDE D80N D154N has reduced activity due to
impaired coordination of the catalytically essential Mn2+ ions,
thus we will describe the metal ion coordination on the basis
of the apo state structure. Here, we could clearly identify the
Mn2+ ions in the active site owing to density in the anomalous
difference map, and we used the apo structure to model the
Mn2+ ions and respective water molecules in the other repre-
sentations of TmPDE structures. Even though all nucleotide li-
gands were already clearly visible in the mFoDFc difference
density of the ligand-bound states after replacement, we also
confirmed the presence and nature of the ligand in the product
state I (AMP:AMP) structure by anomalous difference electron
density map visualizing the phosphate (Figure S3A), and by
calculation of Polder maps (Liebschner et al., 2017) with the
ligand atoms omitted (Figure S3B). As mentioned before, the1894 Structure 25, 1887–1897, December 5, 2017 44active site mutations do not alter the behavior or structure of
TmPDE in solution, suggesting that the mutations only affect
the active site.
As described previously for other DHH/DHHA1-phosphodies-
terases, the 30-50-phosphodiester bond is attacked by a water
molecule that is activated by divalent cations (Mn2+) (He et al.,
2016; Uemura et al., 2013). The nucleophilic attack for the
SN2-reaction is carried out by the activated water WAT1 from
the ‘‘backside’’ of the phosphate and facilitates the planar inter-
mediate state before the final cleavage. Consistent with this, our
D80N D154N mutant, crystallized in the presence of 50-pApA,
shows that the 30-50-phosphodiester bond is in the ideal orienta-
tion for an attack by activatedWAT1 (distance 1.7 A˚; Figure S3C).
The putative reaction mechanism of TmPDE is also in good
agreement with data on Rv2837 (He et al., 2016), and also
remarkably similar to the EAL domain described for a light-regu-
lated c-di-GMP phosphodiesterase (Barends et al., 2009).
Unbound State (Apo Form)
Interestingly, our ligand-free structure reveals that the dimeric
DHH/DHHA1 assembly has a slightly asymmetric shape,
whereas the ligand-bound structures show almost identical con-
formations in the two chains. Specifically, one-half of the dimer
has amore open cleft, whereas the other half of the PDE is rather
closed and slightly shifted and rotated (Figures 1E and 1F). This
might indicate that TmPDE is dynamic during its reaction cycle,
such that the open form of the empty enzyme facilitates sub-
strate binding, and that substrate binding leads to closure of
the active site (Movie S1). A readily accessible active site would
provide a structural basis for the relatively fast on-rate of sub-
strate binding (Figure 4B). Interestingly, our ITC experiments
show a stoichiometry of n = 0.5 for substrate binding to the inac-
tive enzyme (Figure 2C), this raises the possibility that TmPDE
might function in a flip-flop-like manner in solution, i.e., only
one site is active per cycle, in agreement with the half-open
apo structure. In contrast, the crystal structures of ligand- and
product-bound states argue for two active sites, but might be
influenced by crystallization conditions and/or packing. We
cannot exclude an alternating active site in the dimer at this stage
but the conclusions drawn for the reaction chemistry and sub-
strate preference for linear dinucleotides (see below) remain un-
touched by this possibility.
In the active site of TmPDE, two manganese ions are
coordinated by a dense network of highly conserved residues;
His-19 and Asp-23 coordinate Mn2+ 1, Asp-25, His-104, and
Asp-154 coordinate Mn2+ 2, and Asp-80 coordinates both
Mn2+ 1 and 2. The ligand binding site is further occupied by
bulk solvent and some ordered water molecules. In this state,
the enzyme is ready to bind its dinucleotide substrate.
Substrate-Bound Pre-reactive States (Substrates I
and II)
The substrate-bound structures of TmPDE D80N D154N with
50-pApA (substrate I, Figures 3C) and 50-pApG (substrate II, Fig-
ure 3B) reveal that TmPDE dimer is symmetrical and has closed
active site clefts compared with the apo state. The dinucleotides
are oriented with the 30-50-phosphodiester bond facing the
position of the twomodeledmanganese ions, where highly coor-
dinated water molecules are located instead. The bases of sub-
strate molecules are coordinated by a network of polar and
stacking interactions (Figure 3B) that correctly position the sub-
strate. In particular, the 30-base (site B) is stacked by His-160 and
the loop comprising residues 154–160 closes the active site
pocket. The 50-base (site A) stacks on top of the GGG stretch
sheets (b10 and b11; Figure 3B). In good agreement with SPR
and ITC data showing different thermodynamic parameters for
50-pApG and 50-pApA binding, we can identify differences in
the base stabilization in the structures. The guanine base forms
additional interactions compared with the adenine substrate;
Arg-243 of the DHHA1 domain contacts O6 and Asn-162 con-
tacts N2 of the base (Figure S3D). These additional guanine-spe-
cific interactions manifest in both (1) slightly tighter KD values for
the binding of 50-pApG and 50-pGpG compared with 50-pApA,
and (2) a lower turnover (higher KM) for the 5
0-pApG substrate,
indicating either a lower overall activity or a slower rate of sub-
strate-product exchange.4Post-reactive State Formation and Product Release
(Products I–III)
Directly after the phosphodiester bond cleavage of the 50-pApA
substrate, two molecules of AMP are present in the active site
(product state I, Figure 3D). The 50-phosphate of the nucleotide
in site B has moved up, consistent with the directionality of the
SN2-reaction carried out by the activated water WAT1. In the
next step (product state II, Figure 3E), only the AMP moiety in
site A remains present in the binding cleft, kept in position by
the GGG stretch, whereas the nucleotide from site B has already
been released from the cleft. The 50-phosphate of molecule A is
tightly bound by His-263 and Arg-267 in the DHHA1 domain.
The base is stacked by Arg-86 (DHH domain) and Thr-293
(DHHA1 domain) and is located on the surface of the GGG/
AAA-stretch motif of the DHHA1 domain (b10 and b11). The anal-
ogous situation resulting from 50-pGpG-cleavage can be seen in
Figure 3F, where only the GMP remained bound in site A (product
state III). Of note, our AMP structure contains three Mn2+ ions in
the active site. Two of them (Mn2+ 1, Mn2+ 2) are in good agree-
ment with structures of DHH/DHHA1 enzymes described above
and also in (Srivastav et al., 2014). In contrast, Mn2+ 3 is less co-
ordinated (sugar 20 and 30-OH, His-105, His-286), and has a lower
occupancy in the structure. We assume that the third Mn2+ ion is
bound in the active site due to the high Mn2+ concentration in the
crystallization conditions and thus has no physiological relevance.
Conclusion
The structural and biochemical data provide a mechanistic
framework for the phosphodiesterase activity of T. maritima
PDE (summarized in Figure 4A). After high-affinity binding of
the linear dinucleotide substrate to the ligand-free catalytic
site, the phosphodiester bond is hydrolyzed in a SN2 reaction
by an activated water molecule resulting in two NMPs. The
nucleotide in position B leaves the cleft prior to the one in
site A, and the active site is then ready for the next cycle. The re-
ported structures and biophysical data for TmPDE and SpPde2
suggest that linear dinucleotides are the main substrate for the
soluble DHH-type PDEs and supports the idea of a two-step
degradation of c-di-AMP in bacteria.
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Bacterial and Virus Strains
E. coli BL21 (DE3) Rosetta (expression strain) Novagene
T. maritima MSB8 (used for genomic DNA prep.) DSMZ; DSM 3109 https://www.dsmz.de/
B. subtilis subsp. subtilis DSMZ; DSM 402 https://www.dsmz.de/
used for colony PCR
S. pneumoniae DSMZ; DSM 11865 https://www.dsmz.de/
genomic DNA used for PCR
Chemicals, Peptides, and Recombinant Proteins
50-pApA Biolog Cat #P 033
50-pApG Biolog Cat #P 082
50-pGpG Biolog Cat #P 023
c-di-AMP Biolog Cat #C 088
c-di-GMP Biolog Cat #C 057
AMP Sigma-Aldrich Cat #A1752-1G
Deposited Data
TmPDE pre-reaction state (apo) This paper PDB 5O25
TmPDE D80ND154N + 50-pApA This paper PDB 5O4Z
TmPDE D80ND154N + 50-pApG This paper PDB 5O58
TmPDE D80ND154N + pA : pA This paper PDB 5O70
TmPDE D80ND154N + GMP/Mn2+ This paper PDB 5O7F
TmPDE AMP/Mn2+ This paper PDB 5O1U
SAXS data (TmPDE wildtype) This paper SASBDB SASDCD7
SAXS data (TmPDE D80N D154N) This paper SASBDB SASDCC7
SAXS data (SpPde2) This paper SASBDB SASDCB7
Oligonucleotides
RNA sequence: 50-pApApA_ligand: AAA Metabion N/A
Primers for cloning, see Table S1 Metabion N/A
Recombinant DNA
Plasmid: pET-M11-SUMO1 EMBL Heidelberg N/A
Software and Algorithms
XDS/XSCALE (Kabsch, 2010) http://xds.mpimf-heidelberg.mpg.de/
SHELX CDE (Sheldrick, 2010) http://shelx.uni-ac.gwdg.de/SHELX/
HKL2MAP (Pape and Schneider, 2004) http://webapps.embl-hamburg.de/
hkl2map/
PHENIX suite (Adams et al., 2010) https://www.phenix-online.org/
CCP4 suite (Winn et al., 2011) http://www.ccp4.ac.uk/
PHASER (McCoy et al., 2007) (included in CCP4 and PHENIX)
PyMOL (Schrodinger, 2015) https://www.pymol.org/
SWISS-MODEL (Biasini et al., 2014) https://swissmodel.expasy.org/interactive
UCSF Chimera (Pettersen et al., 2004) https://www.cgl.ucsf.edu/chimera/
ATSAS (includes CRYSOL) (Franke et al., 2017) https://www.embl-hamburg.de/biosaxs/
software.html
PEAQ-ITC Analysis Software Malvern Provided with the instrument
(Continued on next page)
e1 Structure 25, 1887–1897.e1–e4, December 5, 2017 48
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Biacore X100+ Data Evaluation Software GE Lifesciences Provided with the instrument
Origin Pro OriginLabs http://www.originlab.de/
Other
Columns (IEX, SEC, Affinity) GE Healthcare Life Sciences http://www.gelifesciences.com/webapp/
wcs/stores/servlet/Home/en/
GELifeSciences-de/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Gregor
Witte (witte@genzentrum.lmu.de)
METHOD DETAILS
Experimental Model and Subject Details
B. subtilis subsp. subtilis (DSM 402) and T. maritima MSB8 (DSM 3109) cells were purchased from the DSMZ (Germany) and used
either for genomic DNA preparation or directly for colony PCR. S. pneumoniae (DSM 11865) genomic DNA was purchased from
DSMZ (Germany).
Cloning, Expression and Purification
T. maritima PDE (TM_1595), S. pneumoniae Pde2 (SPD_1153), B. subtilis GdpP-DTM (GdpP without transmembrane part) and
B. subtilis GdpP-DHH/DHHA1 (active site domains only) were cloned into separate pET28 M11 SUMO1 vectors (EMBL Hei-
delberg) via the AgeI/NotI for the first or BamHI/NotI for the latter constructs restriction sites, respectively. A GSG-linker was
introduced in between the SenP2 cleavage-site and the start of the TmPDE gene to facilitate tag cleavage. Recombinant
expression of all proteins containing a His6-SUMO tag was performed in E. coli Rosetta BL21(DE3) after induction with
0.2 mM IPTG (for TmPDE and BsuGdpP) or 0.1 mM IPTG (for SpPde2) at 18C. Cells were harvested after 18 hours and lysed
in buffer A (50 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole, 5% v/v glycerol, pH 7.5) by sonication. After clarification of the
lysate by centrifugation, the supernatant was loaded onto a Ni-NTA column (Qiagen). The column was washed with buffer
A and followed by buffer B (50 mM Tris-HCl, 300 mM NaCl, 30 mM imidazole, 5% v/v glycerol, pH 7.5) prior to elution of
the proteins with buffer C (50 mM Tris-HCl, 300 mM NaCl, 250 mM imidazole, 5% v/v glycerol, pH 7.5). SenP2 was added
at a ratio of 1:500 (w:w) to TmPDE and SpPde2 in order to cleave the His6-SUMO tag during dialysis into buffer D (20 mM
Tris-HCl, 150 mM NaCl, 5% v/v glycerol, pH 7.5). After separating the tag from the proteins with the aid of a second Ni-col-
umn, TmPDE and SpPde2 were concentrated and loaded onto a HiLoad Superdex 200 column (GE Healthcare) equilibrated
with buffer D. The peak fractions were pooled, concentrated, flash frozen in liquid nitrogen and stored at -80C. TmPDE mu-
tants were created by site-directed mutagenesis using overlap extension PCR. Mutant proteins were expressed and purified
as described for the wild-type protein.
TmPde Crystallization
For determination of the product state structure, TmPDE at a concentration of 10 mg/mL was supplemented with 1 mM MnCl2 and
1 mM AMP. Crystals were grown by hanging-drop vapor diffusion at 20C after mixing 1 mL protein with 1 mL reservoir solution
(0.1 M HEPES-NaOH pH 7.8, 25% w/v PEG4000, 0.2 M CaCl2) with a total reservoir volume of 300 mL. Crystals were cryo-pro-
tected by transfer into mother liquor supplemented with 25% v/v ethylene glycol prior to flash cooling in liquid nitrogen. Crystals of
apo TmPDE were grown similarly, but the protein was concentrated to 15 mg/mL and the reservoir solution contained 0.1 M Tris-
HCl pH 7.5, 25% w/v PEG4000, 0.2 M MgCl2. Cryo-protection was achieved by addition of 25% v/v PEG400 to the reservoir so-
lution. Crystals of the inactive mutant TmPDE D80N D154N with 50-pApA were grown by hanging-drop vapor diffusion with
10 mg/mL protein, 1.5 mM 50-pApA and 1.5 mM MnCl2 and a reservoir solution of 2.2 M ammonium sulfate and 0.1 M sodium
citrate. Crystals were cryo-protected by soaking in reservoir solution supplemented with 25% v/v glycerol. Crystals of the inactive
mutant TmPDE D80N D154N with 50-pApG were obtained by sitting-drop vapor diffusion with 13 mg/mL protein, 1.5 mM 50-pApG
and 5 mM MnCl2 and a reservoir solution of 20% w/v 2-propanol, 0.1 M sodium acetate pH 4.6 and 0.2 M CaCl2. Crystals of the
inactive mutant TmPDE D80N D154N with GMP (product III) were obtained by sitting-drop vapor diffusion with 13 mg/mL protein,
1.5 mM 50-pGpG and 5 mM MnCl2 and a reservoir solution of 30% w/v PEG4000, 0.1 M Tris pH 8.5 and 0.2 M MgCl2. For both the
50-pApG and 50-pGpG complexes cryo-protection was achieved by the addition of 50% v/v ethylene glycol to the reservoir
solution.Structure 25, 1887–1897.e1–e4, December 5, 2017 e249
Data Collection and Processing
Diffraction data of the AMP/Mn2+-TmPDE and apo TmPDE crystals were collected at the EMBL P14 beamline at PETRA III (DESY
Hamburg, Germany). Diffraction data of the TmPDE D80N D154N mutant with 50-pApA were measured at the ESRF ID30A
MASSIF-1 (ESRF Grenoble, France). TmPDE with 2 AMP (product state II) and 50-pApG were collected at the EMBL P13 beamline
at PETRA III (DESY Hamburg, Germany). Diffraction data of the TmPDEmutant crystallized in presence of 50-pGpG (GMP state) were
collected at SLS X06SA (Swiss Light Source, Villigen, Switzerland). All data were indexed and scaled using XDS and XSCALE,
respectively (Kabsch, 2010).
Phasing, Model Building and Refinement
Phaseswere determined by the use of a single anomalous diffraction dataset collected fromTmPDE-AMP/Mn2+ crystals. Identification
of Mn2+ sites, phasing and solvent flattening was performed using SHELXCDE (Sheldrick, 2010) through the HKL2MAPGUI (Pape and
Schneider, 2004). The relatively high resolution allowed automaticmodel buildingwith PHENIX (Adams et al., 2010) followed bymanual
model building in COOT (Emsley and Cowtan, 2004) and automatic refinement in PHENIX (Afonine et al., 2012). The product state III
was phased similarly. The structures of the apo TmPDE and both TmPDE D80N D154N nucleotide complexes were phased by mo-
lecular replacement with PHASER (McCoy et al., 2007) within the CCP4 suite (Winn et al., 2011) using the DHH and DHHA1 domains
as separate search models. Model building and refinement was performed with Coot and PHENIX as described above. All crystallo-
graphic figureswere preparedwith PyMOL (Schrodinger, 2015).Morphing inMovie S1was prepared inChimera (Pettersen et al., 2004)
using the apo state and 50-pApA bound state of TmPDE to illustrate the potential dynamics of the ligand-binding cleft.
Small-Angle X-ray Scattering
Small-angle X-ray scattering experiments were performed at the EMBL P12 beamline at PETRA III (DESY Hamburg, Germany). To
remove potential aggregates, all samples were additionally purified by size-exclusion chromatography and centrifuged prior to mea-
surements. Size-exclusion chromatography coupled SAXS was performed for the TmPDE D80N D154N mutant (Blanchet et al.,
2015; Jeffries et al., 2016). The running buffer of the chromatography step was used as a buffer reference for buffer subtraction of
the protein sample scattering data. Proteins in batch mode were measured at different concentrations and all data sets were
analyzed using the ATSAS software package (Franke et al., 2017) as described in (Mertens and Svergun, 2010; Putnam et al.,
2007). Calculation of theoretical scattering curves from crystal structures was performed using CRYSOL (Svergun et al., 1995). Fig-
ures of ab initiomodels with docked crystal structures were prepared with UCSF Chimera (Pettersen et al., 2004). Scattering data of
SpPde2, wild type TmPDE and TmPDE D80N D154N have been deposited in the SASBDB.
Static Light Scattering
Size-exclusion chromatography coupled light scattering was performed using an A¨KTA micro chromatography system equipped
with a Superdex 200 10/300 Increase column (GE Healthcare Life Sciences) and a right-angle laser light scattering device and refrac-
tive index detector (Malvern/Viscotek). BSA (66 kDa) was used to calibrate the system. Evaluation was performed using theOmniSEC
software (Malvern/Viscotek) provided with the instrument.
Enzymatic Activity Assay
To check the activity of TmPDE and SpPde2 we used a LC-based assay to quantify the reaction products. A 100 mL reaction mix
containing 50 mM Tris pH 8.5, 20 mMKCl, 0.1 mMMnCl2, 62.5-2000 mMc-di-AMP or 5
0-pApA, and 10 nM-10 mMenzyme (monomer
concentration) was incubated at room temperature for 15-60 min. This was then quickly diluted with assay buffer A (50 mM Tris-HCl
pH 9.0) and the nucleotides were separated from the protein by spin concentrators (30 kDa cutoff). 500 mL of the flow-through was
loaded on to aMono Q 5/50 GL column (GE Lifesciences) equilibrated with buffer A (50mM Tris-HCl pH 9.0). A linear gradient to 50%
buffer B (50 mM Tris-HCl pH 9, 1 M NaCl) over 30 column volumes was used to elute the reaction products. The peaks were then
compared to standard nucleotides (AMP, 50-pApA, c-di-AMP). The individual chromatogram peaks were integrated using Origin
(OriginLabs). Please note, for assays shown in Figures 2G, 2J, and S2A–S2D a linear gradient to 35% buffer B over 28 column vol-
umes was used.
Surface Plasmon Resonance
c-di-AMP and 50-pApA binding was analyzed by SPR using a Biacore X100+ as previously described (M€uller et al., 2015b). 5278 RU
TmPDE D80N D154N were coupled to flow cell 2 (FC2) of an activated CM-5 (GE Life sciences) chip using amino reactive EDC/NHS
coupling chemistry. FC1 was only activated and blocked with ethanolamine to serve as a reference for unspecific binding of the an-
alyte to the chip and the reported data therefore correspond to RU(FC2-FC1). Different concentrations of nucleotides in HBS-EP
buffer (150 mM NaCl, 10 mM HEPES-NaOH pH 7.4, 3 mM EDTA, 0.05% v/v surfactant P20) were injected to monitor binding of
c-di-AMP and nucleotide substrates. Data were analyzed using the Biacore X100 Evaluation software. All experiments were repeated
at least once to confirm the robustness of the assay.
Isothermal Titration Calorimetry
ITC data were collected using aMalvern PEAQ-ITC systemwith 20 mMTmPDED80ND154N in HBS-EP buffer in the cell. The respec-
tive nucleotide at a concentration of 200 mM in HBS-EP buffer was titrated into the cell by 19 injections of 2 mL, spaced 150 s apart, ate3 Structure 25, 1887–1897.e1–e4, December 5, 2017 50
25C. Data evaluation was performed with the Malvern software package. All experiments were repeated at least once to confirm the
robustness of the assay.
DATA AND SOFTWARE AVAILABILITY
Coordinates and structure factors have been deposited in the PDB under ID codes 5O25, 5O4Z, 5O58, 5O70, 5O1U, and 5O7F. SAXS
data have been deposited in the SASBDB under ID codes SASDCB7, SASDCC7, and SASDCD7.Structure 25, 1887–1897.e1–e4, December 5, 2017 e451
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Table S1. Primers used in this study, Related to STAR Methods.  
Name Length Orientation Tm [°C] Sequence (5’3’) 
TmPDE_AgeI_GSG_fwd 51 forward 56 TAATAAACCGGTGGATCCGGCTCTGGC
TGGACGAGATCGTCAAAGTGCTC 
TmPDE NotI_rev 35 reverse 60 TAATAAGCGGCCGCTCATCCCCCCAGT
ACGTCTCC 
TmPDE D80N_fwd 33 forward 67 CTTCTTGTGGTGGTCAACGCCTCCTCTC
CCGAC 
TmPDE D80N_rev 33 reverse 69 GTCGGGAGAGGAGGCGTTGACCACCA
CAAGAAG 
TmPDE D154N_fwd 31 forward 64 CTTGGGATCGCAACCAACACAGGGTTT
TTCA 
TmPDE D154N_rev 31 reverse 63 TGAAAAACCCTGTGTTGGTTGCGATCC
CAAG 
SpPdeI_Lys51_BamHI_fwd 33 forward 49 TAATAAGGATCCAAGAAACTGAGAGT
GCATTAT 
SpPdeI_Lys51_NotI_rev 35 reverse 48 TAATAAGCGGCCGCTCATTCTTCTTTCT
CCTTTTC 
SpPdeII_Lys51_BamHI_fwd 33 forward 51 TAATAAGGATCCATGGAGATTTGCCAA
CAAATT 
SpPdeII_Lys51_NotI_rev 35 reverse 47 TAATAAGCGGCCGCTCAGTTTTTAAGC
AAGTTTTT 
BsGdpP_K1_BamHI_F 33 forward 46 TAATAAGGATCCATTGGAATCATGCTTT
TTAAT 
BsGdpP_NotI_R 32 reverse 53 TAATAAGCGGCCGCTCATCTCTGTACG
CCTCC 
GdpP DHH/DHHA1 B.s. C1 
for 
31 forward 63 TAAGGATCCATGGAGAAACGAACAAG
GGTGC 
GdpP DHH/DHHA1 B.s. C1 
rev 
32 reverse 67 TAAGCGGCCGCTCATCTTTGAACCCCTC
CTTC  
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Figure S1. Molecular weight determination of TmPDE wt (and mutant) and SAXS data, 
Related to Figure 1. 
Molecular weight determination by size-exclusion coupled right-angle light scattering. Panel A and B 
show the TmPDE peaks of a run using a 24ml 10/300 S200 increase column (GE Healthcare) and their 
respective molecular weight determined by RALS for wildtype TmPDE (A) and TmPDE D80N D154N 
(B). Both proteins show molecular weights of approx. 70 kDa and thus TmPDE is dimeric in solution 
(the monomer Mw of the construct is 37.8 kDa). The mutation does not change the oligomeric state 
in solution. 
(C) buffer corrected small-angle X-ray scattering curve of a 7 mg/mL S. pneumoniae Pde2 sample 
(D) Guinier plot analysis, data from (C), RG=2.7nm was determined from the slope of the linear 
regression for s*RG<1.3 (Guinier approximation).The sample is free of aggregates as judged from 
linearity of the Guinier region  
(E) final averaged ab initio shape of S. pneumoniae Pde2 calculated from 20 DAMMIF models (NSD 
0.81) with docked TmPDE dimer in two orientations.  
(F) shows the respective residuals of the linear regression of the Guinier plot (D) 
(G) Chromatogram of SEC-coupled SAXS measurements of the TmPDE D80N D154N mutant using a 
Superdex 200 10/300 column. Shown are scattering intensity and radius of gyration (top) and 
absorbance at 280nm (bottom) versus elution volume.  
(H) Averaged and buffer corrected SAXS curve (grey points) derived from the main peak (RG=2.7nm, 
panel B). Also shown is the theoretical scattering curve (red) calculated with CRYSOL (Svergun et al., 
1995) of the “butterfly” shaped TmPDE D80N D154N dimer shown as cartoon model. 
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 Figure S2. IEX experiments and SPR raw data, Related to Figure 2.  
(A) Ion Exchange chromatography on Mono-Q column. From top:  
a) 125 µM c-di-AMP standard; b) 250 µM AMP standard; c) 125 µM 5′-pApA standard; d) Reaction of 
10 nM TmPDE with 125 µM 5′-pApA; e) Reaction of 25 nM SpPde2 with 125 µM 5′-pApA; f) Reaction 
of 10 µM TmPDE with 250 µM c-di-AMP; g) Reaction of 10 µM SpPde2 with 250 µM c-di-AMP. (t=25 
min reaction time at 20 °C). 
(B) Ion exchange chromatography on Mono-Q 5/50 GL column of the reaction products from 100 µL 
reactions with 10 nM TmPDE + 125 µM 5′-pApA after 25 min incubation. 
(C) Ion exchange chromatography on Mono-Q 5/50 GL column of the reaction products from 100 µL 
reactions with 10 nM TmPDE + 125 µM 5′-pGpG after 25 min incubation. 
(D) Ion exchange chromatography on Mono-Q 5/50 GL column of the reaction products from 100 µL 
reactions with 10 nM TmPDE + 125 µM 5′-pApG after 25 min incubation. 
(E) SPR measurements of TmPDE D80N 154N mutant (on chip) with injections of 8 – 1000 µM c-di-
GMP analyte concentrations. 
(F) SPR measurements of TmPDE D80N 154N mutant (on chip) with injections of 8 – 1000 µM 5′-
pApG analyte concentrations. 
(G) SPR measuremenst of TmPDE D80N 154N mutant (on chip) with injections of 8 – 1000 µM 5′-
pGpG analyte concentrations. 
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Figure S3. Detailed view on the active site of TmPDE, Related to Figure 3.  
(A) Active site of TmPDE D80N D154N shown in cartoon representation, DHH domain (light blue) and 
DHHA1 domain (grey) with hydrolyzed 5′-pApA (i.e. 2 AMP in red) and anomalous difference map 
(yellow) shown at 3.7σ contour level clearly defining the phosphate positions.  
(B) Active site of TmPDE D80N D154N shown in cartoon representation, DHH domain (light blue) and 
DHHA1 domain (grey) with hydrolyzed 5′-pApA (2 AMP, red) and the respective Polder map (dark 
blue) shown at 4σ contour level. 
(C) Close-up view on the active site of TmPDE D80N D154N shown in cartoon representation, DHH 
domain (light blue), DHHA1 domain (grey), with interacting residues and 5′-pApG shown as sticks, 
water molecules as red crosses and manganese ions (purple) as spheres. Distances are given in Å and 
shown as dashed lines (yellow).  
(D) Active site superposition of TmPDE D80N D154N with 5′-pApA and 5′-pApG, respectively. TmPDE 
is shown in cartoon representation, DHH domain (light blue), DHHA1 domain (grey), with interacting 
residues, 5′-pApA (cyan) and 5′-pApG (orange) shown as sticks, water molecules as red crosses and 
manganese ions (purple) as spheres. 
(E) Overall structure superposition of the modelled GdpP DHH/DHHA1 domains (green, based on the 
TmPDE D80N D154N structure with 5′-pApG as template using SWISS-MODEL) and the template. 
Protein structures are shown in cartoon representation, TmPDE DHH domain (light blue), DHHA1 
domain (grey) and 5′-pApG (orange) shown as sticks. 
(F) Active site close-up of the superposition of the modelled GdpP DHH/DHHA1 domain (green) and 
TmPDE D80N D154N (with 5′-pApG) illustrate a potential clash between L191 and N314 (site B) of the 
GdpP-model and the second base of the ligand.  
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2. C-di-AMP hydrolysis by a novel phosphodiesterase is crucial for 
differentiation of antibiotic-producing bacteria (submitted) 
 
Latoscha, A.*; Drexler, D. J.*, Al-Bassam, M. M.; Kaever, V.; Findlay, K. C.; Witte, G.; 
Tschowri, N. C-di-AMP hydrolysis by a novel phosphodiesterase is crucial for differentiation of 
antibiotic-producing bacteria. (submitted) (online on bioRxiv) 
*: equal contribution 
DOI: https://doi.org/10.1101/789354 
URL: https://www.biorxiv.org/content/10.1101/789354v1 
 
This publication describes the effects of c-di-AMP levels in S. venezuelae, including the 
identification and characterization of a novel phosphodiesterase for c-di-AMP degradation. The 
hydrolysis of c-di-AMP is unclear in species that lack all of the so far identified c-di-AMP 
specific phosphodiesterases. The herein identified PDE, termed AtaC, is mainly present in 
Actinobacteria and contributes to the understanding of c-di-AMP degradation in many species. 
AtaC was shown to hydrolyze c-di-AMP and 5′-pApA specifically in high turnover rates. A 
manganese-dependent reaction mechanism was elucidated based on binding analysis and 
mutational approaches. In addition, right-angle light scattering and small-angle x-ray scattering 
data indicate AtaC to be a monomer in solution. The deletion of AtaC in S. venezuelae revealed 
significantly increased c-di-AMP levels, which confirmed the physiological relevance of AtaC. 
Furthermore, this mutation leads to delayed growth and sporulation defects. In contrast, the 
deletion of the c-di-AMP synthase DisA results in altered growth only under high salt conditions, 
which indicates an important role of c-di-AMP on osmolyte homeostasis.  
 
Author contribution 
The author of the present thesis expressed and purified AtaC for structural and biochemical 
analysis. He performed ion exchange chromatography activity assays to describe the substrate 
specificity. Furthermore, he analyzed manganese binding using differential scanning fluorimetry. 
In addition, he constructed an inactive mutant of AtaC based on structure prediction analysis. He 
described the binding affinity of c-di-AMP to this AtaC mutant by isothermal titration calorimetry 
and differential scanning fluorimetry. To elucidate the monomeric state of AtaC, he performed 
right-angle light scattering and small-angle x-ray scattering. He supported A. Latoscha, N. 
Tschowri and G. Witte in writing the manuscript. 
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ABSTRACT 25 
Antibiotic-producing Streptomyces use the diadenylate cyclase DisA to synthesize the 26 
nucleotide second messenger c-di-AMP but the mechanism for terminating c-di-AMP signaling 27 
and the proteins that bind the molecule to effect signal transduction are unknown. Here, we 28 
identify the AtaC protein as a new type of c-di-AMP-specific phosphodiesterase that is also 29 
conserved in pathogens such as Streptococcus pneumoniae and Mycobacterium tuberculosis. 30 
AtaC is monomeric in solution and binds Mn2+ to specifically hydrolyze c-di-AMP to AMP via 31 
the intermediate 5’-pApA. As an effector of c-di-AMP signaling, we characterize the RCK-32 
domain protein CpeA as the first c-di-AMP-binding protein to be identified in Streptomyces. 33 
CpeA interacts with the predicted cation / proton antiporter, CpeB, linking c-di-AMP signaling 34 
to ion homeostasis in actinobacteria. Hydrolysis of c-di-AMP is critical for normal growth and 35 
differentiation in Streptomyces, connecting osmotic stress to development. Thus, we present 36 
the discovery of two novel components of c-di-AMP signaling in bacteria and show that precise 37 
control of this second messenger is essential for osmoregulation and coordinated development 38 
in Streptomyces. 39 
 40 
 41 
 42 
 43 
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INTRODUCTION  45 
Bacteria use mono-, di-, and trinucleotides as second messengers to control fundamental 46 
physiological functions in response to signal sensing (1). Among these molecules, cyclic di-47 
3´,5´-adenosine monophosphate (c-di-AMP) is the only nucleotide messenger that must be 48 
precisely balanced, since both, its depletion and overproduction can be toxic (2). Its core 49 
function is to control cellular integrity by setting homeostasis of osmolytes that in many bacteria 50 
are used for osmoregulation (3, 4). Changes of external osmolarity trigger water fluxes across 51 
the membrane, which can lead to cell dehydration or swelling and finally collapse or burst when 52 
osmobalance mechanisms fail to respond properly (5). As a key component of these 53 
mechanisms, c-di-AMP directly targets transport systems for osmoactive and osmoprotective 54 
substances such as potassium ions and low-molecular-weight compatible solutes in many 55 
bacteria (6-10).  56 
c-di-AMP also plays a central role in host-pathogen interactions and bacterial virulence 57 
(11). Secreted c-di-AMP is recognized by host’ innate immunity receptors STING, DDX41 and 58 
RECON to regulate type I interferon immune response and NF-kB pathways, respectively (12-59 
15). Modulation of intracellular c-di-AMP has been reported to affect virulence of 60 
Streptococcus pyogenes (16), Listeria monocytogenes (17), Streptococcus pneumonia (18) and 61 
Mycobacterium tuberculosis so that the molecule is considered as an attractive antimicrobial 62 
target (19).  63 
c-di-AMP synthesis out of two ATP molecules is catalyzed by the diadenylate cyclase 64 
(DAC) activity of the DisA_N domain (Pfam PF02457), which was identified in the structural 65 
and biochemical analysis of the DNA-integrity scanning protein A (DisA) of Thermotoga 66 
maritima (20). DisA is mainly present in sporulating firmicutes and actinobacteria (21) and has 67 
a conserved domain organization consisting of a N-terminal DAC domain and a C-terminal 68 
DNA-binding helix-hairpin-helix domain separated by a linker region (20). C-di-AMP 69 
hydrolysis is mediated by the DHH-DHHA1 domain containing the Asp-His-His motif. The 70 
multidomain membrane-associated GdpP protein in Bacillus subtilis was the first characterized 71 
DHH-DHHA1-type phosphodiesterase (PDE) (22). In addition, HD domains with a catalytic 72 
His-Asp motif, which were first identified in the PgpH protein in L. monocytogenes, also 73 
degrade c-di-AMP (17).  74 
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However, most actinobacteria contain DisA for c-di-AMP synthesis but do not encode 75 
DHH-DHHA1-domain containing or HD-type c-di-AMP PDEs. Hence, we wondered how 76 
actinomycetes balance intracellular c-di-AMP. Within actinobacteria, Streptomyces are the 77 
most extensively studied mycelial organisms and the richest natural source of antibiotics (23). 78 
For growth and reproduction, Streptomyces undergo a complex developmental life cycle, which 79 
involves the conversion between three morphologically and physiologically distinct forms of 80 
cell existence. During exponential growth, they proliferate by extension and branching of 81 
vegetative hyphae. The switch to stationary phase and onset of the reproductive phase is marked 82 
by the erection of aerial hyphae. These filaments elongate and divide into unigenomic prespore 83 
compartments that ultimately mature into chains of spores. Completion of the developmental 84 
program is easily visible by eye since mature Streptomyces spores accumulate a spore pigment. 85 
For example, our model species, the chloramphenicol producer S. venezuelae, is characterized 86 
by a green spore pigment such that colonies turn green at the end of the life cycle (24, 25). 87 
Importantly, antibiotic production and morphological differentiation are co-regulated in 88 
Streptomyces. Hence, studying their developmental biology also provides a better 89 
understanding of the control of their secondary metabolism. 90 
In this work, we identified and characterized the PDE superfamily protein AtaC as the 91 
founding member of a novel type of c-di-AMP-specific hydrolases. AtaC is broadly distributed 92 
in bacteria and the only known c-di-AMP PDE in most actinomycetes. Among others, 93 
pathogens such as the causative agent of pneumonia, S. pneumoniae, contain an AtaC homolog 94 
that we characterize here to be a functional c-di-AMP hydrolase. Our biochemical and structural 95 
analyses show that AtaC is a monomeric Mn2+-dependent PDE with high affinity for c-di-AMP. 96 
Moreover, we provide direct biochemical evidence that Streptomyces DisA is an active DAC 97 
and that c-di-AMP produced by DisA is crucial for survival under ionic stress conditions. 98 
Further, we show that accumulation of c-di-AMP in the S. venezuelae ataC mutant results in 99 
profound developmental and growth defects and report the identification of the RCK_C-domain 100 
(RCK for regulator of conductance of K+) containing protein CpeA as the first c-di-AMP 101 
binding protein in Streptomyces. Overall, in this study we identified and functionally 102 
characterized core components of c-di-AMP signaling in Streptomyces and link c-di-AMP 103 
regulation with ion homeostasis to control differentiation in multicellular bacteria. 104 
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5 
RESULTS  105 
 106 
DisA is the major c-di-AMP synthetase in S. venezuelae 107 
 108 
DisA is the sole DAC protein encoded in the S. venezuelae genome and is conserved in all 109 
sequenced Streptomyces strains. To demonstrate DisA DAC activity, we purified N-terminally 110 
his-tagged DisA and DisAD86A that carries an alanine instead of aspartate in the active site. We 111 
included his-tagged B. subtilis DisA (DisABsu) as a positive control for enzymatic activity (20). 112 
[32P]-labeled ATP was added as substrate for in vitro DAC assays and the reactions were 113 
separated by thin layer chromatography (TLC). DisA synthesized c-di-AMP whereas the 114 
mutated DisAD86A failed, demonstrating that S. venezuelae DisA is a functional DAC, which 115 
requires the conserved catalytic aspartate D86 for activity (Figure 1A). 116 
  In vivo, DisA is the major source for c-di-AMP in S. venezuelae (Figure 1B) (26), 117 
however, we reproducibly detected low c-di-AMP levels in ΔdisA during vegetative growth (10 118 
and 12 h), which disappeared upon onset of sporulation (14 h), suggesting that S. venezuelae 119 
might contain a non-DAC-domain enzyme capable of c-di-AMP production (Figure 1B). The 120 
presence of c-di-AMP throughout the wild type S. venezuelae life cycle suggested that disA 121 
expression is constitutive. To confirm this, we complemented the disA mutant by chromosomal 122 
insertion of a C-terminally 3xFLAG-tagged disA under control of its native promoter. Using a 123 
monoclonal anti-FLAG antibody, we detected constant DisA-3xFLAG expression in all 124 
developmental stages, which correlated with c-di-AMP production in the wild type under the 125 
conditions tested (Figure 1C).  126 
Altogether, our data show that DisA is a functional DAC in vitro and in vivo and the 127 
major enzyme for c-di-AMP production in S. venezuelae.  128 
 129 
The phosphodiesterase superfamily protein AtaC (Vnz_27310) degrades c-di-AMP 130 
 131 
Streptomycetes do not possess PDEs with a DHH-DHHA1 domain or a PgpH-type HD domain, 132 
known to degrade c-di-AMP in other bacteria (17, 22), raising the question as to how S. 133 
venezuelae removes c-di-AMP from the cytoplasm. To find a potentially novel c-di-AMP PDE, 134 
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6 
we used interproscan (http://dx.doi.org/10.7717/peerj.167) to search for Pfam PF01663, which 135 
is associated with putative type I phosphodiesterases/nucleotide pyrophosphatases. Among 136 
others, we found two proteins (Vnz_27310 and Vnz_31010) belonging to the phosphodiesterase 137 
and metallophosphatase superfamilies, respectively, that we selected for in vitro PDE activity 138 
tests. 139 
 Purified N-terminally his-tagged Vnz_27310 and Vnz_31010 were assayed in vitro 140 
using [32P]-labeled c-di-AMP as substrate. While we could not detect [32P]-c-di-AMP cleavage 141 
activity for Vnz_31010, Vnz_27310 clearly degraded c-di-AMP to 5′-pApA and finally to AMP 142 
(Figure 2A) so that we named Vnz_27310 AtaC for actinobacterial PDE targeting c-di-AMP. 143 
Addition of unlabeled c-di-AMP but not of c-di-GMP or cAMP competed with [32P]-c-di-AMP 144 
and led to reduced cleavage of the radiolabeled substrate, showing specificity for c-di-AMP 145 
(Figure 2A). We analyzed the kinetics of c-di-AMP hydrolysis activity of Vnz_27310 using 146 
anion exchange chromatography assays and determined a kcat of 0.2 s-1 (Figure S1 A-B), while 147 
only a negligible c-di-GMP hydrolysis activity was detected (Figure S1 C). We also compared 148 
Vnz_27310-dependent hydrolysis of the linear dinucleotides 5′-pApG and 5′-pGpG to the 149 
hydrolysis of 5′-pApA and observed a high hydrolysis activity for 5′-pApA (kcat= 2.1 s-1), 150 
whereas the other substrates tested were only degraded to a small extent (Figures 2B and S1 D-151 
F). 152 
 Using the PATRIC database (https://www.patricbrc.org), we examined the distribution 153 
of the here discovered c-di-AMP PDE (PGF_00172869) and found at least 5374 prokaryotic 154 
species containing homologs to AtaC (Table S2), including pathogens such as S. pneumoniae 155 
and M. tuberculosis. AtaC from S. pneumoniae (AtaCSPN; sequence ID: CVN04004.1) and from 156 
M. tuberculosis (AtaCMTU; sequence ID: CNE38097.1) share 41 % and 47 %, respectively, 157 
identical residues with AtaC from S. venezuelae. In agreement with the high degree of protein 158 
identity, enzyme assays data shown in Figure 2C demonstrate that AtaCSPN also represents a c-159 
di-AMP PDE and AtaCMTU likely has the same function. 160 
In summary, we identified and functionally characterized the sole c-di-AMP hydrolase 161 
in Streptomyces and a new c-di-AMP signaling component in pathogens and show that AtaC is 162 
a conserved phosphodiesterase that efficiently and specifically hydrolyzes c-di-AMP to AMP 163 
via the intermediate 5′-pApA.  164 
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7 
 165 
AtaC is a monomeric Mn2+-dependent phosphodiesterase 166 
 167 
To further characterize the c-di-AMP hydrolysis mechanism of AtaC and to gain some 168 
structural insights into this PDE, we used HHpred (27) and found two close structural 169 
homologs. The core domain of a phosphonoacetate hydrolase (PhnA) from Sinorhizobium 170 
meliloti 1021 (28) and PDB code 3SZY) showed highest similarity and served as a template for 171 
the structural model of AtaC including the putative active site. The predicted active site 172 
comprises three aspartates (D68, D227 and D269), three histidines (H231, H270 and H384) and 173 
one threonine (T108) (Figure 3A). 174 
Our size-exclusion chromatography (SEC) coupled multi-angle laser light scattering 175 
(MALLS) data show that AtaC is a monomer in solution with a molecular weight of 43.7 kDa 176 
(Figure S2A). The calculated ab initio shape of AtaC from SEC-SAXS (size-exclusion coupled 177 
small-angle X-ray scattering) data superimposes well with the HHpred model structure (Figure 178 
3B) and the measured SAXS curve of AtaC is very similar to the theoretical scattering curve of 179 
PhnA (Figure S2 B-D), indicating that AtaC and PhnA have a similar shape in solution.  180 
The enzymatic reaction of the PhnA-class hydrolases is known to be catalyzed by two 181 
metal ions in the active site (28) so we tested metal binding for AtaC by thermal unfolding 182 
assays using nano differential scanning fluorimetry (nanoDSF) assay and observed protein 183 
stabilization upon addition of manganese ions (Mn2+) (Figure 3C). Based on the structural 184 
similarity to PhnA, we identified potential metal-binding residues in AtaC and generated a 185 
variant, AtaCD269N, that we expected to lack Mn2+ coordination but retain nucleotide binding, 186 
as shown for DHH-DHHA1-type PDEs (22, 29). NanoDSF data confirmed stability of 187 
AtaCD269N with a melting temperature comparable to the wild type protein when incubated with 188 
ethylenediaminetetraacetic acid (EDTA) (Figure 3D). Moreover, AtaCD269N behaved 189 
identically to the wild type protein during purification and final SEC. In line with our 190 
predictions, AtaCD269N failed to bind Mn2+ (Figure 3E) and did not hydrolyze c-di-AMP, as 191 
shown using ion exchange chromatography (IEX) based assays (Figure S3A). However, 192 
AtaCD269N was still capable of c-di-AMP binding, as confirmed by nanoDSF experiments that 193 
showed a shift in the melting curve with increasing ligand concentration (Figure 3F). Using 194 
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8 
isothermal titration calorimetry (ITC) analysis we determined the dissociation constant (Kd) of 195 
AtaCD269N for c-di-AMP to be 731 ± 266 nM, whereas binding of c-di-GMP could not be 196 
detected (Figures 3G-H, and Figure S3B).  197 
Altogether, our combined structural analysis and biochemical data strongly suggest that 198 
AtaC uses the same metal-ion dependent mechanism as its structural homolog PhnA for 199 
substrate cleavage.  200 
 201 
AtaC hydrolyzes c-di-AMP in vivo 202 
 203 
We quantified c-di-AMP in cell extracts isolated from wild type S. venezuelae and the 204 
ataC null mutant using LC-MS/MS. Our data show that c-di-AMP levels are elevated in the 205 
ataC mutant during all developmental stages when compared to the wild type, demonstrating 206 
that AtaC degrades c-di-AMP in vivo and thus is an important component of c-di-AMP 207 
metabolism in S. venezuelae (Figure 4A). Western blot analysis showed that AtaC is 208 
constitutively expressed across the developmental cycle (Figure 4B). 209 
 210 
Inactivation of AtaC delays S. venezuelae development 211 
 212 
To investigate the physiological functions of disA and ataC and thus of c-di-AMP in S. 213 
venezuelae, we first analyzed the developmental phenotypes of mutant strains. Colonies of S. 214 
venezuelae ΔdisA became green (Figure 5A) and scanning electron microscopy (SEM) 215 
confirmed that the ∆disA mutant produced spore chains with identical morphology to those of 216 
the wild type (Figure 5B). Thus, neither the DisA protein nor the c-di-AMP produced by DisA 217 
is required for differentiation.  218 
In contrast, the ataC mutant showed a severe delay in development. After 4 days, the 219 
ΔataC strain developed aerial hyphae but did not turn green as the wild type (Figure 5A) and 220 
SEM imaging showed mainly undifferentiated aerial hyphae, in contrast to the fully sporulated 221 
hyphae seen in the wild type (Figure 5B). Moreover, many of the aerial hyphae of the ∆ataC 222 
mutant had lysed. After extended incubation (7 days), the aerial hyphae of the ∆ataC mutant 223 
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9 
had largely sporulated, with sporadic non-differentiated and lysed filaments still detected 224 
(Figure 5B).  225 
The lysed hyphae seen in the SEMs led us to analyze the growth the ∆ataC strain in 226 
liquid MYM. As shown in Figure 5C, the ataC mutant grew slower than the wild type in 227 
exponential phase but reached a similar final OD578 after 20 hours. Notably, deletion of disA 228 
had no effect on growth (Figure 5C).  229 
We could fully complement the defects of ∆ataC in development and growth by 230 
introduction of the ataC wild type allele under the control of its native promoter from the 231 
pIJ10170 vector (30) that integrates into the chromosomal attBΦBT1 site (Figure 5A and S4A). 232 
In contrast, expression of the ataCD269N, which cannot cleave c-di-AMP (Figure S3A) from the 233 
same integrative vector did not restore the developmental defects caused by ataC deletion 234 
(Figure 5A), showing that the cleavage of c-di-AMP by AtaC is crucial for normal development 235 
of Streptomyces. 236 
Altogether, these results demonstrate that elevated levels of c-di-AMP impair growth 237 
and development, whereas reduced levels of c-di-AMP do not affect differentiation under 238 
standard growth conditions.  239 
 240 
disA mutant is more susceptible to ionic osmostress  241 
 242 
Since regulation of osmotic balance is a major function of c-di-AMP in many bacteria 243 
(3), we next investigated the osmotic stress resistance of strains with altered c-di-AMP levels 244 
due to mutations in either ataC or disA. We spotted serially diluted spores on nutrient agar (NA) 245 
medium plates supplemented with 0.5 M NaCl and a control plate without extra added NaCl. 246 
On both plates, the growth of the ∆ataC strain was slightly impaired resulting in smaller colony 247 
size compared to the wild type (Figure 5D), which likely reflects the growth defect of this strain 248 
(Figure 5C). We complemented the growth phenotype of ∆ataC with the ataC wild type allele 249 
expressed in trans from the integrative vector pIJ10170 from the attBΦBT1 site under the control 250 
of the native promoter (Figure 5D). 251 
 In contrast, when grown on NA plates containing 0.5 M NaCl, ΔdisA and disAD86A 252 
showed pronounced reduction in growth. Expression of wild type disA from pIJ10170 fully 253 
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10 
complemented the growth defect of ΔdisA (Figure 5D). The identical ΔdisA and disAD86A 254 
phenotypes demonstrate that c-di-AMP produced by DisA is crucial for osmotic stress 255 
resistance in S. venezuelae (Figure 5D). 256 
In summary, our data revealed that accumulation of c-di-AMP due to ataC inactivation, 257 
delays development and slows down Streptomyces growth in the exponential phase. On the 258 
other hand, depletion of c-di-AMP due to disA inactivation renders S. venezuelae highly 259 
susceptible to ionic osmostress. 260 
 261 
The RCK_C domain protein CpeA (Vnz_28055) binds c-di-AMP 262 
 263 
RCK_C domains are established direct targets of c-di-AMP that have the 264 
I(L)I(L)X2DX1RX5NI(L)I(L) signature for ligand binding (Figure 6A) (31). We found the 265 
RCK_C-domain protein Vnz_28055 with a putative c-di-AMP binding motif (Figure 6A-B) in 266 
93 Streptomyces species for which complete genome sequences are available (32). We purified 267 
N-terminally His-tagged Vnz_28055 and applied differential radial capillary action of ligand 268 
assay (DRaCALA) to probe interaction between Vnz_28055 and c-di-AMP. DRaCALA allows 269 
visualization of protein-bound radiolabeled ligand as a concentrated ring after the application 270 
of the protein-ligand mixture onto nitrocellulose (33). With this assay, we confirmed that 271 
Vnz_28055 binds [32P]-labeled c-di-AMP (Figure 6C). Excess unlabeled c-di-AMP but not c-272 
di-GMP competed with [32P]-c-di-AMP for binding to Vnz_28055. Thus, we identified 273 
Vnz_28055 as the first c-di-AMP binding protein in the genus Streptomyces.  274 
 Vnz_28055 forms a conserved operon with vnz_28050. Some Streptomyces species, 275 
such as S. venezuelae, contain the small open reading frame vnz_28045 in the same operon 276 
(Figure 6B). Vnz_28050 is a structural homolog of the sodium/proton antiporter NapA (PDB 277 
code 5BZ3_A) from Thermus thermophilus (34), as predicted with 100 % probability using 278 
HHpred (27). To test whether Vnz_28055 and Vnz_28050 form a functional interacting unit, 279 
we used a bacterial two-hybrid system in which an interaction between bait and target protein 280 
reconstitutes a functional adenylate cyclase (Cya), that allows a E. coli ∆cya mutant to utilize 281 
maltose as a carbon source (35). The two proteins were found to form a complex (Figure 6D), 282 
supporting our model that c-di-AMP controls the transport activity of Vnz_28050 by binding 283 
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11 
to its interaction partner Vnz_28055. Thus, we connect the c-di-AMP function to ionic balance 284 
in Streptomyces and renamed Vnz_28055-28045 to CpeABC for cation proton exchange 285 
component A, B and C. 286 
 287 
DISCUSSION  288 
 289 
In this work, using the chloramphenicol-producer S. venezuelae as a model and a combination 290 
of bioinformatic, biochemical, structural and genetic analyses, we identified AtaC as a novel 291 
class of c-di-AMP specific PDEs. AtaC is widely distributed in bacteria and represent the only 292 
c-di-AMP PDE in the majority of actinobacteria and an up to now unrecognized c-di-AMP 293 
signaling component in pathogens, such as S. pneumoniae (Figure 2 and Table S2).  294 
AtaC is a soluble, single-domain phosphodiesterase superfamily protein that is 295 
monomeric in solution (Figure S2). In solution, AtaC is structurally similar to the alkaline 296 
phosphatase superfamily domain of the C-P bond-cleaving enzyme PhnA from S. meliloti 1021 297 
(Figure 3A) (28). As described for DHH-DHHA1 domain-containing proteins GdpP and DhhP, 298 
and the HD-domain PDE PgpH, AtaC binds Mn2+ to hydrolyze c-di-AMP and we show that 299 
residue D269 participates in metal-ion coordination contributing to the active site formation 300 
(Figure 3C-E) (17, 22, 36). AtaC has a kcat of 0.2 s-1 which is comparable to the reported kcat of 301 
GdpP (0.55 s-1). Hydrolytically inactive AtaCD269N has a dissociation constant of 0.7 µM, which 302 
is highly similar to the Kd of wild type PgpH (0.3 - 0.4 µM) (Figures 3G-H) (17, 22). Since we 303 
determined the AtaC dissociation constant using a protein carrying the D269N mutation lacking 304 
Mn2+-coordination, the Kd value represents a lower limit as the metal ions bound by the wild 305 
type protein likely contribute to c-di-AMP binding. However, while PgpH- and GgdP-type 306 
PDEs hydrolyze c-di-AMP exclusively to the linear 5′-pApA, AtaC cleaves c-di-AMP and the 307 
intermediate product 5′-pApA to AMP, which has also been shown for DhhP-type PDEs 308 
(Figures 2A-B and S1A-B, D) (17, 22, 36). The substrate specificity of AtaC is strictly 309 
dependent on two adenosine bases as it shows only weak hydrolysis activity for 5′-pApG and 310 
5′-pGpG in contrast to the DhhP-type PDE TmPDE, which does not distinguish between 311 
different nucleobases (Figures 2B and S1E-F) (29). 312 
  313 
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12 
 In Streptomyces, AtaC and the DAC DisA are the major regulators of c-di-AMP 314 
(Figures 1B and 4A). However, strikingly, the phenotypes of the ∆ataC and ∆disA mutants with 315 
high and low c-di-AMP, respectively, are not invers. On standard growth medium, elevation of 316 
intracellular c-di-AMP in ∆ataC interferes with growth and ordered hyphae-to-spores 317 
transition, while reduction of the second messenger in ∆disA does not have any noticeable 318 
consequences on these cell functions. On the other hand, when incubated at high external NaCl 319 
concentrations, ∆disA is severely inhibited in growth, whereas ∆ataC grows similarly to the 320 
wild type (Figure 5). We found that the RCK_C-domain protein CpeA senses c-di-AMP signals 321 
by direct binding of the ligand (Figure 6C). CpeA interacts with CpeB (Figure 6), a structural 322 
homolog of the Na+/H+ antiporter NapA from T. thermophilus and a member of the large 323 
monovalent cation / proton antiporter (CPA) superfamily (34). Sodium / proton antiporters exist 324 
in all living cells, where they regulate intracellular pH, sodium levels, and cell volume (37). In 325 
some bacteria, Na+/H+ antiporters use the proton-motive force to extrude sodium out of the cell 326 
and are activated at alkaline pH (38). However, in Staphylococcus aureus, the CPA-family 327 
transporter CpaA has a cytosolic RCK_C domain that binds c-di-AMP to regulate transport 328 
activity (6, 39). Similarly, the regulatory RCK_C-domain proteins KtrA and KtrC bind c-di-329 
AMP to control the activity of the corresponding transport units KtrB and KtrD, respectively 330 
(31). Thus, in agreement with this general concept and our data, we propose that c-di-AMP 331 
binds to the regulatory RCK_C-domain protein CpeA to activate sodium export via CpeB in 332 
Streptomyces. At low c-di-AMP, CpeB is presumably inactive allowing accumulation of toxic 333 
Na+-ions in the cell and leading to growth defects of ∆disA on NaCl containing medium. 334 
However, on the other hand, likely constant activity of CpeB at high c-di-AMP in ∆ataC may 335 
result in continuous proton influx affecting intracellular pH and thus important cellular 336 
functions causing growth and developmental defects. 337 
In summary, in this study we identified AtaC as a new component of c-di-AMP 338 
metabolism in bacteria and uncovered CpeA as the link between c-di-AMP and ion balance in 339 
multicellular actinomycetes.  340 
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13 
MATERIAL AND METHODS  341 
For a full explanation of the experimental protocols, see Extended Experimental Procedures in 342 
Supplemental Information. 343 
Bacterial strains and plasmids 344 
All strains, plasmids and oligonucleotides used in this study are listed in Table S1. Plasmids 345 
and strains were constructed as described in Extended Experimental Procedures. 346 
Protein overexpression and purification 347 
E. coli BL21 (DE3) pLysS and Rosetta (DE3), respectively, were used for protein 348 
overexpression. Cultures were grown in presence of required antibiotics at 37°C and induced 349 
with IPTG in the logarithmic phase and transferred for growth at 16°C overnight. Strains 350 
overexpressing 6xHis-AtaC, 6xHis-AtaCD269N, 6xHis-Vnz_31010, and 6xHis-AtaCSpn were 351 
supplemented with MnCl2 (17). Cultures were harvested and lysed using a FrenchPress and the 352 
proteins were purified via Ni-NTA chromatography. 6xHis-DisA variants and 6xHis-353 
Vnz_28055 were dialyzed twice against 2 L of DisA cyclase buffer (40), and tested PDEs were 354 
dialyzed twice against 2 L PDE buffer with 5-10% glycerol (17) at 4°C. Dialyzed proteins were 355 
stored at -20 °C. For characterization of biophysical properties of 6xHis-AtaC and 6xHis-356 
AtaCD269N, the protein elution was concentrated prior to size exclusion chromatography, flash 357 
frozen in liquid nitrogen and stored at -80°C. 358 
Biochemical characterization of DisA and AtaC variants 359 
Biochemical assays using radioactive-labeled substrates were conducted as described in (32). 360 
For diadenylate cyclase (DAC) assays, 5 µM 6xHis-tagged DisASven, DisAD86A or DisABsu were 361 
incubated with 83 nM [32P]-ATP (Hartmann Analytic) in DisA cyclase buffer. For 362 
phosphodiesterase (PDE) assays, 100 nM 6xHis-AtaC or 8 µM 6xHis-Vnz_31010 were mixed 363 
with 2 nM [32P]-c-di-AMP (Hartmann Analytic, synthesized using purified 6xHis-DisABsu) in 364 
PDE buffer. For competition, 100 µM unlabeled c-di-AMP, c-di-GMP or cAMP were added 365 
on ice prior to starting the PDE reactions with [32P]-c-di-AMP.  366 
Alternatively, enzymatic activity of 6xHis-AtaC and 6xHis-AtaCD269N was detected by 367 
separation of non-labeled reaction products by anion exchange chromatography as described in 368 
(29). Reaction solutions contained 50 mM Tris (pH = 7.5), 20 mM NaCl, 100 µM MnCl2, 62.5 369 
– 2000 µM ligand (c-di-NMP, 5'-pNpN; N = A or G), 100 nM - 10 µM of 6xHis-AtaC and were 370 
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14 
incubated at 37°C for 1 h. The reaction was stopped by separating the reaction products from 371 
the protein by ultrafiltration (Centricon, 30 kDA cutoff). The filtrate was diluted to 500 µl with 372 
running buffer A (50 mM Tris, pH 9) and loaded on a 1 ml Resource™ Q anion exchange 373 
column (GE Healthcare Life Sciences). A linear gradient to 40% running buffer B (50 mM Tris, 374 
1 M NaCl, pH 9) over 20 column volumes (CV) was used to separate the nucleotides. The 375 
product peaks were identified by comparison to nucleotide standards, c-di-NMP, pNpN, N = A 376 
or G obtained from BioLog. 377 
Differential radial capillary action of ligand assay 378 
DRaCALAs were performed using 2 µg of purified 6xHis-CpeA (Vnz_28055) as described in 379 
Roelofs et al 2011 (33) with minor modifications. Purified HD domain of PgpH from L. 380 
monocytogenes (17) fused to an N-terminal GST tag was used as a positive control. For 381 
competition, reactions were supplemented 100 µM of non-labeled c-di-AMP or c-di-GMP prior 382 
to addition of [32P]-c-di-AMP. 383 
Western blotting 384 
For detection of 3xFLAG-tagged DisA, Western blot analysis was performed as described in 385 
(32) using 5 µg total protein of S. venezuelae ∆disA expressing the FLAG-tagged disA allele 386 
from the ՓBT1 integration site under the control of the native promoter. Anti-FLAG primary 387 
antibody (Sigma) and the anti-mouse IgG-HRP (Thermo Fisher Scientific) were used for 388 
detection. AtaC was detected in the wild type strain (10 µg total protein) using polyclonal rabbit 389 
anti-AtaC antiserum as primary antibody (generated by Pineda GmbH using purified 6xHis-390 
AtaC) and donkey anti-rabbit-HRP secondary antibody (GE Healthcare). ECL 391 
chemiluminescent detection reagent (Perkin Elmer) was used for visualization. 392 
c-di-AMP extraction and quantification 393 
The nucleotide extraction protocol from (2) was adapted to Streptomyces. Wild type, ΔdisA and 394 
ΔataC strains were grown in MYM. Samples for c-di-AMP extraction and for determination of 395 
the protein concentration were taken every 2 h after initial growth for 10 h. c-di-AMP was 396 
extracted using acetonitrile/methanol from cells disrupted using the BeadBlaster (Biozym). 397 
Samples were analyzed using LC-MS/MS as described in (2). 398 
Bacterial Adenylate Cyclase Two-Hybrid (BACTH) assays 399 
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15 
BACTH system was used to assay protein-protein interaction of CpeA and CpeB in vivo (35). 400 
Plasmids expressing C-terminal fusions of CpeA and CpeB to T18 and T25 fragments of cyaA 401 
from Bordetella pertussis, respectively, were transformed into E. coli W3110 lacking cya (41). 402 
Co-transformants were spotted on MacConkey agar supplemented with maltose (1%), 403 
ampicillin (100 µg/ml), and kanamycin (50 µg/ml). Red colonies indicate cAMP-dependent 404 
fermentation of maltose which occurs upon direct interactions of the proteins fused to the 405 
otherwise separate adenylate cyclase domains.  406 
Small-angle X-ray scattering  407 
Size-exclusion chromatography coupled small-angle X-ray scattering data (42, 43) for AtaC 408 
were collected at the EMBL Hamburg P12 beamline at PETRA3 (DESY, Hamburg). 409 
CHROMIXS of the ATSAS Suite (44) was used for analysis and processing of the 410 
chromatogram results. In brief, after choosing an appropriate buffer region and averaging of the 411 
respective frames, the protein scattering frames from the elution peak were buffer subtracted 412 
and averaged. The final protein scattering data were then analyzed using the ATSAS suite. The 413 
theoretical scattering curve of the AtaC model derived from HHpred/MODELLER was 414 
obtained using CRYSOL (45). Ab initio models were calculated using DAMMIF and averaged 415 
using DAMAVER as described earlier (29). 416 
Nano differential scanning fluorimetry 417 
Thermal unfolding experiments of AtaC were performed with a Tycho NT.6 instrument 418 
(NanoTemper Technologies). The samples were heated in a glass capillary at a rate of 30 K/min 419 
and the internal fluorescence at 330 nm and 350 nm was recorded. Data analysis, data 420 
smoothing and calculation of derivatives was done using the internal evaluation features of the 421 
Tycho instrument.  422 
Bioinformatic characterization of AtaC and its abundance in prokaryotes 423 
AtaC was identified as a member of the phosphodiesterase family of proteins by annotation of  424 
the S. venezuelae genome with interproscan (version 5.27-66.0; 425 
http://dx.doi.org/10.7717/peerj.167) and searching for proteins harboring type I 426 
phosphodiesterase / nucleotide pyrophosphatase domain (Pfam: PF01663).   427 
Scanning electron microscopy (SEM) 428 
SEM was performed as previously described (46). 429 
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20 
FIGURES WITH LEGENDS 574 
 575 
 576 
Figure 1. DisA is an active diadenylate cyclase in vitro and in vivo.  577 
(A) Thin layer chromatography of diadenylate cyclase (DAC) assay with purified 6xHis-578 
DisASven and 6xHis-DisAD86A, and [32P]-ATP as substrate. Migration of [32P]-ATP in buffer is 579 
shown in lane 1. 6xHis-DisABsu served as positive control for DAC activity.  580 
(B) Intracellular c-di-AMP levels in S. venezuelae wild type and ΔdisA during late vegetative 581 
growth (10 to 12 h), early sporulation (14 to 16 h) and sporulation (from 18 h). Data are 582 
presented as mean of biological replicates ± standard deviation (n=3).  583 
(C) Expression profile of DisA-3xFLAG in a disA mutant complemented with disA-3xFLAG 584 
under control of disA promoter grown in liquid sporulation medium (MYM). DisA-3xFLAG 585 
was detected using a monoclonal anti-FLAG antibody. Wild type served as negative control.  586 
 587 
 588 
 589 
 590 
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 592 
 593 
Figure 2. AtaC is a c-di-AMP-specific phosphodiesterase (PDE).  594 
Thin layer chromatography of PDE assay of AtaC and Vnz_31010 from S. venezueale (A) and 595 
S. pneumoniae (AtaCSPN) (C) with [32P]-c-di-AMP. Radioactively labeled c-di-AMP in buffer 596 
migrates as shown in lane 1. In samples used for competition, unlabeled c-di-AMP, c-di-GMP 597 
or cAMP (indicated by “+”) were added in excess before starting the reaction with [32P]-c-di-598 
AMP.  599 
(B) AtaC activity assay by ion-exchange chromatography runs on a 1 ml Resource Q column 600 
of the reaction products after 1 h incubation from 100 µl reactions containing 100 nM AtaC + 601 
250 µM c-di-AMP, 5′-pApA, c-di-GMP, 5′-pGpG or 5′-pApG (n=3). 602 
  603 
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22 
 604 
 605 
Figure 3. AtaC is a monomeric Mn2+-dependent phosphodiesterase.  606 
(A) Model of AtaC obtained from HHpred/MODELLER (green) superimposed with best match 607 
3SZY (beige), Zoom-In shows the predicted active site, annotated with all most conserved 608 
residues. 609 
(B) Modelled structure from (A) superimposed with the final averaged and filtered ab initio 610 
shape (16 ab initio models averaged) from SEC-SAXS with front view (left) and side view 611 
(right). 612 
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23 
(C) nanoDSF thermal shift first derivative curves of 10µM apo AtaC (black), 10µM AtaC + 0.2 613 
mM MnCl2 (red) and 10µM AtaC + 0.5 mM MnCl2 (blue). 614 
(D) nanoDSF thermal shift first derivative curves of 10 µM AtaC + 1 mM EDTA (black) and 615 
10µM AtaCD269N (red). 616 
(E) nanoDSF thermal shift first derivative curves of 10 µM AtaCD269N (black) and AtaCD269N + 617 
0.5 mM MnCl2 (red). 618 
(F) nanoDSF thermal shift first derivative curves of 10 µM AtaCD269N + c-di-AMP (25 µM - 619 
3200 µM). 620 
(G) ITC measurement raw data of 23 µM AtaCD269N mutant titrated with 231 µM c-di-AMP. 621 
(H) Binding curve and fit of ITC titration of the AtaCD269N mutant with c-di-AMP (KD = 731 ± 622 
266 nM) (n=3). 623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
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 643 
 644 
Figure 4. AtaC hydrolyzes c-di-AMP in vivo and is constitutively expressed during the life 645 
cycle of S. venezuelae. 646 
(A) Intracellular c-di-AMP levels in S. venezuelae wild type and ΔataC during late vegetative 647 
growth (10 to 12 h), early sporulation (14 to 16 h) and sporulation (from 18 h). Data are 648 
presented as mean of biological replicates ± standard deviation (n=3).  649 
(B) Expression profile of AtaC in S. venezuelae wild type grown in liquid sporulation medium 650 
(MYM). AtaC was detected using a polyclonal anti-AtaC antiserum. Protein samples harvested 651 
from ΔataC served as negative control and purified 6xHis-AtaC as positive control, 652 
respectively.   653 
 654 
 655 
 656 
 657 
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 659 
 660 
Figure 5. Mutagenesis of c-di-AMP metabolizing enzymes impacts development and ionic 661 
stress resistance in S. venezuelae. 662 
(A) Green morphologies of S. venezuelae wild type and ∆disA indicate formation of mature 663 
spores after 4 days of growth at 30°C on solid sporulation medium (MYM agar). S. venezuelae 664 
∆ataC fails to accumulate the spore pigment and remains white after the same incubation time. 665 
Wild type ataC allele complements the ∆ataC phenotype but not the enzymatically inactive 666 
variant ataCD269N, when expressed in trans under control of the native promoter. 667 
(B) Scanning electron micrographs showing that after 4 days of incubation on MYM, S. 668 
venezuelae wild type and ∆disA form spores but ∆ataC consists predominantly of non-669 
sporulating aerial hyphae (white arrows) and forms flat, likely lysed hyphae (red arrows). After 670 
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26 
7 days of growth, ∆ataC produced wild type-like spore chains but occasional non-differentiated 671 
and lysed hyphae were still detectable. 672 
(C) Deletion of ataC leads to a growth defect in S. venezuelae. c-di-AMP mutants were grown 673 
in liquid sporulation medium (MYM) at 30°C and optical density was measured at 578 nm. 674 
ΔataC growth is delayed by 3 h and can be restored by expression of the wild type allele under 675 
control of its native promoter from the attBΦBT1 site. 676 
(D) Osmotic stress resistance of c-di-AMP mutants. Serial dilutions of spores were spotted on 677 
nutrient agar [NA] without additional salt or supplemented with 0.5 M NaCl and grown at 30°C 678 
for ~2 days. ΔdisA and disAD86A (expressing inactive DisA) are hypersensitive to salt stress. 679 
  680 
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 681 
 682 
Figure 6. Vnz_28055 (CpeA) binds c-di-AMP. 683 
(A) Alignment of the c-di-AMP binding regions in RCK_C (regulator of conductance of K+, 684 
Carboxy-terminal) domains was generated using Clustal Omega. C-di-AMP binding residues 685 
in KtrA (S. aureus;(47)), KtrC (B. subtilis;(48)) and conserved amino acids in CpeA are 686 
highlighted. Amino acids that form the hydrophobic patch are shown in yellow, residues 687 
involved in hydrophilic coordination are highlighted in cyan. 688 
(B) CpeA (vnz_28055), cpeB (vnz_28050) and cpeC (vnz_28045) form an operon in S. 689 
venezuelae. CpeA has an N-terminal domain (NTD) of unknown function and a C-terminal 690 
RCK_C domain. NheB is a predicted structural homolog to the Na+/H+ antiporter NapA (34). 691 
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28 
It consists of 13 transmembrane (TM) domains and a cytosolic fraction at the C-terminus 692 
(CTD). NheC is a predicted membrane protein with 3 TM domains.  693 
(C) CpeA binds [32P]-c-di-AMP in DRaCALAs. Binding of the radiolabeled ligand is indicated 694 
by dark spots centered on the nitrocellulose. In competition assays, excess (100 µM) cold c-di-695 
AMP or c-di-GMP, respectively, was added to the binding reaction containing [32P]-c-di-AMP 696 
and 6xHis-CpeA. 697 
(D) Adenylate cyclase-based two hybrid assays revealing that CpeA and CpeB interact in vivo. 698 
Using pKNT25 and pUT18, the T25 and T18 fragments of adenylate cyclase are attached at the 699 
C-termini of CpeB and CpeA, respectively. As a positive control, the leucin zipper part of the 700 
yeast GCN4 protein was used. Spotted co-transformants were grown for 20 h at 30°C with 701 
further incubation at room temperature for ca. 3 days.  702 
 703 
 704 
 705 
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SUPPLEMENTARY MATERIAL 1 
c-di-AMP hydrolysis by a novel type of phosphodiesterase 2 
promotes differentiation of multicellular bacteria 3 
 4 
 5 
Andreas Latoscha, David Jan Drexler, Mahmoud M. Al-Bassam, Volkhard Kaever4, Kim 6 
C. Findlay, Gregor Witte* and Natalia Tschowri* 7 
* Corresponding author: natalia.tschowri@hu-berlin.de 8 
* Correspondence may also be addressed to: witte@genzentrum.lmu.de  9 
 10 
SUPPLEMENTARY EXPERIMENTAL PROCEDURES 11 
Bacterial strains and growth conditions 12 
All strains used in this study are listed in Table S1. Escherichia coli strains were grown in LB 13 
medium under aerobic conditions at 37°C. If required, LB was supplemented with 100 µg/ml 14 
ampicillin (Amp), 50 µg/ml kanamycin (Kan), 50 µg/ml apramycin (Apr) and/or 15 µg/ml 15 
chloramphenicol (Cam). If hygromycin B (Hyg) was used, LB agar was replaced by Nutrient 16 
Agar (NA; Roth) and LB was substituted by LBon (LB without salt) with addition of 16 µg/ml 17 
and 22 µg/ml Hyg, respectively. S. venezuelae strains (Table S1) were grown aerobically at 30 18 
°C in liquid Maltose-Yeast Extract-Malt Extract (MYM) medium (1) supplemented with trace 19 
element solution (2) or on MYM agar. For growth analysis, 50 ml MYM were inoculated with 20 
spores at a final concentration of 106 CFU/µl and OD was measured at 578 nm. To study 21 
development, 12 µl of 105 CFU/ml S. venezuelae spores were spread as patches on MYM agar 22 
and bacteria were photographed using a Canon EOS 1300D (W) camera after 4 days of growth 23 
at 30 °C. For osmostress experiments, 10 µl of serially diluted of S. venezuelae spores (101 to 24 
104 CFU/µl) were dropped on NA medium with or without 0.5 M NaCl, respectively. Plates 25 
were incubated at 30°C and pictures were taken using a Canon EOS 1300D (W) camera. For in 26 
vivo interaction studies using Bacterial Adenylate Cyclase Two-Hybrid (BACTH) assays three 27 
corresponding single transformants of E. coli W3110 ∆cya were suspended in 1 ml of sterile 28 
phosphate buffered saline (PBS) and 3 µl of the resulting suspension was spotted on a plate 29 
containing MacConkey Base Agar (Difco) supplemented with Amp (100 µg/ml), Kan (50 30 
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µg/ml) and maltose (1%). The plate was photographed using a Canon EOS 1300D (W) camera 31 
after growth at 30 °C for 20 h with further incubation at room temperature for three days.  32 
 33 
Generation and complementation of S. venezuelae c-di-AMP mutants 34 
Oligonucleotides and bacterial strains used for mutagenesis are listed Table S1. 35 
Generation of vnz_27310 (ataC) deletion mutant and phage transduction. The ataC 36 
deletion was conducted using a modified Redirect PCR targeting protocol (3, 4). E. coli 37 
BW25113/pIJ790 cells induced for λ Red mediated recombination and containing cosmid 38 
PI1_F15 (with ataC) were transformed with PCR amplified aac(3)IV-oriT (apr-oriT) cassette 39 
extended with regions homologous to the ataC locus. After growth of transformants in presence 40 
of apramycin only, cosmids were isolated and re-transformed into E. coli W3110 with selection 41 
for Apr resistance. Correct integration of the Apr resistance cassette was verified by PCR using 42 
test primers annealing to the ataC flanking region (Table S1). PI1_F15 ataC::apr was 43 
transformed into strain ET12567/pUZ8002 and conjugated into wild type S. venezuelae. 44 
Bacteria were plated on SFM agar, incubated overnight at room temperature (RT), overlaid 45 
with 20 µl of 25 mg/ml nalidixic acid (Nal) and 50 mg/ml Apr in 2 ml ddH2O and incubated at 46 
30°C. S. venezuelae colonies were selected on NA containing Apr and Nal to remove E. coli. 47 
KanS and AprR mutants were confirmed by PCR. 48 
The ataC::apr allele was transduced into a new wild type background via SV1 phage 49 
using a modified protocol from (5). Briefly, SV1 wild type phages were diluted and mixed with 50 
S. venezuelae ΔataC spores. After overnight incubation at 30°C, plates were soaked with LB at 51 
RT and phages were gathered and filtered using a 0.45 µm filter. 100 µl phages containing the 52 
ataC::apr allele were plated with wild type spores on MYM agar and incubated overnight at 53 
RT. For selection of desired transductants, plates were overlaid with 20 µl 50 mg/ml Apr in 2 54 
ml ddH2O. The ataC deletion was confirmed by PCR. 55 
Generation of disA deletion mutant. The disA mutant was generated by transduction of 56 
the disA::apr allele (6) into the S. venezuelae wild type using SV1 phage. 57 
Generation of disAD86A point mutation. The point mutation was introduced using a 58 
combination of modified Redirect PCR targeting and single stranded DNA recombineering 59 
protocols as described in (7).The Kan resistance cassette in cosmid SV-4-B12 (containing disA) 60 
was exchanged with apr-oriT extended with homologous regions to neo. The resulting cosmid 61 
was used to generate the E. coli strain HME68/SV-4-B12 neo::apr-oriT which was induced for 62 
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λ Red recombination and electroporated with the mutagenic oligonucleotide 63 
disA_D86Achr_rev and oligo100 (8) and plated on MacConkey agar containing 1% galactose 64 
and Apr. Red, AprR clones were analyzed for the disA::disAD86A allele by PCR using a primer 65 
pair specific for the D86A mutation and sequencing. Purified cosmid was electroporated into 66 
ET12567/pUZ8002 and conjugated into wild type S. venezuelae. Single colonies were selected 67 
on NA medium containing Apr and Nal followed by growth on NA without antibiotics to 68 
achieve loss of the cosmid. Colonies sensitive to Apr were verified for the disA D86A mutation 69 
by sequencing.  70 
Complementation of the deletion mutants. To complement the disA deletion, a DNA 71 
fragment containing the wild type allele with 528 bp upstream of the start codon (including 72 
disA promoter) was cloned into pIJ10170 or its derivative p3xFLAG which allow integration 73 
at the attBΦBT1 site in the S. venezuelae chromosome. pIJ10170-disA and p3xFLAG-disA, 74 
respectively, were conjugated into disA::apr using E. coli ET12567/pUZ8002. After selection 75 
on NA medium containing Nal and Hyg, HygR colonies were grown on MYM agar for spore 76 
stock generation. 77 
The complementation of the ataC deletion mutant with the wild type allele was 78 
conducted similarly. Here, using an overlap PCR, a DNA fragment corresponding to 200 bp 79 
upstream of the start codon of vnz_27305 was fused to full length ataC resulting in the construct 80 
vnz_27305prom-ataC. The fragment was cloned into pIJ10170 resulting in the plasmid 81 
pSVAL11 and introduced into the ΔataC chromosome as described above. For 82 
complementation of ΔataC with the D269N allele, pSVAL11 was used as template in a 83 
backbone PCR to amplify a circular construct with the primers D269N_backbone_f and 84 
D269N_backbone_r. The plasmid pIJ10170-vnz_27305prom-ataCD269N was generated, the 85 
mutation confirmed by sequencing and conjugated into ΔataC as described above. 86 
Construction of plasmids  87 
Oligonucleotides used for cloning are listed in Table S1. disA, vnz_31010, ataC and vnz_28055 88 
were amplified from S. venezuelae genomic DNA (gDNA). D86A point mutation in disA was 89 
introduced by following the four-primer/two-step PCR protocol (9). PCR products of all 90 
constructs were cloned into the pET15b vector. The ataCD269N construct was obtained using 91 
quick change site directed mutagenesis using the pET15b-ataC plasmid as a template. Codon 92 
optimized ataCSpn was synthesized de novo and cloned into pET15b via the NdeI and BamHI 93 
restriction sites by GenScript.  94 
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Full-length cpeA (vnz_28055) and cpeB (vnz_28050) excluding the respective stop codons were 95 
cloned into pUT18 and pKNT25 (Euromedex). The resulting constructs carry in-frame fusions 96 
of the sequences encoding the T18 and T25 fragments of cyaA from Bordetella pertussis to the 97 
3’ end of cpeA and cpeB, respectively. Expression of the fused genes is under control of the lac 98 
promoter. 99 
Protein overexpression and purification 100 
pET15b constructs were transformed into E. coli BL21 (DE3) pLysS. Strain Rosetta (DE3) 101 
pET28-disABsu was directly used for overexpression. 1 L LB containing Amp and Cam (and 102 
0.2% glucose in case of PDEs) was inoculated 1:100 with overnight cultures and grown with 103 
shaking at 37°C. For DisABsu overexpression Amp was replaced with 25 µg/ml Kan. Cultures 104 
were induced with a final concentration of 0.1-0.2 mM IPTG at OD578 between 0.5 and 0.7; 105 
cultures for PDE overexpression were supplemented with 0.35 mM MnCl2 (10). Proteins were 106 
overexpressed overnight at 16°C and shaking. Subsequently, cultures were pelleted and lysed 107 
using a FrenchPress. Strains expressing DisA variants and 6xHis-Vnz_28055 were lysed in 108 
DisA lysis buffer (20 mM Tris HCl, pH 8; 300 mM NaCl, 10% glycerol, 20 mM imidazole; 109 
0.05% Triton X-100; 0.5 mM DTT; 5 mM MgCl2) supplemented with cOmplete protease 110 
inhibitor cocktail tablets, EDTA-free (Roche). Strains expressing 6xHis-Vnz_31010, 6xHis-111 
AtaC and 6xHis-AtaCSpn were lysed in PDE lysis buffer containing cOmplete protease inhibitor 112 
cocktail tablets, EDTA-free (similar to DisA lysis buffer but Tris HCl, pH 8 replaced by 20 mM 113 
Tris HCl 7.5; MgCl2 replaced by 10 mM MnCl2). Clarified lysate supernatants of 6xHis-tagged 114 
proteins were loaded on 0.5-1 ml 50% Ni-NTA SuperFlow (iba) overnight at 4°C. Then, the 115 
matrix was washed with respective lysis buffers. DisA protein variants and 6xHis-Vnz_28055 116 
were eluted with the following buffer: 50 mM Tris HCl, pH 8; 300 mM NaCl; 10% glycerol; 117 
250 mM imidazole; 0.5 mM DTT; 5 mM MgCl2. The PDE elution buffer was similar to DisA 118 
elution buffer but containing 50 mM Tris HCl, 7.5 instead of Tris HCl, pH 8 and 10 mM MnCl2 119 
instead of MgCl2. Fractions containing eluted proteins (identified by Coomassie staining of 120 
12% polyacrylamide gels) were pooled. Eluates of DisA variants and 6xHis-Vnz_28055 were 121 
dialyzed twice against 2 L of DisA cyclase buffer (25 mM Tris HCl, pH 8; 250 mM NaCl, 10 122 
mM MgCl, 5 mM β-mercaptoethanol, 10% glycerol (modified from (11), and tested PDEs were 123 
dialyzed twice against 2 L PDE buffer with 5-10% glycerol (20 mM Tris HCl, pH 7.5; 50 mM 124 
NaCl; 10 mM MnCl2 (modified from(10) at 4°C under stirring. Dialyzed proteins were stored 125 
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at -20°C until further use in diadenylate cyclase (DAC), differential radial capillary action of 126 
ligand (DRACaLA) or phosphodiesterase (PDE) assays. 127 
For characterization of biophysical properties of 6xHis-AtaC and 6xHis-AtaCD269N, Rosetta 128 
(DE3) cell pellets containing pET15b-ataC and pET15b-ataCD269N constructs, respectively, 129 
were resuspended in buffer A (20 mM HEPES, 300 mM NaCl, 20 mM Imidazole, 10% glycerol, 130 
0.5 mM MnCl2, pH 7.5) and lyzed by sonication. After centrifugation, clear supernatant was 131 
loaded on Ni-NTA columns. The columns were washed with buffer A and the protein was 132 
eluted with buffer B (20 mM HEPES, 100 mM NaCl, 250 mM imidazole, 10% glycerol, 0.5 133 
mM MnCl2, pH 7.5). The protein elution was concentrated prior to size exclusion 134 
chromatography on a HiLoad Superdex 200 column (GE Healthcare) equilibrated with buffer 135 
C (20 mM HEPES, 100 mM NaCl, 0.5 mM MnCl2, pH 7.5). The pure protein was concentrated, 136 
flash frozen in liquid nitrogen and stored at -80°C. 137 
c-di-AMP extraction and quantification 138 
The nucleotide extraction protocol from (12) was adapted to Streptomyces. Wild type, ΔdisA 139 
and ΔataC strains were grown in 100 ml MYM. Beginning with 10 h, 5 ml samples for c-di-140 
AMP extraction and two 1 ml samples for protein determination were taken every 2 h. c-di-141 
AMP samples were centrifuged at 4000 rpm and 4°C for 15 min using a swing rotor (Heraeus 142 
Megafuge 16R, Thermo Scientific), frozen in liquid nitrogen and stored at -80°C. Protein 143 
samples were centrifuged at max. speed and stored at -20°C.  144 
For c-di-AMP extraction, samples were suspended in 800 µl Extraction mixture II 145 
(acetonitrile/methanol/water [2:2:1]), transferred into 2 ml screw cap tubes prefilled with 0.1 146 
mm silica beads (Biozym), shock frozen for 15 s in liquid nitrogen and heated for 10 min at 147 
95°C. After cooling on ice, samples were disrupted using the BeadBlaster at 4°C with 2 cycles 148 
at 6 m/s for 45 s and 2 min interval. Samples were cooled for 15 min on ice and centrifuged at 149 
max. speed and 4°C for 15 min. Supernatants were transferred into a 2 ml reaction tubes. 150 
Remaining pellets were suspended in 600 µl Extraction mixture I (acetonitrile/methanol [1:1]), 151 
pulsed two times for 30 s at 6 m/s with a 60s interval, incubated on ice and centrifuged as above. 152 
The extraction with 600 µl Extraction mixture I was repeated once. All supernatants (~2 ml) 153 
were combined and stored for protein precipitation for two days at -20°C. Precipitated proteins 154 
were removed by centrifugation and the precipitation step was repeated. Finally, samples were 155 
air dried in a SpeedVac Plus SC110A connected to Refrigerated Vapor Trap RVT100 (Thermo 156 
Scientific) at low temperature settings and analyzed using LC-MS/MS as described in (12). 157 
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Samples for protein quantification were suspended in 800 µl 0.1 M NaOH, transferred into 2 158 
ml screw cap tubes prefilled with 0.1 mm silica beads (Biozym) and heated for 10 min at 98°C. 159 
Cell lysis was performed in BeatBlaster with 2 pulses for 30 s at 6 m/s and an interval of 2 min. 160 
Lysates were centrifuged at max. speed and 4°C for 15 min. Supernatant was saved and the 161 
extraction step was repeated. Supernatants were combined and protein concentration was 162 
determined via Bradford using Roti-Quant. 163 
For normalization of c-di-AMP concentration to the protein amount, following formula was 164 
used:  165 
 
𝑐−𝑑𝑖−𝐴𝑀𝑃 [𝑛𝑀] ⋅ 200
𝑐𝑉 [𝑚𝑙] ⋅ 𝑐590 [
µ𝑔
𝑚𝑙 𝑐𝑒𝑙𝑙𝑠
]
=
𝑐−𝑑𝑖−𝐴𝑀𝑃 [𝑝𝑚𝑜𝑙]
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 [𝑚𝑔]
 166 
Isothermal Titration Calorimetry 167 
ITC experiments were performed using a Malvern PEAQ-ITC system with 21 µM protein in 168 
ITC buffer (20 mM HEPES, pH = 7.5; 100 mM NaCl) in the cell. The respective nucleotides 169 
(210 µM) were titrated into the cell by 19 injections of 2 µl, spaced 150 s apart, at 25°C. The 170 
data was analyzed using the MicroCal PEAQ-ITC analysis software provided with the 171 
instrument. All titrations were repeated to confirm robustness of the assay. 172 
Size-exclusion coupled static light scattering 173 
Determination of the molecular weight of AtaC was performed using a 24 ml Superdex S200 174 
increase size-exclusion coupled to multi-angle laser light scattering and refractive index 175 
monitor (WYATT miniDAWN TREOS, WYATT Optilab T-rEX). Data were analyzed using 176 
the ASTRA software package provided with the instrument (Wyatt).   177 
Bioinformatic characterization of AtaC and its abundance in prokaryotes 178 
A local PATRIC database was installed and used to determine the conservation of AtaC 179 
(PGF_00172869) across prokaryotes (Suppl. Table 2). Duplicated entries with identical 180 
genome were removed (177 in total), but keeping the first entry. The same database was also 181 
used to determine the conservation of DisA (PGF_00421347), PgpH homologues 182 
(PGF_03110657), GdpP-type proteins (PGF_00033444) and DhhP-like proteins 183 
(PGF_01833449). An in-house python script was used to extract taxonomic information for 184 
each of the AtaC homologues. Specifically, the accession number of each species was used to 185 
access NCBI taxonomy and the taxonomic information was integrated with the original 186 
PATRIC table. Only phyla with more than 5 genomes were kept, and entries with no taxonomic 187 
information were excluded from the analysis. Finally, a total of 5200 entries were used to 188 
93
  
 
 
7 
generate the AtaC abundance pie chart. Multiple sequence alignment of AtaC proteins (see 189 
Suppl. Table S2 for respective PATRIC IDs) from different phyla was performed using 190 
CLUSTAL OMEGA (1.2.4) on https://www.ebi.ac.uk/Tools/msa/clustalo/.  191 
 192 
 193 
SUPPLEMENTARY INFORMATION 194 
Table S1. Strains, plasmids and oligonucleotides used in this study 195 
 Genotype or comments Source or reference 
Strains   
S. venezuelae   
NRRL B-65442 Wild type (NCBI Reference 
Sequence: 
NZ_CP018074.1) 
disA::apr ATCC 10712 SVEN_3211::aac(3)IV; AprR  (6) 
SVAL5 ΔdisA::apr, attBΦBT1::p3xFLAG-disA; AprR, HygR  This study 
SVAL8 disA::disAD86A This study 
SVAL19 ΔdisA (SV1-transduction); AprR This study 
SVAL20 Δvnz_27310::apr (Redirect); AprR  This study 
SVAL22 ΔataC::apr (SV1-transduction from SVAL20); AprR  This study 
SVAL24 ΔdisA::apr, attBΦBT1::pIJ10170-disA; AprR, HygR This study 
SVAL26 ΔataC::apr, attBΦBT1::pIJ10170-vnz_27305prom-ataC; 
AprR, HygR 
This study 
SVAL27 ΔataC::apr, attBΦBT1::pIJ10170-vnz_27305prom-
ataCD269N;  
AprR, HygR 
This study 
E. coli   
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W3110 K-12 derivative; F-, λ- ,rpoS(Am), rph-1, Inv(rrnD-rrnE)   (13) 
W3110 ∆cya W3110 derivative with deleted adenylate cyclase   (14) 
ET12567/pUZ8002 dam, dcm, hsd; KanR, CmR (15) 
BW25113/pIJ790 (Δ(araD-araB)567, ΔlacZ4787(::rrnB-4), lacIp-
4000(lacIQ), λ-, rpoS369(Am), rph-1, Δ(rhaD-
rhaB)568, hsdR514; CmR 
(16) 
BL21 (DE3) pLysS F– ompT hsdS(rB– mB–) gal dcm λ(DE3), CmR Promega 
HME68 W3110 Δ(argF-lac)U169 galKtyr145UAG 
mutS<>cat   
(17) 
Rosetta (DE3) 
pET28-disABsu 
Overexpression of Bacillus subtilis DisA; KanR, CmR (18) 
Rosetta 2 (DE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 
(CamR) 
Novagen 
Plasmids   
pIJ773 Plasmid template for amplification of the apr-oriT 
cassette for ‘Redirect’ PCR-targeting; AprR 
(3) 
pIJ790 Modified λRED recombination plasmid [oriR101] 
[repA101(ts)] araBp-gam-be-exo; CmR 
(3) 
pIJ10170 pMS82 derivative; HygR (19) 
pUZ8002 RP4 derivative with defective oriT; KanR (15) 
p3xFLAG pIJ10170 derivative containing 3xFLAG sequence 
downstream of MCS; HygR 
(20) 
pGEX_6P_1 T7 expression vector (modified MCS); AmpR GE Healthcare 
pET15b T7 expression vector; AmpR Novagen 
pKNT25 Low copy vector encoding the T25 fragment of 
Bordetella pertussis cyaA downstream of the MCS; 
KanR 
Euromedex 
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pUT18 High copy vector encoding the T18 fragment of B. 
pertussis cyaA downstream of the MCS; AmpR 
Euromedex 
pECAL1 pET15b-disA; AmpR This study 
pECAL4 pET15b-disAD86A; AmpR This study 
pECAL12 pET15b-ataC; AmpR This study 
pECAL13 pET15b-vnz_31010; AmpR This study 
pECAL16 pET15b-ataCSpn; AmpR This study 
pECAL17 pET15b-vnz_28055 (cpeA); AmpR This study 
pECAL18 pKNT25-vnz_28050 (cpeB); KanR This study 
pECAL19 pUT18-vnz_28055 (cpeA); AmpR This study 
pSVAL6 pIJ10170-disA; HygR This study 
pSVAL11 pIJ10170-vnz_27305prom-ataC (200 bp upstream of 
vnz_27305 start codon fused to ataC); HygR 
This study 
pSVAL12 pIJ10170-vnz_27305prom-ataCD269N (pSVAL11 
derivative); HygR 
This study 
pSVNT-10 p3xFLAG-disA; HygR This study 
pDD29 pET15b-ataCD269N (pECAL12 derivative); AmpR This study 
Underlined nucleotides indicate restriction sites, nucleotides in bold represent introduced mutations and 196 
nucleotides in italics indicate sequences overlapping to other genes 197 
Oligonucleotide Sequence 
Oligonucleotides used for chromosomal disA D86A point mutation, PCR verification and sequencing 
disA_D86Achr_rev TCTTGGTGATGTCCTTGTCGAGGACGAGCGCGCCCGCGAGCTTGCAC
AGCTCCCGCAGCCGCGTGGCGGC 
disA_D86A_check_fwd GGAGCTGTGCAAGCTCGCG 
disA_fwd_NdeI  TATCATATGGTGGCAGCCAAGGAC 
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disA_rev_XhoI TATCTCGAGCTAGACGTACCGCTCAAG 
Oligonucleotides used for verification of disA deletion 
disA_test_f  GTGGTTCACTCACGCCGCATGAACGGTTC 
disA_test_r GGCACGTACCTGGTGGAGGCGAAGGTG 
Oligonucleotides used for complementation of disA deletion with disA-3xFLAG 
3142_NdeI-for GCTGCATATGGGCCGGCGGGTCG 
3142_XhoI-rev GCAGCCTCGAGGACGTACCGCTCAAGGATC 
Oligonucleotides used for complementation of disA deletion with wild type disA 
3142_NdeI-for GCTGCATATGGGCCGGCGGGTCG 
disA_rev_XhoI TATCTCGAGCTAGACGTACCGCTCAAG 
Oligonucleotides used for vnz_27310 (ataC) deletion and PCR verification 
27310_fwd_Apra CGAAGCGATCGCGGCCACCGCCGCGCCCACCCGCTGATGATTCCGGG
GATCCGTCGACC 
27310_rev_Apra GGTCGTGGGGGGGGAGGAGACGGGTGAGGAGTGGGCTCATGTAGGC
TGGAGCTGCTTC 
27310_test_f ACACCGTGCGGCAGACCC 
27310_test_r TTCCCGCAGTCCATGGTTCC 
Oligonucleotides used for complementation of ataC deletion (sequences overlapping to putative promoter 
in italics) 
27305prom_f_NdeI TATCATATGGGTGTCCCGGCTCGTCGAC 
27305prom_r_OL_ataC GCTGCACCATGGACTCCATCCTACGGGGCT 
ataC_f_OL_27305prom GATGGAGTCCATGGTGCAGCCGACCGCCGT 
5409_rev_XhoI  TATACTCGAGTCAGGTGCGGACTTCGAG 
Oligonucleotides used for generation of pIJ10770-27305prom-ataCD269N 
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D269N_backbone_f CGGCGCTGTACGTCACGGCCAACCACGGCATGGTCGACAT 
D269N_backbone_r ATGTCGACCATGCCGTGGTTGGCCGTGACGTACAGCGCCG 
Oligonucleotides used for generation of pET15b overexpression constructs 
disA_fwd_NdeI  TATCATATGGTGGCAGCCAAGGAC 
disA_rev_XhoI TATCTCGAGCTAGACGTACCGCTCAAG 
disA_D86A_fwd GCAAGCTCGCGGGCGCGCTC 
disA_D86A_rev GAGCGCGCCCGCGAGCTTGC 
5409_fwd_NdeI TATCATATGATGGTGCAGCCGACCG 
5409_rev_XhoI  TATACTCGAGTCAGGTGCGGACTTCGAG 
6143_fwd_NdeI (for 
vnz_31010) 
TATCATATGGTGATCGTCATCGCCCATGT 
6143_rev_BamHI (for 
vnz_31010) 
TATGGATCCTCAGACCGGCACGGTC 
28055_fwd_NdeI TAT CATATG GTGCCTGCTCCACGGATG 
28055_rev_XhoI TATA CTCGAG TCACTCCCGTCCGAGTATGG 
Oligonucleotides used for generation of the pET15b-ataCD269N construct 
DD60AtaC(D269N)_fwd GTACGTCACGGCCAACCACGGCATGGTCGA 
DD61AtaC(D269N)_rev GGCCGTGACGTACAGCGCCGAGC 
Oligonucleotides used for generation of the constructs for interaction studies 
28050_NT25f_XbaI TATTCTAGACGTGCATTCCGCTCTGTTCCT 
28050_NT25r_KpnI TATGGTACCCGCGCGCGGCCGGCCGGATCCT 
28055_T18f_KpnI TATGGTACCGCCTGCTCCACGGATGAGC 
28055_T18r_EcoRI TAGCAGAATTCGACTCCCGTCCGAGTATGGAGG 
  198 
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 199 
Figure S1. Hydrolysis activity of AtaC is specific for adenosine bases. 200 
(A) Ion-exchange chromatography run on a Resource Q column of the reaction products after 201 
1 h incubation from a 100 µl reaction containing 100 nM AtaC + 250 µM c-di-AMP. 202 
(B) Michaelis-Menten kinetics of the reactions from 400 nM AtaC + c-di-AMP (62.5 – 2000 203 
µM) and 100 nM AtaC + 5′-pApA (62.5 – 2000 µM) after 1 h of incubation at 37°C. c-di-AMP, 204 
KM= 285 ± 32 µM, kcat= 0.2 s-1; 5′-pApA, KM= 698 ± 32 µM, kcat= 2.1 s-1. 205 
(C) Ion-exchange chromatography run on a Resource Q column of the reaction products after 206 
1 h incubation from a 100 µl reaction containing 100 nM AtaC + 250 µM c-di-GMP. 207 
(D) Ion-exchange chromatography run on a Resource Q column of the reaction products after 208 
1 h incubation from a 100 µl reaction containing 100 nM AtaC + 250 µM c-di-AMP. 209 
(E) Ion-exchange chromatography run on a Resource Q column of the reaction products after 210 
1 h incubation from a 100 µl reaction containing 100 nM AtaC + 250 µM 5′-pGpG. 211 
(F) Ion-exchange chromatography run on a Resource Q column of the reaction products after 1 212 
h incubation from a 100 µl reaction containing 100 nM AtaC + 250 µM 5′-pApG. 213 
 214 
 215 
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 216 
Figure S2. AtaC is a monomer in solution. 217 
(A) Molecular weight determination of AtaC by SEC coupled multi-angle laser light scattering. 218 
The obtained molecular weight is 43.7 kDa and stable for the main protein peak at 25 ml. 219 
(B) shows the relative scattering intensity of the sample during a size-exclusion coupled SAXS 220 
run at EMBL-P12 using a 24 ml Superdex increase S200 10/300 column (Intensity vs. frame 221 
No.). The respective estimated radius of gyration for each frame in the main peak is shown in 222 
red (right Y-axis).  223 
(C) Measured SAXS curve of AtaC and a theoretical scattering curve (red) of the model of 224 
AtaC using PhnA as template (obtained from HHpred/MODELLER (21), χ2=3.6). 225 
(D) Guinier plot ln I(s) vs. s² (top part) of the averaged buffer corrected scattering data (from 226 
B) and the respective residuals of the linear regression (RG= 2.41 ± 0.1nm). The equally 227 
distributed errors of the linear regression (for s*RG<1.3, Guinier approximation) indicates that 228 
the sample is not aggregating. 229 
 230 
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 231 
Figure S3. AtaCD269N does not cleave c-di-AMP and does not bind c-di-GMP. 232 
(A) Ion-exchange chromatography run on a Resource Q column of the reaction products after 233 
1 h incubation from a 100 µl reaction containing 1 µM AtaCD269N + 250 µM c-di-AMP. 234 
(B) ITC measurement of 20 µM AtaC titrated with 140 µM c-di-GMP. No binding was 235 
detected. 236 
 237 
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 238 
Figure S4. Complementation of the ∆ataC and ∆disA mutants with the wild type alleles.  239 
(A) Scanning electron micrographs show that expression of ataC from the attBΦBT1 site under 240 
the control of the native promoter from pIJ10170 complemented the delayed developmental 241 
phenotype of the ∆ataC mutant. (B) Expression of disA from pIJ10170 in the ∆disA mutant did 242 
not alter the wild type phenotype of the mutant. For comparison see also Figure 5B in the main 243 
text. Cells were grown on MYM for 4 days at 30 °C. 244 
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In this publication, the mechanism of DNA sensing by the mammalian cyclic GMP-AMP 
synthase cGAS is characterized in detail. The cGAS-STING pathway is an important component 
of the innate immune system, thus representing an emerging research topic. Upon DNA detection 
in the cytosol, cGAS produces 2′3′-cGAMP, which binds the adaptor protein STING to induce a 
type I interferon response. However, the precise mechanisms of cGAS activation are not fully 
explored, in particular, regarding the activity of cGAS in correlation with DNA length. This study 
provides results that indicate a protein-DNA ladder model for cGAS, induced by prearranged 
U-turned DNA. The crystal structure cGAS in complex with 39 bp DNA reveals a cGAS4:DNA2 
tetramer, with bent DNA. Furthermore, a cooperative cGAS-DNA association was observed in 
binding studies. These observations lead to the suggestion, that DNA binding by the first cGAS 
dimer prearranges the DNA to facilitate the association of further cGAS dimers. Of note, proteins 
that bend the DNA in a similar way were shown to increase cGAS activity significantly, while 
inhibiting cGAS activity in high concentrations. These proteins include the bacterial nucleoid 
packaging HU proteins and the eukaryotic TFAM (mitochondrial transcription factor A) and 
HMGB1 (high-mobility group box 1), which can both occur in the cytosol under mitochondrial 
stress conditions or DNA transfection. In this study, HMGB1 was shown to co-localize with DNA 
and cGAS in the cytosol, supporting the physiological relevance of the present model. The DNA 
bending proteins could allow cGAS to discriminate between short non-pathogenic DNA 
fragments and damage-derived or foreign DNA.  
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cGAS senses long and HMGB/TFAM-bound U-turn 
DNA by forming protein–DNA ladders
Liudmila Andreeva1,2, björn Hiller1,2, Dirk Kostrewa1,2, Charlotte Lässig1,2, Carina C. de Oliveira mann1,2,†, David Jan Drexler1,2, 
Andreas maiser3, moritz Gaidt1,2, Heinrich Leonhardt3,4, Veit Hornung1,2,4 & Karl-peter Hopfner1,2,4
Cytosolic DNA arising from intracellular pathogens triggers a 
powerful innate immune response1,2. It is sensed by cyclic GMP–AMP 
synthase (cGAS), which elicits the production of type I interferons 
by generating the second messenger 2′3′-cyclic-GMP–AMP 
(cGAMP)3–5. Endogenous nuclear or mitochondrial DNA can also 
be sensed by cGAS under certain conditions, resulting in sterile 
inflammation. The cGAS dimer binds two DNA ligands shorter 
than 20 base pairs side-by-side6–9, but 20-base-pair DNA fails to 
activate cGAS in vivo and is a poor activator in vitro. Here we show 
that cGAS is activated in a strongly DNA length-dependent manner 
both in vitro and in human cells. We also show that cGAS dimers 
form ladder-like networks with DNA, leading to cooperative sensing 
of DNA length: assembly of the pioneering cGAS dimer between 
two DNA molecules is ineffective; but, once formed, it prearranges 
the flanking DNA to promote binding of subsequent cGAS dimers. 
Remarkably, bacterial and mitochondrial nucleoid proteins HU 
and mitochondrial transcription factor A (TFAM), as well as high-
mobility group box 1 protein (HMGB1), can strongly stimulate long 
DNA sensing by cGAS. U-turns and bends in DNA induced by these 
proteins pre-structure DNA to nucleate cGAS dimers. Our results 
suggest a nucleation-cooperativity-based mechanism for sensitive 
detection of mitochondrial DNA10 and pathogen genomes11, and 
identify HMGB/TFAM proteins as DNA-structuring host factors. 
They provide an explanation for the peculiar cGAS dimer structure 
and suggest that cGAS preferentially binds incomplete nucleoid-like 
structures or bent DNA.
cGAS detects a broad range of intracellular viral and bacterial 
pathogens11–16 but also senses mitochondrial (mt)DNA in the  cytosol 
upon mitochondrial stress10. cGAS dimers bind two DNA ligands 
side-by-side, whereby each cGAS monomer directly recognizes fewer 
than 20 base pairs (bp). In principle, 20 bp DNA should be sufficient 
to fully activate cGAS; however, it does not activate cGAS in human 
cells17. Longer DNA ligands were even proposed to lead to steric clashes 
unless cGAS binds near DNA ends8. Thus, the current model fails to 
explain the detection of immunostimulatory DNA. Keeping the overall 
amount of DNA constant, we stimulated a human monocyte cell line 
(BLaER1 cells) with DNA of different lengths and observed a striking 
 concentration- and length-dependent activation of cGAS by  measuring 
C-X-C motif chemokine 10 (CXCL10) production as an appropriate 
surrogate parameter of cGAS activity18, as well as interferon-β (IFN-β ) 
mRNA expression levels (Fig. 1a and Extended Data Fig. 1a–c). Long 
herring testis DNA robustly activated cGAS at all tested DNA amounts, 
while shorter cGAS ligands required increasing amounts of DNA. 
Consistent with previous studies, DNA of ~ 45 bp constituted a ‘length’ 
threshold, below which no activation was observed.
Since other cellular factors could contribute to the length- sensitive 
detection, we analysed the intrinsic capability of mouse (m)cGAS 
and human (h)cGAS to sense DNA length in vitro, using a new 
fluorescent-based assay (Extended Data Fig. 2 and Methods). Both 
hcGAS and hcGAScd (catalytic domain) showed a remarkable DNA 
length-dependent activation, which appears to be independent of the 
cGAS N-terminal part (Fig. 1b). Like the ~ 45 bp threshold in vivo, 
robust activation at physiologically relevant cGAS concentrations 
in vitro required DNA > 40 bp. Plasmid DNA was the most potent 
activator. Mouse mcGAScd exhibited a comparable length-dependent 
activation, with a gradual increase in activity until about 75 bp (Fig. 1c 
and Extended Data Fig. 1d). At higher DNA concentrations and short 
DNA lengths, mcGAS was activated in an almost stepwise fashion, 
with a first plateau between 30 and 45 bp and a second above 50 bp 
(Fig. 1c inset), perhaps reflecting stepwise binding along DNA. DNA 
< 20 bp can also activate cGAS but requires 10–20 times higher cGAS 
and 50–250 times higher DNA amounts to induce activities similar to 
50 bp DNA (Extended Data Fig. 1e, f). Finally, circular and linearized 
plasmid DNA activated cGAS equally well, ruling out the possibility 
that cGAS needs DNA ends (Extended Data Fig. 1g).
To determine a mechanism for the DNA length sensing, we crys-
tallized mcGAScd in complex with 39 bp DNA. The crystals diffracted 
 anisotropically to 3.6–4.8 Å resolution and we determined the structure 
by molecular replacement. In the crystal, two cGAS dimers and two 
DNA 39-mers form a cGAS4–DNA2 complex (Fig. 1d and Extended 
Data Fig. 3a). Each of the two cGAS dimers in our cGAS4–DNA2  
complex is similar to the dimers seen in cGAS2–DNA2 complexes 
determined with < 20 bp DNA (Extended Data Fig. 3b, c), indicating 
that long DNA does not induce a substantially different structural state 
in cGAS than short DNA. The two cGAS dimers are arranged in a 
‘head-to-head’ orientation along the DNA. DNA between the cGAS 
dimers is slightly curved (Fig. 1d), avoiding the proposed clashes and 
showing that cGAS does not need DNA ends (Extended Data Fig. 3c, d).
The asymmetric unit contains one full cGAS4–DNA2 complex along 
with one half cGAS4–DNA2 complex situated on a twofold crystallo-
graphic symmetry axis (Extended Data Fig. 4a). Remarkably, these 
cGAS4–DNA2 complexes are further stacked into fibrils with alternating 
‘head-to-head’- and ‘tail-to-tail’-oriented cGAS dimers (Fig. 1e), 
forming a DNA–protein ladder with rungs (cGAS dimers) and two 
ladder sides (DNA). The DNA is continuous between ‘head-to-head’-
oriented cGAS dimers and quasi-continuous (stacked 3′ to 3′ and 
5′ to 5′ ) between the ‘tail-to-tail’-oriented cGAS dimers. A ~ 5 bp (half 
helical turn) increased spacing of ‘tail-to-tail’-oriented cGAS dimers, 
however, would allow an energetically favourable continuous assembly 
of alternatingly oriented cGAS dimers between two long DNA elements 
(Extended Data Fig. 3e, f).
Neighbouring cGAS dimers along the DNA barely interact in 
either ‘head-to-head’ or ‘tail-to-tail’ orientations in the crystal lattice 
(Extended Data Fig. 4a). Consistently, mutational analysis in vitro and 
in vivo showed that whereas protein–DNA contacts are critical, protein–
protein contacts between adjacent cGAS dimers in either orientation 
1Department of Biochemistry, Ludwig-Maximilians-Universität München, 81377 Munich, Germany. 2Gene Center, Ludwig-Maximilians-Universität München, 81377 Munich, Germany. 3Department 
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are not (Extended Data Fig. 4b–d)8,9. Accordingly, the DNA– protein 
ladder does not require direct interactions between neighbour-
ing cGAS dimers to be stable, because cGAS–DNA contacts and 
cGAS–cGAS dimer contacts between the DNA already generate a mesh- 
like structure.
To see whether ladder-like structures exist in solution, we used 
 isothermal titration calorimetry (ITC) and size-exclusion chroma-
tography coupled to right-angle light scattering (SEC–RALS). ITC 
showed a DNA length-dependent increase in affinity and at the same 
time an increase in cGAS:DNA molar ratio (Fig. 2a and Extended Data 
Fig. 5). DNA of ~ 45 bp conferred a threshold, resulting in higher 
affinity and at the same time binding of two cGAS molecules per 
DNA ligand. The affinity increase was driven by a decrease in  binding 
enthalpy that also compensated a decreasing entropy (Fig. 2b and 
Extended Data Fig. 6a, b). The latter suggests the formation of ordered 
structures on DNA > 45 bp. Together with ITC, SEC–RALS showed 
that cGAS forms single homogeneous complexes with DNA of  different 
lengths: a cGAS1–DNA1 complex for 20-mer DNA, a cGAS4–DNA2 
complex for 50-mer DNA, and cGAS6–DNA2 complexes for 70/80-mer 
DNA (Fig. 2c–f and Extended Data Fig. 6c). Of note, cGAS2–DNA2 
complexes were unstable in the presence of 20 bp DNA and only the 
cGAS1–DNA1 complex robustly formed with 20 bp DNA that poorly 
activates cGAS (Fig. 1a–c). Given that activation of cGAS requires 
additional dimerization8, this explains why 20 bp DNA is not a good 
cGAS activator.
The DNA–protein ladders offer an intriguing mechanism for the 
DNA length-dependent activation of cGAS. Formation of a pioneering 
cGAS2–DNA2 complex is highly unfavourable, but once formed, it pre-
arranges the two DNA molecules in its vicinity to promote  formation of 
adjacent cGAS dimers with increased affinity (Fig. 3a). Multiple cGAS 
dimers in cGAS2n–DNA2 (n ≥ 2) ladders stabilize each other by coop-
eratively holding together the two DNA ladder sides. An  analytical 
equation for this ‘DNA–protein ladder’ model can be derived (see 
Supplementary Methods) and comprises a Vmax (maximal reaction 
velocity); three DNA constants K1, K22, and K3 that describe interaction 
of monomeric cGAS with DNA (K1), interaction of cGAS dimers with 
two DNA ligands (K22), and the association/dissociation of cGAS–DNA 
and cGAS2–DNA2 states (K3); and a parameter s that is a measure of 
cooperative binding sites of cGAS dimers along DNA (equivalent to a 
Hill coefficient).
To test this model, we measured cGAS activity by varying both 
mcGAScd concentration and DNA length. We observed a dramatic 
length-dependent activation that was not due to an increase in Vmax, 
consistent with our model, but was due to a DNA length-dependent 
increase in binding affinity, as seen with ITC (Fig. 3b). The data can be 
globally fitted with a simplified equation derived from the mathe matical 
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Figure 1 | cGAS shows DNA length-dependent activity and forms DNA–
protein ladders. a, cGAS activation in transdifferentiated BLaER1 cells. 
Cells were stimulated with 20, 40, and 60 ng DNA of different length  
(20–100 bp in 5 bp intervals) and herring testis (HT) DNA. First two bars 
each represent unstimulated cells and Lipofectamine controls. Shown are 
mean values ± s.d., n = 3. b, In vitro activity of hcGAS, hcGAScd, and  
c, mcGAScd in the presence of DNA of increasing length (20–100 bp in 5 bp 
intervals) or plasmid DNA (last bar). Mean values of initial cGAS reaction 
rates (∆ F/∆ t, relative fluorescence units (RFU) min−1), measured by the 
rate of fluorescent ATP analogue (fATP) incorporation into fluorescent 
cGAS product (fGAMP, see Extended Data Fig. 2) are plotted against 
DNA length ±  s.d., n = 3–5. d, Crystal structure of cGAS in complex with 
39 bp DNA. Two cGAS dimers (green and orange) assemble on DNA in 
‘head-to-head’ orientation. Zinc-thumb dimerization elements and the 
nucleotidyl-transferase (NT) sites are indicated. e, Ladder-like cGAS 
assembly along a quasi-continuous DNA in the crystal lattice through 
alternating ‘head-to-head’ or ‘tail-to-tail’ orientations of cGAS dimers.
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model (Supplementary Methods equation 3.6 and sections 4.1 and 4.2) 
and can be explained by a model in which Vmax and the DNA  binding 
constants do not depend on the length of DNA, while s increases as a 
function of DNA length (Fig. 3c). Parameter s  measures cooperativity 
between adjacent cGAS dimers owing to the DNA  arranging  activity19. 
The transitions of s around 40–50 bp and 2s ~ 2.8 for  plasmid DNA 
suggest that length sensing can be explained by  cooperative bind-
ing of two or more adjacent cGAS dimers. Furthermore, titrating 
 catalytically inactive mcGAScd(D307N) to low amounts of active 
mcGAScd  markedly increased cGAS activity about 200-fold, providing 
direct evidence for cooperative sequestering of cGAS into oligomeric 
structures on DNA (Fig. 3d). Higher amounts of the inactive mutant 
gradually competed mcGAScd away from DNA, as expected. These 
data can be fitted well (R2 = 0.96) with the ‘DNA–protein ladder’ equa-
tion (Supplementary Methods) and result in a cooperativity parameter 
2s = 3.6, similar to that described in Fig. 3c. In summary, cGAS length 
sensing emerges from cooperative formation of cGAS2n–DNA2 (n ≥ 2) 
complexes.
Cellular factors could enhance detection of DNA by cGAS if they 
suitably structure the DNA. We noticed that the HMGB proteins 
HMGB1/2 and mitochondrial nucleoid organizing protein TFAM 
could be well suited to nucleate cGAS dimers because they properly 
prearrange DNA by forming U-turns20,21 (Extended Data Fig. 7a, b) 
and because mtDNA activates cGAS10 and HMGB1/2 facilitate cyto-
solic nucleic-acid sensing22. Bacterial HU proteins, for  example from 
Listeria monocytogenes (lHU), also bend DNA to form  bacterial 
nucleoids. Indeed, adding increasing amounts of mTFAM, mHMGB1, 
and lHU robustly activated mcGAScd in vitro up to ~ 25-fold 
(Fig. 4a–c and Extended Data Fig. 7c). A similar activation was also 
seen for hTFAM and full-length hcGAS (Fig. 4d). cGAS activation 
required the DNA-bending ability of HMGB1, since mutations that 
decreased DNA-bending capacity without significantly affecting DNA 
binding23 reduced or nearly abolished cGAS activation (Extended Data 
Fig. 8a–d). TFAM activates cGAS both on circular and on linear  plasmid 
DNA (Extended Data Fig. 8e), works without direct TFAM–cGAS 
interactions (Extended Data Fig. 8f), and even does not require  proteins 
from the same species (Extended Data Fig. 8g, h). Thus, these proteins 
presumably activate cGAS not by protein–protein interactions but 
rather by prestructuring DNA to nucleate or stabilize cGAS dimers. 
At higher concentrations, TFAM and lHU sharply abolished cGAS 
activity, presumably because of cooperative formation of nucleoid-like 
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Figure 2 | cGAS and DNA assemble into cGAS2n–DNA2 complexes  
in solution. a, ITC of mcGAScd and DNA. Enthalpy (∆ H) values 
are plotted against the molar ratio of DNA:mcGAScd. Obtained 
dissociation constant (Kd) values for 20, 40, 50, and 80 bp 
DNA are 2.4 × 10−6 ±  1.89 × 10−6, 507 × 10−9 ± 128 × 10−9, 
165 × 10−9 ± 166 × 10−9, and 73.3 × 10−9 ± 25.5 × 10−9 M, respectively. 
Molar ratios are 1.28 ± 0.125, 0.364 ± 0.01, 0.371 ± 0.027, and 
0.274 ± 0.006, respectively. b, Thermodynamic parameters obtained with 
ITC. c–f, SEC–RALS analysis of mcGAScd with 20 bp (c), 50 bp (d), 70 bp 
(e), and 80 bp (f) DNA; mAU, milli absorption units. Estimated molecular 
masses are indicated. Molecular masses 12.2, 30.8, 43.1, and 49.3 kDa were 
used as reference for 20, 50, 70, and 80 bp DNA, respectively; mcGAScd was 
estimated with 43 kDa (see also Extended Data Fig. 6c). Some molecular 
mass deviation from reference values occurred because of limitations of 
measurement accuracy.
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Figure 3 | DNA–protein ladder model. a, Kinetic scheme for the  
DNA–protein ladder model. cGAS binds as monomer to DNA 
(dissociation constant K1). These cGAS1–DNA1 complexes can assemble 
into cGAS2–DNA2 structures with parallelized DNA (K3). Finally, two 
cGAS molecules can directly bind as dimer to the parallelized DNA 
ligands (K22). Overall, this scheme describes a cooperative, DNA length-
dependent interaction of cGAS with DNA (see Supplementary Methods). 
b, Activity of mcGAScd on different DNA ligands as a function of  
protein concentration (symbols: circle, plasmid; downward arrowhead, 
100 bp; diamond, 60 bp; square, 50 bp; rightward arrowhead, 40 bp; 
leftward arrowhead, 35 bp; upward arrowhead, 30 bp; star, 20 bp).  
The overall concentration of base pairs in each reaction is kept constant. 
Mean values of cGAS activity (see Fig. 1c legend) are plotted against 
mcGAScd concentrations ± s.d., n = 3. Superposed is a global least square 
minimization of the data with an equation describing the DNA–protein 
ladder model (R2 = 0.988) (see Supplementary Methods). c, Plot of the 
cooperativity parameter s obtained from b as a function of DNA length. 
d, Titration of catalytically inactive mcGAScd (D307N) into a sub-active 
solution of mcGAScd. Mean values of cGAS activity (see Fig. 1c legend) 
are plotted against mcGAScd (D307N) concentrations ± s.d., n = 3. 
Superposed is a least square minimization of the data with the  
DNA–protein ladder model (R2 = 0.96) (see Supplementary Methods).
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 structures24. HMGB1 inhibited cGAS more gradually, probably because 
it does not cooperatively form compact nucleoids. Strong stimulation 
of cGAS activity by TFAM required DNA > 100 bp (Extended Data 
Fig. 7d), suggesting that robust activation still involves cGAS2n–DNA2 
complexes (n ≥ 2).
TFAM normally resides in mitochondria; however, under mito-
chondrial stress conditions, induced by a combination of caspase 
and Bcl-2 inhibitors25,26, we saw increased TFAM presence in the 
 cytosol (Extended Data Fig. 9a–d) where it can assist  detection 
of leaked mtDNA. Consistently, cytosolic hcGAS and hTFAM 
co- immunoprecipitated (Extended Data Fig. 9e). Importantly, we found 
that upon DNA transfection of mouse embryonic fibroblasts (MEFs), 
endogenous HMGB1 co-localized with cytosolic DNA and cGAS in 85% 
of the observed cytosolic DNA loci (Fig. 4e and Extended Data Fig. 10). 
This is consistent with previous findings that HMGB1 is involved in 
cytosolic DNA sensing22 even though it normally resides in the nucleus. 
However, HMGB1 shuttles between nucleus and cytoplasm27, enabling 
it to encounter cytosolic DNA where it could assist cGAS.
In summary, we provide a molecular mechanism for the sensitive 
detection of long DNA by cGAS (Fig. 4f). cGAS1–DNA1 complexes 
appear to be inactive and cGAS2–DNA2 complexes unstable, requiring 
DNA of sufficient length to form stable cGAS2n–DNA2 ladders (n ≥ 2). 
Nucleic-acid-stress HMGB proteins and nucleoid-structuring proteins 
(TFAM, HU) can additionally nucleate and stabilize cGAS ladders by 
prearranging DNA. Thus, cGAS preferentially senses structured DNA 
ligands and DNA with residual nucleoid proteins bound, rather than 
naked DNA. In terms of recognizing danger or pathogen-associated 
molecular patterns in the form of mtDNA and bacterial nucleoids, these 
findings make biological sense and provide a plausible rationale for the 
evolution of the peculiar cGAS dimer structure. TFAM/HMGB1/HU- 
enhanced stimulation of cGAS could be especially helpful for the 
initial detection of long cytosolic DNA with low amounts of cGAS 
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Figure 4 | DNA-bending proteins enhance cGAS activity by 
prearranging DNA into U-shaped structures. a–d, cGAS activities  
(see Fig. 1c legend) in the presence of different DNA-bending proteins. 
The last value corresponds to a control without DNA (woDNA). Mean 
values of initial cGAS reaction rates (∆ F/∆ t) are plotted against increasing 
concentrations of DNA-bending proteins ± s.d., n = 3–6. mTFAM (a), 
mHMGB1 (b) and lHU (c) robustly enhance mcGAScd activity in a  
dose-dependent manner until they eventually compete cGAS away.  
d, hTFAM activates hcGAS. e, HMGB1 (red), cGAS (green), and cytosolic 
DNA (blue) co-localization. Wild-type (WT) or HMGB1-knockout 
(KO) MEFs were transfected with an enhanced green fluorescent protein 
(eGFP)–cGAS-expressing vector and stained for wide-field fluorescence 
microscopy (pDV) (compare with Extended Data Fig. 10). DNA was 
stained with 4,6-diamidino-2-phenylindole (DAPI, blue). Fluorescent 
signal within enlarged images is enhanced until saturation of the nuclear 
signal to better visualize cytoplasmic structures. f, Model for DNA length- 
and structure-dependent cGAS activation. Activation of cGAS requires 
the formation of cGAS2–DNA2 dimers, which are very unstable. Multiple 
cGAS dimers along DNA ≥ 45 bp stabilize each other by cooperatively 
holding DNA together, leading to stable, active ladders (shaded panels). 
DNA-bending/U-turn-inducing proteins prearrange DNA, nucleating the 
formation of cGAS dimers and ladders (darker shaded panel).
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present. In this context, it should be noted that short ~ 20-mer DNA 
can also strongly activate cGAS if it additionally contains G-rich 
ssDNA Y overhangs17. In principle, this flanking G-rich DNA could 
also stabilize cGAS dimers, but the precise mechanism, as well as that 
of other postulated host proteins28,29, remains to be uncovered. In any 
case, the nucleation- and cooperativity-based mechanism imposes 
a threshold-like response that conceptually unifies DNA sensing by 
the cGAS–STING axis with other oligomerization-based nucleic- 
acid-sensing pathways30.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Constructs and cloning. The plasmids encoding full-length (amino acids (aa) 
1–522) and truncated (catalytic domain, ‘cd’) Homo sapiens (h) (aa 155–522) and 
Mus musculus (m) (aa 141–507) cGAS for N-terminal His6–MBP (maltose-binding 
protein) fusion protein expression were described before7.
The sequence encoding mTFAM without a mitochondrial localization signal 
(aa 43–243) optimized for Escherichia coli expression was synthesized by Eurofins 
Genomics and cloned for N-terminal His6 fusion protein expression into modified 
pET28a vector (Novagen), where the thrombin cleavage site was exchanged with 
a tobacco etch virus protease cleavage site.
hTFAM (aa 43–246) sequence was obtained from total cDNA and inserted 
into pET28a for His6 fusion protein expression in E. coli. Full-length mHMGB1 
(aa 1–215), as well as L. monocytogenes HU (lHU) (aa 1–121) sequences were 
 purchased from Eurofins Genomics and cloned into pET28a for His6 fusion 
protein expression. Truncated mHMGB1 (aa 1–185) (mHMGB1dCTT) was 
cloned  analogously. cGAS and mHMGB1dCTT point mutants were generated 
by QuikChange site-directed mutagenesis with Pfu-Ultra polymerase (Agilent) 
followed by DpnI (Fermentas) digestion. For expression in human cells, Flag/ 
haemagglutinin (HA)-tagged hcGAS (aa 1–522) and HA-tagged hTFAM 
(aa 43–246) were cloned into pcDNA5/FRT/TO (Invitrogen, Thermo Fisher 
Scientific). For localization studies, hcGAS was cloned into pEGFP-C1vector 
(Clontech) for N-terminal eGFP-tagged cGAS expression. All protein constructs 
abbreviations and descriptions are listed in Supplementary Table 1.
Cell lines and reagents. All DNA oligonucleotides were purchased from Metabion. 
The exact sequences of stimulatory DNAs are listed in Supplementary Table 2. 
Linearized plasmid DNA was obtained by digestion of pET28M–SUMO1–GFP 
vector (EMBL) with BamHI (NEB). A 200 bp PCR fragment was amplified from 
the MBP sequence. Anti-hcGAS (catalytic domain) and a control antibody 
were  produced by The Service Unit Monoclonal Antibodies (German Research 
Center for Environmental Health, Helmholtz Zentrum München). The following 
antibodies were purchased commercially: anti-HA–HRP (Cell Signaling, clone 
6E2), mouse anti-hTFAM (Abnova), rabbit anti-hTOM20 (FL-145) (Santa Cruz 
Biotechnology), mouse anti-HMGB1 (Sigma, clone 2F6), goat anti-mouse Alexa 
Fluor 594 (Life Technologies), goat anti-rabbit Alexa Fluor 488 (Life Technologies), 
donkey anti-rabbit Alexa Fluor 594 (Life Technologies), and donkey anti-mouse 
Alexa594 and Alexa Fluor 488 (Life Technologies). The following cell lines were 
used: HEK293T (American Type Culture Collection, CRL-11268), HEK293T 
STING-KI31, primary human fibroblasts (provided by M. Cremer, T. Cremer’s 
group (Ludwig-Maximilians-University Munich, Biocentre Martinsried)), 
BLaER132 (provided by T. Graf ’s group (Center for Genomic Regulation, 
Universidad Pompeu Fabra and Institució Catalana de Recerca i Estudis Avançats, 
Barcelona)), and BLaER1 cGAS-KO, HMGB1-KO and HMGB1-WT MEF 
(HMGBiotech, HM-221).
For generation of cGAS-deficient BLaER1 cells (BLaER1 cGAS-KO), a single- 
guide (sg)RNA targeting the sequence GAACTTTCCCGCCTTAGGCAGGG 
(protospacer adjacent motif is in bold type) of the human MB21D1 gene was cloned 
via ligation-independent cloning into pR-U6-gRNA to yield pR-U6-MB21D1 as 
previously described33. BlaER1 cells were electroporated with pR-U6-MB21D1 
and pCMV-mCherry-T2A-Cas9 (ref. 31) expression plasmids using a GenePulser 
device (Biorad), and 2 days later FACS-sorted mCherry-positive cells were sub-
cloned by limiting dilution. Monoclonal cell lines were rearranged and duplicated 
for genotyping. The genomic locus surrounding the sgRNA binding site was PCR 
amplified (cGAS forward p ri me r: A CA CT CT TT CC CT AC AC GA CG CT CT TC CG 
AT CT CT TT TT GGCGCGGGCCCCAGTTG; cGAS reverse primer: T GA CTGGA
GTTCAGACGTGTGCTCTTCCGATCTAAGGCCATGCAGAGAGCTTCCGA) 
and subjected to deep sequencing using a MiSeq platform (Illumina) as previously 
described34. KO cell clones contained all-allelic frame shift mutations without any 
WT reads. The deficiency for cGAS was not validated at the protein level.
All bought cell lines were kept at low passages to maintain their identity. Non-
commercially available HEK293T STING-KI, BLaER1, and BLaER1 cGAS-KO 
cell lines were not authenticated.
The female primary human fibroblast cell line was authenticated as follows. 
DNA was isolated separately from the samples. Genetic characteristics were 
 determined by PCR-single-locus-technology. Twenty-one independent PCR-
systems (Amelogenin, D3S1358, D1S1656, D6S1043, D13S317, Penta E, D16S539, 
D18S51, D2S1338, CSF1PO, Penta D, TH01, vWA, D21S11, D7S820, D5S818, 
TPOX, D8S1179, D12S391, D19S433, and FGA) were investigated (PowerPlex 
21 PCR Kit, Promega). In parallel, positive and negative controls were performed 
yielding correct results.
No mycoplasma contamination of the used cells was detected in regular 
 screenings.
Cell culture. WT and cGAS-KO BLaER1 cells were cultivated in RPMI medium 
containing heat-inactivated 10% FCS, penicillin (100 U ml−1), streptomycin 
(100 μ g ml−1) (Thermo Fisher Scientific), and 1 mM sodium pyruvate (Thermo 
Fisher Scientific). For transdifferentiation, 5 × 104 cells were seeded per well of a 
flat bottomed 96-well plate and cultivated in the presence of β -oestradiol (100 nM, 
Sigma-Aldrich), hr-IL-3 (10 ng ml−1), and M-CSF (10 ng ml−1) (both PeproTech) 
for 5 days before the experiment35. HEK293T, HEK293T STING-KI, and human 
fibroblasts were cultured in DMEM (Thermo Fisher Scientific or Sigma-Aldrich, 
respectively) supplemented with 10–20% heat-inactivated FBS (Thermo Fisher 
Scientific or Biochrom, respectively). All cells were incubated at 37 °C with 5% CO2.
HMGB1-KO and WT MEFs were cultured in DMEM (Thermo Fisher 
Scientific) supplemented with 15% heat-inactivated FBS (Thermo Fisher 
Scientific), 2 mM l-glutamine (Sigma, G7513), 1% non-essential amino acids 
(Sigma, M7145), 0.1 mM β -mercaptoethanol (Sigma, M3148), and 0.1 mg ml−1 
penicillin– streptomycin (Sigma, P4333) and incubated at 37 °C with 5% CO2.
Protein expression and purification. All proteins were overexpressed in E. coli 
Rosetta (DE3) for 16–18 h at 18 °C after induction with 0.2 mM IPTG. Cells were 
lysed by sonication in 50 mM Tris, 500 mM NaCl, 5 mM MgCl2, 10 mM  imidazole, 
10% glycerol, pH 7.5, supplemented with 2 mM β -mercaptoethanol and protease 
inhibitor cocktail (Sigma-Aldrich) and purified with Ni-NTA agarose resin 
(Qiagen). For truncated cGAS proteins and human full-length cGAS without 
MBP-tag, His6–MBP-tag was removed with tobacco etch virus protease (1:50 
mass ratio) during 16 h dialysis against 30 mM Tris, 100 mM NaCl, 2 mM DTT, 
pH 7.0. cGAS proteins were further purified by cation-exchange chromatography 
(30 mM Tris, 100 mM/1 M NaCl, 2 mM DTT, pH 7.0) on HiTrap SP HP columns 
(GE Healthcare) followed by size-exclusion chromatography (SEC) on HiLoad 
S200 16/60 column (GE Healthcare) equilibrated with 20 mM Tris, 100 mM NaCl, 
pH 7.5. Full-length hcGAS with or without N-terminal His6–MBP-tag (hcGAS) 
and mcGAS proteins was concentrated to 8–12 mg ml−1. Truncated hcGAS was 
concentrated to 4 mg ml−1. All proteins were flash-frozen in liquid nitrogen and 
stored at − 80 °C. mTfam and mHMGB1 variants were purified as described for 
full-length hcGAS with His6–MBP-tag, except the cation-exchange chromatogra-
phy step was  omitted and after dialysis against 20 mM Tris, 300 mM NaCl, pH 7.5 
SEC on HiLoad S75 16/60 (GE Healthcare) column was performed. Proteins were 
concentrated to 10–13 mg ml−1.
lHU was purified as described for full-length hcGAS  with His6–MBP-tag, 
except after dialysis  affinity chromatography on a HiTrap Heparin HP (GE 
Healthcare) column was performed (20 mM Tris, 100 mM/1 M NaCl, 2 mM DTT, 
pH 7.5). HiLoad S75 16/60 (GE Healthcare) equilibrated with 20 mM Tris, 100 mM 
NaCl, pH 7.5 was used for SEC. Protein was concentrated to 7 mg ml−1.
Crystallization of cGAS–DNA complex. For crystallization, purified 
mcGAS (aa 141–507) 6 mg  ml−1 was mixed with 39 bp DNA (39 bp-s: 
AGATCTACTAGTGATCTATGACTGATCTGTACATGATCT; 39 bp-as: 
AGATCATGTACAGATCAGTCATAGATCACTAGTAGATCT) in a molar ratio 
of 1:0.6 protein:DNA in a buffer containing 20 mM Tris pH 7.5, 300 mM NaCl 
and 20 mM MgCl2. Crystals were obtained by hanging-drop vapour diffusion in 
0.1 M Tris pH 8, 0.2 M ammonium citrate pH 7, 27.5% w/v PEG3350 after 1 month 
at 20 °C. The crystals were soaked in 25% glycerol diluted in reservoir solution, 
flash-frozen, and stored in liquid nitrogen.
Data collection and refinement. X-ray diffraction data were collected at the 
beamline PXI (X06SA) at the Swiss Light Source, Switzerland, using a Pilatus 6M 
detector. Data sets were processed with XDS and merged with XSCALE36. The 
STARANISO server37 was used to generate structure factor amplitudes and their 
s.d. with a local I/σ(I) cut-off of 1.9. The resulting data set showed varying high- 
resolution cut-offs between 4.8 Å and 3.6 Å and an effective resolution of ~ 4.2 Å. 
The crystal structure was solved by molecular replacement with PHASER38,39 using 
six copies of a search model based on the published structure of mouse cGAScd in 
complex with 18 bp DNA8 (Protein Data Bank (PDB) accession number 4LEY). 
Iterative model building and refinement was done with the molecular graphics 
program MOLOC40 and the CCP4 suite refinement program REFMAC5 (ref. 41). 
Owing to the rather low resolution, we could not identify the DNA sequence. 
Thus, sense and anti-sense strands, as well as the starting nucleotide, were chosen 
 arbitrarily. At the symmetry contact between two neighbouring cGAS dimers, we 
saw continuous electron density for a 34 bp DNA passing through the crystallo-
graphic twofold axis. Since the DNA sequence was not palindromic, we modelled 
the DNA with two 17 bp long symmetry-halves. Except for removal of a steric 
clash with the bound DNA by choosing a different rotamer for Arg244, we did not 
attempt to re-model the cGAS protein. Data collection and refinement statistics 
are listed in Supplementary Table 3.
Fluorescence-based cGAS activity assays. In fluorescence-based cGAS activity 
assays, a fluorescent analogue of ATP (2-aminopurine riboside-5′ -O-triphosphate 
(Biolog) (fATP)) was used. DNA (6.5 ng μ l−1) of different lengths (20–100 bp in 
5 bp intervals, and pET28M–SUMO1–GFP vector (EMBL) (6.2 kbp, plasmid)) 
corresponding to roughly 0.5 μ M 20 bp (approximate length of cGAS  binding 
site) was premixed with 0.5 μ M cGAS in 40 mM Tris pH 7.5 and 100 mM 
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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NaCl. Alternatively, 2.6 ng μ l−1 DNA (~ 0.2 μ M binding sites) and 1 μ M cGAS, 
13 ng μ l−1 DNA (~ 1 μ M binding sites), and 0.2 μ M cGAS or 2.6 ng μ l−1 DNA 
(~ 0.2 μ M binding sites) and 0.2 μ M cGAS were used. To compare cGAS mutants, 
the same 2.6 ng μ l−1 DNA (~ 0.2 μ M binding sites) was mixed with 1 μ M cGAS. The 
reaction was started by adding 5 mM MgCl2 with 500 μ M GTP and 50 μ M fATP 
and performed at 32 °C. Fluorescence decrease was measured in 96-well black 
non-binding PS plates (Greiner Bio-One) on Tecan infinite M1000 (λex = 305 nm, 
λem = 363 nm, gain 100, settle time 10 ms, kinetic interval 2 min). In cGAS titration 
experiments, 2.6 ng μ l−1 DNA (~ 0.2 μ M binding sites) was mixed with increasing 
cGAS concentrations from 0.05 to 20 μ M.
cGAS stimulation assays induced by DNA-bending protein were performed 
analogously. Briefly, 13 ng μ l−1 DNA (~ 1 μ M binding sites) was premixed with 
DNA-bending proteins or cGAS inactive mutant in concentrations of 0–5 μ M, 
after which 100 nM or 50 nM cGAS in 40 mM Tris pH 7.5 and 100 mM NaCl was 
added. The reaction was started by adding 5 mM MgCl2 together with 500 μ M 
GTP and 50 μ M fATP and performed at 32 °C for mcGAScd or 37 °C for hcGAS. 
Fluorescence measurement was made as described above.
Data were analysed with OriginPro 8G (OriginLab).
Radiolabelled cGAS activity assays. Radiolabelled cGAS activity assays were 
performed analogously as previously described7. Briefly, 13 ng μ l−1 DNA 
(~ 1 μ M binding sites) were mixed with 2 μ M mcGAScd and the reaction started 
by adding 50 μ M ATP, 500 μ M GTP, 5 mM MgCl2 in 40 mM Tris pH 7.5, and 
100 mM NaCl containing 1:800 [α 32P]ATP (3,000 Ci mmol−1, Hartman Analytic). 
Samples were incubated at 35 °C and the reactions were stopped by plotting on 
PEI-Cellulose F plates (Merck) and analysed by thin-layer chromatography with 
1 M (NH4)2SO4/1.5 M KH2PO4 as running buffer. The radiolabelled  products 
were visualized with a Typhoon FLA 9000 phosphor imaging system. For 
testing of fATP incorporation into cGAS enzymatic activity product, 1 μ M 
mcGAScd was mixed with 13 ng μ l−1 (~ 1 μ M binding sites) 55 bp, 500 μ M fATP/ATP, 
500 μ M GTP, 5 mM MgCl2, and 1:160 [α 32P]ATP or [α 32P]GTP (3,000 Ci mmol−1, 
Hartman Analytic) in the same condition. For testing TFAM-dependent increase 
in cGAS activity, 250 nM mcGAScd was mixed with 13 ng μ l−1 (~ 1 μ M binding 
sites) plasmid in the same condition and 1:1,000 instead of 1:160 [α 32P]ATP 
was added. The reaction was incubated at 32 °C and the radiolabelled  products 
were separated and visualized as described previously. For testing cGAS activa-
tion by short DNAs, the previously described protocol was used8. Briefly, 10 μ M 
or 5 μ M cGAS was mixed with 650 ng μ l−1 or 325 ng μ l−1 DNA, respectively, in 
buffer containing 5 mM MgCl2, 2 mM ATP and GTP, and 1:400 [α 32P]ATP. The 
reaction mixture was incubated at 37 °C and the radiolabelled products were 
separated and visualized as described previously.
Anion-exchange chromatography of cGAS reaction products. Ten micromolar 
mcGAScd or hcGAScd and 195 ng μ l−1 (~ 15 μ M binding sites) plasmid DNA were 
incubated at 35 °C for 2 h in buffer containing 40 mM Tris pH 7.5, 100 mM NaCl, 
10 mM MgCl2, 2 mM fATP, and 2 mM GTP. Reaction mixtures were centrifuged 
for 10 min at 16,100 relative centrifugal force, and the supernatant was separated 
from cGAS by ultrafiltration (30 kDa, Amicon). Resulting flow through was diluted 
in 50 mM Tris pH 9.0 and loaded on a Mono Q 5/50 GL (GE Healthcare) for 
anion-exchange chromatography (50 mM Tris, 0 M/1 M NaCl, pH 9.0). Control 
runs with fATP, GTP, 2′ 3′ - and 3′ 3′ -cGAMP were made analogously to validate 
the resulting peaks of cGAS reaction products.
Electrophoretic mobility shift assay. DNA (2.6 ng μ l−1) of length 200 bp (~ 0.2 μ M 
binding sites) was incubated with 0–2.5 μ M WT or mutant mHMGB1dCTT for 
30 min on ice in the buffer containing 50 mM Tris pH 7.5 and 100 mM NaCl. 
Samples were separated in 0.6% agarose gel prepared with Gel-Red (Biotium) in 
40 mM Tris pH 9.2 as running buffer. The gel images were obtained with Gel iX 
Imager (Intas).
ITC. The calorimetric titration of DNA (60–400 μ M in the syringe) to mcGAScd 
(20 μ M in the reaction cell) was performed with MicroCal PEAQ-ITC (Malvern) in 
buffer containing 30 mM HEPES, 100 mM NaCl, pH 7.5. The following  parameters 
were used: 25 °C, 1 × 0.4 μ l + 13 × 3 μ l injections,10 μ cal s−1 reference offset, 
750 revolutions per minute syringe stirring speed, 60 s initial delay, 6 s injection 
duration, 150 s spacing between injections, high feedback. To study TFAM direct 
interaction with cGAS, 50 μ M human full-length cGAS without MBP-tag in the 
reaction cell and 400–500 μ M hTFAM in the syringe were used. ITC was performed 
with the same parameters as above at 25 °C, 35 °C, and 15 °C. Kd, molar ratio, Gibbs 
free energy, enthalpy, and entropy of the binding were calculated with MicroCal 
PEAQ-ITC analysis software (Malvern).
SEC–RALS. SEC of cGAS–DNA complexes was performed on a Superose 6 
increase 10/300 column (GE Healthcare). mcGAScd (4 mg ml−1) was mixed with 
DNA in 1:0.6 molar ratio for 50 bp DNA or 1:0.3 molar ratio for 70 and 80 bp DNA 
in binding buffer containing 20 mM Tris, 243 mM NaCl, pH 7.5. Alternatively, 
6 mg ml−1 mcGAScd and 20 bp DNA in 1:1.1 molar ratio were used. One  hundred 
microlitres of the mix were loaded to Superose 6 increase 10/300 column 
(GE Healthcare) equilibrated with 20 mM Tris, 100 mM NaCl, pH 7.5 buffer 
and separate peaks were analysed with RALS using Viscotek 270 Dual Detector 
(Malvern) and Viscotek VE3580 Refractive Index Detector (Malvern). Molecular 
masses of the complexes were calculated with OmniSEC 4.7.0 software (Malvern).
ELISA. Fifty thousand trans-differentiated BLaER1 cells were transfected with 
20, 40, or 60 ng DNA of different lengths (20–100 bp in 5 bp intervals) and  herring 
testis DNA using 0.5 μ l Lipofectamine 2000 Transfection Reagent (Thermo Fisher 
Scientific) in 50 μ l Opti-MEM Reduced Serum medium (Thermo Fisher Scientific). 
CXCL10 expression in the supernatants was quantified 8 h after transfection using 
ELISA (BD OptEIA, human IP-10 ELISA Set). Cells stimulated with transfection 
reagent only and unstimulated cells served as control.
IFN-β mRNA expression analysis. Fifty thousand trans-differentiated WT and 
cGAS-KO BLaER1 cells were transfected with 40 ng DNA of different lengths 
(20, 40, 60, 80, 100 bp and herring testis DNA). Eight hours after stimulation, total 
RNA was isolated from 7.5 × 105 pooled cells using an RNeasy Mini Kit (Qiagen) 
following the vendor’s recommendations. Subsequently, RNA was digested with 
DNase I (Thermo Fisher Scientific) to remove residual DNA. Five hundred 
nanograms of RNA were reverse transcribed using poly (dT)18 oligonucleotides 
according to the manufacturer’s instructions (RevertAid cDNA Synthesis Kit). 
IFN-β expression levels were analysed by quantitative PCR, using gene-specific 
primers (IFN-β forward primer: CAGCATCTGCTGGTTGAAGA; reverse primer: 
CATTACCTGAAGGCCAAGGA), normalized to GAPDH expression measured 
analogously (GAPDH forward primer: GAGTCAACGGATTTGGTCGT; reverse 
primer: GACAAGCTTCCCGTTCTCAG) and the fold change was calculated on 
the basis of the unstimulated control.
Luciferase reporter assays. All immunostimulatory assays were performed in 
HEK293T STING-KI cells31. Five hundred thousand cells were seeded on 24-well 
plates and transfected with 100 ng p-125Luc42, 10 ng pGL4.74 (Promega), 50 ng 
Flag/HA–cGAS plasmids, and a total of 500 ng DNA per well (filled up with an 
empty vector pcDNA5) using Lipofectamine 2000 (Invitrogen, Thermo Fisher 
Scientific) as transfection reagent according to the vendor’s protocol. After 
14 h, cells were lysed in 200 μ l passive lysis buffer (Promega). Immunoactivity 
 experiments using a Dual-Glo luciferase assay system (Promega) were performed 
as previously described43.
Co-immunopurification of cGAS and TFAM from HEK293T cells. Ten million 
HEK293T cells were transfected with 10 μ g Flag–HA–cGAS and 10 μ g HA–TFAM 
expression vectors and harvested 24 h after transfection. Cell pellets were flash- 
frozen in liquid nitrogen and stored at − 20 °C. For immunoprecipitation, cells 
were incubated in Nonidet P-40 lysis buffer (50 mM HEPES, 150 mM KCl, 1 mM 
NaF, 0.5% NP-40, 2 mM DTT, 10 μ M ZnCl2, protease inhibitor (Sigma-Aldrich), 
pH 7.5) for 10 min on ice. Lysates were cleared by centrifugation for 30 min. 
Proteins were immunoprecipitated for 1.5 h with anti-hcGAS or a control 
 antibody bound to magnetic protein G Dynabeads (Novex, Life Technologies). 
Beads were washed four times with Nonidet-P40 lysis buffer and subjected to 
SDS– polyacrylamide gel electrophoresis and immunoblotting.
Fluorescence microscopy. HEK293T cells and primary human fibroblasts were 
grown at 40–45% and 50–60% confluency, respectively, on coverslips in a six-well 
plate overnight and treated the next day with the inhibitors Q-VD-OPH (MP 
Biomedicals) and ABT-737 (Santa Cruz Biotechnology) at a final  concentration 
of 10 μ M for 0 h or 6 h. Cells were fixed with 3% paraformaldehyde and 0.1% 
 glutaraldehyde in PBS for 12 min, reduced with 1 mg ml−1 NaBH4 for 7 min, 
 permeabilized with 0.25% (v/v) Triton X-100, and blocked with 3% (w/v) BSA 
in PBS for 3 h.
MEF and MEF HMGB1-KO cells were grown at 40–50% confluency on 
 coverslips in a six-well plate overnight and transfected with 2 μ g pcDNA5/FRT/TO 
(Invitrogen, Thermo Fisher Scientific) or eGFP–cGAS expression vectors 
 overnight. Cells were then fixed with 2% paraformaldehyde in PBS for 10 min at 
room temperature, permeabilized with 0.5% (v/v) Triton X-100, and blocked with 
2% (w/v) BSA in PBST for 10 min.
Immunostaining was performed for 1 h at room temperature with primary anti-
bodies against TFAM (1:50), TOM20 (1:250), or HMGB1 (1:100). The  primary 
antibodies were detected with the secondary anti-mouse or anti-rabbit goat or 
donkey antibodies (1:500) by incubation for 1 h. After immunostaining,  samples 
were post-fixed in 4% paraformaldehyde for 10 min, stained with 1 μ g ml−1 
(HEK293T and primary human fibroblasts) or 10 μ g ml−1 DAPI (MEF) for 10 min, 
and mounted in VECTASHIELD (Vector Laboratories). Cells were washed three 
times with PBST after each step.
Three-dimensional structured illumination microscopy (3D SIM) was 
 performed with a DeltaVision OMX V3 microscope (GE Healthcare), equipped 
with a × 100/1.40 numerical aperture PlanApo oil-immersion objective (Olympus), 
Cascade II:512 EMCCD cameras (Photometrics), and lasers for 405 nm, 488 nm, 
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and 594 nm. Image stacks were first reconstructed and corrected for colour shifts 
with softWoRx 6.0 Beta 19 (unreleased) software. After establishing composite tiff 
stacks with a custom-made macro in Fiji, the data were subsequently aligned again 
and maximum intensity projections were used.
Wide-field fluorescent microscopy was performed with a personal DeltaVision 
(pDV) microscope (GE Healthcare) equipped with a × 60/1.42 oil-immersion 
objective PlanApo U (Olympus), Cool-Snap camera (12 bit, 1024 pixels × 1024 
pixels, Photometrics) by acquiring one focal plane. Insight SSI LEDs 
(GE Healthcare) for 405 nm, 488 nm, 594 nm were used.
Statistical analysis. No statistical methods were used to predetermine sample 
size. The experiments were not randomized and investigators were not blinded to 
allocation during experiments or accessing the outcome.
All experiments were conducted at least three times and the mean values and 
s.d. of technical or biological replicates (BLaER1 stimulation experiments) were 
calculated. Statistical significance, if applicable, was calculated on the basis of 
unpaired one-sided t-tests.
For the data fitting in Fig. 3, the description is included in the figure legend and 
in Supplementary Methods.
For quantification of TFAM signal in microscopy images presented in Extended 
Data Fig. 9c, maximum intensity projections were subsequently loaded as RGB into 
Volocity calculation software (Volocity 6.1.2 (Perkin Elmer)). Areas corresponding 
to mitochondria, nucleus, and cytosol were obtained, segmented, and measured 
in all channels by defining intensity threshold and minimum object size on each 
channel. Cytosolic TFAM signal was quantified according to number of counts 
and signal area, and additionally corrected and normalized to the cytosolic area 
in an image. For each calculation, three different cells and three segments per cell 
were used.
Figure preparation. Figures showing protein structures and electron densities 
were prepared with PyMOL Molecular Graphic Systems44. Sequence alignment 
(Extended Data Fig. 8a) was prepared with Jalview45. All other figures were 
 prepared with Microsoft Excel, OriginPro 8G (OriginLab), or Matlab_R2015a 
(MathWorks).
Data availability. The coordinates and structure factors have been deposited 
in the PDB under accession number 5N6I. All other data are available from the 
 corresponding author upon reasonable request.
Code availability. Matlab code used in this study is available from the 
 corresponding author upon reasonable request.
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Extended Data Figure 1 | cGAS activity increases with DNA length 
in vitro and in vivo. a, b, CXCL10 cytokine production of WT (a) and 
cGAS-KO (b) transdifferentiated BLaER1 cells. Cells were transfected 
with 20, 40, and 60 ng DNA of increasing length (20–100 bp in 5 bp 
intervals) and herring testis (HT) DNA, and CXCL10 concentration in 
the supernatant was measured by ELISA. The first two bars of each series 
represent unstimulated cells and Lipofectamine controls. Shown are 
mean values ± s.d., n = 3. c, Fold change of IFN-β mRNA expression in 
WT and cGAS-KO BLaER1 cells transfected with 20–100 bp and herring 
testis DNA. IFN-β mRNA expression levels were normalized to GAPDH 
mRNA and the fold change was calculated on the basis of the unstimulated 
control. Shown are mean values ± s.d., n = 3. d, Radiolabelled cGAMP 
production of cGAS stimulated with DNA of different lengths (20, 35, 
55 bp, and plasmid). cGAS reactions in the presence of [α 32P]ATP were 
stopped at the indicated time points and radiolabelled compounds 
(shown with black arrows) were visualized. e, f, Radiolabelled cGAMP 
production by (left to right) hcGAScd, hcGAS, and mcGAScd stimulated 
with 14, 16, 18, 20, 50 bp and plasmid DNA. cGAS (e, 5 μ M; f, 10 μ M) was 
incubated with 325 ng μ l−1 (e) or 650 ng μ l−1 (f) DNA of indicated length 
in the presence of ATP, GTP, and [α 32P]ATP at 37 °C. The reactions were 
stopped at the indicated time points and radiolabelled compounds (shown 
with black arrows) were visualized. g, mcGAScd activity measured by the 
rate of fATP incorporation into fGAMP (see Extended Data Fig. 2 for 
the assays) in the presence of linearized or circular plasmid DNA. Mean 
values of initial cGAS reaction rates (∆ F/∆ t) are plotted against DNA 
constructs ± s.d., n = 3. No significant difference between linearized and 
circular plasmid could be detected.
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Extended Data Figure 2 | Description of the fluorescence-based cGAS 
activity assay. a, Radiolabelled cGAS products obtained with different 
NTP combinations. Reactions were stopped at the indicated time points, 
and products separated by thin-layer chromatography and visualized by 
radiography. b, The principle of the fluorescence-based cGAS activity 
assay. cGAS catalyses the conversion of fluorescent ATP analogue fATP 
(2-aminopurine riboside triphosphate, three orange stars) into less 
fluorescent fGAMP (fluorescent cGAS product, one orange star), resulting 
in a gradual decrease in fluorescence intensity during the reaction.  
c, General workflow for calculating the initial cGAS reaction rates. 
From initial fluorescence curves (left), the background fluorescence was 
subtracted and the resulting curve was inverted for better visualization  
(∆ F). Initial rates were calculated as a slope of the linear intervals (red 
dashed lines) and defined as ∆ F/∆ t (relative fluorescence units per 
minute) (right). d, e, fGAMP mobility in anion-exchange chromatography 
on a MonoQ 5/50 GL column. d, Comparison of fGAMP, produced by 
cGAS from fATP and GTP (red), 2′ 3′ -cGAMP (black), and 3′ 3′ -cGAMP 
(blue) mobilities. e, Comparison of fGAMP (red), fATP (black), and GTP 
(blue) mobilities.
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Extended Data Figure 3 | Electron densities and comparison with cGAS 
in complex with 18 bp DNA. a, 2Fo − Fc electron density of 39 bp DNA 
within the complex at a contour level of 1σ. b, Close-up view of the cGAS 
active site (orange) superposed with a previously published structure of 
cGAS bound to 18 bp DNA (PDB accession number 4LEY, blue). Shown 
is the 2Fo − Fc electron density of the active-site residues at a contour level 
of 1σ. c, Superposition of the cGAS complex with 39 bp DNA (green and 
grey) with 18 bp DNA-bound cGAS (PDB accession number 4LEY, blue). 
A slight rotation of superposed 18 bp-cGAS (blue) relative to 39 bp-cGAS 
(grey) is shown with a black arrow. The superposition shows the difference 
between a hypothetical straight (red dashed line) DNA, leading the 
previously proposed DNA end preference of cGAS, and the curved DNA 
observed in our crystal structure. d, Binding mode of the DNA strands to 
cGAS within the previously published structure (PDB accession number 
4LEY). Two neighbouring crystallographic asymmetric units represent 
a ‘head-to-tail’ cGAS dimer orientation. Elongation of both strands (red 
dashed line) leads to a steric clash (orange star). e, Schematic model of 
cGAS binding to continuous DNA in alternating ‘head-to-head’ and ‘tail-
to-tail’ arrangements. DNA curves over λ bp (black arrows). f, Schematic 
model of cGAS binding to continuous DNA in a (not observed) ‘head-
to-tail’ arrangement. DNA curves over λ/2 bp (black arrows), if the same 
density of cGAS per DNA is assumed. Thus DNA must be bent twice more 
often than in model e to sustain the parallel DNA arrangement and is 
energetically less favourable.
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Extended Data Figure 4 | Asymmetric unit of the cGAS–39 bp complex 
and details of protein–protein and protein–DNA contacts. a, An 
overview of the asymmetric unit of 39 bp DNA-bound cGAS. Filled oval-
like symbol represents a twofold crystallographic symmetry axis; black 
dashed lines represent non-crystallographic twofold symmetry axes. The 
asymmetric unit contains one full and one half ‘head-to-head’-oriented 
cGAS4–DNA2 complex. Residues mutated to examine four areas (encircled 
1–4) are shown as red sticks. b, Close-up view of mutated interfaces: 
1, cGAS active site (yellow) with superimposed cGAMP (from PDB 
accession number 4LEZ, grey) and labelled active-site residues D213 and 
D307; 2–4, potential protein–protein or DNA–protein interaction sites, 
respectively. Mutated residues are in red. c, d, Mutational analysis of the 
described regions of mcGAScd in vitro and hcGAS in vivo, respectively. 
D307N and D319N correspond to active-site mutations in mouse and 
human cGAS, respectively. c, cGAS activity measured by the rate of 
fATP incorporation into fGAMP (∆ F/∆ t, see Extended Data Fig. 2) and 
normalized to WT. Mean values represent percentage of WT activity ± s.d., 
n = 3. d, Percentage change of IFN-β promoter-driven luciferase activity 
upon the expression of WT or mutant cGAS. IFN-β response was 
measured as a proportion of firefly (FF) to Renilla (REN) luciferase activity 
in HEK293T STING-KI cells upon Flag/HA–hcGAS overexpression. All 
ratios were normalized to WT. Mean values represent the percentage of 
WT activity ± s.d., n = 3. Mutants are named according to their position 
in hcGAS: D319N (active site), Q454R, S263K, R166E, K173E, K458E, 
K258E mutants refer to D307N, Q439R, S249K, K151E, R158E, R443E, 
and R244E in mcGAS.
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Extended Data Figure 5 | cGAS affinity to DNA increases with DNA 
length accompanied by increase in number of cGAS binding sites along 
the DNA. ITC measurements of mcGAScd binding to 20, 40, 45, 50, 70, 
and 80 bp DNA. For each DNA, the power differential (DP) is plotted 
against time and ∆ H is plotted against the molar ratio of DNA:cGAS. 
Calculated binding parameters are given on each graph.
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Extended Data Figure 6 | cGAS forms higher-ordered structures on 
long DNA. a, Signature plots for each ITC measurement (Extended Data 
Fig. 5) showing ∆ G (green), ∆ H (blue), and − T∆ S (red) for each binding 
reaction. b, ∆ H and − T∆ S components of Gibbs free energy measured 
with ITC for mcGAScd binding to 20–80 bp DNA are plotted against 
DNA length ± s.d. of the measured values from the fit. c, Molecular mass 
distribution within SEC peaks (Fig. 2c–f) containing mcGAScd1–DNA1 
(with 20 bp DNA), mcGAScd4–DNA2 (with 50 bp DNA), and  
mcGAScd6–DNA2 (with 70 and 80 bp DNA) calculated with RALS. 
Refractive index (red) and estimated molecular mass (black) are plotted 
against retention volume.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
119
LetterreSeArCH
Extended Data Figure 7 | TFAM enhances cGAS activity by 
prearranging DNA into U-shape. a, DNA ladders (blue) and (b) DNA-
bound TFAM structure (PDB 3TMM, red) arrange DNA in a remarkably 
similar fashion. The two similarly spaced DNA strands flanking cGAS 
ladders or the TFAM U-turn (black dotted lines) provide a possible 
explanation for the effect of TFAM on cGAS activity. c, Radiolabelled 
cGAMP production in the presence of increasing TFAM concentrations. 
cGAS reactions with ATP, GTP, and [α 32P]ATP were stopped at the 
indicated time points and the radiolabelled compounds (shown with black 
arrows) were visualized. d, Activation of mcGAScd by mTFAM and DNA 
of increasing length (20–200 bp or plasmid DNA). Mean values of initial 
cGAS reaction rates (∆ F/∆ t, see Extended Data Fig. 2) are plotted against 
increasing concentrations of mTFAM ± s.d., n = 4–8.
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Extended Data Figure 8 | See next page for caption.
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Extended Data Figure 8 | HMGB proteins activate cGAS through DNA 
bending. a, Sequence alignment of HMG boxes from different HMG 
proteins. Positions of intercalating residues, responsible for the DNA-
bending activity (red), are shown with respect to their location within 
helices I, II, or III of HMGB1_boxA (green lines) and HMGB1_boxB 
(blue lines). b, Structures of box A in complex with DNA (PDB accession 
number 4QR9) and box B (PDB accession number 1HME) of rat HMGB1 
with indicated intercalating residues (red). c, mcGAScd activity measured 
by the rate of fATP incorporation into fGAMP (see Extended Data  
Fig. 2) in the presence of increasing concentration of mHMGB1dCTT 
WT and intercalating residues mutants. Double mutations (F38A in box 
A, and F103A or I122A in box B) or triple mutants (F38A in box A, and 
both F103A and I122A in box B) were used. Mean values of initial cGAS 
reaction rates (∆ F/∆ t) are plotted against increasing concentrations 
of mHMGB1dCTT ± s.d., n = 7. d, Electrophoretic mobility shift assay 
of mHMGB1dCTT WT and point mutants with 2.6 ng μ l−1 (~ 200 nM 
binding sites) 200 bp DNA. Introduced mutations do not reduce DNA 
binding of mHMGB1 mutants under conditions used for cGAS activity 
assays (c). e, mcGAScd activity measured by the rate of fATP incorporation 
into fGAMP (see Extended Data Fig. 2) in the presence of mTFAM with 
circular or linearized plasmid. Mean values of initial cGAS reaction rates 
(∆ F/∆ t) are plotted against increasing concentrations of mTFAM ± s.d., 
n = 3. f, ITC of hcGAS with hTFAM at 35, 25, and 15 °C. Power differential 
(DP) is plotted against time of the experiment. hTFAM (~ 530 μ M) was 
titrated to ~ 50 μ M hcGAS. No binding is observed, indicating Kd > 100 μ M.  
g, h, cGAS activity measured by the rate of fATP incorporation into 
fGAMP (see Extended Data Fig. 2) in the presence of increasing TFAM 
concentrations. Mean values of initial cGAS reaction rates (∆ F/∆ t) are 
plotted against increasing concentrations of TFAM ± s.d., n = 3 or 4. 
mcGAScd (g) and hcGAS (h) are activated by both human and mouse 
TFAM.
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Extended Data Figure 9 | See next page for caption.
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Extended Data Figure 9 | TFAM relocalizes from mitochondria into 
cytosol during mitochondrial stress. a, b, TFAM (green) localization 
upon mitochondrial stress induction. Cells were incubated with caspase 
and Bcl-2 inhibitors for indicated time and stained for super-resolution 
fluorescence microscopy (3D SIM). Mitochondria were visualized by 
TOM20 (mitochondrial import receptor subunit, red) staining, cell nuclei 
by DAPI (blue). a, TFAM cytosolic localization under mitochondrial stress 
conditions in HEK293T cells. b, TFAM decondensation in mitochondria 
and its leakage into cytoplasm in human primary fibroblasts in response to 
mitochondrial stress. c, Example of statistical analysis in human primary 
fibroblasts (b). Cells were incubated with caspase and Bcl-2 inhibitors for 
6 h and stained for super-resolution fluorescence microscopy (3D SIM). 
Mitochondria were visualized by TOM20 (mitochondrial import  
receptor subunit) staining, cell nuclei by DAPI. Areas stained for  
TFAM (green), TOM20 (red), and nucleus (blue) are defined with  
yellow line. Cytosolic TFAM spots are depicted on the top left view.  
d, Comparison of cytosolic TFAM signal in control cells (0 h) and under 
mitochondrial stress conditions (6 h) (b, c). Plotted are mean values 
of cytosolic TFAM signal calculated as area (top) or number of spots 
(bottom) ± s.d. Three cells of each type and three segments per cell were 
used (n = 9). Single asterisk indicates a statistically significant difference 
(P < 0.05, P = 0.0267), double asterisk indicates a statistically significant 
difference (P < 0.01, P = 0.0050), compared with control. The TFAM 
signal in the cytosol of control cells (0 h) represents background signal.  
e, Co-immunopurification of cGAS and TFAM. Cell lysates with 
overexpressed Flag/HA–cGAS and HA–TFAM were incubated with anti-
hcGAS or with a control antibody (A/b) and the proteins in total lysates 
(TL) and elution fractions (IP) were visualized by immunoblotting (IB).
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 10 | HMGB1 but not eGFP co-localizes with 
cytosolic DNA. a, b, HMGB1 (red), eGFP (green), and DNA (blue) 
localization in WT or HMGB1-KO MEFs. DNA was stained by DAPI 
(blue). Images were obtained by wide-field fluorescence microscopy 
(pDV). Fluorescent signal within enlarged images is enhanced until 
saturation of the nuclear signal to better visualize cytoplasmic structures. 
a, Cells were transfected with eGFP expression construct. HMGB1 co-
localizes with DAPI-staining in WT but not HMGB1-KO cells. eGFP 
does not co-localize with DNA or HMGB1. b, In non-transfected 
cells, HMGB1 and DAPI stainings are present only in the nucleus. The 
HMGB1 staining in the cytosol of non-transfected and HMGB1-KO cells 
represents background signals that become visible with the artificial signal 
amplification beyond saturation, as shown in the zoom-in images.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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`    Experimental design
1.   Sample size
Describe how sample size was determined. Sample sizes varied between different types of experiments. Sample sizes were at 
least n=3.
2.   Data exclusions
Describe any data exclusions. No data were excluded
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
Experimental findings were reliably reproduced
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
No randomization
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
No blinding
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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`   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
OriginPro 8G (OriginLab), MatLab R2015a (MatLab scripts are available upon 
request), crystallographic software (XDS, XSCALE, STARANISO server, PHASER, 
REFMAC - see Methods section), OmniSEC 4.7.0 (Malvern), Volocity 6.1.2 (Perkin 
Elmer, Waltham, MA, USA), MicroCal PEAQ-ITC analysis software (Malvern), 
Microsoft Excel.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
`   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
Unique materials such as the protein expression vectors or the cGAS antibody are 
available upon request. The Tom20 antibody from Santa Cruz Biotechnology is 
discontinued and cannot be purchased anymore. The source of all other materials 
is listed in the Methods part and can be purchased as indicated.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
1) The monoclonal anti-human cGAS antibody (raised against the human cGAS 
Mab21 domain in rat) and a control antibody were produced at the Helmholtz 
Zentrum München (Monoclonal Antibody Core Facility, German Research Center 
for Environmental Health) and have been validated in both Western Blots and IPs 
with purified proteins or human cell lysates containing endogenous or 
overexpressed human cGAS.  
2) The HA antibody coupled to horseradish peroxidase was purchased from Cell 
Signaling (monoclonal AB raised in mouse , clone 6E2, cat# 2999S, lot# 3) and 
validated in Western Blots of cell lysates containing overexpressed HA-tagged 
proteins. 
3) The TFAM antibody was purchased from Abnova (polyclonal AB against human 
full length TFAM produced in mouse, cat# H00007019-B01P, lot# G5251) and 
validated in Western Blots of human cell lysates containing endogenous and 
overexpressed TFAM. 
4) The Tom20 antibody was purchased from Santa Cruz Biotechnology (polyclonal 
AB against full length human Tom20 produced in rabbit, cat# sc-11415, lot# K1915) 
and was validated before (Wurm et al, 2011, PNAS and Kukat et al, 2011, PNAS).  
5) The HMGB1 antibody was purchased from Sigma Aldrich (monoclonal AB against 
human HMGB1 aa 1-91 produced in mouse, clone 2F6, cat# WH0003146M8, lot# 
FB201-2F6) and was validated in Western Blots of human and mouse cell lysates 
containing endogenous and/or overexpressed HMGB1 and 
immunocytofluorescence (M.K. Gunasekaran et al, 2013, Cytokine). 
6) All Alexa-coupled secondary antibodies were purchased from Thermo Fisher 
Scientific (goat anti-mouse Alexa594: cat# A11032; goat anti-rabbit Alexa488 cat# 
A11034, lot# 1141875; donkey anti-rabbit Alexa594 cat# A21207, lot# 1454437; 
donkey anti-mouse Alexa488 cat# A21202, lot# 1423052; donkey anti-mouse 
Alexa594 cat# A21203, lot# 431805) and were validated in fixed cells that were not 
stained with primary antibodies.
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10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. HEK293T cells were purchased from ATCC (cat# CRL-11268). MEF and MEF 
HMGB1-KO cells were purchased from HMGBiotech (cat# HM-221). 
HEK293T STING-KI cells (knock in of mCherry fused to mouse STING) were 
generated by transduction of HEK293T cells and are described in Ablasser et al. 
Nature, 2011. 
Female primary human fibroblast cell line is a kind gift from Dr. med. Marion 
Cremer (T. Cremer group, Ludwig-Maximilians-University Munich, Biocenter 
Martinsried). 
BLaER1 cells were transdifferentiated from a B cell lymphoma cell line (a subclone 
of the Seraphina Burkitt lymphoma line expressing the transcription factor C/EBPα 
fused to the estrogen receptor hormone binding domain) which are a kind gift 
from Thomas Graf, Center for Genomic Regulation, Universidad Pompeu Fabra and 
Institució Catalana de Recerca i Estudis Avançats, Barcelona. BlaER1 cells are 
described and functionally validated in Rapino et al. Cell Reports, 2013.  
BLaER1 cGAS-KO cells were generated through genomic silencing the cGAS gene in 
the Seraphina cell line and subsequent transdifferentiation of these cells. 
All knock-in or knock-out cell lines were validated by Western Blots of cell lysates 
and in functional or microscopy assays as written in the manuscript. BLaER1 cGAS-
KO cells were further validated by sequencing.
b.  Describe the method of cell line authentication used. All bought cell lines were kept at low passages in order to maintain their identity. 
Non-commercially available HEK293T STING-KI, BLaER1 and BLaER1 cGAS-KO cell 
lines have not been authentificated. 
Female primary human fibroblast cell line was authentificated as follows. DNA was 
isolated separately from the samples. Genetic characteristics were determined by 
PCR-single-locus-technology. 21 independent PCR-systems Amelogenin, D3S1358, 
D1S1656, D6S1043, D13S317, Penta E, D16S539, D18S51, D2S1338, CSF1PO, Penta 
D, TH01, vWA, D21S11, D7S820, D5S818, TPOX, D8S1179, D12S391, D19S433 and 
FGA were investigated (Promega, PowerPlex 21 PCR Kit). In parallel, positive and 
negative controls were carried out yielding correct results.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
All cell lines were routinely tested for mycoplasm contaminations.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used in this study.
`    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
No animals were used in this study.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
The study did not involve human research participants.
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Supplementary	Methods	
Quantitative	 analysis	 of	 cooperative	 binding	 of	 cGAS	
along	DNA	
1 Introduction	
The	catalytic	activity	of	cGAS	is	activated	by	binding	to	DNA,	which	induces	a	structural	change	
that	properly	forms	the	active	site.	 Initial	structural	studies	showed	that	two	cGAS	molecules	
form	 a	 heterotetrameric	 complex	 with	 two	 DNA	 ligands.	 Hereby,	 the	 two	 cGAS	 molecules	
sandwich	2,	approx.	30°	angled	DNA	duplex	molecules.	cGAS	binds	approx.	16-20	base	pairs	of	
each	DNA	ligand.	However,	dsDNA	that	in	principle	fully	spans	the	cGAS	dimer	(20	bp)	does	not	
activate	the	enzyme	to	any	appreciable	amounts	in	vitro	and	in	human	cells	in	vivo	as	well.	An	
activating	transition	is	observed	if	the	DNA	length	is	increased	to	40-50	bp.	Longer	DNA	activates	
cGAS	even	more	robustly,	and	long	plasmid	DNA	is	a	"gold	standard"	for	cGAS	activation.	Even	if	
we	account	for	“DNA	end”	effects,	i.e.	the	enzyme	falling	off	ends	more	rapidly	than	dissociation	
from	internal	DNA	binding	sites	through	Brownian	motion,	the	evident	incapability	of	short	blunt	
ended	DNAs	to	activate	cGAS	and	the	increasing	activity	with	increasing	DNA	length	(keeping	the	
molarity	of	base	pairs	constant)	is	not	explained	by	the	cGAS	dimer	model.	Our	structural	results	
indicate	that	once	the	DNA	ligands	are	long	enough	to	bind	two	cGAS	dimers	next	to	each	other,	
a	DNA:protein	network		is	formed	that	resembles	a	twisted	ladder.		
2 DNA-Protein	Ladder	Model	(DPL)	
Our	new	crystal	structures	suggest	that	pairs	of	cGAS	dimers	mutually	stabilize	each	other	via	a	
DNA:protein	network:	cGAS	dimers	are	positioned	like	the	rungs	of	a	ladder,	with	the	two	DNA	
strands	being	the	beams.	A	mathematical	treatment	for	the	cooperative	binding	of	cGAS	dimers	
to	 DNA	 can	 be	 formulated	 along	 the	 general	 ideas	 of	 the	Monod-Wyman-Changeux	 (MWC)	
model	for	cooperative	transitions	in	proteins:	proteins	bind	as	monomers	along	a	single	duplex	
of	DNA	with	a	dissociation	constant	K1[mol/l].	Along	two	parallel	DNA	duplexes,	such	as	those	
prearranged	in	the	vicinity	of	a	cGAS:DNA	heterotretramer,	two	cGAS	molecules	bind	with	an	
overall	microscopic	dissociation	 constant	K2[mol/l].	 Since	we	assume	 for	 the	model	 that	 two	
cGAS	molecules	 bind	 simultaneously,	 the	macroscopic	 dissociation	 constant	 for	 assembly	 of	
cGAS	 dimers	with	 two	 parallel	 DNA	molecules	would	 be	 K22,	 analogous	 to	 the	 empirical	 Hill	
equation.	 Furthermore,	 the	 binding	 of	 two	 cGAS:DNA	 heterodimer	 into	 a	 cGAS2:DNA2	
heterotetramer	is	characterized	by	a	dissociation	constant	K3	[mol/l].	The	overall	binding	scheme	
is	depicted	in	(Fig.	3a).	The	model	includes	simplifications.	In	particular,	we	neglect	binding	of	
single	 cGAS	molecules	 to	 the	 prearranged	 "dimeric"	DNA	 lattice	 and	 the	 equilibrium	 can	 be	
formulated	 as:	 2	𝑐𝐺𝐴𝑆 + 2	𝐷𝑁𝐴 *++ 𝑐𝐺𝐴𝑆,: 𝐷𝑁𝐴,.	 Furthermore,	 we	 neglect	 interactions	 between	
DNA	molecules	with	unequal	number	of	bound	cGAS	molecules.	 Such	an	assumption	can	be	
justified,	if	interaction	between	DNA	molecules	with	equal	number	of	bound	cGAS	molecules	is	
much	 stronger	 than	 interaction	 between	 DNA	 molecules	 with	 unequal	 numbers	 of	 cGAS,	
because	latter	has	"less"	interacting	cGAS	dimers	between	the	two	DNA	molecules.	
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3 Mathematical	Modelling	
3.1 Nomenclature	DNA-Protein	Ladder	Model	(DPL)	
In	deriving	an	expression	for	the	activity	as	a	function	of	the	concentration	and	lengths	of	DNA	
ligands	and	the	concentration	of	protein,	we	use	the	following	terminology:	
p0:	 total	concentration	of	protein	(cGAS	monomer)	
l0:	 total	concentration	of	DNA	molecules		
s:	 number	of	binding	sites	per	DNA	molecule	
pilj:	 complex	of	j	DNA	with	i	cGAS	molecules	
K1:	 equilibrium	dissociation	constant	cGAS	monomer	with	DNA	
K2:	 equilibrium	dissociation	 constant	 for	 binding	 of	 cGAS	 to	 prearranged	DNA	molecules,	
forming	the	cGAS2:DNA2	complex	
K3:	 equilibrium	 dissociation	 constant	 for	 the	 interaction	 of	 two	 cGAS:DNA	 complexes,	
forming	the	cGAS2:DNA2	complex	
a:	 a	constant	relating	the	concentration	of	DNA	bound	cGAS	to	the	observed	rate	of	product	
formation	
3.2 General	dimer	equilibrium	
In	general,	the	formation	of	a	dimer,	e.g.	the	association	of	two	DNA	molecules	by	cGAS,	can	be	
described	in	its	simplest	form	with	the	following	equilibrium	scheme:	
𝑙 + 𝑙 * 𝑙,	 (1.1)	
with	𝐾 = 1off1on	.	Using	the	resulting	equations	𝑙 ∗ 𝑙 = 𝐾𝑙,	 (1.2)	𝑙6 = 𝑙 + 2𝑙,	 (1.3)	
one	can	derive	expression	for	l	and	l2	as	a	function	of	l0	and	K:	
𝑙 = − 89 𝐾 − 𝐾 𝐾 + 8𝑙6 (1.4)	𝑙, = 8; 𝐾 + 4𝑙6 − 𝐾 𝐾 + 8𝑙6 (1.5)	
If	l	has	some	form	of	associated	activity	a1	(e.g.	fluorescence,	enzymatic	activity)	and	l2	a	related	
property	 2*a2	 (since	 l2	 has	 two	 "active"	 sites),	 one	 can	 combine	 equations	 (1.4	 and	 1.5)	 to	
compute	the	overall	activity	A:	
𝐴 = 89 𝑎, − 𝑎8 𝐾 + 4𝑎,𝑙6 − 𝑎, − 𝑎8 𝐾 𝐾 + 8𝑙6 (1.6)	
With	𝑎 = 𝑎, − 𝑎8,	𝑏 = 𝑎,	and	K'	=	K/4	one	obtains	
𝐴 = 𝑎𝐾′ + 𝑏𝑙6 − 𝑎 𝐾′ 𝐾′ + 2𝑙6	 (1.7)	
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3.3 DNA-Protein	Ladder	Model	(DPL)	
We	now	turn	to	the	scheme	outlined	in	(Fig.	3a)	and	derive	an	equation	for	the	concentration	of	
DNA	bound	cGAS.	In	doing	so,	we	assume	that	under	steady	state	conditions,	ATP/2APTP,	GTP	
and	cGAMP/fGAMP	have	no	substantial	influence	on	K1,	K2	and	K3.		The	experimentally	observed	
steady	 state	 activity	 A	 of	 product	 formation	 (in	 our	 case	 measured	 by	 (∆F/∆t:	 change	 in	
fluorescence	per	time)	can	be	written	as	
𝐴 = 𝑎8 ∗ 𝑖 ∗ 𝑝B𝑙si=1 	+ 	 𝑎, ∗ 2	𝑖 ∗ 𝑝,B𝑙,si=1 (2.1)	
with	a1	and	a2	constants	that	relate	the	concentration	of	DNA	bound	cGAS	monomers	(e.g.	p1l)	
and	dimers	(e.g.	p2l2)	to	the	rate	of	product	formation.	The	factor	of	2	in	the	second	sum	accounts	
for	the	two	"active"	sites	in	each	p2il2.	For	a	given	number	of	binding	sites	s,	at	equilibrium,	the	
scheme	in	(Fig.	3a)	has	the	following	equilibrium	equations:		
a) conservation	of	protein	and	DNA	ligand:
𝑝6 ≈ 𝑝	 (2.2)	𝑙6 = 𝑙 + 2	𝑙, + 𝑝B𝑙GBH8 	+ 	2	𝑝,B𝑙, (2.3)	
To	 derive	 a	 mathematical	 expression,	 in	 2.1	 a	 simplification	 is	 used:	 we	 designed	 our	
experiments	with	for	the	most	part	a	surplus	of	protein	over	DNA	binding	sites,	assuming	that	
one	 molecule	 of	 cGAS	 covers	 ~20	 bp	 of	 DNA.	 For	 the	 purpose	 of	 deriving	 an	 analytic	
mathematical	equation,	we	assume	p0>>s*l0,	i.e.	p≈p0.	
b) binding	of	cGAS	to	DNA:	we	assume	that	cGAS	can	bind	anywhere	on	DNA.	The	DNA	has	s
non-overlapping	binding	sites	(e.g.	one	per	20	bp)	all	s	binding	sites	are	equal.
G	∗IJ	∗K	ILK = 𝐾8	 (2.4)	
GM8 	∗IJ∗ILK	,	∗I+K = 𝐾8	 (2.5)	
...	
GM BM8 	∗IJ∗INOLK	B	∗INK = 𝐾8	 (2.6)	
...	
	IJ∗IPOLK	G	∗IPK = 𝐾8	 (2.7)	
Likewise	for	the	cGAS	dimers	bound	to	two	DNA	molecules	(l2	denotes	the	prearranged	“DNA	
dimer”):	
G∗IJ+∗K+	I+K+ = 𝐾,,	 (2.8)	
...	
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	 GM BM8 	∗IJ+∗I+NO+K+	B∗I+NK+ = 𝐾,,	 (2.9)	
	
	 ...	
	
	 IJ+∗I+PO+K+	G	∗I+PK+ = 𝐾,,	 (2.10)	
	
	
Finally,	we	have	the	interaction	of	two	cGAS	bound	DNA	molecules	p1l.	We	only	need	one	
equation;	all	others	are	redundant	due	to	thermodynamic	linkage.	
	
	 ILK∗ILKI+K+ = 𝐾Q	 (2.11)	
	
	
For	a	given	s,	the	equations	2.1a,	2.2,	...2.7	can	now	be	used	to	eliminate	all	but	one	pil	or	one	
p2il2.	Repeating	this	procedure	for	each	of	the	pil	and	p2il2,	we	obtain	a	set	of	expressions	for	the	
concentrations	of	the	pil	and	p2il2	(i=1...s)	as	functions	of	s,	p0,	l0,	K1,	K2	and	K3.		
	
For	 example,	 let's	 look	 at	 the	 case	 s=3.	 In	 Mathematica	 code,	 we	 formulate	 the	 following	
expressions	for	equations	2.2,	...2.10:	
	
eq1 = l0 - (l + p1l + p2l + p3l +2*l2+2*p2l2 + 2*p4l2 + 2*p6l2) 
eq2 = 3*p0*l - k1*p1l 
eq3 = 2*p0*p1l - 2*k1*p2l 
eq4 = p0*p2l - 3*k1*p3l 
eq5 = 3*p0*p0*l2 - k2^2*p2l2 
eq6 = 2*p0*p0*p2l2 - 2 k2^2*p4l2 
eq7 = p0*p0*p4l2 - 3 k2^2*p6l2 
eq8 = p1l*p1l - k3*p2l2 
	
In	 equilibrium,	 eq0=0,	 eq1=0,	 eq2=0	 ...	 We	 now	 use	 these	 expressions	 in	 Mathematica	 to	
eliminate	l	and	all	pil	but	pl:	
	
Eliminate[{eq1==0,eq2==0,eq3==0,eq4==0,eq5==0,eq6==0,eq7==0,eq8==0},{l,l2,p2l,p3l,p2l2,p4l2,p6l2
}] 
	
This	procedure	results	in	the	following	equation:		
	
p1l (k1^3 k2^4 k3 p0 + 3 k1^2 k2^4 k3 p0^2 + 3 k1 k2^4 k3 p0^3 + k2^4 k3 p0^4 + 2 k1^2 k2^6 p1l 
+ 6 k1^2 k2^8 p0^2 p1l + 6 k1^2 k2^4 p0^4 p1l + 2 k1^2 p0^6 p1l) == 3 k1^2 k2^4 k3 l0 p0^2 
 
The	equation	can	be	solved	for	p1l	with	
	
Solve[p1l (k1^3 k2^4 k3 p0 + 3 k1^2 k2^4 k3 p0^2 + 3 k1 k2^4 k3 p0^3 + k2^4 k3 p0^4 + 2 k1^2 
k2^6 p1l + 6 k1^2 k2^4 p0^2 p1l + 6 k1^2 k2^2 p0^4 p1l + 2 k1^2 p0^6 p1l) == 3 k1^2 k2^4 k3 l0 
p0^2, {p1l}] 
	
resulting	in	a	solution	that	describes	the	concentration	of	pil	as	a	function	of	s=3,p0,	l0,	K1,	K2:	
	
p1l = (k1^3 k2^4 k3 p0 - 3 k1^2 k2^4 k3 p0^2 - 3 k1 k2^4 k3 p0^3 - k2^4 k3 p0^4 +  
Sqrt((k1^3 k2^4 k3 p0 + 3 k1^2 k2^4 k3 p0^2 + 3 k1 k2^4 k3 p0^3 + k2^4 k3 p0^4)^2 + 12 k1^2 k2^4 
k3 l0 p0^2 (2 k1^2 k2^6 + 6 k1^2 k2^4 p0^2 + 6 k1^2 k2^2 p0^4 + 2 k1^2 p0^6)))/ 
(4 (k1^2 k2^6 + 3 k1^2 k2^4 p0^2 + 3 k1^2 k2^2 p0^4 + k1^2 p0^6)) 
 
p2l = (-k1^3 k2^4 k3 p0^2 - 3 k1^2 k2^4 k3 p0^3 - 3 k1 k2^4 k3 p0^4 - k2^4 k3 p0^5 +  
Sqrt((k1^3 k2^4 k3 p0^2 + 3 k1^2 k2^4 k3 p0^3 + 3 k1 k2^4 k3 p0^4 + k2^4 k3 p0^5)^2 + 12 k1 k2^4 
k3 l0 p0^4 (2 k1^3 k2^6 + 6 k1^3 k2^4 p0^2 + 6 k1^3 k2^2 p0^4 + 2 k1^3 p0^6)))/ 
(4 (k1^3 k2^6 + 3 k1^3 k2^4 p0^2 + 3 k1^3 k2^2 p0^4 + k1^3 p0^6)) 
 
p3l = (-k1^3 k2^4 k3 p0^3 - 3 k1^2 k2^4 k3 p0^4 - 3 k1 k2^4 k3 p0^5 - k2^4 k3 p0^6 +  
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Sqrt(4 k2^4 k3 l0 p0^6 (6 k1^4 k2^6 + 18 k1^4 k2^4 p0^2 + 18 k1^4 k2^2 p0^4 + 6 k1^4 p0^6) + (k1^3 
k2^4 k3 p0^3 + 3 k1^2 k2^4 k3 p0^4 + 3 k1 k2^4 k3 p0^5 + k2^4 k3 p0^6)^2))/(12 (k1^4 k2^6 + 3 k1^4 
k2^4 p0^2 + 3 k1^4 k2^2 p0^4 + k1^4 p0^6)) 
	
Inserting	 the	 three	 expression	 into	 𝐴8 = 𝑎8 ∗ 𝑖 ∗ 𝑝B𝑙si=1 	(first	 half	 of	 (eq.	 2.1)),	 one	 can	
formulate	the	following	sum	(s=3):	
	
𝐴8 = 𝑎8 ∗ 𝑓8 ∗ 3𝑖 𝑖𝑝6B𝐾8BT8
Q
BH8 	
with	 	 (3.1)	𝑓8 = −𝐾,9𝐾Q 𝐾8 + 𝑝6 Q + 𝐾,9𝐾Q 𝐾,9𝐾Q 𝐾8 + 𝑝6 U + 24𝐾89𝑙6 𝐾,, + 𝑝6, Q12 𝐾,, + 𝑝6, Q 	
	
Generalizing	s	results	in	the	following	expression:	
	
𝐴8 = 𝑎8 ∗ 𝑓8 ∗ 𝑠𝑖 𝑖𝑝6B𝐾8BTGM,
G
BH8 	
with	 	 (3.2)	𝑓8 = −𝐾,,GM,𝐾Q 𝐾8 + 𝑝6 G + 𝐾,,GM,𝐾Q 𝐾,,GM,𝐾Q 𝐾8 + 𝑝6 ,G + 8𝑠𝐾89GM9𝑙6 𝐾,, + 𝑝6, G4𝑠 𝐾,, + 𝑝6, G 	
	
The	summation	has	an	explicit	expression:	
	 𝑠𝑖 𝑖𝑝6B𝐾8BTGM,
G
BH8 = 𝐾8,𝑠 𝑝6𝐾8 + 𝑝6 𝐾8 + 𝑝6𝐾8,
G
	
	
With	this	expression	and	reformulation,	3.2	can	be	written	as:		 	
	 (3.3)	𝐴8 = −𝑎84 𝑝6𝐾8 + 𝑝6 ∗ 𝐾8,𝐾Q𝐾,, 𝐾,, 𝐾8 + 𝑝6 ,𝐾8, 𝐾,, + 𝑝6, G − 𝐾8,𝐾Q𝐾,, 𝐾,, 𝐾8 + 𝑝6 ,𝐾8, 𝐾,, + 𝑝6, G 𝐾8,𝐾Q𝐾,, 𝐾,, 𝐾8 + 𝑝6 ,𝐾8, 𝐾,, + 𝑝6, G + 8𝑠𝑙6 	
	
Note	that	this	expression	has	the	general	form	of	(1.4).	Using	the	same	procedure,	one	obtains	
an	expression	for	A2:	 	
	 (3.4)	𝐴, = 𝑎,4 𝑝6,𝐾,, + 𝑝6, ∗ 𝐾8,𝐾Q𝐾,, 𝐾,, 𝐾8 + 𝑝6 ,𝐾8, 𝐾,, + 𝑝6, G + 4𝑠𝑙6
− 𝐾8,𝐾Q𝐾,, 𝐾,, 𝐾8 + 𝑝6 ,𝐾8, 𝐾,, + 𝑝6, G 𝐾8,𝐾Q𝐾,, 𝐾,, 𝐾8 + 𝑝6 ,𝐾8, 𝐾,, + 𝑝6, G + 8𝑠𝑙6 	
	
In	our	experiments	we	study	 the	activation	of	 cGAS	as	 function	of	DNA	 length	and	keep	 the	
effective	concentration	of	binding	sites	leff	=l0*s	constant.	Combining	A1	and	A2	results	in	the	final	
formula	for	the	concentration	of	cGAS	bound	to	DNA	and	hence	steady	state	activity	A	of	product	
formation	as	a	function	of	s:	
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	 𝐴(𝑠) = 𝑎𝐾′(𝑠) + 𝑏𝑙eff − 𝑎 𝐾′(𝑠) 𝐾′(𝑠) + 2𝑙eff	 (3.5)	
with	 𝑙eff = 𝑠𝑙0	𝐾′(𝑠) = 𝐾8,𝐾Q4𝐾,, 𝐾,, 𝐾8 + 𝑝6 ,𝐾8, 𝐾,, + 𝑝6, G	𝑎 = 𝑎,𝑝6,𝐾,, + 𝑝6, − 𝑎8𝑝6𝐾8 + 𝑝6	
	 𝑏 = [+IJ+*++TIJ+	
	
	
3.4 DPL	Model:	Special	Cases	and	Simplifications	
a)	K3	→	∞	(no	“dimer”	state)	
	
A	Taylor	series	expansion	of	(3.5)	around	leff	results	around	0	yields	
	 𝐴 𝑠 = −𝑎 + 𝑏 𝑙eff + 𝑎2𝐾′ 𝑙eff, − 𝑎2𝐾′, 𝑙effQ ⋯	
hence	for	K3	→	∞	(therefore		K’→	∞),	𝐴 𝑠 = −𝑎 + 𝑏 𝑙eff = 𝑎8 𝑙eff	𝑝6𝐾8 + 𝑝6	
which	 describes	 bind	 of	 cGAS	 monomers	 on	 a	 single	 DNA	 ligand	 with	 s	 binding	 sites	 and	
concentration	l0.		
	
b)	K3	→	0	(no	“monomer”	state)	
	
Setting	K3	=	0	in	(3.5)	yields		 𝐴 𝑠 = 𝑏𝑙eff = 𝑎, 𝑙eff	𝑝6,𝐾,, + 𝑝6,	
	
with	describes	a	(maximally)	cooperative	formation	of	cGAS	dimers	on	(prearranged)	DNA	with	
s	binding	sites	and	a	concentration	of	l0.	Binding	along	DNA	of	cGAS	dimers	is	non-cooperative.	
		
c)	K1	≫	p0	
	
This	condition	is	a	reasonable	assumption	for	our	studies	since	the	experimentally	determined	
DNA	binding	affinity	for	short	DNA	is	only	~20	µM.	In	this	case	(3.5)	simplifies	to:	
	
	 𝐴(𝑠) = 𝑎 𝐾′(𝑠) + 𝑙eff − 𝐾′(𝑠) 𝐾′(𝑠) + 2𝑙eff 	 (3.6)	
with	 𝑙eff = 𝑠𝑙0	𝐾′(𝑠) = 𝐾8′ 𝐾,,𝐾,, + 𝑝6, G	𝐾8] = 𝐾8,𝐾Q4𝐾,, 	𝑎 = 𝑎, 𝑝6,𝐾,, + 𝑝6,	
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Note,	in	this	case,	there	are	only	two	independent	binding	constants	K2	and	K1’=K12K3/	4K22.	
Eq.	3.6	is	the	one	used	to	fit	the	experimental	data	in	our	study.	
	
4 Fitting	of	experimental	data	
	
For	global	fitting	of	the	data	matrix	(8	different	DNA	ligands	by	8	different	cGAS	concentrations),	
we	used	the	fminsearch	procedure	as	implemented	in	Matlab_R2015a	(The	MathWorks,	Inc).		
	
4.1 Fitting	with	Hill	equations	
	
First,	the	data	were	fitted	using	a	set	of	empirical	Hill	equations		
	 	 (4.1)	𝑉_BKK(𝑉 [a, 𝑠B, 𝐾B) = 𝑉 [a 𝑙eff,i		𝑝6GN𝐾B + 𝑝6GN 	
	
with	Vmax	fitted	globally	(i.e.	it	is	assumed	to	be	the	same	for	all	ligands)	and	si,	Ki	fitted	for	each	
DNA	ligand	li	individually.	Here,	leff,i	is	the	concentration	of	DNA	ligand	i	times	its	number	of	bps	
and	 leff,i=constant	 in	 all	 reactions.	 fminsearch	was	used	 to	minimize	 the	 following	 function	 (i	
ligands,	 j	 protein	 concentrations,	 rij:	 experimentally	 measured	 rate	 for	 ligand	 i	 and	 protein	
concentration	j,	wij:	standard	deviation	of	rij	from	three	independent	experiments):	
	 𝑅𝑒𝑠 = 1𝑤Bf 𝑉_BKK 𝑉 [a, 𝑠B, 𝐾B − 𝑟B,f ,B,f 	
	
Minimization	of	17	parameters	(Vmax,	8	si,	8	Ki)	resulted	in	an	R2=0.991.		Fig.	S1	(left	panel)	shows	
the	experimental	data	along	with	the	fit	of	the	set	of	Hill	equations,	the	right	panel	is	a	plot	of	
the	“Hill	coefficients”	si	as	a	function	of	DNA	length.	 In	general,	the	data	show	an	increase	in	
“cooperativity”	for	longer	DNA	as	expected.	
	
	
Figure	S1.	Left	panel:	Experimental	data	(see	also	legend	for	Fig.	3c)	fitted	to	a	set	of	Hill	equations	
with	a	global	Vmax,	and	individual	Ki,si.	Plotted	is	the	rate	of	substrate	turnover	(∆F/∆t	[RFU	min-1])	as	a	
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The	empirical	Hill	equation,	although	being	able	to	generally	fit	the	data	with	an	R2=0.991,	has	
no	direct	physical	interpretation,	because	it	is	unclear	how	Ki	and	si	correlate	with	the	underlying	
molecular	events.		
	
4.2 Fitting	with	DPL	equation	
Using	the	same	procedure,	we	fitted	the	experimental	data	with	the	simplified	DPL	model	(eq.	
3.6)	through	least	square	minimization	and	the	fminsearch	procedure	(Fig.	S2):	
	 𝑅𝑒𝑠 = 1𝑤Bf 𝑉hij 𝑉 [a, 𝑠B, 𝐾8], 𝐾, − 𝑟B,f ,B,f 	
	
	
	
Although	here	only	11	(Vmax,	8	si,	K1’,	K2)	compared	to	the	17	parameters	of	the	Hill	equations	
(Vmax,	8	si,	8	Ki)	are	optimized,	the	resulting	R2=0.988	is	very	close	to	that	obtained	using	the	Hill	
equations.	 In	the	DPL	model,	K1’	and	K2	have	a	physical	 interpretation	 in	the	assembly	of	the	
DNA-protein	ladder	(see	above).	s	corresponds	to	effective	number	of	cooperative	binding	sites	
along	the	ladder.	It	should	be	noted,	that	p0	appears	in	the	equation	already	as	quadratic	form	
p02,	since	cGAS	is	assumed	to	bind	as	dimer,	so	the	overall	“cooperativity”	with	respect	to	cGAS	
concentration	 is	 2s,	 the	 “cooperativity”	 between	 adjacent	 cGAS	dimers	 is	 s.	 In	 the	DPL	 fit,	 s	
smoothly	increases	with	increasing	DNA	length,	showing	a	steeper	transition	around	40-50	base	
pairs,	corresponding	well	to	the	observed	in	vivo	threshold	(Fig.	1a).	For	longer	DNA,	s	is	1.2-1.4,	
but	not	higher.	 Thus,	 per	 this	modeling,	 cooperative	binding	of	 two	 cGAS	dimers	 along	DNA	
(short	ladder)	would	be	in	principle	sufficient	to	account	for	the	cooperativity.		The	yet	higher	
function	of	cGAS	concentration.	Right	panel:	Plot	of	si	as	a	function	of	DNA	length	(number	of	base	
pairs).	Longer	DNA	leads	to	an	increase	in	si,	which	can	be	interpreted	as	an	increase	in	cooperative	
binding.	
	
Figure	S2.	Left	panel:	Experimental	data	(see	also	legend	for	Fig.	3c)	fitted	to	the	DPL	equation	(3.6)	
with	a	global	Vmax,	K1’	and	K2,	and	individual	si.	Plotted	is	the	rate	of	substrate	turnover	(∆F/∆t	[RFU	
min-1])	as	a	function	of	cGAS	concentration.	Right	panel:	Plot	of	si	as	a	function	of	DNA	length	(number	
of	 base	 pairs).	 Longer	 DNA	 leads	 to	 an	 increase	 in	 si,	 which	 can	 be	 interpreted	 as	 an	 increase	 in	
cooperative	binding.	
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activity	 of	 very	 long	DNA	 could	 originate	 from	more	 efficient	 assembly	 of	 cGAS	 dimer	 in	 cis	
because	long	DNA	could	easily	bend	back	and	thus	can	help	assemble	cGAS	dimers	at	low	DNA	
concentrations.		
	
4.3 Titration	with	inactive	cGAS	D307N	
In	the	titration	experiment,	an	increasing	amount	of	cGAScd	(D307N),	i.e.	a	mutant	that	does	not	
turn	over	substrate	GTP	and	ATP,	is	titrated	into	a	solution	of	a	fixed	amount	of	cGAScd	and	a	
fixed	amount	of	DNA.	The	ladder	model	predicts	a	hill	or	bell	shaped	curve.	In	the	absence	of	
cGAScd	(D307N),	the	low	amount	of	cGAScd	results	in	low	fGAMP	production,	because	most	if	not	
all	of	cGAScd	is	not	bound	to	DNA	in	catalytically	active	cGASn:DNA2	complexes.	Titrating	in	cGAScd	
(D307N)	 will	 cooperatively	 promote	 ladder	 formation	 and	 therefore	 help	 trap	 cGAScd	 in	
cGASn:DNA2	 ladders,	 therefore	 increasing	 activity.	 Increasing	 amounts	 of	 cGAScd	 (D307N),	
however,	 will	 more	 and	 more	 compete	 cGAScd	 away	 from	 DNA:protein	 ladders	 due	 to	 the	
limiting	number	of	protein	binding	sites	on	DNA.	Thus,	after	a	maximum	stimulation,	 further	
increase	of	 cGAScd	 (D307N)	will	 result	 in	a	 gradual	 reduction	of	 the	observed	 rate	of	 fGAMP	
production.	
	
The	observed	activity	is	as	follows:	 𝐴 = 𝑝[𝑝klk ∗ 𝑓(𝑝klk)	
	
Here,	pa	is	the	concentration	of	catalytic	active	cGAS	and	pi	the	concentration	of	catalytic	inactive	
cGAS	(D307N).	ptot=pa+pi	is	the	total	concentration	of	cGAS	molecules,	both	active	and	inactive.	
f	 is	 the	DPL	 function	 (3.5	 or	 3.6)	 or	 e.g.	 an	 empirical	Hill	 function	 (4.1).	 Fitting	was	 done	 as	
described	for	4.2	using	the	fminsearch	function	as	implemented	in	Matlab.	For	fitting,	K1’	was	
set	fixed	to	the	value	obtained	from	the	fit	in	Fig.	S2	(to	reduce	the	number	of	free	paramteter),	
all	other	parameters	(Vmax,	K2	and	s)	were	kept	free	and	optimized.	It	should	be	noted	that	our	
premise	that	p0>>s*l0,	i.e.	p≈p0	is	not	exactly	true	for	the	experimental	conditions	used	in	Fig.	
3d,	 so	both	a	Hill	equation	and	 the	DPL	equation	are	only	approximations.	Nevertheless,	we	
obtain	a	good	fit.	The	important	point	here	is	that	a	good	fit	of	the	data	lead	to	s=1.8.	Since	the	
protein	 concentration	 scales	 with	 p2s	 in	 the	 DPL	 model,	 2*1.8=3.6	 indicates	 substantial	
cooperativity	for	the	stimulation	of	active	cGAS	by	titrating	in	inactive	cGAS.	
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Supplementary	Table	1	Protein	constructs	and	their	descriptions	
Construct	Name	 Protein	Name	
Source	
Organism	
Fragment,	
aa	
Modification	
mcGAScd	
Cyclic	GMP-AMP	
synthase	(cGAS)	
Mus	musculus	 141-507	 -	
hcGAScd	
Cyclic	GMP-AMP	
synthase	(cGAS)	
Homo	sapiens	 155-522	 -	
hcGAS	
Cyclic	GMP-AMP	
synthase	(cGAS)	
Homo	sapiens	 1-522	
N-terminal	His6-
MBP-tag	
Flag/HA-hcGAS	
Cyclic	GMP-AMP	
synthase	(cGAS)	
Homo	sapiens	 1-522	
N-terminal	
Flag/HA-tag	
eGFP-hcGAS	
Cyclic	GMP-AMP	
synthase	(cGAS)	
Homo	sapiens	 1-522	
N-terminal	eGFP-
tag	
mTFAM	
Transcription	factor	
A,	mitochondrial	
(TFAM)	
Mus	musculus	 43-243	
N-terminal	His6-
tag	
hTFAM	
Transcription	factor	
A,	mitochondrial	
(TFAM)	
Homo	sapiens	 43-246	
N-terminal	His6-
tag	
HA-TFAM	
Transcription	factor	
A,	mitochondrial	
(TFAM)	
Homo	sapiens	 43-246	 N-terminal	HA-tag	
mHMGB1	
High	mobility	group	
protein	B1	(HMGB1)	
Mus	musculus	 1-215	
N-terminal	His6-
tag	
mHMGB1dCTT	
High	mobility	group	
protein	B1	(HMGB1)	
Mus	musculus	 1-	185	
N-terminal	His6-
tag	
lHU	
DNA-binding	
protein	HU	
Listeria	
monocytogenes	
1-121	
N-terminal	His6-
tag	
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Supplementary Table 2 Stimulatory DNA sequences 
	
Construct 
Name 
Sequence 
20 bp-s CTACTAGTGATCTATGACTG 
20 bp-as CAGTCATAGATCACTAGTAG 
25 bp-s CTACTAGTGATCTATGACTGATCTG 
25 bp-as CAGATCAGTCATAGATCACTAGTAG 
30 bp-s CTACTAGTGATCTATGACTGATCTGTACAG 
30 bp-as CTGTACAGATCAGTCATAGATCACTAGTAG 
35 bp-s ATCTACTAGTGATCTATGACTGATCTGTACATGAT 
35 bp-as ATCATGTACAGATCAGTCATAGATCACTAGTAGAT 
40 bp-s AGTGTCTACTAGTGATCTATGACTGATCTGTACATGATCT 
40 bp-as AGATCATGTACAGATCAGTCATAGATCACTAGTAGACACT 
45 bp-s TACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA 
45 bp-as TGTAGATCATGTACAGATCAGTCATAGATCACTAGTAGATCTGTA 
50 bp-s GATACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA
ATC 
50 bp-as GATTGTAGATCATGTACAGATCAGTCATAGATCACTAGTAGATCTGT
ATC 
55 bp-s TCGATACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTA
CAATCACT 
55 bp-as AGTGATTGTAGATCATGTACAGATCAGTCATAGATCACTAGTAGATC
TGTATCGA 
60 bp-s AGTCGATACAGATCTACTAGTGATCTATGACTGATCTGTACATGATC
TACAATCACTGCA 
60 bp-as TGCAGTGATTGTAGATCATGTACAGATCAGTCATAGATCACTAGTA
GATCTGTATCGACT 
65 bp-s CCAAGTCGATACAGATCTACTAGTGATCTATGACTGATCTGTACAT
GATCTACAATCACTGCAGT 
65 bp-as ACTGCAGTGATTGTAGATCATGTACAGATCAGTCATAGATCACTAG
TAGATCTGTATCGACTTGG 
70 bp-s GACTACCAAGTCGATACAGATCTACTAGTGATCTATGACTGATCTG
TACATGATCTACAATCACTGCAGT 
70 bp-as ACTGCAGTGATTGTAGATCATGTACAGATCAGTCATAGATCACTAG
TAGATCTGTATCGACTTGGTAGTC 
75 bp-s GACTACCAAGTCGATACAGATCTACTAGTGATCTATGACTGATCTG
TACATGATCTACAATCACTGCAGTTACCG 
75 bp-as CGGTAACTGCAGTGATTGTAGATCATGTACAGATCAGTCATAGATC
ACTAGTAGATCTGTATCGACTTGGTAGTC 
80 bp-s GACTACCAAGTCGATACAGATCTACTAGTGATCTATGACTGATCTG
TACATGATCTACAATCACTGCAGTTACCGTGACC 
80 bp-as GGTCACGGTAACTGCAGTGATTGTAGATCATGTACAGATCAGTCAT
AGATCACTAGTAGATCTGTATCGACTTGGTAGTC 
85 bp-s TCCTAGACTACCAAGTCGATACAGATCTACTAGTGATCTATGACTG
ATCTGTACATGATCTACAATCACTGCAGTTACCGTGACC 
85 bp-as GGTCACGGTAACTGCAGTGATTGTAGATCATGTACAGATCAGTCAT
AGATCACTAGTAGATCTGTATCGACTTGGTAGTCTAGGA 
90 bp-s TCCTAGACTACCAAGTCGATACAGATCTACTAGTGATCTATGACTG
ATCTGTACATGATCTACAATCACTGCAGTTACCGTGACCAATGT 
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90 bp-as ACATTGGTCACGGTAACTGCAGTGATTGTAGATCATGTACAGATCA
GTCATAGATCACTAGTAGATCTGTATCGACTTGGTAGTCTAGGA 
95 bp-s TCCTAGACTACCAAGTCGATACAGATCTACTAGTGATCTATGACTG
ATCTGTACATGATCTACAATCACTGCAGTTACCGTGACCAATGTCG
ACT 
95 bp-as AGTCGACATTGGTCACGGTAACTGCAGTGATTGTAGATCATGTACA
GATCAGTCATAGATCACTAGTAGATCTGTATCGACTTGGTAGTCTA
GGA 
100 bp-s TCCTAGACTACCAAGTCGATACAGATCTACTAGTGATCTATGACTG
ATCTGTACATGATCTACAATCACTGCAGTTACCGTGACCAATGTCG
ACTGGATC 
100 bp-as GATCCAGTCGACATTGGTCACGGTAACTGCAGTGATTGTAGATCAT
GTACAGATCAGTCATAGATCACTAGTAGATCTGTATCGACTTGGTA
GTCTAGGA 
200 bp-s ATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACT
TTAAGAAGGAGATATACATATGTCGTACTACCATCACCATCACCATC
ACGATTACATGATCGAAGAAGGTAAACTGGTAATCTGGATTAACGG
CGATAAAGGCTATAACGGTCTCGCTGAAGTCGGTAAGAAATTCGAG
AAAGATACCGGAAT 
200 bp-as ATTCCGGTATCTTTCTCGAATTTCTTACCGACTTCAGCGAGACCGTT
ATAGCCTTTATCGCCGTTAATCCAGATTACCAGTTTACCTTCTTCGA
TCATGTAATCGTGATGGTGATGGTGATGGTAGTACGACATATGTAT
ATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGGAATTGTT
ATCCGCTCACAAT 
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Supplementary Table 3 Data processing and refinement statistics 
 
Space group C2 (No. 5) C2 (No. 5) 
Unit cell dimensions a, b, 
c, α, β, γ 
168.5 Å, 122.9 Å, 180.0 Å, 
90º, 96.4º, 90º 
168.5 Å, 122.9 Å, 180.0 Å, 
90º, 96.4º, 90º 
 XDS STARANISO 
Resolution rangea 50 – 3.6 (4.2) Å 50 – 3.6 (4.2) Å 
No. of observed 
reflections 
212879 –  
No. of unique reflections 41980 28400 
Completenessb 0.99 0.67 / 0.91 
I/σ(I)c 9.4 9.3 / 12.6 
Rsym 22.4% (91.0%) – 
No. of protein atoms  17712 
No. of DNA atoms  4370 
No. of zinc ions  6 
R-factor / Free-R-factor  0.204 / 0.256 
Rmsd bond lengths / 
bond angles 
 0.010 Å / 1.4º 
Ramachandran plot  
preferred / allowed / 
outliers 
 
 
94.9% / 3.1% / 2.0% 
 
 
aApproximate effective resolution in parentheses 
bResulting completeness after STARANISO for spherical / elliptical shells 
cResulting signal-to-noise ratio after STARANISO for spherical / elliptical shells 
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4. A fluorescent cyclic dinucleotide and its use in methods of identifying 
substances having an ability to modulate the cGAS/STING pathway 
(patent application) 
 
Hopfner, K. P.; Andreeva, L.; Drexler, D. J.; 2019. A fluorescent cyclic dinucleotide and its use in 
methods of identifying substances having an ability to modulate the cGAS/STING pathway. 
European Patent Application EP 17182689.4. 
 
This work provides fluorescence-based assays for analysis of the cGAS-STING pathway using a 
fluorescent analogue of ATP. The cGAS-STING pathway is an important component of the innate 
immune system. As it was discovered to have a high potential for immunotherapy, a great interest 
for drug development has raised. The results of this work include a fluorescence-based assay for 
quantitative analysis of cGAS activity. This assay uses the fluorescent ATP analogue 
2-aminopurine riboside-5′-triphosphate, which is accepted by cGAS. The resulting compound, 
termed fGAMP, is less fluorescent, allowing a high-throughput real time detection of cGAS 
activity. In addition, fGAMP was identified as suitable compound for fluorescent STING binding 
assays. Upon STING binding, the fluorescence of fGAMP is quenched. Subsequently, the 
flurorescence can be restored by adding STING binding molecules, which correlates with the 
binding affinity. Major advantages of the provided methods are a simple experimental set-up and 
readout, high-throughput feasibility and similar properties to the physiological substrates. In 
particular, fGAMP was shown to bind STING and induce a type I interferon response in 
HEK293T cells. In conclusion, this work describes methods for drug discovery for the 
cGAS-STING pathway, which are suitable for industrial applications. 
 
Author contribution 
The author of the present thesis analyzed cGAS reaction products. He identified, purified and 
characterized fGAMP by NMR, mass-spectrometry and ion exchange chromatography. 
Furthermore, he analyzed the binding affinity of fGAMP to STING by isothermal titration 
calorimetry. Together with L. Andreeva, he described the fluorescent properties of fGAMP and 
tested STING binding effects using a fluorescence plate reader. In addition, he performed 
luciferase reporter assays to analyze STING activation in HEK293T cells, assisted by C. Lässig. 
He assisted L. Andreeva and K.P. Hopfner in writing the patent application. 
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Description
Field of the invention
[0001] The present invention relates to a non-canonical cyclic di-nucleotide containing an asymmetric 2’-5’ and 3’-5’
phosphodiester linkage and its use in a method for identifying a substance having an ability to modulate cGAS activity
or bind to STING. Furthermore, the cyclic dinucleotide is used in a method of identifying a substance having an ability
to modulate the activity of a 2’-5’ phosphodiesterase.
Background of the invention
[0002] The innate immune system relies on germline-encoded recognition receptors (PRRs) to survey the extracellular,
endosomal, and cytosolic milieu for signs of pathogen invasion or cellular damage. Following ligand binding, PRRs
trigger downstream signaling to elicit innate immune responses and to activate the adaptive immune system. Since
nucleic acids are central to the replication and propagation of most if not all pathogens, the detection of aberrant DNA
and RNA has evolved as a fundamental mechanism of host defense.
[0003] DNA is usually confined within the nucleus and mitochondria of eukaryotic cells. The presence of cytosolic
DNA either through infections or cellular damage triggers robust immune responses including type I interferon induction.
The cyclic GMP-AMP synthase (cGAS) is a key sensor required for DNA recognition in the cytosol. Beside endogenous
DNA, cGAS senses DNA from cytosolic bacteria, HIV (cDNA) and herpes viruses. In its inactive state cGAS exists in a
monomeric apo-form. Upon recognition of cytosolic DNA, cGAS undergoes a conformational change resulting in the
formation of an active cGAS2:DNA2 tetramer. Activated cGAS synthesizes cyclic dinucleotides comprising a conventional
3’-5’ phosphodiester linkage and an unconventional 2’-5’ phosphodiester linkage between a first nucleoside monophos-
phate and a second nucleoside monophosphate (2’3’ cyclic dinucleotide CDNs). These CDNs serve as second mes-
sengers which then bind to the transmembrane adaptor protein stimulator of interferon genes (STING) associated with
the endoplasmic reticulum. Upon binding to STING the adapter protein is activated, interacts with TBK 1 (TANK-binding
kinase 1) and traffics through the Golgi to perinuclear endosomal compartments, where TBK 1 phosphorylates IRF 3
and IRF 7 to trigger type I interferon production.
[0004] While under normal conditions DNA sensing by the cGAS/STING axis protects the organism from harmful
infections by DNA viruses, retroviruses and bacteria, unsolicited self-DNA sensing can result in autoimmune diseases
such as systemic lupus erythematosus (SLE) and Aicardi-Goutières syndrome (AGS). AGS is a rare but generally fatal
childhood inflammatory condition with neurological dysfunction which is caused by loss-of-function mutations in nucleic
acid metabolizing enzymes resulting in accumulation of endogenous DNA in the cytosol.
[0005] Many genes have been identified as being involved in the development of autoimmune diseases. For instance,
TREX1 encodes a 3’-5’ DNA exonuclease, and it has been found that a loss of function mutation in this gene results in
AGS and SLE (Crow, Hayward et al. "Mutations in the gene encoding the 3[prime]-5[prime] DNA exonuclease TREX1
cause Aicardi-Goutieres syndrome at the AGS1 locus". Nat Genet 38, 917-920, 2006; Lee-Kirsch, Gong et al. "Mutations
in the gene encoding the 3[prime]-5[prime] DNA exonuclease TREX1 are associated with systemic lupus erythematosus".
Nat Genet 39, 1065-1067, 2007). Interestingly, crossing TREX1-deficient mice with mice lacking either STING or the
IFNα/β receptor resulted in a rescue of the autoinflammatory phenotypes (Gall, Treuting et al. "Autoimmunity Initiates
in Nonhematopoietic Cells and Progresses via Lymphocytes in an Interferon-Dependent Autoimmune Disease". Immunity
36, 120-131, 2012; Ahn, Ruiz et al. "Intrinsic Self-DNA Triggers Inflammatory Disease Dependent on STING". The
Journal of Immunology 2014), placing STING signaling central to these interferonopathies. Mutations in RNASEH2A,
RNASH2B and RNASEH2C have also been linked to AGS (Crow, Hayward et al. "Mutations in the gene encoding the
3[prime]-5[prime] DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus". Nat Genet 38,
917-920, 2006; Crow, Chase et al. "Characterization of Human Disease Phenotypes Associated with Mutations in TREX1,
RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1". American journal of medical genetics. Part A 0,
296-312, 2015). The proteins encoded by these genes form the RNase H2 complex and function to degrade cellular
RNA/DNA hybrids. In a mouse model of the disease due to a homozygous A174T knock-in-mutation, the cGAS/STING
pathway was central to the autoinflammatory pathology, since the loss of STING in these mice reduced levels of inflam-
matory cytokines. Taken together, there is increasing evidence that STING plays a central role in autoimmune interfer-
onopathies.
[0006] Several studies indicate that cGAS activation by cytosolic self-DNA is also responsible for the lethal phenotypes
associated with SLE and ALS (Gao, Li et al. "Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune
diseases". Proceedings of the National Academy of Sciences 112, E5699-E5705, 2015). Overall, these studies provide
evidence that the inhibition of the cGAS/STING axis may be an effective therapeutic tool for the treatment of autoimmune
diseases such as AGS and SLE.
[0007] Chronic inflammatory signaling may not only initiate autoinflammatory diseases but can also contribute to the
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development of cancer, probably through cytokines, chemokines and growth factors that stimulate cellular proliferation
and survival, as well as by promoting angiogenesis (Nowarski, Gagliani et al. "Innate Immune Cells in Inflammation and
Cancer". Cancer Immunology Research 1, 77-84, 2013). Adaptive T cell responses are important for the control and
eradication of tumor cells. Numerous immunotherapeutic strategies involving stimulating the adaptive immune response
against cancers through checkpoint blockade are presently under evaluation in clinical trials. It has been shown that
type I interferon production is involved in tumor antigen specific T cell activation and that the cGAS/STING pathway
plays a key role in stimulating adaptive T cell responses against tumor cells (Woo, Fuertes et al. "STING-Dependent
Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors". Immunity 41, 830-842, 2014).
Overall, the targeted inhibition or activation of the cGAS/STING pathway by small molecule compounds or therapeutic
nucleic acids provide a promising tool for the pharmaceutical industry to develop strategies for the treatment of cancer,
inflammatory diseases, and autoimmune disorders. In view of the numerous promising therapeutic approaches to mod-
ulate the cGAS/STING pathway intensive efforts are currently underway to identify small molecule compounds which
are capable to modulate and fine-tune the innate immune system via the cGAS/STING pathway. However, large-scale
screening assays for the identification of such modulators are currently hampered by the general lack of sensitive and
scalable assays that allow a direct readout of the activity. Measuring the activity of cGAS is usually done via thin-layer
chromatography of the produced 2’3’CDNs, using radioactive nucleoside triphosphates as substrates, which is impractical
in high-throughput assays.
[0008] Alternatively, 2’3’CDN can be directly detected by mass spectrometry. The latter approach is sensitive and to
some extent quantitative, however, it is difficult to measure reactions in parallel at high-throughput or at different time
points to analyze steady-state rates. One approach of detecting CDNs is described by Roembke et al. (Roembke, Zhou
et al. "A cyclic dinucleotide containing 2-aminopurine is a general fluorescent sensor for c-di-GMP and 3’,3’-cGAMP".
Molecular BioSystems 10, 1568-1575, 2014). In this article the authors suggest using the properties of fluorescent 3’3’-
cGAMP analogue - 3’3’-cG(d2AP)MP. The method is based on Mn2+-induced 3’3’-cG(d2AP)MP association with c-
diGMP or 3’3’-cGAMP resulting in 3’3’-cG(d2AP)MP quenching. However, the method failed to detect 2’3’-cGAMP and
c-di-AMP due to the lack of its association with 3’3’-cG(d2AP)MP. Hence, direct determination of human STING activating
CDNs produced by cGAS was not successful with this assay. Furthermore, there is currently no robust and simple-to-
implement high-throughput assay that directly measures ligand binding to STING in a quantitative manner, because
STING is a receptor protein and not an enzyme. Very elaborate FRET 3’3’-cG(d2AP)MP (Roembke, Zhou et al. "A cyclic
dinucleotide containing 2-aminopurine is a general fluorescent sensor for c-di-GMP and 3’,3’-cGAMP". Molecular Bio-
Systems 10, 1568-1575, 2014) methods have been proposed to measure the conformational change of STING, but
these require very specialized equipment and also require modification of STING itself.
[0009] In view of all of the above, there is still a need for a sensitive and scalable biochemical assay that allows a
direct readout of cGAS/STING activity, thereby providing a tool for identifying, on industrial scale, small molecule com-
pounds that could modulate the cGAS/STING pathway and which could therefore be promising candidates in anti-
inflammatory, anti-autoimmune, and anti-cancer therapy. The object of the present invention is to provide such means.
Summary of the invention
[0010] The present invention relates to a fluorescent cyclic dinucleotide and its preparation. Furthermore, the present
invention relates to a method for measuring cGAS activity. The present invention further relates to a method of identifying
a substance having an ability to modulate cGAS activity. The present invention also relates to a method of identifying a
substance having an ability to bind to STING. The present invention further relates to a method of indentifying a substance
having an ability to modulate the activity of a 2’-5’ phosphodiesterase. Finally, the present invention relates to a fluorescent
cyclic dinucleotide and its use to label cGAS and STING and/or to identify substances having an ability to bind to STING
and to complexes of the fluorescent cyclic dinucleotide with cGAS and STING.
[0011] According to one aspect, the invention relates to a cyclic dinucleotide comprising a 3’-5’ phosphodiester linkage
and a 2’-5’ phosphodiester linkage between a first nucleoside monophosphate and a second nucleoside monophosphate,
wherein at least one of the first and second nucleoside monophosphates is a fluorescent nucleoside monophosphate.
[0012] In a further aspect, the invention relates to a method of measuring cGAS activity, wherein the method comprises
the steps of: (i) providing an aqueous solution comprising cGAS, cGAS-activating nucleic acid, a first nucleoside triphos-
phate, a second nucleoside triphosphate, and one or more divalent cation, wherein at least one of the first and second
nucleoside triphosphates is a fluorescent nucleoside triphosphate, and wherein one of the first and second nucleoside
triphosphates has a free 2’ hydroxyl group and the other one has a free 3’ hydroxyl group; and (ii) measuring the change
of the fluorescence signal of the aqueous solution over time.
[0013] In another aspect, the invention provides a method of identifying a substance having an ability to modulate the
activity of cyclic GMP-AMP synthase (cGAS), wherein the method comprises the steps of: (i) providing an aqueous
solution comprising cGAS, cGAS-activating nucleic acid, a first nucleoside triphosphate, a second nucleoside triphos-
phate, and one or more divalent cation, wherein at least one of the first and second nucleoside triphosphates is a
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fluorescent nucleoside triphosphate, and wherein one of the first and second nucleoside triphosphates has a free 2’
hydroxyl group and the other one has a free 3’ hydroxyl group; (ii) measuring the fluorescence signal of the aqueous
solution; (iii) repeating steps (i) and (ii), wherein upon said repetition the aqueous solution further comprises the substance,
and wherein the fluorescence signal is measured under identical or substantially identical conditions following the pro-
vision of the respective aqueous solution; and (iv) comparing the fluorescence signal measured in the presence of the
substance with the fluorescence signal measured in the absence of the substance; wherein a measured fluorescence
signal which is higher in the presence of the substance than in the absence of the substance indicates that the substance
is a cGAS antagonist, while a measured fluorescence signal which is lower in the presence of the substance than in the
absence of the substance indicates that the substance is a cGAS agonist.
[0014] A further aspect of the invention relates to a method of preparing a cyclic dinucleotide, wherein the method
comprises the steps of (i) providing an aqueous solution comprising cGAS, cGAS-activating nucleic acid, a first nucleoside
triphosphate, a second nucleoside triphosphate, and one or more divalent cation, wherein at least one of the first and
second nucleoside triphosphates is a fluorescent nucleoside triphosphate, and wherein one of the first and second
nucleoside triphosphates has a free 2’ hydroxyl group and the other one has a free 3’ hydroxyl group, thereby preparing
the cyclic dinucleotide; and, optionally, (ii) purifying the cyclic dicnucleotide.
[0015] Another aspect of the invention relates to a method of identifying a substance having an ability to bind to
stimulator of interferon genes (STING), wherein the method comprises the steps of (i) providing an aqueous solution
comprising a cyclic dinucleotide and STING, wherein the cyclic dinucleotide comprises a 3’-5’ phosphodiester linkage
and a 2’-5’ phosphodiester linkage between a first nucleoside monophosphate and a second nucleoside monophosphate,
wherein at least one of the first and second nucleoside monophosphates is a fluorescent nucleoside monophosphate;
(ii) measuring the fluorescence signal of the aqueous solution; (iii) repeating steps (i) and (ii), wherein upon said repetition
the aqueous solution further comprises the substance, and wherein the fluorescence is measured under identical or
substantially identical conditions following the provision of the respective aqueous solution; and (iv) comparing the
fluorescence signal measured in the presence of the substance with the fluorescence signal measured in the absence
of the substance; wherein a measured fluorescence signal which is higher in the presence of the substance than in the
absence of the substance indicates that the substance has an ability to bind to STING.
[0016] According to a further aspect, the invention provides a method of identifying a substance having an ability to
modulate the activity of a 2’-5’ phosphodiesterase enzyme, wherein the method comprises the steps of (i) providing an
aqueous solution comprising a cyclic dinucleotide and a 2’-5’ phosphodiesterase, wherein the cyclic dinucleotide com-
prises a 3’-5’ phosphodiester linkage and a 2’-5’ phosphodiester linkage between a first nucleoside monophosphate and
a second nucleoside monophosphate, wherein at least one of the first and second nucleoside monophosphates is a
fluorescent nucleoside monophosphate; (ii) measuring the fluorescence signal of the aqueous solution; (iii) repeating
steps (i) and (ii), wherein upon said repetition the aqueous solution further comprises the substance, and wherein the
fluorescence is measured under identical or substantially identical conditions following the provision of the respective
aqueous solution; and (iv) comparing the fluorescence signal measured in the presence of the substance with the
fluorescence signal measured in the absence of the substance; wherein a measured fluorescence signal which is higher
in the presence of the substance than in the absence of the substance indicates that the substance is a 2’-5’ phosphodi-
esterase agonist, while a measured fluorescence signal which is lower in the presence of the substance than in the
absence of the substance indicates that the substance is a 2’-5’ phosphodiesterase antagonist.
[0017] Another aspect of the invention relates to a use of a fluorescent nucleoside triphosphate for measuring cGAS
activity.
[0018] A further aspect of the invention provides a use of a fluorescent nucleoside triphosphate for identifying a
substance with an ability to modulate cGAS activity.
[0019] According to another aspect, the invention also relates to a use of a cyclic dinucleotide for identifying a substance
having an ability to bind to STING.
[0020] A further aspect of the invention relates to a use of a cyclic dinucleotide for labeling cGAS or STING.
[0021] In a final aspect, the invention relates to complexes of cGAS or STING with a cyclic dinucleotide.
[0022] Other embodiments of the invention are set out below.
Brief description of the Figures
[0023]
Figure 1: The cGAS/STING axis. Scheme depicting the cGAS/STING axis of cytosolic DNA sensing. Upon DNA
recognition, the cGAS protein synthesizes 2’3’ cyclic dinucleotides (2’3’CDN) from nucleoside triphosphates (here
shown by the example of 2’3’cGAMP synthesized from GTP and ATP). 2’3’CDN binds to the adaptor molecule
STING and induces a conformational change, leading to activation of TBK1 and type I interferon (IFN) production.
Figure 2: Domain structure of STING. STING comprises four N-terminal transmembrane domains (TM 40-135aa),
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a central c-di-GMP-binding domain (CBD, 150-345aa) and a C-terminal tail (CTT, 346-379). The C-terminal part
CBD+CTT - cytosolic domain (CD) - is responsible for CDN binding and signal transduction.
Figure 3: Domain structure of cGAS. cGAS comprises an unstructured and poorly conserved N-terminus spanning
amino acid sequences 1-159 and a highly conserved C-terminus (160-513aa, catalytic domain - CD) including Mab-
21 domain (213-513 aa). The conserved CD domain comprises both DNA-binding capacity and enzymatic activity.
Figure 4: Structure of 2’3’cGAMP (a) and 2’3’fGAMP (b). 2’3’fGAMP is synthesized by cGAS using 2-aminopurine
riboside triphosphate (2-APTP) and GTP substrates.
Figure 5: cGAS activity increases with DNA length. (a) cGAS activation determined by CXCL 10 cytokine expression
in BLaER1 cells. Cells were stimulated with 20, 40 and 60 ng DNA of different length (20-100 bp in 5 bp intervals)
and herring testes (HT) DNA, and CXCL 10 concentration in the supernatant was measured by ELISA. First two
bars of each series represent unstimulated cells and lipofectamine controls. Shown are mean values 6 standard
deviation, n=3. (b) and (c) Activity of hcGAScd (truncated human), hcGAS (full length human) (b) and mcGAScd
(truncated mouse) (c) in the presence of DNA of increasing length (20-100 bp) or plasmid DNA. Mean values of
initial cGAS reaction rates (ΔF/Δt) measured by the rate of 2-APTP incorporation into 2’3’fGAMP are plotted against
DNA length 6 standard deviation, n=3-5. (d) Radiolabeled cGAMP production of cGAS stimulated with DNA of
different lengths (20 bp, 35 bp, 55 bp and plasmid). cGAS reactions in presence of [α32P]ATP were stopped at the
indicated time points and radiolabeled compounds (shown with black arrows) were visualized.
Figure 6: Fluorescence-based cGAS activity assays. (a) cGAS radiolabeled products formation with different sub-
strate composition: ATP+GTP, 2-APTP +GTP, GTP in presence of [α32P]GTP; or ATP+GTP, 2-APTP+ATP, ATP
in presence of [α32P]ATP. Reactions were stopped at the indicated time points and radiolabeled compounds and
cGAS reaction products (shown with black arrows) were visualized. (b) and (c) 2’3’fGAMP mobility in anion-exchange
chromatography on MonoQ 5/50 GL column. (b) Comparison of 2’3’fGAMP (straight line) arising from cGAS reaction
with 2-APTP and GTP, 2-APTP (dashed line) and GTP (dotted line) mobilities. (c) Comparison of 2’3’fGAMP (straight
line), 2’3’-cGAMP (dashed line) and 3’3’-cGAMP (dotted line) mobilities. (d) ESI LC/MS spectrum of enzymatically
synthesized fGAMP. Arrows indicate ions corresponding to fGAMP-H (m/z 673.09) and fGAMP-2H+Na+ (m/z
695.07). (e) Tandem mass spectrometry spectrum derived from a parent fGAMP ion (m/z 673.09). Arrows highlight
ion products corresponding to depurination of the dinucleotide: guanine (m/z 522.19) or 2-AP (m/z 538.15). The
ratio of these peaks is characteristic for the linkage between 2’-OH of GTP and 5’-phosphate of 2-APTP within
fGAMP molecule (Ablasser, Goldeck et al. "cGAS produces a 2[prime]-5[prime]-linked cyclic dinucleotide second
messenger that activates STING". Nature 498, 380-384, 2013).
Figure 7: The principle of fluorescence-based cGAS activity assay. (a) Fluorescence of 2-APTP is quenched upon
its incorporation into cyclic 2’3’ fluorescent GMP-AMP (2’3’fGAMP) during the reaction that allows the measurement
of the reaction rate by differences in fluorescence intensity. (b) Comparison of 2-APTP fluorescence intensity under
physiologically relevant conditions: in ultrapure water (1), 100 mM NaCl+5 mM MgCl2 (2), 40 mM Tris pH 7.5 (3),
500 mM GTP (4), 40 mM Tris pH 7.5 + 100 mM NaCl + 5 mM MgCl2 (5), 40 mM Tris pH 7.5 + 100 mM NaCl + 5
mM MgCl2 + 500 mM GTP (6). 2-APTP fluorescence intensity is not altered by cGAS activity assay buffer in com-
parison to water. (c-e) General workflow for calculating the initial cGAS reaction rates. Initial fluorescence read-out
curves (c) represent the changes in fluorescence during the reaction. Next, for each curve the background fluores-
cence values were subtracted and inverted to give a positive value (ΔF). The resulting curves were scaled, such
that ΔF at time point 0 min equals 0 (ΔF-ΔFt=0) (d). The initial cGAS reaction rates were calculated as a slope of the
linear intervals (d, dashed lines) on the resulting curves and are defined as ΔF/Δt [RFU min-1] (e).
Figure 8: Reactions of 2-APTP and GTP with different cGAS constructs. (a) Anion exchange chromatography of
Homo sapiens (straight line), Mus musculus (dashed line) and Sus scrofa (dotted line) truncated (Mab21 domain)
cGAS reactions with 2-APTP and GTP. 2-APTP is incorporated into 2’3’fGAMP in species-unspecific manner. (b),
(c) and (d) - Fluorescence quenching assays with truncated mouse cGAS (mcGAScd) (b) and human cGAS (hcGAScd)
(c), as well as with full length human cGAS (hcGAS) (d). Bar charts represent mean values of initial steady state
activity rates of reactions (calculated as described in Fig.7) plotted against DNA length 6 standard deviation, n=3.
The assays are suitable for evaluating activity of different cGAS constructs from different species.
Figure 9: DNA-bending proteins boost cGAS activity. (a-d) cGAS activity measured by the rate of 2-APTP incorpo-
ration into 2’3’fGAMP in presence of DNA-bending proteins. Mean values of initial cGAS reaction rates (ΔF/Δt) are
plotted against increasing concentrations of DNA bending proteins 6 standard deviation, n=3-8. (a) mTFAM, (b)
mHMGB1 and (c) 1HU robustly enhance mcGAScd activity in a dose dependent manner until they eventually compete
cGAS away. (d) hTFAM activates hcGAS.
Figure 10: STING-fGAMP binding. (a) Luciferase activity assays in HEK293T-mSTING flip-in cells (Ablasser, Schmid-
Burgk et al. "Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP". Nature 503,
530-534, 2013) upon the induction with fluorescent cGAS product fGAMP. IFN-β response was measured as a
proportion of firefly (FF) luciferase activity to Renilla (Ren) luciferase activity. All ratios were normalized to fGAMP
buffer control. Plotted values correspond to mean values, error bars represent 6 standard deviation, n=3. IFB-β
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response increases with fGAMP concentration meaning fGAMP is capable of STING activation in vivo. (b) STING-
dependent fGAMP quenching assay. Mean values of fluorescence read-outs 6 standard deviation (n=3) are plotted
against increasing concentration of hSTING cytoplasmic domain (STINGcd). fGAMP fluorescence decreases with
increasing STING concentration suggesting STING-binding induced fGAMP quenching. (c) and (d) Competition
assays based on reversal of fGAMP quenching by STING. 2’5’-cGAMP (c, d) or c-di-GMP (d) were titrated into
fGAMP-STING complex. Diagrams represent fluorescence read-outs. Maximal fGAMP fluorescence in the absence
of STING for each experiment is shown with horizontal lines. The observed differences in maximal fGAMP fluores-
cence are due to inaccuracy in experimental setup and can be better estimated by higher number of replicates.
STING ligands displace fGAMP from STING binding pocket resulting in an increase of fluorescence. High affinity
STING ligands (e.g. cGAMP, c and d) replace fGAMP more efficiently and at lower concentrations than weaker
binding ligands (e.g. c-di-GMP, d) leading to a bigger slope of fluorescence intensity increase (dotted lines s1 and
s2, s1 (c-di-GMP)<S2 (cGAMP)). The method offers a quick and high-throughput approach for searching for potent STING
activators or inhibitors using the simple fluorescence readout.
General
[0024] It is to be understood that the forgoing general description as well as the following detailed description are
exemplary and explanatory only and are not restrictive of the invention as claimed. In this application, the use of the
singular may include the plural unless specifically stated otherwise. Further, the use of the term "including" as well as
other grammatical forms such as "includes" and "included", is not limiting.
[0025] As used herein the term "comprising" has the broad standard meaning "including", "encompassing", or "con-
taining". It includes the explicitly recited elements, and also allows the presence of other elements not recited. In addition
to this broad meaning, as used herein, the term "comprising" also encompasses the limiting meaning "consisting of’.
This means that any aspect or embodiment of the present invention that is defined as comprising features, also includes,
in its most limited form, the meaning of consisting (only) of said features and no others, whether this is explicitly stated
or not. In addition, the term "comprising" also includes the meaning of "consisting essentially of", which means that other
elements may be present which do not alter the technical effect achieved by the explicitly recited elements.
[0026] As used herein the term "about" when referring to a particular value such as a wavelength, sequence homology,
and the like, is meant to encompass, in addition to the recited value itself, variations of 6 5.0, 6 4.9%, 6 4.8%, 6 4.7%,
6 4.6%, 6 4.5%, 6 4.4%, 6 4.3%, 6 4.2%, 6 4.1%, 6 4.0%, 6 3.9%, 6 3.8%, 6 3.7%, 6 3.6%, 6 3.5%, 6 3.4%, 6
3.3%, 6 3.2%, 6 3.1%, 6 3.0%, 6 2.9%, 6 2.8%, 6 2.7%, 6 2.6%, 6 2.5%, 6 2.4%, 6 2.3%, 6 2.2%, 6 2.1%, 6
2.0%, 6 1.9%, 6 1.8%, 6 1.7%, 6 1.6%, 6 1.5%, 6 1.4%, 6 1.3%, 6 1.2%, 6 1.1%, 6 1.0%, 6 0.9%, 6 0.8%, 6
0.7%, 6 0.6%, 6 0.5%, 6 0.4%, 6 0.3%, 6 0.2%, or 6 0.1% from the specified value. It is to be understood that the
term "about", in reference to the particular value, includes that exact particular value itself, irrespective of any explicit
mention that this exact particular value is included. Thus, the absence of an explicit indication that the term "about"
includes the particular exact recited values is not to be understood that this particular recited values is excluded from
the range of variations created by the term "about". Even in the absence of an explicit indication that the term "about"
includes the particular exact recited value, this exact particular value is still included in the range of variation created by
the term "about". If the term "about" is recited before a numerical range, the term "about" may refer to the lower end
point, the upper end point or both the lower end point and the upper end point.
[0027] The skilled person will understand that "measuring a fluorescent signal" as recited in the methods of the invention
requires that the parameters (e.g. excitation and emission wavelength or wavelength range) of the fluorescent signal
measured should be adapted to each fluorescent nucleoside either in free form or in a form incorporated into a cyclic
dinucleotide in order to obtain optimal quantum yields. Different fluorescent nucleosides either in free form or in a form
incorporated into a cyclic dinucleotide will have different excitation and emission wavelength optima. This means for
example that depending on the fluorescent nucleoside used in the methods of the invention the wavelengths or range
of wavelengths at which a fluorescent nucleoside or a cyclic dinucleotide comprising it is excited (i.e. the excitation
maxima) and the wavelengths or range of wavelengths at which the fluorescence signal is measured (i.e. the emission
maxima) need to be adapted for each fluorescent nucleoside individually in order to avoid false positives by measuring
a fluorescence signal outside the optimal wavelength or range of wavelengths for a given fluorescent nucleoside or a
cyclic dinucleotide comprising it. The skilled person will know or can readily determine the wavelength or range of
wavelengths at which the fluorescence signal for a given fluorescent nucleoside either in free form or in a form incorporated
into a cyclic dinucleotide should be measured in order to obtain optimal quantum yields of the fluorescence signal.
[0028] The methods of the invention include the step of measuring the fluorescence signal "of a solution", e.g. of the
aqueous solution. By this is meant that the fluorescence signal which is measured is that which arises from the totality
of all fluorescing entities present in the respective solution. This fluorescence may for example arise from fluorescent
nucleoside triphosphates in free form or fluorescent nucleoside monophosphates already incorporated into a CDN, which
itself may either be a free CDN or a CDN bound by STING, depending on the particular embodiment of the invention,
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or may arise from a combination of the above. As such, the intensity of the overall "fluorescence signal of the aqueous
solution" measured will depend on how much of a respective fluorescent nucleoside is in a form in which the fluorescence
arising from the fluorescent nucleoside is quenched, i.e. reduced. The skilled person understands, for instance, that the
measured intensity of the fluorescence of an aqueous solution containing only free (unquenched) fluorescent nucleoside
will be greater than that of an aqueous solution in which a fraction of the fluorescent nucleoside is present in free
(unquenched) form and another fraction of the fluorescent nucleoside is present in a quenched form. In either case, the
readout is the overall fluorescence signal which arises as a summation of the fluorescence intensity from all fluorescing
entities in the respective solution, whether free, partially quenched or fully quenched.
[0029] The term "identical conditions" as used herein means that the composition of the aqueous solution in the
methods of the invention is the same in the presence and absence of a given substance to be tested. This means that
the aqueous solution in the presence and absence of the substance has the same concentrations of e.g. proteins (e.g.
cGAS, STING and/or 2’-5’ phosphodiesterases), nucleoside triphosphates or cGAS-activating nucleic acids (i.e. for
methods relating to cGAS), cyclic dinucleotides (i.e. for methods relating to STING and 2’-5’phosphodiesterases), salts,
divalent cations, or any other possible solute. Furthermore, the term "identical conditions" as used herein means that
the fluorescence signal of a fluorescent nucleoside or a cyclic dinucleotide comprising it is measured at the same
wavelength or range of wavelengths in the presence and absence of a substance to be tested. For example, if it is known
that the fluorescent nucleoside either in free form or in a form incorporated into a cyclic dinucleotide fluoresces using a
certain excitation wavelength or wavelength range, and that this fluorescence may be measured at a certain emission
wavelength or wavelength range, then that same wavelength or wavelength range should be used in measuring the
fluorescence of the fluorescent nucleoside or cyclic dinucleotide comprising it in the presence and absence of the
substance to be tested. The "identical conditions" as recited in the methods of the invention therefore help ensure
comparability of the fluorescence signals measured in the presence and absence of the substance to be tested, so that
any change in the relative levels of these signals can confidently be attributed to the effect of that substance itself.
[0030] The term "substantially identical" as used herein has the meaning of identical within normal experimental error,
e.g. with regard to the reaction conditions used in the measurement of a fluorescent signal in order to allow valid
comparison of the measured fluorescence signals from two or more measuring steps. For example, the term "substantially
identical" as used in accordance to the present invention refers to the measurement of two or more fluorescence signals
at the same time points in the same aqueous solution (i.e. the aqueous solutions of two or more measuring steps
comprises same salt and protein concentrations, same pH and the like) in order to allow a reliable comparison of the
measured fluorescence signals in the presence or absence of a substance. The skilled person recognizes that normal
variance within experimental error, e.g. due to pipetting solution volumes, weighing solutes and the like, are unavoidable,
but still lead to results which are substantially identical.
[0031] The features of any one embodiment disclosed herein are intended as being combinable with those of any
other embodiment. Such combinations of one or more features in any one embodiment with one or more features in any
other embodiment belong to the disclosure of the present application as filed.
[0032] All documents or portions of documents cited in this application, including but not limited to patents, patent
applications, articles and books, are hereby expressly incorporated by reference in their entirety for any purpose.
Detailed description
[0033] As used herein the term "cyclic dinucleotide" (CDN) refers to a molecule in which two nucleoside monophos-
phates are covalently joined, via two phosphodiester linkages, into a single species. Such "head to toe"-linked CDNs
sometimes serve as a second messenger secreted by certain bacteria, such as Listeria monocytogenes, or generated
by the cyclic GMP-AMP synthase (cGAS) following binding to cytosolic DNA. CDNs produced by the enzyme cGAS
comprise an asymmetric 2’-5’ and 3’-5’ phosphodiester linkage between a first nucleoside monophosphate and a second
nucleoside monophosphate. CDNs produced by cGAS are referred to as "2’3’ cyclic dinucleotide" or "2’3’CDN" according
to the present invention. The first and the second nucleoside monophosphate in the CDN according to the invention can
be either a deoxyribonucleoside monophosphate or a ribonucleoside monophosphate provided that one of the first and
second nucleoside monophosphate has a free 2’ hydroxyl group and the other one has a free 3’ hydroxyl group in order
to enable the 2’-5’ and 3’-5’ phosphosdiester linkages. Positions of the sugar backbone of the CDN according to the
invention which do not participate in cyclization can be substituted with any moiety such as H-, OH-, methyl-, amino-,
methoxy-, fluoro-, methoxyethyl-, -O-propargyl, and O-propylamine, provided that such moiety does not impede cycli-
zation of the two nucleoside monophosphates. Furthermore, the phosphodiester linkages of the 2’3’CDN according to
the invention may comprise modifications such as thiophosphate, boranophosphate, methyl phosphonate, N-3’-phos-
phoramidate (O2P-NH-ribose) e.g. in order to enhance the stability of the phosphodiester linkage.
[0034] As used herein, the terms "nucleoside" and "nucleotide" used in various forms (e.g. "nucleoside monophos-
phate", "cyclic dinucleotide", etc.) have the commonly accepted meaning in the art. These species contain a 1-β-D-
furanose moiety with its stereochemical configuration as in naturally occurring DNA and RNA.
150
EP 3 431 484 A1
8
5
10
15
20
25
30
35
40
45
50
55
[0035] As used herein the term "cyclic GMP-AMP synthase" or "cGAS" refers to an enzyme belonging to the nucle-
otidyltransferase (NTase) superfamily which is responsible for cytosolic DNA recognition. Upon recognition of cytosolic
dsDNA, cGAS becomes activated by the formation of a cGAS/dsDNA complex. Activated cGAS converts free nucleotide
triphosphates into cyclic dinucleotides having an asymmetric 3’-5’ and 2’-5’ phosphodiester linkage between a first and
a second nucleoside monophosphate (i.e. 2’3’CDN). These cyclic dinucleotides can serve as second messengers in
downstream signaling. Non-limiting examples for variants of cGAS may be defined by e.g. SEQ ID NO: 10 and SEQ ID
NO: 12.
[0036] As used herein the term "stimulator of interferon genes" or "STING" refers to a protein associated with the
endoplasmic reticulum that binds to cyclic dinucleotides to trigger cytokine production. STING is expressed in various
endothelial and epithelial cell types, as well as in haematopoietic cells, such as T cells, macrophages and dendritic cells.
STING is activated upon binding of CDNs and formation of a complex consisting of a V-shaped STING dimer and a
CDN molecule. CDNs which are capable of activating STING are either secreted by various bacteria or produced by the
enzyme cGAS. 2’3’CDNs produced by cGAS have a much higher binding affinity for STING than CDNs secreted by
bacteria which have two conventional 3’5’ phosphodiester linkages between the first and the second nucleoside mono-
phosphates (3’3’CDN). Therefore, 2’3’CDNs produced by cGAS play a key role in STING activation. Activated STING
then interacts with Tank-binding kinase 1 (TBK1) and traffics through the Golgi to perinuclear endosomal compartments,
where TBK1 phosphorylates the transcription factors IRF3 and IRF7 to induce the expression of pro-inflammatory cy-
tokines and chemokines. Non-limiting examples for variants of STING may be defined by e.g. SEQ ID NOs: 2, 4, 6 and 8.
[0037] As used herein the term "2’-5’ phosphodiesterase" refers to a pyrophosphate/phosphodiesterase enzyme which
degrades the phosphodiester bond in 2’3’CDNs. The enzyme regulates the localization, duration and amplitude of cyclic
dinuleotide signaling within subcellular domains and therefore plays an important role in the signal transduction mediated
by 2’3’CDN second messenger molecules. Beside the cleavage of 2’3’CDNs, the 2’-5’ phosphodiesterase is also capable
of cleaving 3’3’CDNs secreted by various bacteria, such as Listeria monocytogenes.
[0038] As used herein the term "DNA-bending protein" refers to proteins that upon interaction with DNA induce a
structural bend or kink in the DNA. In general, bending or introducing curves or kinks in DNA can lead to DNA compac-
tification or to structural arrangement of DNA binding sites in cis. Examples are bacterial and mitochondrial genome
structuring protein (e.g. bacterial HU, mitochondrial TFAM), where DNA bending in conjunction with protein dimerization
induces loop structures in DNA, resulting in genome packaging as nucleoids. Other DNA bending proteins such as the
transcription factor TBP shape DNA to be recognized by the transcription complexes. Histone proteins also bend or
curve DNA, forming nucleosomes. HMG box proteins also bend DNA upon binding. These proteins function in stress
response. In one illustrative example of the present invention, a "DNA-bending protein" may represent a "substance"
having an ability to enhance cGAS activity. The "DNA-bending proteins" as used in the illustrative examples of the
present invention therefore provide evidence that the below described methods of the invention are suitable to identify
a substance having an ability to modulate (e.g. enhance) cGAS activity. In any event, the skilled person will understand
that a "DNA-bending protein" is nonessential for the herein described methods of the invention and merely serves as
an illustrative example representing a substance having the ability to enhance cGAS activity.
[0039] As used herein the term "affinity tag" refers to a peptide sequence which is genetically linked to the N- or C-
terminus of an amino acid sequence of a protein or a polypeptide. Affinity tags according to the invention are used for
protein purification, protein detection and enhancing the solubility of a protein. Examples of affinity tags include but are
not limited to albumin-binding protein (ABP), alkaline phosphodiesterase (AP), AU1 epitope, AU5 epitope, bacteriophage
T7 epitope, bacteriophage V5 epitope, biotin-carboxy carrier protein (BCCP), bluetongue virus tag (B-tag), calmodulin
binding peptide (CBP), chloramphenicol acetyl transferase (Crow, Chase et al. "Characterization of Human Disease
Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1".
American journal of medical genetics. Part A 0, 296-312) cellulose binding domain (CBP), chitin binding domain (CBD),
choline-binidng domain (CBD), dihydrofolate reductase (DHFR), E2 epitope, FLAG epitope, galactose-binding protein
(GBP), green fluorescent protein (GFP), Glu-Glu (EE-tag), glutathione S-transferase (GST), human influenza hemag-
glutinin (HA), Halo Tag® (Promega), histidine affinity tag (Li, Shu et al. "Cyclic GMP-AMP Synthase Is Activated by
Double-Stranded DNA-Induced Oligomerization". Immunity 39, 1019-1031), horseradish peroxidase (HRP), HSV
epitope, ketosteorid isomerase (KSI), KT3 epitope, LacZ, luciferase, maltose-binding protein (MBP), Myc epitope, NusA,
PDZ domain, PDZ ligand, polyarginine (Arg-tag), polyaspartate (Asp-tag), polycysteine (Cys-tag), polyhistidine (e.g.
His6-tag), polyphenylalanine (Phe-tag), Profinity eXact™ fusion Tag (Bio-Rad), protein C, S1-tag, S-tag, streptavidin-
binding peptide (SBP), Staphylococcal protein A (protein A), Staphylococcal protein G (protein G), Strep-tag, Streptavidin,
small ubiquitin-like modifier (SUMO), tandem affinity purification (TAP), T7 epitope, thioredoxin (Trx), TrpE, ubiquitin,
Universal, VSV-G. Furthermore, the term "affinity tag" as used herein may refer to a combination of one or more of the
above recited peptide sequences.
[0040] As used herein the term "nucleoside" refers to a molecule comprising a ribofuranosyl or deoxyribofuranosyl
ring linked to a nucleobase via a beta glycosidic linkage. If the 5’oxygen of the (deoxy)ribofuranosyl is linked to one, two
or three phosphate groups, the nucleoside is referred to as a nucleoside monophosphate, diphosphate or triphosphate,
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respectively, as commonly denoted in the art. The one, two or three phosphate groups can comprise modifications such
as thiophosphates, boranophosphate, methyl phosphonate, N-3’-phosphoramidate (O2P-NH-ribose) e.g. in order to
increase the stability of phosphodiester bonds. Examples of nucleobases comprised in the nucleoside molecule include
but are not limited to adenine, guanine, thymine, uracil, cytosine and fluorescent nucleobase analogues.
[0041] As used herein the term "fluorescent nucleoside" refers to a nucleoside comprising a fluorescent nucleobase
analogue having an intrinsic fluorescence, i.e. the fluorescence is a property of the heterocyclic ring of the nucleobase
analogue itself and not a property from an extrinsic fluorescent label attached to it. Fluorescent nucleobase analogues
resemble the shape of naturally occurring nucleobases, such as cytosine (C), guanine (G), adenine (A), thymine (T) or
uracil (U), and also have the ability to form hydrogen bonds with other nucleobases, e.g. in the manner known for nucleic
acid base-pairing. The fluorescent nucleobase analogues herein therefore include those having a high structural similarity
to the respective natural nucleobases and, when incorporated into cyclic dinucleotides (CDNs) or polynucleotides, result
in fluorescent CDNs or fluorescent poynucleotides which resemble the shape of the natural molecules. Importantly, the
fluorescent nucleobase analogues according to the present invention have a fluorescence activity which is higher than
the fluorescence activity of natural occurring nucleobases. According to the present invention, the intensity of the fluo-
rescence emitted by the fluorescent nucleobase analogue in a "fluorescent nucleoside" is quenched, i.e. reduced, by a
change in the chemical environment surrounding the fluorescent nucleobase analogue in the manner well known for
fluorescence resonance energy transfer (FRET), as known in the art. This means that if the fluorescent nucleoside
changes its location, e.g. when it is incorporated into a larger molecule such as a CDN, the quantum yield of the fluorescent
signal emitted by the fluorescent nucleobase analogue will be quenched, i.e. reduced, thereby allowing one to analyze
environmental changes of the fluorescent nucleoside comprising the fluorescent nucleobase analogue by measuring its
fluorescence. In particular, the fluorescence intensity (i.e. the quantum yield ϕ) of a fluorescent nucleoside decreases
upon incorporation of the fluorescent nucleoside into a CDN molecule, and/or upon binding of the fluorescent nucleoside
or a CDN comprising the fluorescent nucleoside to the cGAS/STING signaling pathway, e.g. upon binding to cGAS
and/or STING. Due to the dependence of fluorescence intensity of the fluorescent nucleosides on environment, the
fluorescent nucleosides of the present invention can therefore be utilized to measure physiological processes including
but not limited to enzymatic activity and interaction of molecules as described herein.
[0042] As used herein the term "2-aminopurine" or "2-AP" refers to a highly fluorescent nucleobase analogue of adenine
having the lowest energy absorption band centered at 305 nm and a molar absorptivity (ε) of 6000 M-1 cm-1. The position
of the band is outside the absorption of the natural nucleic acids, so 2-AP can be selectively excited in the presence of
natural nucleobases. The high quantum yield of free 2-AP in water at 25°C (ϕ=0.68) is considerably quenched, i.e.
reduced, (∼100 fold) when 2-AP is incorporated into a CDN or nucleic acid. It is quenched further still when the 2’3’CDN
in which 2-AP exists is bound by the protein STING. This high sensitivity of 2-AP to its microenvironment can be utilized
in a variety of assays to study e.g. DNA or nucleotide/protein interactions and enzymatic activity. 2-AP has the following
structure:
[0043] As used herein the term "quantum yield" refers to the efficiency of the fluorescence process. The term "quantum
yield" as used herein is defined as the ratio of the number of photons emitted to the number of photons absorbed. It is
defined by the following equation: 
[0044] The maximum fluorescence quantum yield is 1.0 (100%), which means that each photon absorbed results in
a photon emitted. The fluorescence signal of a "fluorescent nucleoside" according to the present invention may have a
quantum yield (ϕ) in free form in water at 25°C of about 0.10 to about 1.0 or between about 0.10 and 1.0. In one
embodiment of the invention a fluorescent nucleoside according to the invention has a quantum yield in free form in
water at 25°C of at least: about 0.10, about 0.11, about 0.12, about 0.13, about 0.14, about 0.15, about 0.16, about 0.17,
about 0.18, about 0.19, about 0.20, about 0.21, about 0.22, about 0.23, about 0.24, about 0.25, about 0.26, about 0.27,
about 0.28, about 0.29, about 0.30, about 0.31, about 0.32, about 0.33, about 0.34, about 0.35, about 0.36, about 0.37,
about 0.38, about 0.39, about 0.40, about 0.41, about 0.42, about 0.43, about 0.44, about 0.45, about 0.46, about 0.47,
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about 0.48, about 0.49, about 0.50, about 0.51, about 0.52, about 0.53, about 0.54, about 0.55, about 0.56, about 0.57,
about 0.58, about 0.59, about 0.60, about 0.61, about 0.62, about 0.63, about 0.64, about 0.65, about 0.66, about 0.67,
about 0.68, about 0.69, about 0.70, about 0.71, about 0.72, about 0.73, about 0.74, about 0.75, about 0.76, about 0.77,
about 0.78, about 0.79, about 0.80, about 0.81, about 0.82, about 0.83, about 0.84, about 0.85, about 0.86, about 0.87,
about 0.88, about 0.89, about 0.90, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96, about 0.97,
about 0.98, about 0.99, or about 1.00. A nucleoside is still considered "intrinsically fluorescent", and therefore a "fluo-
rescent nucleoside" according to the present invention, if it has a quantum yield in free form in water at 25°C of at least 0.10.
[0045] As used herein the term "molar absorptivity" refers to the molar attenuation coefficient or molar extinction
coefficient and is a measurement of how strongly a chemical species, e.g. a fluorophore, absorbs light at a given
wavelength. It is an intrinsic property of the chemical species, i.e. it depends on the chemical structure of the species.
[0046] As used herein the term "aqueous solution" refers to a solution comprising water, e.g. a solution comprising
water and at least one buffer. A buffer comprises a weak acid and its conjugate base or a weak base and its conjugate
acid. A buffer keeps the pH of a solution constant by taking up protons that are released during reactions, or by releasing
protons when they are consumed by reactions. A buffer therefore stabilizes the H+ concentration in vitro without affecting
the functioning of a system under investigation. As used herein, an "aqueous solution" can further comprise essential
cofactors for enzymatic reaction, such as metal ions, critical salts and essential nutrients for cells or tissues. An aqueous
solution may also comprise one or more solvents other than water, as long as such solvents are sufficiently miscible in
water such that multiple phases do not form.
[0047] As used herein the term "cGAS-activating nucleic acid" refers to any nucleic acid molecule capable of activating
cGAS. In particular, a cGAS-activating nucleic acid may be a double-stranded (ds), single-stranded (ss) DNA or a
DNA/RNA hybrid. In the case of nucleic acid, e.g. dsDNA, the cGAS-activating nucleic acid has a length of at least 10
base pairs (bp). Furthermore, the double-stranded cGAS-activating nucleic acid may have a minimal length selected
from the group consisting of at least 11bp, 12bp, 13bp, 14bp, 15bp, 16bp, 17bp, 18bp, 19bp, 20bp, 21bp, 22bp, 23bp,
24bp, 25bp, 26bp, 27bp, 28bp, 29bp, 30bp, 31bp, 32bp, 33bp, 34bp, 35bp, 36bp, 37bp, 38bp, 39bp, 40bp, 41bp, 42bp,
43bp, 44bp, 45bp, 46bp, 47bp, 48bp, 49bp, 50bp, 51bp, 52bp, 53bp, 54bp, 55bp, 56bp, 57bp, 58bp, 59bp, 60bp, 61bp,
62bp, 63bp, 64bp, 65bp, 66bp, 67bp, 68bp, 69bp, 70bp, 71bp. 72bp, 73bp, 74bp, 75bp, 76bp, 77bp, 78bp, 79bp, 80bp,
81bp, 82bp, 83bp, 84bp, 85bp, 86bp, 87bp, 88bp, 89bp, 90bp, 91bp, 92bp, 93bp, 94bp, 95bp, 96bp, 97bp, 98bp, 99bp,
and 100bp. The double-stranded cGAS-activating nucleic acid may also have a minimal length of at least 200bp, 300bp,
400bp, 500bp, 600bp, 700bp, 800bp, 900bp, 1kbp, 2kbp, 3kbp, 4kbp, 5kbp, 6kbp and the like. Corresponding lengths
also apply in the event the cGAS-activating nucleic acid, e.g. DNA, is single-stranded. The double-stranded cGAS-
activating nucleic acid may be DNA, for example a plasmid, such as a commonly known expression vector. The cGAS-
activating nucleic acid may also be in the form of single-stranded DNA or DNA/RNA hybrids. Such DNA/RNA hybrids
may also have the lengths as set out above.
[0048] As used herein the term "substance" refers to any molecule which can be tested for its binding to cGAS or
STING. The term "substance" as used herein may for example refer to any molecule having an ability to modulate cGAS
or 2’-5’ phosphodiesterase activity. A "substance" according to the invention may be a small molecule, a protein, a
polypeptide, or a single amino acid. The protein may be an enzyme having biological activity, or an antibody. The term
"antibody" as used herein comprises the full-length antibody or fragments thereof, wherein the term "antibody fragment"
comprises a Fab, F(ab’)2, monospecific Fab2, bispecific Fab2, trispecific Fab2, monovalent IgG, scFv, bispecific scFv,
bispecific diabody, trispecific triabody, scFv-Fc, minibody and the like. The term "substance" as used herein may also
comprise chemical molecules having saturated or unsaturated hydrocarbons, such as alkanes, cycloalkanes, alkenes
and the like, i.e. may generally represent any member of the class of "small molecules" which the skilled person recognizes
as constituted by substances which may be synthesized by an organic synthetic chemist without the need to implement
microorganisms. A "substance" according to the invention may further comprise an alcohol, ester, ether, amide and the
like. Furthermore, a "substance" as used herein may be a carbohydrate or a lipid. Nucleic acids or single nucleotides
may also be a "substance" according to the present invention. A nucleic acid may be a double-stranded (ds) or single
standed (ss) DNA. A nucleic acid may also be an RNA, such as a miRNA or siRNA, or a DNA/RNA hybrid. A nucleic
acid may also refer to poly(I:C), poly(dI:dC), poly(dA:dU), or any combination of ribose and deoxyribose backbones. The
backbones furthermore can contain phosphothioate esters, instead of phosphates esters between the backbone sugars.
In addition, it may contain or consist of peptide nucleic acid (PNA) backbones, locked nucleic acid (LNA) backbones,
Glycol nucleic acid (GNA) backbones, threose nucleic acid (TNA) backbones and other Xeno nucleic acid (XNA) alter-
natives. In one illustrative example, a substance according to the present invention is represented by a "DNA bending
protein" which is capable of enhancing cGAS activity as shown by the methods of the present invention.
[0049] As used herein the term "systemic lupus erythematosus" or "SLE" refers to an autoimmune disease in which
antibodies specific for DNA, RNA or proteins associated with nucleic acids form immune complexes that damage small
blood vessels, especially in the kidneys. Patients with SLE generally have abnormal B and T cell function. SLE can be
associated with hyperproduction of type I interferon.
[0050] As used herein the term "Aicardi-Goutières syndrome" or "AGS" refers to a neurodegenerative disorder that
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can be caused by STING-dependent cytokine hyperproduction owing to mutations in genes such as TREX-1 (three-
prime repair exonuclease 1).
[0051] As used herein the term "idiopathic arterial calcification of infancy" or "IAIC" refers to a rare condition charac-
terized by extensive calcification and stenosis of large and medium sized arteries. IACI is an unusual genetically inherited
autosomal recessive condition which may be dystrophic or metastatic.
[0052] As used herein the term "stenosis" refers to an abnormal narrowing in a blood vessel or other tubular organ or
structure.
[0053] As used herein the term "pseudoxanthoma elasticum" or "PXE" refers to a progressive disorder that is char-
acterized by the accumulation of deposits of calcium and other minerals (mineralization) in elastic fibers. Elastic fibers
are a component of connective tissue, which provides strength and flexibility to structures throughout the body.
[0054] As used herein the term "diabetic kidney disease" refers to a kidney disease caused by or coexistent with
diabetes.
[0055] As used herein the terms "engineered", "genetic engineering" or "genetic modification" refer to the manipulation
of a nucleotide sequence of a gene encoding a protein or enzyme. A nucleotide sequence may for example be manipulated
by introducing mutations into the nucleotide sequence of the gene, thereby altering the amino acid sequence of the
encoded protein or enzyme. For example, mutations can be introduced into the active site of an enzyme, thereby altering
its enzymatic activity. By choosing the appropriate mutation the enzymatic activity can be increased, decreased or
completely silenced compared to the unmodified enzyme. A mutation in the nucleotide sequence of a gene encoding a
protein can alter the conformation of the protein thereby influencing its functionality and stability. Furthermore, specific
mutations can be introduced into the nucleotide sequence of a gene to investigate polymorphisms, such as single
nucleotide polymorphisms, that might be associated with specific diseases. A mutation can be a substitution, deletion
or insertion of a single nucleotide or more than one nucleotide in the nucleotide sequence of a gene encoding a protein,
e.g. an enzyme. As used herein the terms "engineered", "genetic engineering" or "genetic modification" may also refer
to the deletion of nucleotide sequences encoding one or more specific domains of the protein or enzyme, resulting in a
truncated version of the molecule. For example, a truncated protein, e.g. a truncated enzyme, might only include the C-
terminus, N-terminus or one or more highly conserved catalytic domains compared to the full length molecule. By deleting
nucleotide sequences encoding e.g. unstructured regions, the truncated protein, e.g. the enzyme, may gain advantageous
properties compared to the full length molecule, including but not limited to increased expression, improved solubility,
increased activity or binding affinity. Nucleotide sequences can be further engineered by replacing specific nucleotide
sequences of a gene with orthologous nucleotide sequences from different species. Furthermore, nucleotide sequences
can be engineered to comprise affinity tags or other labels at their N- or C-terminus allowing for purification or detection
of the encoded protein or enzyme. "Genetic engineering" or "genetic modification" is achieved by well known methods
in the art including chemical synthesis and PCR technology (Russell. "Molecular Cloning, a laboratory manual". Cold
Spring Harbor Laboratory Press 1, 2012);(Hughes, Miklos et al. "Chapter twelve - Gene Synthesis: Methods and Appli-
cations". Methods in Enzymology Volume 498, 277-309, 2011; Throop and LaBaer. "Recombinational Cloning Using
Gateway and In-Fusion Cloning Schemes". Current protocols in molecular biology / edited by Frederick M. Ausubel ...
[et al.] 110, 3.20.21-23.20.23, 2015).
[0056] As used herein the term "modulate" or "modulating" refers to the capability of a substance to inhibit, activate
or enhance the activity or properties of another substance, e.g. cGAS, STING or 2’-5’ phosphodiesterase, thereby
changing the concentration of CDNs, in particular 2’3’CDNs. A substance that acts as an antagonist of one of the
aforementioned enzymes may partially or fully reduce the physiological function of said protein, thereby resulting in a
reduction of CDN production (in the case of cGAS inhibition) or CDN cleavage (in the case of 2’-5’ phosphodiesterase
inhibition). Specifically, a substance which antagonizes the activity of cGAS may partially or fully inhibit the conversion
of the nucleoside triphosphates into 2’3’CDNs. A substance which is an antagonist of cGAS might bind to the active
center of the enzyme thereby competing with the nucleoside triphosphates for binding to cGAS. A substance which
antagonizes cGAS activity (partially or fully) might also bind to the enzyme in an uncompetitive manner, i.e. to an allosteric
site of cGAS which results in an alteration of the active binding site thereby preventing nucleoside triphosphate binding.
A substance that acts as an antagonist of 2’-5’ phosphodiesterase may function in a competitive or uncompetitive manner
similar to a substance inhibiting cGAS activity. A substance which acts as an agonist of cGAS may enhance (partially
or fully) cGAS activity, e.g. an agonist of cGAS enhances the conversion of nucleoside triphosphates into 2’3’CDNs in
comparison to the conversion of nucleoside triphosphates into 2’3’CDNs in the absence of such an agonist. A substance
which activates 2’-5’ phosphodiesterase (partially or fully) may enhance the cleavage of the 2’-5’ phosphodiester linkage
of the 2’3’ CDN, e.g. an agonist of 2’-5’ phosphodiesterase reduce the overall concentration of 2’3’ CDN molecules in
a biological system.
[0057] As used herein the term "divalent cation" refers to a cation having a valence of 2. A "divalent cation" according
to the invention is selected from the group consisting of Mg2+, Ca2+, Zn2+, Fe2+, Cu2+, Ni+2 and Mn2+.
[0058] As used herein the term "measuring" refers to determining the intensity of a fluorescence signal measured at
a predetermined time point or to determining the change of a fluorescence signal measured continuously or at intervals
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over a predetermined time interval.
[0059] The present invention is now described in more detail by reference to certain preferred embodiments.
Cyclic dinucleotides
[0060] As mentioned above, one aspect of the present invention relates to a cyclic dinucleotide comprising a 3’-5’
phosphodiester linkage and a 2’-5’ phosphodiester linkage between a first and a second nucleoside monophosphate,
wherein at least one of the first and second nucleoside monophosphates is a fluorescent nucleoside monophosphate.
The fluorescent cyclic dinucleotides of the present invention are hereinafter referred to as 2’3’fCDNs.
[0061] The fluorescent nucleoside comprises a fluorescent nucleobase analogue which possesses intrinsic fluores-
cence. Furthermore, the intrinsic fluorescence of the fluorescent nucleobase analogue is sensitive to environmental
changes. This means that if the fluorescent nucleoside comprising the fluorescent nucleobase analogue changes its
disposition with respect to other chemical species, e.g. other nucleobases in a CDN, the quantum yield will be quenched,
i.e. reduced, thereby allowing the analysis of environmental changes of the fluorescent nucleoside. In particular, the
fluorescence intensity, i.e. the quantum yield of the fluorescent nucleoside, is reduced upon incorporation of the fluo-
rescent nucleoside into a CDN, and/or upon binding of the nucleoside or a CDN comprising it to cGAS and/or STING.
Due to their environmental sensitivity the fluorescent nucleosides of present invention can therefore be utilized to measure
physiological processes including but not limited to enzymatic activity and interaction of molecules as will be discussed
in more detail below.
[0062] The fluorescent nucleoside according to the present invention has a fluorescence which is higher than the
fluorescence of natural occurring nucleosides, such as adenosine, guanosine, cytosine, thymidine, uracil and the like.
In a further embodiment of the present invention, the fluorescence signal of a fluorescent nucleoside according to the
present invention has a quantum yield (ϕ) in free form in water at 25°C of about 0.10 to about 1.0 or between about 0.10
and 1.0. In one embodiment of the invention a fluorescent nucleoside according to the invention has a quantum yield in
free form in water at 25°C of at least: about 0.10, about 0.11, about 0.12, about 0.13, about 0.14, about 0.15, about 0.16,
about 0.17, about 0.18, about 0.19, about 0.20, about 0.21, about 0.22, about 0.23, about 0.24, about 0.25, about 0.26,
about 0.27, about 0.28, about 0.29, about 0.30, about 0.31, about 0.32, about 0.33, about 0.34, about 0.35, about 0.36,
about 0.37, about 0.38, about 0.39, about 0.40, about 0.41, about 0.42, about 0.43, about 0.44, about 0.45, about 0.46,
about 0.47, about 0.48, about 0.49, about 0.50, about 0.51, about 0.52, about 0.53, about 0.54, about 0.55, about 0.56,
about 0.57, about 0.58, about 0.59, about 0.60, about 0.61, about 0.62, about 0.63, about 0.64, about 0.65, about 0.66,
about 0.67, about 0.68, about 0.69, about 0.70, about 0.71, about 0.72, about 0.73, about 0.74, about 0.75, about 0.76,
about 0.77, about 0.78, about 0.79, about 0.80, about 0.81, about 0.82, about 0.83, about 0.84, about 0.85, about 0.86,
about 0.87, about 0.88, about 0.89, about 0.90, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96,
about 0.97, about 0.98, about 0.99, or about 1.00. Any of the above recited quantum yield values may be combined with
one another to form a quantum yield range. Also contemplated within such quantum yield ranges are corresponding
ranges in which the lower quantum yield is included while the upper quantum yield is excluded, as well as ranges in
which the lower quantum yield is excluded while the upper quantum yield is included. In a particular preferred embodiment,
the quantum yield of a fluorescent nucleoside in free form in water at 25°C is about 0.68, more preferably is 0.68. This
is for example the fluorescent yield of 2-AP in free form in water at 25°C.
[0063] In one embodiment of the present invention, the 3’-5’ phosphodiester linkage of the cyclic dinucleotide is
between the 3’ oxygen of the first nucleoside monophosphate and the 5’ oxygen of the second nucleoside monophosphate
and the 2’-5’ phosphodiester linkage of the cyclic dinucleotide is between the 5’ oxygen of the first nucleoside mono-
phosphate and the 2’ oxygen of the second nucleoside monophosphate. This asymmetric nature of the phosphodieseters
is advantageous for high affinity binding to human STING.
[0064] In a further embodiment of the present invention, the fluorescent nucleoside monophosphate is a fluorescent
purine nucleoside monophosphate. The fluorescent purine nucleoside monophosphate is advantageous for recognition
by cGAS and may also enhance binding to STING.
[0065] In a preferred embodiment of the present invention, the fluorescent nucleoside monophosphate is selected
from the group consisting of a 2-aminopurine nucleoside monophosphate (2-APMP), a 3-methyl-isoxanthopterin nucl-
eoside monophosphate (3-MIMP), a 6-methyl isoxanthopterin nucleoside monophosphate (6-MIMP), 4-amino-6-methyl-
8-(2-deoxy-beta-d-ribofuranosyl)-7(8H)-pteridone nucleoside monophosphate (6-MAPMP), a 4-amino-2,6-dimethyl-
8-(2’-deoxy-beta-d-ribofuranosyl)-7(8H)-pteridone nucleoside monophosphate (DMAPMP), a pyrrolocytosine nucelo-
side monophosphate (pyrrolo-CMP), a 6-phenylpyrrolocytosine nucleoside monophosphate (PhpCMP), a (ami-
noethoxy)phenylpyrrolocytosine nucleoside monophosphate (moPhpCMP), a [bis-o-(aminoethoxy)phenyl]pyrrolocyto-
sine nucleoside monophosphate (boPhpCMP), a hydropyrimidopyrimidine nucleoside monophosphate (ChppMP), a pyr-
rolopyrimidopyrimidine nucleoside monophosphate (CpppMP), a pyrimidopyrimidoindole nucleoside monophosphate
(CppiMP), a benzopyridopyrimidine nucleoside monophosphate (BPPMP), a naphthopyridopyrimidine nucleoside mono-
phosphate (NPPMP), a methoxybenzodeazaadenine nucleoside monophosphate (MDAMP), a methoxybenzodeazain-
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osine nucleoside monophosphate (MDIMP), a naphthodeazaadenine nucleoside monophosphate (NDAMP), a furan-
modified pyrimidine nucleoside mohophosphate, a thieno[3,2]pyrimidine nucleoside monophosphate, a thieno[3,4]pyri-
midine nucleoside monophosphate, a 5-methoxy-quinazoline-2,4-(1H,3H) dione nucleoside monophosphate, a 5-meth-
ylpyrimidine-2-one nucleoside monophosphate, a 7-deazapurine nucleoside monophosphate, a 5-alkyluridine nucleo-
side monophosphate, a benzoquinalozines nucleoside monophosphate, a triazoleadenosine nucleoside monophos-
phate, and a 1,N6-ethenoadenosine nucleoside monophosphate.
[0066] In a further embodiment of the present invention, a fluorescent nucleoside monophosphate can comprise further
chemical modification to the fluorescent nucleobase analogue and the ribofuranosyl backbone provided that such mod-
ification does not affect the fluorescence of the fluorescent nucleobase analogue. Furthermore, such modification should
not affect the structural and chemical properties of a fluorescent nucleoside monophosphate, i.e. the modification may
not affect the fluorescent nucleoside monophosphate’s ability to incorporate into nucleotide molecules, such as polynu-
cleotides and CDNs. Possible modifications of the fluorescent nucleoside monophosphate according to the present
invention include but are not limited to phosphothioate linker. In addition, it may contain or consist of peptide nucleic
acid (PNA) backbones, locked nucleic acid (LNA) backbones, Glycol nucleic acid (GNA) backbones, threose nucleic
acid (TNA) backbones and other Xeno nucleic acid (XNA) alternatives.
[0067] In a particularly preferred embodiment, the fluorescent nucleoside monophosphate is a 2-aminopurine nucle-
oside monophosphate (2-APMP), wherein the fluorescent nucleobase analogue is 2-aminopurine. 2-aminopurine (2-
AP) is a highly fluorescent nucleobase analogue of adenine having the lowest energy absorption band centered at 305
nm and a molar absorptivity (ε) of 6000 M-1 cm-1. The position of the band is outside the absorption of the natural nucleic
acids and, thus, 2-AP can be selectively excited in the presence of natural nucleobases. The high quantum yield of free
2-AP in water (ϕ=0.68) is considerably quenched, i.e. reduced, (∼100 times) when incorporated into biological molecules
such as nucleic acids or CDNs. This high sensitivity of 2-AP to its microenvironment can be utilized in a variety of methods
of measuring enzyme activity or investigating molecule interactions as will be discussed in more detail below.
[0068] In a further preferred embodiment of the present invention, 2-APMP is the first nucleoside monophosphate. A
CDN comprising 2-APMP as the first nucleoside monophosphate resembles the shape of 2’3’CDNs made by cGAS and
recognized by STING, thereby making such CDN in particular suitable for methods of e.g. measuring cGAS activity or
identifying substances with an ability to modulate the properties of another substance, e.g. cGAS, STING or 2’-5’ phos-
phodiesterases.
[0069] Due to the chemical structure of the 2’3’CDN it is necessary that one of the two nucleoside monophosphates
has a free 2’ hydroxyl group and the other one has a free 3’ hydroxyl group in order to enable the 2’-5’ and 3’-5’
phosphodiester linkages in the 2’3’CDN. Thus, in a further embodiment of the invention the second nucleoside mono-
phosphate of the cyclic dinucleotide is a purine ribonucleoside monophosphate, preferably a guanosine monophosphate
(GMP) having a free 2’ hydroxyl group, whereas 2-APMP is the first nucleoside monophosphate having a free 3’ hydroxyl
group. The chemical structure of a CDN comprising 2-APMP as the first nucleoside monophosphate and guanosine
monophosphate as the second nucleoside monophosphate is almost identical to the chemical structure of the 2’3’CDN
made by cGAS. Such a CDN is therefore an ideal fluorescent analogue of the naturally occurring 2’3’CDN made by
cGAS and recognized by STING, and may thus be used in various methods as set out below in more detail.
[0070] In another preferred embodiment of the present invention, the fluorescent cyclic dinucleotide has the following
formula
wherein
when R1 is bound to P through a single bond, R1 is independently selected from the group consisting of O, S, BH3
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and CH3;
when R1 is bound to P through a double bond, R1 is independently selected from the group consisting of O, S and NH;
wherein at least one R1 bound to each P is O;
R2 is independently selected from the group consisting of H, OH, methyl, amino-, methoxy-, fluoro-, methoxyethyl-,
-O-propargyl and O-propylamine; and
R3 is O.
[0071] In a particularly preferred embodiment of the present invention, the cyclic dinucleotide has the following formula:
or
This cyclic dinucleotide resembles the structural and chemical properties of cyclic dinucleotide generated by cGAS and
recognized by STING and can thus be used in a variety of methods according to the present invention as will be discussed
in more detail below.
[0072] For example, the 2’3’fCDNs according to the present invention can be used to identify a substance having an
ability to bind to STING. The cyclic dinucleotide of the present invention can be further used to identify a substance
having an ability to modulate 2’-5’ phosphodiesterase activity. Furthermore, the cyclic dinucleotide of the present invention
can be used in vitro to label enzymes or proteins, such as cGAS and STING, in order to investigate their cellular localization
during different diseases and during bacterial or viral infection. For example, the cyclic dinucleotide according to the
present invention may form a complex with cGAS or STING, which can be readily localized in an in vitro system, such
as a mammalian cell culture, due to the fluorescence signal of the fluorescent nucleoside of the cyclic dinucleotide. The
fluorescence signal can be detected by using commonly known techniques such as fluorescence microscopy (Lakowicz.
"Principles of Fluorescence Spectroscopy". Springer 3th edition, 2006).
Method of identifying a substance having an ability to bind to STING
[0073] Stimulator of interferon genes (STING) is a protein which is expressed in various endothelial and epithelial cell
types, as well as in hematopoietic cells, such as T cells, macrophages and dendritic cells. Homologues of STING have
been identified in different eukaryotic species as well as in invertebrates. STING stimulates the transcription of numerous
innate immune genes, including type I interferon encoding genes, upon binding of cyclic dinucleotides (CDNs). Beside
the bacterial 3’3’ CDNs, it was found out that the most potent activator of STING is a 2’3’CDN generated by the enzyme
cGAS. This second messenger binds STING with approximately 250-fold higher affinity compared to CDNs secreted by
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bacteria. Binding of 2’3’CDN to STING results in dimerization of the signaling molecule and triggers a signaling cascade
resulting in the expression of various immune modulatory molecules including proinflammatory cytokines, such as type
I interferon, and chemokines. STING therefore plays an essential role in controlling the transcription of numerous immune
modulatory genes and its dysfunction is related to the development of several diseases. For example, hyperactivity of
STING results in hyperproduction of proinflammatory cytokines and chemokines causing autoimmune disorders and
inflammatory diseases such as systemic lupus erythematosus (SLE) and Aicardi-Goutières Syndrome (AGS). On the
other hand, impaired activity of STING is associated with the development of cancer, promoting the proliferation and
spread of tumor cells (Nowarski, Gagliani et al. "Innate Immune Cells in Inflammation and Cancer". Cancer Immunology
Research 1, 77-84, 2013).
[0074] Up to now, methods for identifying substances that are capable of binding to STING do not provide a reliable
and simple assay for identifying STING ligands in a quantitative manner. However, due to its central role in the regulation
of the innate immune system and its involvement in the development of various diseases, it would be of great importance
to have a robust and simple-to-implement high-throughput method that enables for direct identification of substances
capable to bind to STING. Such substances could then serve as a promising starting point in the development of
therapeutic drugs specifically targeting STING protein and modulating its activity.
[0075] A further aspect of the present invention therefore relates to a method of identifying a substance having an
ability to bind to stimulator of interferon genes (STING), wherein the method comprises the steps of (i) providing an
aqueous solution comprising a cyclic dinucleotide and STING, wherein the cyclic dinucleotide comprises a 3’-5’ phos-
phodiester linkage and a 2’-5’ phosphodiester linkage between a first nucleoside monophosphate and a second nucle-
oside monophosphate, wherein at least one of the first and second nucleoside monophosphate is a fluorescent nucleoside
monophosphate; (ii) measuring the fluorescence signal of the aqueous solution; (iii) repeating steps (i) and (ii), wherein
upon said repetition the aqueous solution further comprises the substance, and wherein the fluorescence signal is
measured under identical or substantially identical conditions following the provision of the respective aqueous solution,
and (iv) comparing the fluorescence signal measured in the presence of the substance with the fluorescence signal
measured in the absence of the substance; wherein a measured fluorescence signal which is higher in the presence of
the substance than in the absence of the substance indicates that the substance has an ability to bind to STING.
[0076] The above method of the present invention is based on the unexpected finding that the fluorescent cyclic
dinucleotide (2’3’fCDN) of the present invention, e.g. a CDN comprising 2-APMP, binds to STING, thereby activating
the signaling molecule. The inventors surprisingly found out that upon binding of 2’3’fCDN to STING, the fluorescence
signal of the cyclic dinucleotide is quenched, thereby allowing the measurement of 2’3’fCDN binding to STING with a
simple fluorescence read out technique. While incorporation of 2-AP in the 2-APTP into cyclic 2’3’ fluorescent GMP/AMP
(2’3’fGAMP) quenches the fluorescence signal of 2-AP relative to its fluorescence as observed in free solution, the
binding of 2’3’fGAMP to STING quenches the fluorescence signal of 2-AP further still. Based on this further fluorescence
quenching it is thus possible to measure the fluorescence signal in the absence or presence of a substance with a
simple-to-implement method and to reliably identify substances that bind to STING. These STING ligands could than
serve as promising starting points for the development of therapeutic drugs that specifically modulate STING activity.
[0077] According to the present invention, STING is a protein which may be obtained by conventional cloning and
expression systems, including E. coli expression strains (e.g. BL21(DE3), Lemo21(DE3), ArcticExpress), baculovirus
expression systems (ex. in High Five insect cell line), non-viral insect cells expression system (ex. transient transfection
to S2 insect cell line using ExpreS2), yeast strains (ex. BCY123) or mammalian cell line (ex. HEK293T, CHO) expression
systems. STING can be expressed as full-length protein or as a truncated version comprising the catalytic domain only.
Furthermore, STING can be engineered to contain modifications in its nucleic acid sequence altering the amino acid
sequence of the protein. For example, STING can be engineered (Gao, Ascano et al. "Structure-Function Analysis of
STING Activation by c[G(2’,5’)pA(3’,5’)p] and Targeting by Antiviral DMXAA". Cell 154, 748-762, 2013; Gao, Zillinger et
al. "Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA".
Cell Reports 8, 1668-1676, 2014) in its CDN binding site to result in an increased or decreased binding affinity for the
2’3’CDN compared to unmodified STING. Furthermore, STING can be engineered to be constitutively active. Modifica-
tions in its nucleic acid can facilitate STING dimerization and/or TBK1 binding (Tang and Wang. "Single Amino Acid
Change in STING Leads to Constitutive Active Signaling". PLOS ONE 10, e0120090, 2015). STING may also be modified
by expressing the protein as a fusion construct together with a tag, such as a GFP tag that would allow for determination
of its cellular localization.
[0078] In a further embodiment of the present invention, the protein may further comprise affinity tags allowing purifi-
cation and detection of the expressed protein.
[0079] According to the method of the present invention, STING may be derived from any vertebrate, including mam-
mals such as human, macaque, mouse, sus, bos, and the like, birds, such as chicken and duck, fish, such as zebra fish,
other vertebrates such as Xenopus laevis, Choanoflagellate (e.g. Nematostella vectensis), or invertebrates (e.g. insects).
[0080] In a preferred embodiment of the present invention, STING is human STING. The nucleotide sequence of full-
length human STING is defined by SEQ ID NO: 1.
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SEQ ID NO: 1
[0081]
[0082] SEQ IN NO: 1 as shown above includes the terminal TGA stop codon. The stop codon may be useful in
expressing the protein as a discrete product. However, there might be instances where the protein is to be expressed
together with at least one other protein product, e.g. as a protein fusion. In such instances, it is possible to remove the
terminal TGA stop codon, replacing it with a nucleic acid sequence encoding the other protein(s) of interest. The skilled
person understands under what circumstances the terminal stop codon TGA is to be retained or dispensed with, and is
readily able to reproduce the above sequence in the presence or absence of the terminal stop codon TGA.
[0083] In some embodiments of the invention, the identity between STING nucleotide sequence and SEQ ID NO: 1
is at least about 54% to 100% or between about 54% and 100%. In some embodiments of the invention, the identity
between STING nucleotide sequence and SEQ ID NO: 1 is at least: about 54%, about 55%, about 56%, about 57%,
about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%,
about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%,
about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%,
about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%,
about 98%, about 99%; or is 100%. Any of the above recited percent identities may be combined with one another to
form a range. Also contemplated within such ranges are corresponding ranges in which the lower percent identity is
included while the upper percent identity is excluded, as well as ranges in which the lower percent identity is excluded
while the upper percent identity is included. In a particularly preferred embodiment of the invention, the identity between
STING nucleotide sequence and SEQ ID NO: 1 is about 100%, more preferably is 100%. In view of the teaching of the
present invention, the skilled person will understand that any STING nucleotide sequence having the above recited
sequence identities to SEQ ID NO: 1 may be used according to the present invention, provided that such sequence still
has the same qualitative or qualitative and quantitative physiological activity as STING defined by SEQ ID NO: 1. The
skilled person can incorporate and express sequences comprising the above sequences in recombinant expression
systems according to known methods in the art, in order to obtain recombinant STING for use in the present invention.
[0084] The amino acid sequence of human full-length STING is defined by SEQ ID NO: 2.
SEQ ID NO: 2
[0085]
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[0086] In some embodiments of the present invention, the identity between STING amino acid sequence and SEQ ID
NO: 2 is at least about 36% to 100% or between about 36% and 100%. In some embodiments of the invention, the
identity between STING amino acid sequence and SEQ ID NO: 2 is at least: about 36%, about 37%, about 38%, about
39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about
49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about
59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about
69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about
79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about
89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about
99%; or is 100%. Any of the above recited percent identities may be combined with one another to form a range. Also
contemplated within such ranges are corresponding ranges in which the lower percent identity is included while the
upper percent identity is excluded, as well as ranges in which the lower percent identity is excluded while the upper
percent identity is included. In a particularly preferred embodiment of the invention, the identity between STING amino
acid sequence and SEQ ID NO: 2 is about 100%, more preferably is 100%. In view of the teaching of the present
invention, the skilled person will understand that any STING amino acid sequence having the above recited sequence
identities to SEQ ID NO: 2 may be used according to the present invention, provided that such sequence still has the
same qualitative or qualitative and quantitative physiological activity as STING defined by SEQ ID NO: 2. The skilled
person can incorporate and express sequences comprising the above sequence identities to SEQ ID NO: 2 in recombinant
expression systems according to known methods in the art, in order to obtain recombinant STING for use in the present
invention.
[0087] In another preferred embodiment of the present invention, the nucleotide sequence of full-length STING is as
defined by SEQ ID NO: 3. This sequence encodes a human STING variant which is derived from a macrophage cell
line having an arginine to histidine substitution at position 220 (R220H) and a histidine to arginine substitution at position
232 (H232R). The STINGH220R232 variant was shown to have greater affinity to 2’3’ cyclic dinucleotides generated by
cGAS than wild-type STING encoded by SEQ ID NO: 1, represented by SEQ ID NO: 2.
SEQ ID NO: 3
[0088]
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[0089] SEQ IN NO: 3 as shown above includes the terminal TGA stop codon. The stop codon may be useful in
expressing the protein as a discrete product. However, there might be instances where the protein is to be expressed
together with at least one other protein product, e.g. as a protein fusion. In such instances, it is possible to remove the
terminal TGA stop codon, replacing it with a nucleic acid sequence encoding the other protein(s) of interest. The skilled
person understands under what circumstances the terminal stop codon TGA is to be retained or dispensed with, and is
readily able to reproduce the above sequence in the presence or absence of the terminal stop codon TGA.
[0090] In some embodiments of the present invention, the identity between STING nucleotide sequence and SEQ ID
NO: 3 is at least about 54% to 100% or between about 54% and 100%. In some embodiments of the invention, the
identity between STING nucleotide sequence and SEQ ID NO: 3 is at least: about 54%, about 55%, about 56%, about
57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about
67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about
77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about
87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about
97%, about 98%, about 99%; or is 100%. Any of the above recited percent identities may be combined with one another
to form a range. Also contemplated within such ranges are corresponding ranges in which the lower percent identity is
included while the upper percent identity is excluded, as well as ranges in which the lower percent identity is excluded
while the upper percent identity is included. In a particularly preferred embodiment of the invention, the identity between
STING nucleotide sequence and SEQ ID NO: 3 is about 100%, more preferably is 100%. In view of the teaching of the
present invention, the skilled person will understand that any STING nucleotide sequence having the above recited
sequence identities to SEQ ID NO: 3 may be used according to the present invention, provided that such sequence still
has the same qualitative or qualitative and quantitative physiological activity as STING defined by SEQ ID NO: 3. The
skilled person can incorporate and express sequences comprising the above sequence identities to SEQ ID NO: 3 in
recombinant expression systems according to known methods in the art, in order to obtain recombinant STING for use
in the present invention, in order to obtain recombinant STING for use in the present invention. The amino acid sequence
of human full-length STING H220R232 is as defined by SEQ ID NO: 4.
SEQ ID NO: 4
[0091]
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[0092] In some embodiments of the present invention, the identity between STING amino acid sequence and SEQ ID
NO: 4 is at least about 36% to 100% or between about 36% and 100%. In some embodiments of the invention, the
identity between STING amino acid sequence and SEQ ID NO: 4 is at least: about 36%, about 37%, about 38%, about
39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about
49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about
59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about
69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about
79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about
89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about
99%; or is 100%. Any of the above recited percent identities may be combined with one another to form a range. Also
contemplated within such ranges are corresponding ranges in which the lower percent identity is included while the
upper percent identity is excluded, as well as ranges in which the lower percent identity is excluded while the upper
percent identity is included. In a particularly preferred embodiment of the invention, the identity between STING amino
acid sequence and SEQ ID NO: 4 is about 100%, more preferably is 100%. In view of the teaching of the present
invention, the skilled person will understand that any STING amino acid sequence having the above recited sequence
identities to SEQ ID NO: 4 may be used according to the present invention, provided that such sequence still has the
same qualitative or qualitative and quantitative physiological activity as STING defined by SEQ ID NO: 4. The skilled
person can incorporate and express sequences comprising the above sequence identities to SEQ ID NO: 4 in recombinant
expression systems according to known methods in the art, in order to obtain recombinant STING for use in the present
invention. As can be seen from Figure 2 of the description, human STING comprises an endoplasmic reticulum localization
signal (1-36 aa) followed by transmembrane domain (TM) at the N-terminus (40-135 aa), a highly conserved cyclic
dinucleotide binding domain (CBD) at the C-terminus (139-344 aa) which is sufficient for CDN binding and a C-terminal
tail (CTT, 345-379) responsible for signal transduction. The inventors have found that truncated human STING consisting
only of the highly conserved CBD domain has improved characteristics when used in the herein described methods of
the invention. In particular, truncated human STING consisting only of CBD or of CBD and CTT has improved solubility
in the aqueous solution, while retaining its capability to bind to CDN and to form STING dimers upon CDN binding. In
addition, the truncated construct can efficiently produced recombinantly in soluble form in E. coli.
[0093] Thus, in a further preferred embodiment of the present invention, STING is a truncated version of the human
full-length protein comprising the soluble CDN-binding domain CBD (139-344 aa). The nucleotide sequence of truncated
human STING is defined by SEQ ID NO: 5.
SEQ ID NO: 5
[0094]
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[0095] In some embodiments of the invention, the identity between STING nucleotide sequence and SEQ ID NO: 5
is at least about 58% to 100% or between about 58% and 100%. In some embodiments of the invention, the identity
between STING nucleotide sequence and SEQ ID NO: 5 is at least: about 58%, about 59%, about 60%, about 61%,
about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%,
about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%,
about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%,
about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%; or is 100%. Any of the
above recited percent identities may be combined with one another to form a range. Also contemplated within such
ranges are corresponding ranges in which the lower percent identity is included while the upper percent identity is
excluded, as well as ranges in which the lower percent identity is excluded while the upper percent identity is included.
In a particularly preferred embodiment of the invention, the identity between STING nucleotide sequence and SEQ ID
NO: 5 is about 100%, more preferably is 100%. In view of the teaching of the present invention, the skilled person will
understand that any STING nucleotide sequence having the above recited sequence identities to SEQ ID NO: 5 may
be used according to the present invention, provided that such sequence still has the same qualitative or qualitative and
quantitative physiological activity as STING defined by SEQ ID NO: 5. The skilled person can incorporate and express
sequences comprising the above sequence identities to SEQ ID NO: 5 in recombinant expression systems according
to known methods in the art, in order to obtain recombinant STING for use in the present invention.
[0096] The amino acid sequence of truncated human STING is defined by SEQ ID NO: 6.
SEQ ID NO: 6
[0097]
[0098] In some embodiments of the present invention, the identity between STING amino acid sequence and SEQ ID
NO: 6 is at least about 43% to 100% or between about 43% and 100%. In some embodiments of the invention, the
identity between STING amino acid sequence and SEQ ID NO: 6 is at least: about 43%, about 44%, about 45%, about
46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about
56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about
66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about
76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about
86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about
96%, about 97%, about 98%, about 99%; or is 100%. Any of the above recited percent identities may be combined with
one another to form a range. Also contemplated within such ranges are corresponding ranges in which the lower percent
identity is included while the upper percent identity is excluded, as well as ranges in which the lower percent identity is
excluded while the upper percent identity is included. In a particularly preferred embodiment of the invention, the identity
between STING amino acid sequence and SEQ ID NO: 6 is about 100%, more preferably is 100%. In view of the teaching
of the present invention, the skilled person will understand that any STING amino acid sequence having the above
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recited sequence identities to SEQ ID NO: 6 may be used according to the present invention, provided that such sequence
still has the same qualitative or qualitative and quantitative physiological activity as STING defined by SEQ ID NO: 6.
The skilled person can incorporate and express sequences comprising the above sequence identities to SEQ ID NO: 6
in recombinant expression systems according to known methods in the art, in order to obtain recombinant STING for
use in the present invention.
[0099] In a further preferred embodiment of the present invention, the nucleotide sequence of truncated human STING
is defined by SEQ ID NO: 7. This sequence represents the truncated STINGH220R232 variant having a higher binding
affinity for 2’3’CDN.
SEQ ID NO: 7
[0100]
[0101] In some embodiments of the invention, the identity between STING nucleotide sequence and SEQ ID NO: 7
is at least about 60% to 100% or between about 60% and 100%. In some embodiments of the invention, the identity
between STING nucleotide sequence and SEQ ID NO: 7 is at least: about 60%, about 61%, about 62%, about 63%,
about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%,
about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%,
about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%,
about 94%, about 95%, about 96%, about 97%, about 98%, about 99%; or is 100%. Any of the above recited percent
identities may be combined with one another to form a range. Also contemplated within such ranges are corresponding
ranges in which the lower percent identity is included while the upper percent identity is excluded, as well as ranges in
which the lower percent identity is excluded while the upper percent identity is included. In a particularly preferred
embodiment of the invention, the identity between STING nucleotide sequence and SEQ ID NO: 7 is about 100%, more
preferably is 100%. In view of the teaching of the present invention, the skilled person will understand that any STING
nucleotide sequence having the above recited sequence identities to SEQ ID NO: 7 may be used according to the
present invention, provided that such sequence still has the same qualitative or qualitative and quantitative physiological
activity as STING defined by SEQ ID NO: 7. The skilled person can incorporate and express sequences comprising the
above sequence identities to SEQ ID NO: 7 in recombinant expression systems according to known methods in the art,
in order to obtain recombinant STING for use in the present invention.
[0102] The amino acid sequence of truncated human STINGH220R232 is defined by SEQ ID NO: 8.
SEQ ID NO: 8
[0103]
[0104] In some embodiments of the present invention, the identity between STING amino acid sequence and SEQ ID
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NO: 8 is at least about 44% to 100% or between about 44% and 100%. In some embodiments of the invention, the
identity between STING amino acid sequence and SEQ ID NO: 8 is at least: about 44%, about 45%, about 46%, about
47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about
57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about
67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about
77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about
87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about
97%, about 98%, about 99%; or is 100%. Any of the above recited percent identities may be combined with one another
to form a range. Also contemplated within such ranges are corresponding ranges in which the lower percent identity is
included while the upper percent identity is excluded, as well as ranges in which the lower percent identity is excluded
while the upper percent identity is included. In a particularly preferred embodiment of the present invention, the identity
between STING amino acid sequence and SEQ ID NO: 8 is about 100%, more preferably is 100%. In view of the teaching
of the present invention, the skilled person will understand that any STING amino acid sequence having the above
recited sequence identities to SEQ ID NO: 8 may be used according to the present invention, provided that such sequence
still has the same qualitative or qualitative and quantitative physiological activity as STING defined by SEQ ID NO: 8.
The skilled person can incorporate and express sequences comprising the above sequence identities to SEQ ID NO: 8
in recombinant expression systems according to known methods in the art, in order to obtain recombinant STING for
use in the present invention.
[0105] In one embodiment of the present invention, the fluorescent signal of the fluorescent nucleoside monophosphate
of the 2’3’fCDN is measured at a predetermined time-point. This time-point should be determined in preliminary exper-
iments taking into account the "dead time" of the instrument used as the fluorescence reader, i.e. the shortest time it
takes between mixing the reagents and measuring the first data point in a given instrument. Once the correct time point
is determined for each experimental setup, measurement of the fluorescent signal at a predetermined time point allows
fast and reliable measurement of the fluorescent signal of the fluorescent nucleoside monophosphate in the aqueous
solution. This allows fast and reliable identification of a substance having an ability to bind to STING.
[0106] In another embodiment of the present invention, the fluorescence signal is measured continuously or at intervals
over a predetermined time interval. In some embodiments of the present invention, the fluorescent signal of the fluorescent
nucleoside is measured starting from about 10 seconds after mixing all compounds together up to about 1 hour after
mixing all compounds together. Measuring over a time interval includes the measurement over a series of specific time
points. This allows one to obtain information about the linearity of the reaction and reduces the possibility that measuring
occurs at a time point when the reaction has already long been completed. The measurement over a time interval
therefore reduces the possibility that the measured fluorescence signal is misinterpreted.
[0107] According to the method of the present invention, the 2’3’fCDN of the present invention binds to STING in the
aqueous solution, thereby resulting in a quenched (i.e. reduced) fluorescent signal of the (at least one) fluorescent
nucleoside monophosphate of the 2’3’fCDN of the present invention. A reduction of the fluorescence signal of the aqueous
solution therefore directly correlates with the binding of 2’3’fCDN to STING. Thus if, after addition of a substance, the
fluorescence signal measured in the presence of the substance increases compared to the fluorescence signal measured
in the absence of the substance, this is an indication that previously bound 2’3’fCDN is released from STING, thereby
reversing the quenching effect of STING on the fluorescence signal of bound 2’3’fCDN. An increase of the fluorescence
signal in the presence of a substance therefore indicates that the 2’3’fCDN of the present invention is released from
STING due to an interaction of the substance with STING. Binding of the substance to STING can either occur at the
same binding site as the 2’3’fCDN of the present invention, thereby displacing the cyclic dinucleotide, or at a site different
from the binding site of 2’3’fCDN, thereby causing a conformational change in STING which then releases the cyclic
dinucleotide. Furthermore, the substance might prevent 2’3’fCDN binding to STING to begin with, by blocking the binding
site of STING. The method according to the present invention thus provides a robust and reliable tool to identify STING
ligands that interfere with 2’3’CDN binding to STING and which could therefore be a promising starting point for the
development of therapeutic strategies to specifically target STING with the aim of modulating its activity.
[0108] In one embodiment of the present invention, the increase of the fluorescence signal measured in the presence
of the substance compared to the fluorescence signal measured in the absence of the substance may indicate that the
substance is a competitive binder of STING. A competitive binder of STING binds at the same site of the signaling
molecule than 2’3’fCDN. Due to its higher binding affinity to STING, the competitive binder either displaces already
bound 2’3’fCDN or blocks the binding site for 2’3’fCDN. A substance which results in an increase of the fluorescence
signal of the aqueous solution may therefore compete with the 2’3’fCDN of the present invention for binding to STING.
[0109] In a further embodiment according to the present invention, the increase in the fluorescence signal measured
in the presence of the substance compared to the fluorescence signal measured in the absence of the substance may
indicate that the substance is a noncompetitive binder of STING. A noncompetitive binder binds to an allosteric site,
other than or in addition to the binding site of 2’3’ fCDN of the present invention, thereby inducing a conformational
change in STING. This conformational change can affect the complex formation between the 2’3’fCDN and STING by
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either preventing binding of 2’3’fCDN to STING, or if the cyclic dinucleotide is already bound to STING, can result in a
release of 2’3’fCDN due to a conformational change in the binding site which reduces the binding affinity of 2’3’fCDN to
STING. Thus, according to a further embodiment of the present invention, a substance which results in an increase of
the fluorescence signal of the aqueous solution may therefore bind in an uncompetitive manner to STING, resulting in
a conformational change in the protein that affects the interaction between STING and the 2’3’fCDN of the present
invention.
[0110] In one embodiment of the invention, the substance is added to the aqueous solution comprising STING after
the addition of the 2’3’fCDN.
[0111] Due to its environmental sensitivity an unchanged fluorescence signal measured in the presence of the sub-
stance in comparison with a fluorescence signal measured in the absence of the substance might indicate that the
2’3’fCDN of the present invention did not change its location or that STING did not undergo a conformational change.
In either case, an unchanged fluorescence intensity in the presence of the substance compared to the fluorescence
signal measured in the absence of the substance might indicate that the 2’3’fCDN is still bound to STING, either because
binding of the substance does not affect 2’3’fCDN binding to STING, or because the substance did not bind to STING
or binds to STING with such a low affinity that it does not affect 2’3’fCDN binding. However, an unchanged fluorescence
signal measured in the presence of the substance compared to the fluorescence signal measured in the absence of the
substance might also indicate that the chemical environment of the 2’3’fCDN has changed, but that the old and new
environments of 2’3’fCDN are sufficiently similar and therefore give rise to a net unchanged fluorescence signal. So
based on an unchanged fluorescence signal measured in the presence of the substance compared to the fluorescence
signal measured in the absence of the substance, it may not be possible to positively conclude that the substance did
not change the location of the 2’3’fCDN of the present invention and thus did not bind to STING, or indeed that the
substance in question bound STING at all. A measured fluorescence signal which is higher in the presence of the
substance than in the absence of the substance may be taken as positive proof that the substance has an ability to bind
sting, as recited in the present method of the invention. Thus, the method according to the invention, is a method for
identifying a substance having an ability to bind to STING, thereby replacing the bound 2’3’fCDN and/or changing its
chemical environment in a manner that the quenching effect caused by STING binding is partially or wholly reversed.
The present method according to the invention may thus also be characterized as a method for identifying a substance
having an ability to bind to STING and modulate, e.g. reduce, binding of the CDN, e.g. the 2’3’fCDN by STING.
[0112] In practice, one would therefore need to tune/choose the system such that a fluorescent change is correlated
with a change in localization of the 2’3’fCDN of the present invention (e.g. by choosing appropriate fluorophores, or
attaching them to sensitive positions at the 2’3’ CDN). In principle, the skilled person could use fluorescence polarization
anisotropy to measure CDN binding in the absence of any quenching effects to fine tune the method in order to allow
an unambiguous interpretation of the measured fluorescence signal (Zhang H, Wu Q, Berezin MY. Fluorescence ani-
sotropy (polarization): from drug screening to precision medicine. Expert Opin Drug Discov. 10(11):1145-61, 2015).
[0113] According to the present invention, a decrease in the fluorescent signal measured in the presence of the
substance in comparison the fluorescent signal measured in the absence of the substance might indicate that the
substance either further quenches the fluorescence signal of the fluorescent nucleoside monophosphate of the 2’3’fCDN
or stabilizes the interaction between 2’3’fCDN and STING. For example, the substance could lower the dissociation
constant resulting in a higher binding affinity of 2’3’fCDN to STING and in increased binding of the molecule to STING,
thereby further reducing the measured fluorescence signal in the reaction mixture containing bound and free 2’3’fCDN .
[0114] In one embodiment of the present invention, the measured fluorescence signal of the fluorescent nucleoside
monophosphate in the 2’3’fCDN is measured at different wavelengths or ranges of wavelengths depending on the
fluorescent nucleoside monophosphate in the 2’3’fCDN used in the method according to the invention. Specifically, each
2’3’fCDN comprising a specific fluorescent nucleoside monophosphate may have different excitation and emission
maxima which influence the wavelengths at which the fluorescence signal is measured. Thus, depending on the fluo-
rescent nucleoside monophosphate of the 2’3’fCDN of the present invention, the wavelengths or range of wavelengths
at which the fluorescent nucleoside monophosphate is excited (i.e. the excitation maxima) and the wavelengths or range
of wavelengths at which the fluorescence signal is measured (i.e. the emission maxima) need to be adapted for each
2’3’fCDN of the present invention individually in order to avoid false positives by measuring a fluorescence signal outside
the optimal wavelength or range of wavelengths for a given 2’3’fCDN of the present invention. In some embodiments of
the present invention, the excitation wavelength is in the range of about 290nm to about 365nm, or between about 290nm
and 365nm. In some embodiments of the invention, the excitation wavelength is about 290nm, about 291nm, about
292nm, about 293nm, about 294nm, about 295nm, about 296nm, about 297nm, about 298nm, about 299nm, about
300nm, about 301nm, about 302nm, about 303nm, about 304nm, about 305nm, about 306nm, about 307nm, about
308nm, about 309nm, about 310nm, about 311nm, about 312nm, about 312nm, about 313nm, about 314nm, about
315nm, about 316nm, about 317nm, about 318nm, about 319nm, about 320nm, about 321nm, about 322nm, about
323nm, is about 324nm, about 325nm, about 326nm, about 327nm, about 329nm, about 330nm, about 331nm, about
332nm, about 333nm, about 334nm, about 335nm, about 336nm, about 337nm, about 338nm, about 339nm, about
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340nm, about 341nm, about 342nm, about 343nm, about 344nm, about 345nm, about 346nm, about 347nm, about
348nm, about 349nm, about 350nm, about 351nm, about 352nm, about 353nm, about 354nm, about 355nm, about
356nm, about 357nm, about 358nm, about 359nm, about 360nm, about 361nm, about 362nm, about 363nm, about
364nm, or about 365nm. Any of the above recited excitation wavelength may be combined with one another to form an
excitation wavelength range. Also contemplated within such excitation wavelength ranges are corresponding ranges in
which the lower excitation wavelength is included while the upper excitation wavelength is excluded, as well as ranges
in which the lower excitation wavelength is excluded while the upper excitation wavelength is included. In a particularly
preferred embodiment of the invention, the excitation wavelength ranges from about 305nm to about 315nm or between
about 305 nm and 315nm. In a most preferred embodiment the excitation wavelength is 305nm.
[0115] In some embodiments of the present invention the emission wavelength ranges from about 345nm to about
500 nm or between about 345nm and 5000nm. In some embodiments the excitation wavelength is about 345nm, about
346nm, about 347nm, about 348nm, about 349nm, about 350nm, about 351nm, about 352nm, about 353nm, about
354nm, about 355nm, about 356nm, about 357nm, about 358nm, about 359nm, about 360nm, about 361nm, about
362nm, about 363nm, about 364nm, about 365nm, about 366nm, about 367nm, about 368nm, about 369, about 370nm,
about 371nm, about 372nm, about 373nm, about 374nm, about 375nm, about 376nm, about 377nm, about 378nm,
about 379nm, about 380nm, about 381nm, about 382nm, about 383nm, about 384nm, about 385nm, about 386nm,
about 387nm, about 388nm, about 389nm, about 390nm, about 391nm, about 392nm, about 393nm, about 394nm,
about 395nm, about 396nm, about 397nm, about 398nm, about 399nm, about 400nm, about 401nm, about 402nm,
about 403nm, about 404nm, about 405nm, about 406nm, about 407nm, about 408nm, about 409nm, about 410nm,
about 411nm, about 412nm, about 413nm, about 414nm, about 415nm, about 416nm, about 417nm, about 418nm,
about 419nm, about 420nm, about 421nm, about 422nm, about 423nm, about 424nm, about 425nm, about 426nm,
about 427nm, about 428nm, about 429nm, about 430nm, about 431nm, about 432nm, about 433nm, about 434nm,
about 435nm, about 436nm, about 437nm, about 438nm, about 439nm, about 440nm, about 441nm, about 442nm,
about 443nm, about 444nm, about 445nm, about 446nm, about 447nm, about 448nm, about 449nm, about 450nm,
about 451nm, about 452nm, about 453nm, about 454nm, about 455nm, about 456nm, about 457nm, about 458nm,
about 459nm, about 460nm, about 461nm, about 462nm, about 463nm, about 464nm, about 465nm, about 466nm,
about 467nm, about 468nm, about 469nm, about 470nm, about 471nm, about 472nm, about 473nm, about 474nm,
about 475nm, about 476nm, about 477nm, about 478nm, about 479nm, about 480nm, about 481nm, about 482nm,
about 483nm, about 484nm, about 485nm, about 486nm, about 487nm, about 488nm, about 489nm, about 490nm,
about 491nm, about 492nm, about 493nm, about 494nm, about 495nm, about 496nm, about 497nm, about 498nm,
about 499nm or about 500nm. Any of the above recited emission wavelength may be combined with one another to
form an emission wavelength range. Also contemplated within such emission wavelength ranges are corresponding
ranges in which the lower emission wavelength is included while the upper emission wavelength is excluded, as well as
ranges in which the lower emission wavelength is excluded while the upper emission wavelength is included. In a
particularly preferred embodiment of the invention, the emission wavelength ranges from about 350nm to about 380nm,
or between about 350nm and 380nm. In a most preferred embodiment of the invention the emission wavelength is 363nm.
[0116] Furthermore, the quantum yield of a fluorescent nucleoside monophosphate of the 2’3’fCDN the present in-
vention may also differ depending on the experimental conditions. Thus, for each 2’3’fCDN used in the method according
to the invention, the experimental conditions may be modified in order to optimize the quantum yield of the fluorescent
molecule. Within the biochemical constraints of the reaction under study, tuning of pH, temperature, buffer composition
could be optimized. A reference for the quantum yield can be measured e.g. in ultrapure water or a standard reaction
buffer. Experimental conditions that might influence the quantum yield of the 2’3’fCDN of the present invention include
but are not limited to temperature, pH, ionic strength.
[0117] The change of the fluorescence signal can be measured by any known fluorescence read out technique using
a conventional plate reader or a single-cuvette photometer. In a preferred embodiment of the invention, the fluorescence
signal is measured with Tecan infinite M1000 using 96-well black non-binding PS plates (Greiner Bio-One), specifically
FluoroMax-P spectrofluorometer (Horiba Scientific) or similar instruments can be used.
[0118] The inventors surprisingly found out that, when incorporated into a cyclic dinucleotide of the present invention,
2-aminopurine nucleoside monophosphate (2-APMP) is still fluorescently active and possess a high fluorescence envi-
ronmental sensitivity which can be exploited to measure 2’3’fCDN binding to STING. In particular, the inventors found
out that the fluorescence signal of the 2’3’fCDN comprising 2-APMP is significantly quenched, i.e. reduced, resulting
from the environmental change of the 2’3’fCDN of the present invention when bound to STING. The quenching of the
fluorescence signal upon binding of 2’3’fCDN comprising 2-APMP to STING thus allows one to measure 2’3’fCDN binding
to STING in the presence or absence of a test substance in a continuous assay using conventional fluorescence plate
readers, to yield valuable information about that substance’s ability to bind to STING.
[0119] Thus, in a preferred embodiment according to the method of the present invention, the 2’3’fCDN comprises 2-
APMP.
[0120] In another preferred embodiment, the 2’3’fCDN has the structure
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wherein
when R1 is bound to P through a single bond, R1 is independently selected from the group consisting of O, S, BH3
and CH3;
when R1 is bound to P through a double bond, R1 is independently selected from the group consisting of O, S and NH;
wherein at least one R1 bound to each P is O;
R2 is independently selected from the group consisting of H, OH, methyl, amino-, methoxy-, fluoro-, methoxyethyl-,
-O-propargyl and O-propylamine; and
R3 is O.
[0121] Most preferred the 2’3’fCDN has the structure:
or
[0122] As can be seen from all of the above, the 2’3’fCDN of the present invention can advantageously be used for
identifying a substance having an ability to bind to STING according to the inventive method set forth herein. Upon
complex formation between STING and the cyclic dinucleotides of the present invention, the cyclic dinucleotides can
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further be used to label STING.
Method of identifying a substance having an abitlity to modulate 2’-5’ phosphodiesterase activity
[0123] Phosphodiesterases (PDE) are an important group of enzymes with an extensive functional range that are
distributed widely and are highly conserved between species. The skilled person can purify any known PDE by commonly
known chromatographic fractionation techniques using a cell extract and test the extract on PDE activity by the method
of measuring PDE activity according to the invention. Furthermore, the skilled person will be able to identify new PDEs
by way of a standard sequence comparison (e.g. BLAST) against a protein and/or nucleic acid sequence data base to
identify similarities to already known PDEs.
[0124] In humans the ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1, UniProtKB Accession P22413;
Human Gene Numberin Committee: 3356; Entrez Gene: 5167) is expressed in a wide range of tissues including cartilage,
heart, kidney, parathyroid and collateral model, and in cells such as vascular smooth muscle cells (VSMCs), osteoblasts
and chondrocytes. ENPP1 specifically cleaves the 2’-5’ phosphodiesterase linkage in cyclic dinucleotides and regulates
the localization, duration and amplitude of 2’3’CDNs produced by cGAS. The enzyme therefore plays an important role
in the control and mediation of immune responses induced via the cGAS/STING axis. Not surprisingly, ENPP1 dysfunction
is associated with a variety of human diseases. For example, mutation in the gene encoding for ENPP1 at the found to
be associated with a rare type of idiopathic infantile arterial calcification demonstrating the importance of ENPP 1 in
maintaining normal tissue function. Furthermore, ENPP 1 mutation have been reported to result in autosomal recessive
conditions causing pre-major onset of arterial calcification resulting in stenosis and pseudoxanthoma elasticum charac-
terized by ectopic calcification of soft connective tissue. Finally, ENPP1 mutations are associated with diabetic kidney
diseases (Mackenzie, Huesa et al. "New insights into NPP1 function: Lessons from clinical and animal studies". Bone
51, 961-968, 2012; Li, Yin et al. "Hydrolysis of 2’3’-cGAMP by ENPP1 and design of nonhydrolyzable analogs". Nat
Chem Biol 10, 1043-1048, 2014; Sortica, Buffon et al. "Association between the ENPP1 K121Q Polymorphism and Risk
of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis". PLOS ONE 10, e0118416, 2015).
[0125] Beside human PDEs, bacteria have developed several immune evasion strategies specifically targeting the
CDN-based immune signaling pathways. For example, M. tuberculosis has developed a mechanism to inhibit STING-
dependent type I interferon expression via a multifunctional mycobacterial phosphodiesterase CdnP. This PDE mediates
hydrolysis of both bacterial-derived and host-derived CDNs thereby directly interfering with the cGAS/STING axis (Dey,
Dey et al. "Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase". Nat Chem Biol
13, 210-217, 2017).
[0126] In view of the essential roles of PDEs in bacterial infections as well as their association with a variety of human
diseases, this group of enzymes represents an attractive target for the development of new immune therapeutic ap-
proaches as well as in treatment of bacterial infections. The basic idea in the pharmaceutical industry therefore is to
modulate the activity of PDE, thereby specifically controlling CDN homeostasis. In particular, it will be of great importance
to identify substances having an ability to modulate PDE activity thereby providing potential vaccines against bacterial
infections or substances that could be used to treat rare human diseases, such as cancer and arterial calcification.
[0127] Thus, in one aspect the present invention relates to a method for identifying a substance having an ability to
modulate 2’-5’ phosphodiesterase activity, wherein the method comprises the steps of (i) providing an aqueous solution
comprising a cyclic dinucleotide and a 2’-5’ phosphodiesterase, wherein the cyclic dinucleotide comprises a 3’-5’ phos-
phodiester linkage and a 2’-5’ phosphodiester linkage between a first nucleoside monophosphate and a second nucle-
oside monophosphate, wherein at least one of the first and second nucleoside monophosphates is a fluorescent nucl-
eoside monophosphate; (ii) measuring the fluorescence signal of the aqueous solution; (iii) repeating steps (i) and (ii),
wherein upon said repetition the aqueous solution further comprises the substance, and wherein the fluorescence is
measured under identical or substantially identical conditions following the provision of the respective aqueous solution;
and (iv) comparing the fluorescence signal measured in the presence of the substance with the fluorescence signal
measured in the absence of the substance; wherein a measured fluorescence signal which is higher in the presence of
the substance than in the absence of the substance indicates that the substance is a 2’-5’ phosphodiesterase agonist,
while a measured fluorescence signal which is lower in the presence of the substance compared to the absence of the
substance indicates that the substance is a 2’-5’ phosphodiesterase antagonist.
[0128] In one embodiment of the invention, the substance is added to the aqueous solution comprising a 2’-5’ phos-
phodiesterase after the addition of the 2’3’fCDN.
[0129] In one embodiment of the present invention, an increase of the measured fluorescence signal in the presence
of the substance compared to the fluorescence signal measured in the absence of the substance, indicates that the
substance activates (partially or fully) or enhances 2’-5’ phosphodiesterase activity, thereby resulting in increased cleav-
age of the 2’3’ fluorescent dinucleotide (2’3’fCDN) of the present invention. Cleavage of the 2’-5’ and/or 3’-5’ phosphodi-
ester linkages results in the release of the first and the second nucleoside monophosphates. The release of the fluorescent
nucleoside monophosphate of the present invention partially or wholly reduces the quenching effect previously caused
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by the incorporation of the free fluorescent nucleoside into the 2’3’fCDN of the present invention by cGAS. Thus, an
increase of the fluorescent signal measured in the presence of the substance in comparison to the fluorescence signal
measured in the absence of the substance directly correlates with an increased cleavage of 2’3’fCDN of the present
invention and indicates that the substance has an ability to activate (partially or fully) or enhance 2’-5’ phosphodiesterase
activity. In this case, the substance is thus a 2’-5’ phosphodiesterase agonist.
[0130] According to another embodiment of the present invention, a decrease in the fluorescence signal in the presence
of the substance compared to the fluorescence signal measured in the absence of the substance indicates that the
substance inhibits (partially or fully) 2’-5’ phosphodiesterase. A decrease in the measured fluorescent signal in the
presence of the substance indicates that less 2’3’fCDN of the present invention is cleaved by the 2’-5’ phosphodiesterase,
resulting in more fluorescent nucleoside monophosphate kept incorporated in 2’3’fCDN which directly correlates with
quenching of the measured fluorescent signal. Thus, a decreased fluorescence signal measured in the presence of the
substance compared to the absence of the substance indicates that less fluorescent nucleoside monophosphate is
released from 2’3’fCDN due to reduced 2’-5’ phosphodiesterase activity. The substance therefore acts as a 2’-5’ phos-
phodiesterase antagonist.
[0131] In a further embodiment of the present invention, the fluorescent signal of the fluorescent nucleoside mono-
phosphate in the 2’3’fCDN is measured at a predetermined time-point. This time-point should be determined in preliminary
experiments taking into account the dead time of the instrument used as the fluorescence reader, i.e. the shortest time
it takes between mixing the reagents and measuring the first data point in a given instrument. Once the correct time
point is determined for each experimental set up, measuring of the fluorescent signal at a predetermined time point
allows fast and reliable identification of a substance having an ability to modulate 2’-5’ phosphodiesterase activity.
Measuring over a time interval includes continuous measurement, and the measurement of a fluorescence signal over
a series of discrete time points. This allows one to obtain information about the linearity of the reaction and reduces the
possibility that the measurement occurs at a time point when the reaction might already have been completed. The
measurement over a time interval may therefore reduce the risk that the measured fluorescence signal is misinterpreted.
[0132] In another embodiment of the present invention, the fluorescence signal is measured over a predetermined
time interval. The advantage is a single readout that does not need to be processed further. In some embodiments of
the present invention, the fluorescent signal is measured starting from about 10 seconds from mixing all compounds
together up to about 1 hour. The advantage is that measuring over a time interval, the slope is a more precise readout
than a single time point and also shows the linearity of the reaction. The time interval of the measurement depends
strongly on 2’-5’ phosphodiesterase activity in the presence of particular fluorescent 2’3’fCDN as substrate and on the
experimental setup, such as buffer condition, temperature and substance concentration. In general, for the low 2’-5’
phosphodiesterase activity higher protein and 2’3’fCDN concentrations may be used, compared to the case of high 2’-
5’ phosphodiesterase activity to perform the measurement within 5 min - 1 h time interval.
[0133] In a preferred embodiment according to the method of the present invention, the 2’3’fCDN comprises 2-APMP.
[0134] In another preferred embodiment, the 2’3’fCDN has the structure
wherein
when R1 is bound to P through a single bond, R1 is independently selected from the group consisting of O, S, BH3
and CH3;
when R1 is bound to P through a double bond, R1 is independently selected from the group consisting of O, S and NH;
wherein at least one R1 bound to each P is O;
R2 is independently selected from the group consisting of H, OH, methyl, amino-, methoxy-, fluoro-, methoxyethyl-,
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-O-propargyl and O-propylamine; and
R3 is O.
[0135] Most preferred the 2’3’fCDN has the structure:
or
[0136] In one embodiment of the invention, the reaction is carried out by incubating 2’3’fCDN with a PDE. The change
of the fluorescence signal is than measured in a commonly known fluorescence reader. Suitable cofactors (typical metal
ions Mn2+, Mg2+, Zn2+ depending on the particular PDE) can be added to the reaction mixture. In case the PDE under
investigation is specific for 2’-5’ or 3-5’ phosphodiesters, an PDE with the other specificity would be added as well, to
ensure that the CDN is cleaved into two single nucleoside monophosphates.
[0137] In view of all of the above, the 2’3’fCDN of the present invention can be used in a method of identifying a
substance having an ability to modulate 2’-5’ phosphodiesterase activity.
Methods of (a) measuring cGAS activity and of (b) identifying a substance having an ability to modulate cGAS 
activity
(a) Method of measuring cGAS activity
[0138] The present invention is based, in part, on the surprising finding that cGAS can incorporate a fluorescent
nucleobase analogue from a fluorescent nucleoside triphosphate into a cyclic dinucleotide which comprises a conven-
tional 3’-5’ phosphodiester linkage and an unconventional 2’-5’ phosphodiester linkage, resulting in 2’3’ fluorescent
dinucleotides (2’3’fCDN). The inventors have found that the fluorescence signal of the fluorescent nucleobase analogue
of the free fluorescent nucleoside triphosphate in aqueous solution is quenched, i.e. reduced, upon incorporation of the
fluorescent nucleoside into a 2’3’fCDN of the present invention. Thus, the change in the measured fluorescence signal
in aqueous solution over time can be used to measure cGAS activity.
[0139] Thus, a further aspect of the present invention relates to a method of measuring cGAS activity, wherein the
method comprises the steps of (i) providing an aqueous solution comprising cGAS, a cGAS-activating nucleic acid, a
first nucleoside triphosphate, a second nucleoside triphosphate, and one or more divalent cation, wherein at least one
of the first and second nucleoside triphosphates is a fluorescent nucleoside triphosphate and wherein one of the first
and second nucleoside triphosphates has a free 2’ hydroxyl group and the other one has a free 3’ hydroxyl group and
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(ii) measuring the change of the fluorescence signal of the aqueous solution over time. Measurement may be continuous
or discontinuous, i.e. at intervals, over a predetermined time interval.
[0140] In one embodiment of the present invention, the method of measuring cGAS activity can be used to study cGAS
variants and their efficiency in converting nucleoside triphosphates into 2’3’CDNs of the present invention. For example,
the claimed method allows for the identification of engineered cGAS variants having increased or decreased cGAS
activity compared to unmodified cGAS. The engineered cGAS variants can be used to study polymorphisms in the gene
encoding cGAS that are associated with different diseases. For instance, it may be possible to analyze the enzymatic
activity of cGAS encoded by polymorphic genes only found in a particular disease, thereby shedding light on the possible
genetic mechanisms underlying said disease. Knowing the genetic mechanism related to cGAS dysfunction in a particular
disease could serve as a promising starting point for the development of a therapeutic treatment.
[0141] In a further embodiment of the present invention, the method of measuring cGAS activity can be used e.g. to
determine any of (a) the start and end points of measuring the fluorescence signal of the aqueous solution in the presence
of different cGAS variants, (b) the effect of different nucleic acids on cGAS activation, (c) the optimal time interval required
for measuring the change of the fluorescence signal of the aqueous solution, and (d) the optimal starting concentrations
of the reaction partners. Furthermore, the method of measuring cGAS activity can be used to determine the standard
fluorescence signal of a given fluorescent nucleoside triphosphate in aqueous solution under predetermined conditions.
Thus, the method of measuring cGAS activity according to the present invention can be used to identify optimal reaction
parameters which could then be used in the methods of the invention described below. The methods of measuring cGAS
activity according to the present invention therefore also serve to calibrate and fine tune the experimental reaction setups
for the methods of the invention described below.
[0142] In one embodiment of the present invention, cGAS activity is calculated based on the time-dependent change
of the measured fluorescence signal of the aqueous solution. In particular, cGAS activity may be calculated by contin-
uously measuring the change in the fluorescence signal of the aqueous solution in a plate reader or in a single cuvette.
The obtained fluorescence curve may then be inverted into a curve representing cGAS activity (see e.g. Figure 7d). The
initial slope of the curve representing cGAS activity may then be used to calculate the reaction velocity, which is one
way of defining cGAS activity according to the present invention. This particular embodiment has the advantage of
determining the linear portion of the curve representing cGAS activity which is not possible when using commonly known
techniques such as mass spectrometry or radioactivity. The determination of the initial slope is a more precise measure
of activity than measuring end points, few or single-time points. The slope, due to many more individual data points is
statistically more significant and allows the determination of the linear range of the reaction, before substrate depletion
or product inhibition slows down the reaction. A single point or few points of measurement are typically not sufficient to
determine the linear range of a reaction, therefore increasing the possibility to underestimate the activity. In view of the
above, the method of measuring cGAS activity can thus be used to optimize and fine-tune cGAS measurement conditions
for other cGAS-related methods of the invention, e.g. for optimizing cGAS measurement conditions in a method of
identifying a substance having an ability to modulate cGAS activity as described below in more detail.
(b) Method of identifying a substance having an ability to modulate cGAS activity
[0143] As discussed above, cGAS is a key sensor for cytosolic DNA in the innate immune system which elicits a
signaling cascade that triggers the host response via production by cyclic dinucleotides comprising a conventional 3’-5’
phosphodiester linkage and an unconventional 2’-5’ phosphodiester linkage between two nucleoside monophosphates
(2’3’CDN). The cyclic dinucleotides generated by cGAS bind to STING, thereby triggering the expression of type I
interferon production. While under normal conditions the cGAS/STING axis protects the cell from bacterial and viral DNA
infections, impairment of this pathway is associated with a variety of different diseases, such as inflammatory diseases
and autoimmune disorders. For example, uncontrolled expression of type-I interferon due to constitutively active
cGAS/STING is associated with various autoimmune disorders including systemic lupus erythematosus (SLE) and
Aicardi-Goutières Syndrome (AGS). Thus, the identification of substances having the ability to act as cGAS/STING
antagonists would be of great importance for the development of therapeutic treatments against such diseases.
[0144] In tumor cells the innate immune response is usually silenced allowing the tumor to proliferate and spread. The
general idea in anti-cancer therapy is therefore to specifically trigger the cGAS/STING pathway in cancer cells, thereby
eliciting a type I interferon immune response. Such an immune response could then instruct the immune system not
only to attack the cancer cells but also to develop longer lasting immunogenic memory T cells against the tumor. Many
cancer types developed strategies to become immunologically invisible and have for instance no T cell infiltrates, ren-
dering anti-cancer immunity unsuccessful.
[0145] In view of the above, the identification of substances having an ability to modulate cGAS activity therefore
represents an emerging technology for the development of new therapeutic strategies for the treatment of immunological
disorders and cancer.
[0146] A further aspect of the present invention therefore relates to a method of identifying a substance having an
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ability to modulate the activity of cGAS, wherein the method comprises the steps of (i) providing an aqueous solution
comprising cGAS, cGAS-activating nucleic acid, a first nucleoside triphosphate, a second nucleoside triphosphate, and
one or more divalent cation, wherein at least one of the first and second nucleoside triphosphates is a fluorescent
nucleoside triphosphate, and wherein one of the first and second nucleoside triphosphates has a free 2’ hydroxyl group
and the other one has a free 3’ hydroxyl group; (ii) measuring the fluorescence signal of the aqueous solution; (iii)
repeating steps (i) and (ii), wherein upon said repetition the aqueous solution further comprises the substance, and
wherein the fluorescence signal is measured under identical or substantially identical conditions following the provision
of the respective aqueous solution; and (iv) comparing the fluorescence signal measured in the presence of the substance
with the fluorescence signal measured in the absence of the substance; wherein a measured fluorescence signal which
is higher in the presence of the substance than in the absence of the substance indicates that the substance is a cGAS
antagonist, while a measured fluorescence signal which is lower in the presence of the substance than in the absence
of the substance indicates that the substance is a cGAS agonist.
[0147] In one embodiment of the invention, the substance is added to the aqueous solution comprising cGAS, cGAS-
activating nucleic acid and one or more divalent cation after the addition of the first and second nucleoside triphosphates.
[0148] In one embodiment of the present invention, an increase of the measured fluorescence signal in the presence
of the substance compared to the fluorescence signal measured in the absence of the substance, indicates that less
fluorescent nucleoside triphosphate is incorporated into 2’3’fCDN resulting in a higher concentration of free fluorescent
nucleoside triphosphate in the aqueous solution. Upon incorporation of the fluorescent nucleobase analogue from the
fluorescent nucleotide triphosphate into 2’3’fCDN by cGAS, the fluorescent signal of the fluorescent nucleobase analogue
is quenched resulting in a decreased fluorescence of the fluorescent nuceobase analogue from the fluorescent nucleoside
triphosphate. Thus, a lower fluorescence signal correlates with increased incorporation of the fluorescent nucleobase
analogue from the fluorescent nucleotide triphosphate into 2’3’fCDN, whereas a higher fluorescence signal correlates
with less incorporation of the fluorescent nucleobase analogue from the fluorescent nucleotide triphosphate into 2’3’fCDN.
The higher comparative amount of the measured fluorescence signal is therefore a direct indication for reduced incor-
poration of the fluorescent nucleoside triphosphate into 2’3’fCDN. Since the reduced incorporation of the fluorescent
nucleoside triphosphate into the 2’3’fCDN is directly associated with reduced cGAS activity in the presence of a substance,
the increased fluorescence signal allows for identification of a substance having an inhibitory effect on cGAS activity.
An increase in the measured fluorescence signal in the presence of the substance compared to the fluorescence signal
measured in the absence of the substance therefore indicates that the substance is a cGAS antagonist.
[0149] According to another embodiment of the present invention, a decrease of the measured fluorescence signal
in the presence of the substance compared to the fluorescence signal measured in the absence of the substance indicates
that more fluorescent nucleoside triphosphate is incorporated into 2’3’fCDN of the present invention which results in a
reduced concentration of free fluorescent nucleoside triphosphate in the aqueous solution. Due to its environmental
sensitivity, the fluorescence signal of the fluorescent nucleoside triphosphate is quenched upon incorporation of the
nucleoside into the 2’3’fCDN of the present invention, which results in a decrease in the measured fluorescence signal
of the aqueous solution. Thus, a decrease in the measured fluorescence signal in the presence of the substance compared
to the fluorescence signal measured in the absence of the substance indicates that cGAS converts more free fluorescent
nucleoside triphosphate into 2’3’fCDN in the presence of the substance than in the absence of the substance. A decrease
of the measured fluorescence signal in the presence of the substance therefore indicates that the substance activates
(partially or fully) or enhances cGAS enzymatic activity; in this case, the substance is thus a cGAS agonist.
[0150] According to the present invention, cGAS is a recombinant protein obtained by conventional cloning and ex-
pression systems. A typical set of cloning and expression systems includes E. coli, Hi5 or SF9 insect cells and e.g.
baculuvirus based expression plasmids or non-viral insect cells expression system (e.g. transient transfection to S2
insect cell line using ExpreS2), Saccharomyces cerevisiae, Pichia pastoris, mammalian cell lines (e.g. HEK293T, CHO).
The protein can also be generated using cell free transcription/translation or translation systems (e.g. based on wheat
germ). cGAS can be expressed as full-length protein or as a truncated version comprising the catalytic domain. Further-
more, cGAS can be engineered to have alteration in its amino acid sequence. For example, cGAS can be engineered
in its active catalytic domain resulting in increased or decreased enzymatic activity of cGAS compared to the activity of
unmodified cGAS. Exemplarily techniques to engineer cGAS include but are not limited to site directed mutagenesis
using polymerase chain reaction, cassette ligation, ligation-during-amplification.
[0151] The protein may further contain affinity tags allowing purification and detection of the expressed protein.
[0152] According to the methods of the invention, cGAS is derived from any vertebrate, including mammals such as
human, macaque, mouse, sus, bos, and the like, chicken, duck, zebra fish and Xenopus laevis.
[0153] In a preferred embodiment of the invention, cGAS is derived from human. The nucleotide sequence of full-
length human cGAS is defined by SEQ ID NO: 9.
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SEQ ID NO: 9
[0154]
[0155] SEQ IN NO: 9 as shown above includes the terminal TGA stop codon. The stop codon may be useful in
expressing the protein as a discrete product. However, there might be instances where the protein is to be expressed
together with at least one other protein product, e.g. as a protein fusion. In such instances, it is possible to remove the
terminal TGA stop codon, replacing it with a nucleic acid sequence encoding the other protein(s) of interest. The skilled
person understands under what circumstances the terminal stop codon TGA is to be retained or dispensed with, and is
readily able to reproduce the above sequence in the presence or absence of the terminal stop codon TGA.
[0156] In some embodiments of the invention, the identity between cGAS nucleotide sequence and SEQ ID NO: 9 is
at least about 50% to about 100% or between about 50% and about 100%. In some embodiments of the invention, the
identity between cGAS nucleotide sequence and SEQ ID NO: 9 is at least: about 50%, about 51%, about 52%, about
53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about
63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about
73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about
83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about
93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%; or is 100%. Any of the above recited
percent identities may be combined with one another to form a percent identity range. Also contemplated within such
percent identity ranges are corresponding ranges in which the lower percent identity is included while the upper percent
identity is excluded, as well as ranges in which the lower percent identity is excluded while the upper percent identity is
included. In a particularly preferred embodiment of the invention, the identity between cGAS nucleotide sequence and
SEQ ID NO: 9 is about 100%, more preferably is 100%. In view of the teaching of the present invention, the skilled
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person will understand that any cGAS nucleotide sequence having the above recited sequence identities to SEQ ID NO:
9 may be used according to the present invention, provided that such sequence still has the same qualitative or qualitative
and quantitative enzymatic activity as cGAS defined by SEQ ID NO: 9. The skilled person can incorporate and express
sequences comprising the above recited sequence identities to SEQ ID NO: 9 in recombinant expression systems
according to known methods in the art, in order to obtain recombinant cGAS for use in the present invention.
[0157] The amino acid sequence of full-length human cGAS is defined by SEQ ID NO: 10.
SEQ ID NO: 10
[0158]
[0159] In some embodiments of the invention, the identity between cGAS amino acid sequence and SEQ ID NO: 10
is at least about 36% to about 100% or between about 36% and about 100%. In some embodiments of the invention,
the identity between cGAS amino acid sequence and SEQ ID NO: 10 is at least: about 36%, about 37%, about 38%,
about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%,
about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%,
about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%,
about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%,
about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%,
about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%,
about 99%; or is 100%. Any of the above recited percent identities may be combined with one another to form a percent
identity range. Also contemplated within such percent identity ranges are corresponding ranges in which the lower
percent identity is included while the upper percent identity is excluded, as well as ranges in which the lower percent
identity is excluded while the upper percent identity is included. In a particularly preferred embodiment of the invention,
the identity between cGAS amino acid sequence and SEQ ID NO: 10 is about 100%, more preferably is 100%. In view
of the teaching of the present invention, the skilled person will understand that any cGAS amino acid sequence having
the above recited sequence identities to SEQ ID NO: 10 may be used according to the present invention, provided that
such sequence still has the same qualitative or qualitative and quantitative enzymatic activity as cGAS defined by SEQ
ID NO: 10. The skilled person can incorporate and express sequences comprising the above recited sequence identities
to SEQ ID NO: 10 in recombinant expression systems according to known methods in the art, in order to obtain recom-
binant cGAS for use in the present invention.
[0160] As can be seen from Figure 3 human cGAS comprises a highly conserved C-terminal domain (catalytic domain
- CD, aa 160-513) containing a Mab21 domain (aa 213 to 513 of human cGAS) and comprising both DNA-binding and
enzymatic activity. The N-terminus of human cGAS is unstructured and not well conserved. The inventors found out that
truncated human cGAS consisting of the highly conserved C-terminal domain (i.e. aa 155 to 522 of human cGAS) but
missing the unstructured N-terminal domain has improved characteristics when used in the herein described methods
of the invention. Specifically, truncated cGAS is less prone to proteolytic degradation and aggregation.
[0161] Thus, in a further preferred embodiment of the invention cGAS is a truncated version of the human full length
protein, wherein the first 154 amino acid sequence encoding for the unstructured N-terminal domain of human cGAS is
missing. The nucleotide sequence of truncated human cGAS is defined by SEQ ID NO: 11.
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SEQ ID NO: 11
[0162]
[0163] SEQ IN NO: 11 as shown above includes the terminal TGA stop codon. The stop codon may be useful in
expressing the protein as a discrete product. However, there might be instances where the protein is to be expressed
together with at least one other protein product, e.g. as a protein fusion. In such instances, it is possible to remove the
terminal TGA stop codon, replacing it with a nucleic acid sequence encoding the other protein(s) of interest. The skilled
person understands under what circumstances the terminal stop codon TGA is to be retained or dispensed with, and is
readily able to reproduce the above sequence in the presence or absence of the terminal stop codon TGA.
[0164] In some embodiments of the invention, the identity between truncated cGAS nucleotide sequence and SEQ
ID NO: 11 is about 56% to about 100% or between about 56% and about 100%. In some embodiments of the invention,
the identity between truncated cGAS nucleotide sequence and SEQ ID NO: 11 is at least: about 56%, about 57%, about
58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about
68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about
78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about
88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about
98%, about 99%; or is 100%. Any of the above recited percent identities may be combined with one another to form
percent identity a range. Also contemplated within such percent identity ranges are corresponding ranges in which the
lower percent identity is included while the upper percent identity is excluded, as well as ranges in which the lower
percent identity is excluded while the upper percent identity is included. In a particularly preferred embodiment of the
invention, the identity between truncated cGAS nucleotide sequence and SEQ ID NO: 11 is about 100%, more preferably
is 100%. In view of the teaching of the present invention, the skilled person will understand that any cGAS nucleotide
sequence having the above recited sequence identities to SEQ ID NO: 11 may be used according to the present invention,
provided that such sequence still has the same qualitative or qualitative and quantitative enzymatic activity as cGAS
defined by SEQ ID NO: 11. The skilled person can incorporate and express sequences comprising the above recited
sequence identities to SEQ ID NO: 11 in recombinant expression systems according to known methods in the art, in
order to obtain recombinant cGAS for use in the present invention.
[0165] The amino acid sequence of truncated cGAS is defined by SEQ ID NO: 12.
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SEQ ID NO: 12
[0166]
[0167] In some embodiments of the invention, the identity between truncated cGAS amino acid sequence and SEQ
ID NO: 12 is about 40% to about 100% or between about 40% and about 100%. In some embodiments of the invention,
the identity between truncated cGAS amino acid sequence and SEQ ID NO: 12 is at least: about 40%, about 41%, about
42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about
52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about
62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about
72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about
82%, about 83%, about 84%, bout 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about
92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%; or is 100%. Any of the above
recited percent identities may be combined with one another to form a percent identity range. Also contemplated within
such percent identity ranges are corresponding ranges in which the lower percent identity is included while the upper
percent identity is excluded, as well as ranges in which the lower percent identity is excluded while the upper percent
identity is included. In a particularly preferred embodiment of the invention, the identity between truncated cGAS amino
acid sequence and SEQ ID NO: 12 is about 100%, more preferably is 100%. In view of the teaching of the present
invention, the skilled person will understand that any cGAS amino acid sequence having the above recited sequence
identities to SEQ ID NO: 12 may be used according to the present invention, provided that such sequence still has the
same qualitative or qualitative and quantitative enzymatic activity as cGAS defined by SEQ ID NO: 12. The skilled person
can incorporate and express sequences comprising the above recited sequence identities to SEQ ID NO: 12 in recom-
binant expression systems according to known methods in the art, in order to obtain recombinant cGAS for use in the
present invention.
[0168] In order to convert nucleoside triphosphates into 2’3’CDN cGAS must be activated by a cGAS-activating nucleic
acid which induces complex formation of cGAS with the cGAS-activating nucleic acid, thereby activating the enzyme.
[0169] According to the methods of the invention, a cGAS-activating nucleic acid comprises double-stranded (ds) and
single-stranded (ss) DNA. Furthermore, the cGAS-activating nucleic acid may be an RNA/DNA hybrid, preferably a
poly(A):poly(dT) or poly(dA):poly(T) hybrid.
[0170] In a preferred embodiment of the present invention, the cGAS-activating nucleic acid, e.g double stranded
DNA, may have a length at least 10 base pairs (bp). In a particular embodiment of the present invention, the cGAS-
activating nucleic acid, e.g. dsDNA, may have a length selected from the group consisting of at least 10bp, 11bp, 12bp,
13bp, 14bp, 15bp, 16bp, 17bp, 18bp, 19bp, 20bp, 21bp, 22bp, 23bp, 24bp, 25bp, 26bp, 27bp, 28bp, 29bp, 30bp, 31bp,
32bp, 33bp, 34bp, 35bp, 36bp, 37bp, 38bp, 39bp, 40bp, 41bp, 42bp, 43bp, 44bp, 45bp, 46bp, 47bp, 48bp, 49bp, 50bp,
51bp, 52bp, 53bp, 54bp, 55bp, 56bp, 57bp, 58bp, 59bp, 60bp, 61bp, 62bp, 63bp, 64bp, 65bp, 66bp, 67bp, 68bp, 69bp,
70bp, 71bp. 72bp, 73bp, 74bp, 75bp, 76bp, 77bp, 78bp, 79bp, 80bp, 81bp, 82bp, 83bp, 84bp, 85bp, 86bp, 87bp, 88bp,
89bp, 90bp, 91bp, 92bp, 93bp, 94bp, 95bp, 96bp, 97bp, 98bp, 99bp, and 100bp. The double-stranded cGAS-activating
nucleic acid may also have a minimal length of at least 200bp, 300bp, 400bp, 500bp, 600bp, 700bp, 800bp, 900bp,
1kbp, 2kbp, 3kbp, 4kbp, 5kbp, 6kbp and the like. Corresponding lengths also apply in the event the cGAS-activating
nucleic acid, e.g. DNA, is single-stranded. The double-stranded cGAS-activating nucleic acid may be DNA, for example
a plasmid, such as a commonly known expression vector. The cGAS-activating nucleic acid may also be in the form of
single-stranded DNA or DNA/RNA hybrids. Such DNA/RNA hybrids may also have the lengths as set out above. Any
of the above recited length of base pairs may be combined with one another to form a length of base pair range. Also
contemplated within such length of base pair ranges are corresponding ranges in which the lower length of base pairs
is included while the upper length of base pairs is excluded, as well as ranges in which the upper length of base pairs
is excluded while the upper length of base pairs is included.
[0171] In a further embodiment of the invention, the cGAS-activating nucleic acid is a dsDNA molecule in the form of
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a plasmid, such as a commonly known expression vector pET, Phil 74, pGEX, pcDNA5, pFBDM, pRS, pETM.
[0172] In a preferred embodiment of the invention, the cGAS-activating nucleic acid is a dsDNA molecule having at
least 12bp flanked by guanosine-rich (G-rich) ssDNA overhangs. G-rich overhangs significantly enhance cGAS binding
to short DNA.
[0173] In a further preferred embodiment of the invention, the cGAS-activating nucleic acid is a dsDNA molecule
having at least 30bp. Below 30bp dsDNA molecules are less efficient in activating cGAS.
[0174] Furthermore, cGAS requires divalent cations as co-factors in order to convert nucleoside triphosphates into
2’3’CDNs. Thus, in a preferred embodiment of the present invention, the one or more divalent cation is selected from
the group consisting of Mg2+, Ca2+, Zn2+, Fe2+, Cu2+, Ni2+, and Mn2+. In a most preferred embodiment of the present
invention, the aqueous solution further comprises Mg2+ and/or Zn2+.
[0175] According to one embodiment, cGAS may be activated by the addition of one or more divalent cations to the
aqueous solution already comprising cGAS, a cGAS-activating nucleic acid, first nucleoside triphosphate, and a second
nucleoside triphosphate, wherein at least one of the first and second nucleoside triphosphate is a fluorescent nucleoside
triphosphate according to the present invention. The conversion of the first and second nucleoside triphosphates into
2’3’fCDN then starts as soon as the first cGAS/cGAS-activating nucleic acid complex is formed. As soon as the first
cGAS/cGAS-activating nucleic acid complex is formed, the conversion rate of the first and second nucleoside triphos-
phates into 2’3’fCDN continuously increases over time as more cGAS molecules become activated. When cGAS acti-
vation reaches equilibrium, the conversion rate of the first and second nucleoside triphosphate into 2’3’fCDN reaches
a stationary phase. This allows fast and direct measurement of cGAS activity and the identification of a substance having
the ability to modulate cGAS activity. Thus, in one embodiment of the present invention, one or more divalent cations
are added to the aqueous solution comprising cGAS, cGAS-activating nucleic acid, and a first and second nucleoside
triphosphate of the present invention to start the 2’3’fCDN-forming reaction.
[0176] According to another embodiment, cGAS may alternatively be activated prior to the addition of a first and a
second nucleoside triphosphates of the present invention. This approach allows cGAS activation to achieve equilibrium
prior to the addition of its substrates and therefore allows accurate measurement of the initial conversion rates of the
nucleoside triphosphates into 2’3’fCDN. Thus, in a further preferred embodiment of the present invention, cGAS is
activated prior to the addition of the first and second nucleoside triphosphates in the aqueous solution comprising cGAS,
cGAS-activating nucleic acid and one or more divalent cations. After cGAS activation reaches equilibrium, the first and
second nucleoside triphosphate according to the present invention are added to the aqueous solution, wherein at least
one of the first and second nucleoside triphosphate is a fluorescent nucleoside triphosphate according to the present
invention. The skilled person will be able to measure DNA binding equilibrium by commonly known techniques such as
EMSA, ITC or fluorescence anisotropy measurements using a fluorophore attached to DNA.
[0177] In a further embodiment of the present invention, the fluorescent signal of the aqueous solution is measured
at a predetermined time-point. This time-point is determined in preliminary experiments taking into account the dead
time of the instrument used as the fluorescence reader, i.e. the shortest time it takes between mixing the reagents and
measuring the first data point in a given instrument. It is advantageous to determine cGAS activity in a preceding
experiment, e.g. by a method of measuring cGAS activity described above, to avoid choosing a time point of measuring
the fluorescence signal when either the conversion of the fluorescent nucleoside triphosphate of the present invention
into the 2’3’fCDN has not yet started (this would be the case for cGAS having a very low nucleotidyltransferase activity)
or all of the free fluorescent nucleoside triphosphate in the aqueous solution has already been converted into 2’3’fCDN
due to very high nucleotidyltransferase activity of cGAS molecules. Once the correct time point is determined for each
experimental set up, measuring of the fluorescent signal at a predetermined time point allows fast and reliable meas-
urement of the fluorescent signal in aqueous solution. According to one embodiment of the invention, this allows fast
and reliable identification of substances having an agonistic or antagonistic effect on cGAS activity.
[0178] In another embodiment of the present invention, the fluorescence signal of the aqueous solution is measured
continuously over a predetermined time interval. Measuring over a time interval, the slope can be determined more
precisely than using a single time point and the linear interval of the reaction can be determined more accurately. In
some embodiments of the present invention, the fluorescent signal is measured starting from about 10 seconds from
mixing all compounds together up to about 1 hour. The time interval of the measurement depends strongly on the
experimental setup, such as buffer condition, temperature and substance concentration. In general, for the low cGAS
activity higher protein and/or activating DNA and/or substance concentrations may be used, compared to the case of
high cGAS activity to perform the measurement within 5 min - 1 h time interval.
[0179] In a further embodiment of the present invention, the measured fluorescence signal of the aqueous solution is
measured at different wavelengths or ranges of wavelengths depending on the fluorescent nucleoside triphosphate or
triphosphates used in the methods according to the invention. Specifically, each fluorescent nucleoside triphosphate
may have different excitation and emission maxima which influence the wavelengths at which the fluorescence signal
is measured. Thus, depending on the fluorescent nucleoside triphosphate or triphosphates used in the methods according
to the invention the wavelengths or range of wavelengths at which the fluorescent nucleoside triphosphate is excited
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(i.e. the excitation maxima) and the wavelengths or range of wavelengths at which the fluorescence signal is measured
(i.e. the emission maxima) need to be adapted for each fluorescent nucleoside triphosphate or triphosphates individually
in order to avoid false positives by measuring a fluorescence signal outside the optimal wavelength or range of wave-
lengths for a given fluorescent nucleoside triphosphate or triphosphates.
[0180] In some embodiments of the present invention, the excitation wavelength is in the range of about 295nm to
about 365nm, or between about 295nm and 365nm. In some embodiments of the invention, the excitation wavelength
is about 295nm, about 296nm, about 297nm, about 298nm, about 299nm, about 300nm, about 301nm, about 302nm,
about 303nm, about 304nm, about 305nm, about 306nm, about 307 nm, about 308nm, about 309nm, about 310nm,
about 311nm, about 312nm, about 312nm, about 313nm, about 314nm, about 315nm, about 316nm, about 317nm,
about 318nm, about 319nm, about 320nm, about 321nm, about 322nm, about 323nm, is about 324nm, about 325nm,
about 326nm, about 327nm, about 329nm, about 330nm, about 331nm, about 332nm, about 333nm, about 334nm,
about 335nm, about 336nm, about 337nm, about 338nm, about 339nm, about 340nm, about 341nm, about 342nm,
about 343nm, about 344nm, about 345nm, about 346nm, about 347nm, about 348nm, about 349nm, about 350nm,
about 351nm, about 352nm, about 353nm, about 354nm, about 355nm, about 356nm, about 357nm, about 358nm,
about 359nm, about 360nm, about 361nm, about 362nm, about 363nm, about 364nm, or about 365nm. Any of the above
recited excitation wavelength may be combined with one another to form an excitation wavelength range. Also contem-
plated within such excitation wavelength ranges are corresponding ranges in which the lower excitation wavelength is
included while the upper excitation wavelength is excluded, as well as ranges in which the lower excitation wavelength
is excluded while the upper excitation wavelength is included. In a particularly preferred embodiment of the invention,
the excitation wavelength ranges from about 295nm to about 315nm or between about 295nm and 315nm. In a most
preferred embodiment the excitation wavelength is 305nm.
[0181] In some embodiments of the present invention, the emission wavelength ranges from about 350nm to about
500nm or between about 350nm and 500nm. In some embodiments the excitation wavelength is about 350nm, about
351nm, about 352nm, about 353nm, about 354nm, about 355nm, about 356nm, about 357nm, about 358nm, about
359nm, about 360nm, about 361nm, about 362nm, about 363nm, about 364nm, about 365nm, about 366nm, about
367nm, about 368nm, about 369nm, about 370nm, about 371nm, about 372nm, about 373nm, about 374nm, about
375nm, about 376nm, about 377nm, about 378nm, about 379nm, about 380nm, about 381nm, about 382nm, about
383nm, about 384nm, about 385nm, about 386nm, about 387nm, about 388nm, about 389nm, about 390nm, about
391nm, about 392nm, about 393nm, about 394nm, about 395nm, about 396nm, about 397nm, about 398nm, about
399nm, about 400nm, about 401nm, about 402nm, about 403nm, about 404nm, about 405nm, about 406nm, about
407nm, about 408nm, about 409nm, about 410nm, about 411nm, about 412nm, about 413nm, about 414nm, about
415nm, about 416nm, about 417nm, about 418nm, about 419nm, about 420nm, about 421nm, about 422nm, about
423nm, about 424nm, about 425nm, about 426nm, about 427nm, about 428nm, about 429nm, about 430nm, about
431nm, about 432nm, about 433nm, about 434nm, about 435nm, about 436nm, about 437nm, about 438nm, about
439nm, about 440nm, about 441nm, about 442nm, about 443nm, about 444nm, about 445nm, about 446nm, about
447nm, about 448nm, about 449nm, about 450nm, about 451nm, about 452nm, about 453nm, about 454nm, about
455nm, about 456nm, about 457nm, about 458nm, about 459nm, about 460nm, about 461nm, about 462nm, about
463nm, about 464nm, about 465nm, about 466nm, about 467nm, about 468nm, about 469nm, about 470nm, about
471nm, about 472nm, about 473nm, about 474nm, about 475nm, about 476nm, about 477nm, about 478nm, about
479nm, about 480nm, about 481nm, about 482nm, about 483nm, about 484nm, about 485nm, about 486nm, about
487nm, about 488nm, about 489nm, about 490nm, about 491nm, about 492nm, about 493nm, about 494nm, about
495nm, about 496nm, about 497nm, about 498nm, about 499nm or about 500nm. Any of the above recited emission
wavelengths may be combined with one another to form an emission wavelength range. Also contemplated within such
emission wavelength ranges are corresponding ranges in which the lower emission wavelength is included while the
upper emission wavelength is excluded, as well as ranges in which the lower emission wavelength is excluded while
the upper emission wavelength is included. In a particularly preferred embodiment of the invention, the emission wave-
length ranges from about 350nm to about 380nm, or between about 350nm and 380nm. In a most preferred embodiment
of the invention the emission wavelength is 363nm.
[0182] Furthermore, the quantum yield of a fluorescent nucleoside triphosphate may also differ depending on the
experimental conditions. Thus, for each fluorescent nucleoside triphosphate the experimental conditions need to be
modified in order to optimize the quantum yield of the fluorescent molecule. Experimental conditions that might influence
the quantum yield of a given fluorescent nucleoside triphosphate of include but are not limited to pH, temperature, ionic
strength, buffer composition
[0183] The change of the fluorescence signal can be measured by any known fluorescence read out technique using
a conventional plate reader or a single-cuvette photometer. In a preferred embodiment of the present invention, the
fluorescence signal of the aqueous solution may be measured by a Tecan infinite M1000 using 96-well black non-binding
PS plates (Greiner Bio-One), however a FluoroMax-P spectrofluorometer (Horiba Scientific) or similar instrument can
be used.
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[0184] According to the invention, the fluorescent nucleoside triphosphate is a fluorescent and purine nucleoside
triphosphate. In one embodiment of the present invention, the fluorescent nucleoside triphosphate can be selected from
the group consisting of a 2-aminopurine nucleoside triphosphate (2-APTP), a 3-methyl-isoxanthopterin nucleoside tri-
phosphate (3-MITP), a 6-methyl isoxanthopterin nucleoside triphosphate (6-MITP), 4-amino-6-methyl-8-(2-deoxy-beta-
d-ribofuranosyl)-7(8H)-pteridone nucleoside triphosphate (6-MAPTP), a 4-amino-2,6-dimethyl-8-(2’-deoxy-beta-d-ribo-
furanosyl)-7(8H)-pteridone nucleoside triphosphate (DMAPTP), a pyrrolocytosine nuceloside triphosphate (pyrrolo-
CTP), a 6-phenylpyrrolocytosine nucleoside triphosphate (PhpCTP), a (aminoethoxy)phenylpyrrolocytosine nucleoside
triphosphate (moPhpCTP), a [bis-o-(aminoethoxy)phenyl]pyrrolocytosine nucleoside triphosphate (boPhpCTP), a hy-
dropyrimidopyrimidine nucleoside triphosphate (ChppTP), a pyrrolopyrimidopyrimidine nucleoside triphosphate (CpppTP),
a pyrimidopyrimidoindole nucleoside triphosphate (CppiTP), a benzopyridopyrimidine nucleoside triphosphate (BPPTP),
a naphtopyridopyrimidine nucleoside triphosphate (NPPTP), a methoxybenzodeazaadenine nucleoside triphosphate
(MDATP), a methoxybenzodeazainosine nucleoside triphosphate (MDITP), a naphtodeazaadenine nucleoside triphos-
phate (NDATP), a furan-modified pyrimidine nucleoside states, a thieno[3,2]pyrimidine nucleoside triphosphate, a
thieno[3,4]pyrimidine triphosphate, a 5-methoxy-quinazoline-2,4-(1H,3H) dione nucleoside triphosphate, a 5-methylpy-
rimidine-2-one nucleoside triphosphate, a 7-deazapurine nucleoside triphosphate, a 5-alkyluridine nucleoside triphos-
phate, a benzoquinalozines nucleoside triphosphate, a triazoleadenosine nucleoside triphosphate, and a 1,N6-ethe-
noadenosine nucleoside triphosphate, wherein the nucleoside triphosphate is a deoxyribonucleoside triphosphate or a
ribonucleoside triphosphate. In a most preferred embodiment, the fluorescent nucleoside triphosphate is 2-amino purine
ribonucleoside triphosphate (2-APTP) comprising the fluorescent nucleobase analogue 2-aminopurine (2-AP). The in-
ventors surprisingly found out that the high fluorescence quantum yield of 2-APTP in aqueous solution (about 0.68) is
considerably reduced when incorporated into 2’3’fCDN. The high sensitivity of 2-AP to the microenvironment can thus
be exploited to measure cGAS activity in the presence or absence of a substance. In particular, the inventors found out
that cGAs can utilize 2-APTP instead of adenine nucleoside triphosphate (ATP) to efficiently generate 2’3’fCDN in the
presence of a second nucleoside triphosphate. The quenching of the fluorescence signal upon incorporation of 2-APTP
into 2’3’fCDN allows the measurement of cGAS activity in a continuous assay using a conventional fluorescence plate
reader or single cuvette photometer. The finding that 2-APTP is utilized by cGAS for incorporation into 2’3’fCDN in
conjunction with a significant quenching of the fluorescence signal allows the determination of quantitative steady state
activity rates of cGAS in an easily scalable and high-throughput manner. Based on the unexpected properties of 2-APTP
in the methods of the present invention, the inventors were thus able to develop a fast and reliable method of measuring
cGAS activity and a method to screen a large range of substances for their ability to modulate cGAS activity in a fast
and reliable manner.
[0185] In a preferred embodiment of the present invention, the first nucleoside triphosphate is 2-APTP.
[0186] As evident from all of the above, the fluorescent nucleoside triphosphate can be used for measuring cGAS
activity or for identifying a substance having an ability to modulate cGAS activity. The fluorescent nucleoside triphosphate
therefore represents a powerful tool to measure cGAS activity and to identify substances having an ability to modulate
cGAS activity in a fast and reliable method according to the invention.
[0187] In a further embodiment of the present invention, the second nucleoside triphosphate is a purine ribonucleoside
triphosphate. The ribofuranosyl backbone of the second nucleoside triphosphate contains a hydroxyl group at position
2 of the ribose ring, thereby allowing the formation of the 2’5’-phosphodiester linkage between the first and the second
nucleoside triphosphate. It is essential that one of the first and second nucleoside triphosphates has a free 2’ hydroxyl
group and the other one has a free 3’ hydroxyl group in order to enable the formation of the 2’-5’ and 3’-5’ phosphodiester
linkages in the 2’3’CDN.
[0188] In a most preferred embodiment of the present invention, the second nucleoside triphosphate is guanosine
triphosphate (GTP) having a free 2’ hydroxyl group, whereas the first nucleoside triphosphate is 2-APTP having a free
3’ hydroxyl group.
[0189] According to the methods of the present invention, the skilled person will realize that the fluorescent nucleoside
triphosphates set forth herein can be used for measuring cGAS activity and for identifying a substance having an ability
to modulate cGAS activity.
Method of preparing a fluorescent cyclic dinucleotide
[0190] In a further aspect, the present invention relates to a method of preparing a fluorescent cyclic dinucleotide
(2’3’fCDN) of the present invention. The method comprises the steps of (i) providing an aqueous solution comprising
cGAS, a cGAS-activating nucleic acid, a first nucleoside triphosphate, a second nucleoside triphosphate, and one or
more divalent cation, wherein at least one of the first and second nucleoside triphosphate is a fluorescent nucleoside
triphosphate of the present invention, and wherein one of the first and second nucleoside triphosphate has a free 2’
hydroxyl group and the other one has a free 3’ hydroxyl group, thereby preparing the cyclic dinucleotide of the present
invention. The method is based on the finding that activated cGAS generates cyclic dinucleotides by utilizing fluorescent
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nucleoside triphosphates of the present invention instead of natural occurring nucleoside triphosphates with only slightly
reduced efficiency.
[0191] In a preferred embodiment of the present invention, the fluorescent cyclic dinucleotide of the present invention
is further purified. For example, the reaction mixture of the method of preparation can be subjected to commonly known
purification techniques such as reversed-phase HPLC, ion exchange chromatography, solid phase extraction, and the
like.
[0192] In a further embodiment of the invention, the method of preparing a 2’3’fCDN further comprises additional steps
of incubating the aqueous solution for a specified time period and under predetermined conditions sufficient to allow
cGAS to convert the first and the second nucleoside triphosphate into a CDN of the invention. In particular, about 50
nM to about 50 mM, most preferably about 10 mM, cGAS is incubated with about 2.6 to 650 ng/ml, most preferably about
195 ng/ml, DNA in the aqueous solution comprising about 40 mM Tris, about 100 mM NaCl, about pH 7.5, about 5 mM
MgCl2, about 50 mM to about 5 mM of a first nucleoside triphosphate (i.e. a fluorescent nucleoside triphosphate), and
about 50 mM to about 5 mM of a second nucleoside triphosphate. The reaction is performed at about 32°C to about
37°C for about 30 minutes to about 3 hours. Most preferably, the reaction mixture is incubated at about 37°C for about
60 minutes.
[0193] As evident from the overall teaching of the present invention, the 2’3’fCDN of the present invention can advan-
tageously be used to label cGAS. Upon complex formation between cGAS and the 2’3’fCDN of the present invention,
the cyclic dinucleotides can further be used to label cGAS due to its (at least one) fluorescent nucleotide monophosphate.
[0194] The following examples, including the experiments conducted and the results achieved, are provided for illus-
trative purposes only and are not construed as limiting the present invention.
Example 1: Cell line and reagents
[0195] The following cell lines and reagents were used in the herein described experiments. All DNA oligonucleotides
were purchased from Metabion.
[0196] The following cell lines were used: HEK293T STING KI (Ablasser, Schmid-Burgk et al. "Cell intrinsic immunity
spreads to bystander cells via the intercellular transfer of cGAMP". Nature 503, 530-534, 2013), BLaER1(Rapino, Robles
et al. "C/EBPα Induces Highly Efficient Macrophage Transdifferentiation of B Lymphoma and Leukemia Cell Lines and
Impairs Their Tumorigenicity". Cell Reports 3, 1153-1163, 2013) and BLaER1 cGAS-KO (cGAS deficient cell line, a
general gift from M. Gaidt, group of V. Hornung, Gene Center, Ludwig-Maximilians-Universitat München, Center for
Integrated Protein Science Munich, Germany).
Example 2: Constructs and cloning
[0197] The following constructs were used in the below described experiments:
The plasmid encoding full-length (aa 1-522) and truncated (catalytic domain - cd) Homo sapiens (h) (aa 155-522),
Mus musculus (m) (aa 141-507) and Sus scrofa (s) (aa 135-495) cGAS for N-terminal His6-MBP fusion protein
expression were obtained from Dr. F. Civril (Civril, Deimling et al. "Structural mechanism of cytosolic DNA sensing
by cGAS". Nature 498, 332-337, 2013). The plasmid encoding hSTING cytosolic domain (cd, aa 139-379,
R220H+H232R variant) for N-terminal His6-SUMO1 fusion protein expression was obtained from Dr. T. Deimling
(Cavlar, Deimling et al. "Species-specific detection of the antiviral small-molecule compound CMA by STING". The
EMBO Jourhal 32, 1440-1450, 2013). These plasmids were used to transform E.coli Rosetta (DE3) protein expression
strain cells (Novagen).
Example 3: Cell lines and cell culture
[0198] HEK293T STING KI were cultured in DMEM (Thermo Fisher Scientific or Sigma-Aldrich, respectively) supple-
mented with 10% heat inactivated FBS (Thermo Fisher Scientific or Biochrom, respectively) and incubated at 37°C with
5% CO2.
[0199] BLaER1 and BLaER1 cGAS-KO cells were cultivated in RPMI medium containing heat-inactivated 10% FCS,
Penicillin (100 U/ml), Streptomycin (100 mg/ml) (Gibco, Life Technologies) and 1 mM sodium pyruvate (Thermo Fisher
Scientific). For trans-differentiation, 5 x 104 cells were seeded per well of a flat bottom 96 well plate and cultivated in the
presence of ß-estradiol (100 nM, Sigma-Aldrich), hr-IL-3 (10 ng/ml) and M-CSF (10 ng/ml) (both PeproTech) for five
days prior to the experiment (Gaidt, Ebert et al. "Human Monocytes Engage an Alternative Inflammasome Pathway".
Immunity 44, 833-846, 2016).
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Example 4: Protein expression and purification
[0200] All cGAS protein constructs (e.g. hcGAScd, mcGAScd, scGAScd) were overexpressed in E. coli Rosetta (DE3)
for 16-18h at 18°C after induction with 0.2 mM IPTG. Cells were lysed by sonication in 50 mM Tris, 500 mM NaCl, 5
mM MgCl2, 10 mM imidazole, 10% Glycerol, pH 7.5, supplemented with 2 mM β-mercaptoethanol and protease inhibitor
cocktail (Sigma-Aldrich) and purified with Ni-NTA agarose resin (Qiagen). For truncated cGAS proteins His6-MBP tag
was removed with TEV protease (1:50 mass ratio) during 16 h dialysis against 30 mM Tris, 100 mM NaCl, 2 mM DTT,
pH 7.0. cGAS proteins were further purified by cation-exchange chromatography (30 mM Tris, 100 mM/l M NaCl, 2 mM
DTT, pH 7.0) on HiTrap SP HP columns (GE Healthcare) followed by size-exclusion chromatography on HiLoad S200
16/60 column (GE Healthcare) equilibrated with 20 mM Tris, 100 mM NaCl, pH 7.5. Full-length hcGAS with N-terminal
His6-MBP tag (hcGAS) and mcGAS proteins were concentrated to 8-12 mg ml-1. Truncated hcGAS was concentrated
to 4 mg ml-1. All proteins were flash-frozen in liquid nitrogen and stored at -80°C.
[0201] mTfam and mHMGB1 (both DNA bending proteins) were purified as described for full-length hcGAS, except
the cation-exchange chromatography step was skipped and after dialysis against 20 mM Tris, 300mM NaCl, pH 7.5 size
exclusion chromatography on HiLoad S75 16/60 (GE Healthcare) column was performed. Proteins were concentrated
to 10-13 mg ml-1.
[0202] 1HU (another DNA bending protein) was purified as described for full-length hcGAS, except instead of cation-
exchange chromatography affinity chromatography on HiTrap Heparin HP (GE Healthcare) column was performed (20
mM Tris, 100 mM/l M NaCl, 2 mM DTT, pH 7.5). HiLoad S75 16/60 (GE Healthcare) equilibrated with 20 mM Tris, 100
mM NaCl, pH 7.5 was used for size exclusion chromatography. Protein was concentrated to 7 mg ml-1.
[0203] hSTINGcd construct was expressed and purified as follows. E. coli Rosetta (DE3) cells were grown in 31 of LB
media supplemented with Kanamycin (50mg/l) and Chloramphenicol (34mg/l) at 37°C for 3 hours, to OD600=0.8. Ex-
pression of N-terminal His6-SUMO1-tagged STING was induced by adding IPTG (Roth) to a final concentration of 0.2mM.
Expression was done overnight at 18°C. Cells were collected by centrifugation and were resuspended in lysis buffer
(50mM Tris, 500mM NaCl, 10mM imidazole, 5% glycerol, 2mM β-mercaptoethanol, pH7.5) and lyzed by sonification.
The soluble His6-SUMO1-STING was purified by Ni-affinity chromatography. The His6-SUMO1-tag was removed by
proteolytic cleavage with SenP2 protease during dialysis over night (20mM Tris, 150mM NaCl, 3% glycerol, 2mM β-
mercaptoethanol, pH7.5) and a second Ni-affinity chromatography step. To remove additional contaminants, a HiTrap
Q FF (GE Healthcare) purification was applied. Finally, the STING containing flow-through was used in a HiLoad 16/60
Superdex 75 prep grade (GE Healthcare) size-exclusion chromatography step (20 mM Tris, 100 mM NaCl, pH 7.5).
Purified STING was concentrated (9-15mg/ml) with a 10kDA cut-off centrifugal concentrator device (Millipore) and was
flash frozen in liquid nitrogen for storage (-80°C).
Example 5: Characterization of cGAS activating nucleic acids
[0204] cGAS is activated by cytosolic DNA. In order to study the effect of different DNA constructs on cGAS activation,
DNA of different length was tested in an enzyme-linked immunoabsorbent assay as follows (ELISA). This assay provided
information about efficient cGAS-activating nucleic acids that could be used to induce robust cGAS activity in the herein
described methods of the invention.
[0205] 5x104 trans-differentiated BLaER1 cells expressing cGAS were transfected with 20, 40 or 60 ng DNA of different
length (20-100 bp in 5 bp intervals) and herring testis (HT) DNA using 0.5 ml Lipofectamine 2000 Transfection Reagent
(Thermo Fischer Scientific) in 50 ml Opti-MEM Reduced Serum medium (Thermo Fischer Scientific). CXCL 10 expression
in the supernatants was quantified 8 h after transfection using ELISA (BD OptEIA™, human IP-10 ELISA Set). Cells
stimulated with transfection reagent only and unstimulated cells served as control.
[0206] As can be seen from Figure 5a, the data indicate a concentration and DNA length-dependent activation of
cGAS measuring CXCL10 production as a surrogate parameter of cGAS activity. Long herring testes (HT) DNA robustly
activated cGAS at all DNA concentrations, while shorter DNA molecules required increasing concentrations of DNA.
The data show a clear preference for long DNA at low DNA concentrations, while short DNA is more effective at higher
DNA amounts.
[0207] The same effect was also observed in fluorescence-based cGAS activity assays described in Example 9. The
data clearly indicate that at a constant concentration of both human full-length cGAS and human truncated cGAS
(hcGAScd) a DNA length-dependent activation was observed which was independent of the presence or absence of
cGAS N-terminal domain (Figure 5b). The data further indicate that robust activation in vitro proceeds most readily when
DNA > 40bp (Figure 5b). The length-dependence was furthermore not species-specific, since truncated mouse cGAS
(mcGAScd) showed a comparable length dependent activation, with a gradual increase in activity until about 75bp (Figure
5c). Plasmid DNA was an even more potent activator (Figure 5c).
[0208] Overall, the data indicate that cGAS is activated in a manner dependent on the length of the nucleic acid used,
wherein cGAS activity directly correlates with the length of the tested DNA. Furthermore, the data indicate that the
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nucleotide sequence does not influence cGAS activation and that the observed length-dependence was not species-
specific. In summary, an increase in DNA length directly correlates with an increase in cGAS activity.
Example 6: Radiolabeled cGAS activity assays
[0209] The above results were confirmed by radiolabeled cGAS assays. In this assay 13 ng ml-1 DNA was mixed with
2 mM truncated mouse cGAS (mcGAScd) and reaction was started by adding 50 mM ATP, 500 mM GTP, 5 mM MgCl2
in 40 mM Tris pH 7.5 and 100 mM NaCl containing 1:800 [α32P]ATP (3000 Ci mmol-1, Hartman Analytic). Samples were
incubated at 35°C and the reaction was stopped by plotting on PEI-Cellulose F plates (Merck) and analyzed by thin layer
chromatography (TLC) with 1M (NH4)2SO4/1.5M KH2PO4 as running buffer. The radiolabeled products were visualized
with Typhoon FLA 9000 phosphor imaging system.
[0210] The results clearly confirmed the length-dependent cGAS activation already described in Example 5 above
(see Figure 5d).
[0211] For testing of 2-APTP incorporation into cGAS enzymatic activity product 1 mM mcGAScd was mixed with 13
ng ml-1 (≈1 mM binding sites) 55 bp, 500 mM 2-APTP/ATP, 500 mM GTP, 5 mM MgCl2 and 1:160 [α32P]ATP or [α32P]GTP
(3000 Ci mmol-1, Hartman Analytic) in the same condition.
[0212] The data demonstrate that cGAS is capable of incorporating 2-APTP together with GTP into 2’3’fGAMP (see
Figure 6a).
Example 7: Analysis of chemical properties of 2’3’fGAMP
[0213] To analyze the physical and chemical properties of 2’3’fGAMP, the fluorescent cyclic dinucleotide was analyzed
by anion-exchange chromatography. 10 mM truncated mouse cGAS (mcGAScd), truncated porcine cGAS (scGAScd) or
truncated human cGAS (hcGAScd) were incubated with 195 ng ml-1 (≈15 mM binding sites) plasmid DNA at 35°C for 2
h in buffer containing 40 mM Tris pH 7.5, 100 mM NaCl, 10 mM MgCl2, 2 mM 2-APTP and 2 mM GTP. Reaction mixtures
were centrifuged for 10 min, 16100 rcf, and the supernatant was separated from cGAS by ultrafiltration (30 kDa, Amicon).
Resulting flow through was diluted in 50 mM Tris pH 9.0 and loaded on Mono Q 5/50 GL (GE Healthcare) for anion
exchange chromatography (50 mM Tris, 0 M/1 M NaCl, pH 9.0). The fractions containing cGAS product fGAMP were
collected, lyophilized and stored at -20°C. Control runs with 2-APTP, GTP, 2’3’- and 3’3’cGAMP were made analogously
to validate the resulting peaks of cGAS reaction products.
[0214] As can be seen from the chromatograms in Figures 6b and 6c, 2’3’fGAMP generated by truncated mouse
(mcGAScd) or human cGAS (hcGAScd) was detected in the same elution volume as natural 2’3’cGAMP at approximately
10 mL, indicating that the fluorescent 2’3’fGAMP has similar chemical and physical properties as the natural 2’3’cGAMP.
Example 8: Analysis of enzymatically synthesized fGAMP by mass spectrometry.
[0215] To further determine the exact chemical composition of fGAMP produced by cGAS from 2-APTP and GTP, the
resulting fGAMP was analyzed with mass spectrometry as follows. 10 mM truncated mouse cGAS (mcGAScd) was
incubated with 195 ng ml-1 (≈15 mM binding sites) plasmid DNA at 35°C for 2 h in buffer containing 40 mM Tris pH 7.5,
100 mM NaCl, 10 mM MgCl2, 2 mM 2-APTP and 2 mM GTP. Reaction mixtures were centrifuged for 10 min, 16100 rcf,
and the supernatant was separated from cGAS by ultrafiltration (30 kDa, Amicon). Resulting flow through was diluted
in 50 mM Tris pH 9.0 and loaded on Mono Q 5/50 GL (GE Healthcare) for anion exchange chromatography (50 mM
Tris, 0 M/l M NaCl, pH 9.0). The fractions containing cGAS product fGAMP were collected, lyophilized and stored at -20°C.
[0216] For further purification reverse phase high-performance liquid chromatography (HPLC) was used with solvent
A (triethylammonium acetate:acetonitrile:H2O [0.1 M:3%:97%], w:v:v) and solvent B (methanol:acetonitrile:H2O
[45%:45%:10%], v:v:v). Lyophilized fGAMP was diluted in solvent A and subjected to a C18 column. Two step linear
gradient 0%-10% B (2 CV), 10%-50% B (2 CV) was used as described in (Gao, Ascano et al. "Cyclic [G(2’,5’)pA(3’,5’)p]
Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase". Cell
153,1094-1107,2013).
[0217] The sample was lyophilized and diluted in 100 mL H2O for ESI LC/MS analysis.
[0218] Flow injection analysis with 10 mL fGAMP sample was performed with a Surveyor MS pump with a flow rate of
100 mL/min 20-80% (H2O:acetonitrile) using an injection filter. ESI-LC/MS analysis was performed using a Finnigan LTQ
FT Ultra Fourier Transform Ion Cyclotron Resonance mass spectrometer (Thermo Fisher Scientific) with an IonMax
source with ESI head. The resolution was set to 100.000 at m/z 400 and the spectra were acquired in a mass range
from m/z 150 to 1,000. The ion transfer capillary temperature was set to 250 °C, the spray voltage to 4 kV, liquid nitrogen
Sheathgasflow to 20 and the Sweepgasflow to 5 units. The acquired spectrum of enzymatically synthesized fGAMP
shows ions corresponding to fGAMP-H (m/z 673.09) and fGAMP-2H+Na+ (m/z 695.07) (Figure 6d). In tandem mass
spectrometry spectrum (Figure 6e) derived from a parent fGAMP ion (m/z 673.09) ion products corresponding to depu-
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rination of the dinucleotide were observed. Depurination of guanine resulted in product with m/z 522.19 and depurination
of 2-AP - in product with m/z 538.15. The ratio of these peaks (more depurinated guanines than 2-AP) is characteristic
for the linkage between 2’-OH of GTP and 5’-phosphate of 2-APTP within the fGAMP molecule corresponding to
2’3’fGAMP as cGAS product (Ablasser, Goldeck et al. "cGAS produces a 2[prime]-5[prime]-linked cyclic dinucleotide
second messenger that activates STING". Nature 498, 380-384, 2013).
Example 9: Fluorescence-based cGAS activity assay
[0219] To precisely measure initial rates of cGAS activity in high-throughput, the inventors developed a fluorescence-
based cGAS activity assay based on the incorporation of the fluorescent nucleoside analog 2-aminopurine nucleoside
triphosphate (2-APTP) along with GTP into cyclic dinucleotide denoted 2’3’fGAMP (Figure 7a).In this assay 2-APTP and
6.5 ng ml-1 DNA of different lengths (20 -100 bp in 5 bp intervals, and pET28M-SUMO1-GFP vector (EMBL) (6.2 kbp,
plasmid)) that corresponds to roughly 0.5 mM 20 bp (approximate length of cGAS binding site) were premixed with 0.5
mM cGAS in 40 mM Tris pH 7.5 and 100 mM NaCl. Alternatively, 2.6 ng ml-1 DNA (≈0.2 mM binding sites) and 1mM
cGAS were used. The reaction was started by adding 5 mM MgCl2 together with 500 mM GTP and 50 mM 2-APTP and
performed at 32°C. Fluorescence decrease was measured in 96-well black non-binding PS plates (Greiner Bio-One) on
Tecan infinite M1000 (λex=305 nm, λem=363 nm, gain 100, settle time 10ms, kinetic interval 2 min).
[0220] Additionally, 2-APTP fluorescence alone was studied in different conditions, relevant for the assay, as follows.
2.5, 10, 50 or 100 mM 2-APTP was mixed in ultrapure water, 100mM NaCl + 5mM MgCl2, 40mM Tris pH 7.5, 500 mM
GTP, 40mM Tris pH 7.5 + 100mM NaCl + 5mM MgCl2 or 40mM Tris pH 7.5 + 100mM NaCl + 5mM MgCl2 and fluorescence
was measured as described above. The fluorescence intensity of 2-APTP was not influenced by the used components
in the aqueous solution and did not differ from that of fluorescence intensity in ultrapure water (Figure 7b).
[0221] The data clearly indicate that the fluorescence signal of free 2-APTP is quenched upon the incorporation of 2-
APTP into 2’3’fGAMP during the reaction which allows the measurement of the reaction rate by measuring the change
in fluorescence intensity (Figure 7a,c). Initial fluorescence read-out curves (Figure 7c) represent the changes in fluores-
cence during the reaction. For each curve the background fluorescence values were subtracted and inverted to give the
positive value (ΔF). The resulting curves were scaled, such that ΔF at time point 0 min equals 0 (ΔF- ΔFt=0) (Figure 7d).
The initial cGAS reaction rates were calculated as a slope of the linear intervals (dashed lines) on the resulting curves
and are defined as ΔF/Δt [RFU min-1] (Figure 7e).
[0222] The data indicate that the new assay allows measurement of cGAS activity in a simple-to-implement high-
throughput assay. Furthermore, the data suggest that the assay can be used to identify substances having an ability to
modulate cGAS activity as described above.
Example 10: cGAS incorporates 2-APTP into 2’3’fGAMP in a species-independent manner
[0223] In order to investigate whether 2-APTP is incorporated into 2’3’fGAMP by cGAS in a species-dependent manner,
three truncated constructs comprising Mab21 from human (hcGAScd), mouse (mcGAScd) and Sus scrofa (scGAScd)
and human full length cGAS (hcGAS) were generated as described above.
[0224] These constructs were then analyzed using anion exchange chromatography of cGAS products on MonoQ
5/50 GL column (GE Healthcare), as described in Example 7. The data show that the incorporation of 2-APTP into
2’3’fGAMP does not depend on the origin of cGAS as indicated by the calculated cGAS activity rates for the different
species (see Figure 8a).
[0225] The constructs were further tested in fluorescence-based cGAS activity assays. 0.5 mM mcGAScd (Figure 8b),
hcGAScd (Figure 8c) or hcGAS (Figure 8d) were premixed with 6.5 ng ml-1 DNA of different lengths (20 -100 bp), and
pET28M-SUMO1-GFP vector (EMBL) (6.2 kbp, plasmid)) that corresponds to roughly 0.5 mM 20 bp in 40 mM Tris pH
7.5 and 100 mM NaCl. The reaction was started by adding 5 mM MgCl2 together with 500 mM GTP and 50 mM 2-APTP
and performed at 32°C. Fluorescence decrease (quenching) was measured in 96-well black non-binding PS plates
(Greiner Bio-One) on Tecan infinite M1000 (λex=305 nm, λem=363 nm, gain 100, settle time 10ms, kinetic interval 2
min). cGAS activity was calculated as described in Example 9 above. All tested constructs showed the same increase
of cGAS activity with DNA length.
[0226] The results further indicate that the described assay is suitable for evaluating the activity of both truncated and
full length cGAS constructs, as well as cGAS constructs originating from different species.
Example 11: DNA-bending proteins enhance cGAS activity
[0227] In order to investigate the effect of DNA-bending proteins on cGAS activity, a fluorescence-based cGAS activity
assay as described above was performed in the presence several DNA stress associated factors. The experiment was
performed as follows:
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13 ng ml-1 DNA was premixed with DNA-bending proteins mTFAM, mHMGB1 or 1HU in concentrations 0-5 mM,
after which 100 nM cGAS in 40 mM Tris pH 7.5 and 100 mM NaCl was added. The reaction was started by adding
5 mM MgCl2 together with 500 mM GTP and 50 mM 2-APTP and carried out at 32°C for mcGAScd or 37°C for hcGAS.
Fluorescence was measured in 96-well black non-binding PS plates (Greiner Bio-One) on Tecan infinite M1000
(λex=305 nm, λem=363 nm, gain 100, settle time 10ms, kinetic interval 2 min). Based on the measured fluorescence
cGAS activity was calculated as described in Example 9 above.
[0228] The data indicate that with low concentrations of cGAS only background activity is observed in the absence of
DNA-bending proteins, whereas adding increasing amounts of mTFAM, mHMGB1 and 1Hu robustly activated truncated
mouse cGAS (mcGAScd) in vitro up to ∼25 fold (Figure 9a-c) A similar activation was also seen for hTFAM and full-
length human cGAS (hcGAS) (Figure 9d). Each DNA-bending protein tested had an optimal concentration at which
maximal stimulation of cGAS activity was observed. Above such concentration cGAS activity was sharply abolished.
[0229] The data indicate that the above described assay is suitable for identifying a substance, illustratively represented
by one or more DNA bending proteins, which has an ability to modulate, e.g. enhance, cGAS activity.
Example 12: STING binding assays
[0230] In order to investigate whether 2’3’fCDN is able to bind to STING, luciferase activity assays were performed in
which HEK293T cells stably expressing STING (HEK293T STING KI) (Ablasser, Schmid-Burgk et al. "Cell intrinsic
immunity spreads to bystander cells via the intercellular transfer of cGAMP". Nature 503, 530-534, 2013) were induced
with 2’3’fGAMP.
[0231] Briefly, 1x105 HEK293T STING KI cells were seeded on 96-well plates and transfected with 100 ng p-125Luc,
10 ng pGL4.74 (Promega) plasmids and fGAMP diluted in DPBS (Gibco, Thermo Scientific) per well using Lipofectamine
2000 (Invitrogen, Thermo Fisher Scientific) as transfection reagent according to the vendor’s protocol. After 14h cells
were lysed in 50 mL passive lysis buffer (Promega, Madison, WI, USA). Immunoactivity experiments using the Dual-Glo
luciferase assay system (Promega, Madison, WI, USA) were performed according to manufacturer’s instructions. The
luciferase activity was determined in a 96-well plate reader.
[0232] Interferon-β response was measured as a proportion of firefly (FF) luciferase activity to Renilla (Ren) lucifearse
activity. All ratios were normalized to 2’3’fGAMP buffer control. The data clearly show that IFN-β response increases
with 2’3’fGAMP concentration (see Figure 10a) indicating that is capable to bind and activate STING in a cellular system.
Example 13: STING-dependent 2’3’fCDN quenching assay
[0233] To investigate the effect of STING binding on the fluorescene signal of 2’3’fCDN, STING-dependent 2’3’fGAMP
assays were performed as follows:
Lyophilized was dissolved in water, diluted for the experiment to the final absorption 2.34 at 250 nm (A250=2.34)
and mixed with 0-250 mM human truncated STING (hSTINGcd). The samples were incubated for 15 min at room
temperature and measured in 96-well black non-binding PS plates (Greiner Bio-One) on Tecan infinite M1000
(λex=305 nm, λem=363 nm, gain 140, settle time 10ms) at 25°C.
[0234] The data indicate that fluorescence considerably decreases with increasing concentrations of STING, suggest-
ing that STING-binding induces fluorescence quenching in 2’3’fCDN (see Figure 10b). Thus, while incorporation of 2-
AP into 2’3’fGAMP quenches the fluorescence signal of 2-APTP as observed in free solution (see e.g. Example 9), the
binding of 2’3’fGAMP to STING quenches the fluorescence signal of 2-AP even further. The results shown in Figure 10b
therefore indicate that 2’3’fCDN can be used in a method to study 2’3’fCDN binding to STING either in the presence of
a substance or in the absence of a substance.
[0235] The quenching effect of STING on 2’3’fGAMP can be further used to search and compare STING-binding
compounds. The competition assays with 2’3’-fGAMP-bound STING were performed as follows:
Lyophilized was dissolved in water, diluted for the experiment to the final absorption 2.34 at 250 nm (A250=2.34)
and mixed with 200 mM human truncated STING (hSTINGcd). The samples were incubated for 15 min at room
temperature after which 0-150 mM cGAMP 2’3’ or c-di-GMP were added. After second round of incubation for 15
min the samples were measured in 96-well black non-binding PS plates (Greiner Bio-One) on Tecan infinite M1000
(λex=305 nm, λem=363 nm, gain 140, settle time 10ms) at 25°C.
[0236] The data show that adding a STING-binding molecule such as 2’3’cGAMP leads to an increase of observed
fluorescent signal (Figure 10c). Such molecules compete for STING binding, leading to the release of 2’3’fGAMP from
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the STING-2’3’fGAMP complex. So the quenched fluorescence of 2’3’fGAMP can be regained. Comparison of two
STING-binding molecules with different affinities - 2’3’cGAMP and c-di-GMP - shows different efficiency of STING binding.
In particular, if comparing the increase in fluorescence by increasing concentrations of STING-binding molecules, those
with higher affinity towards STING (e.g. 2’3’cGAMP) will show a more rapid fluorescence increase than those with lower
affinity (e.g. c-di-GMP) (compare s1 and s2 from Figure 10d).
[0237] Thus, the STING-dependent 2’3’fCDN quenching assay provides a robust tool for the identification of substances
having an ability to bind to STING as discussed above.
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Claims
1. A cyclic dinucleotide comprising a 3’-5’ phosphodiester linkage and a 2’-5’ phosphodiester linkage between a first
nucleoside monophosphate and a second nucleoside monophosphate,
wherein at least one of the first and second nucleoside monophosphates is a fluorescent nucleoside monophosphate.
2. The cyclic dinucleotide according to claim 1, wherein
• the 3’-5’ phosphodiester linkage is between the 3’-oxygen of the first nucleoside monophosphate and the 5’-
oxygen of the second nucleoside monophosphate, and
• the 2’-5’ phosphodiester linkage is between the 5’-oxygen of the first nucleoside monophosphate and the 2’-
oxygen of the second nucleoside monophosphate.
3. The cyclic dinucleotide according to claims 1 or 2, wherein the fluorescent nucleoside monophosphate is a fluorescent
purine nucleoside monophosphate.
4. The cyclic dinucleotide according to claims 1 or 2, wherein the fluorescent nucleoside monophosphate is selected
from the group consisting of a 2-aminopurine nucleoside monophosphate (2-APMP), a 3-methyl-isoxanthopterin
nucleoside monophosphate (3-MIMP), a 6-methyl isoxanthopterin nucleoside monophosphate (6-MIMP), 4-amino-
6-methyl-8-(2-deoxy-beta-d-ribofuranosyl)-7(8H)-pteridone nucleoside monophosphate (6-MAPMP), a 4-amino-
2,6-dimethyl-8-(2’-deoxy-beta-d-ribofuranosyl)-7(8H)-pteridone nucleoside monophosphate (DMAPMP), a pyrrolo-
cytosine nuceloside monophosphate (pyrrolo-CMP), a 6-phenylpyrrolocytosine nucleoside monophosphate (PhpC-
MP), a (aminoethoxy)phenylpyrrolocytosine nucleoside monophosphate (moPhpCMP), a [bis-o-(aminoethoxy)phe-
nyl]pyrrolocytosine nucleoside monophosphate (boPhpCMP), a hydropyrimidopyrimidine nucleoside monophos-
phate (ChppMP), a pyrrolopyrimidopyrimidine nucleoside monophosphate (CpppMP), a pyrimidopyrimidoindole nu-
cleoside monophosphate (CppiMP), a benzopyridopyrimidine nucleoside monophosphate (BPPMP), a naphthopy-
ridopyrimidine nucleoside monophosphate (NPPMP), a methoxybenzodeazaadenine nucleoside monophosphate
(MDAMP), a methoxybenzodeazainosine nucleoside monophosphate (MDIMP), a naphthodeazaadenine nucleoside
monophosphate (NDAMP), a furan-modified pyrimidine nucleoside mohophosphate, a thieno[3,2]pyrimidine nucle-
oside monophosphate, a thieno[3,4]pyrimidine nucleoside monophosphate, a 5-methoxy-quinazoline-2,4-(1H,3H)
dione nucleoside monophosphate, a 5-methylpyrimidine-2-one nucleoside monophosphate, a 7-deazapurine nucl-
eoside monophosphate, a 5-alkyluridine nucleoside monophosphate, a benzoquinalozines nucleoside monophos-
phate, a triazoleadenosine nucleoside monophosphate, and a 1,N6-ethenoadenosine nucleoside monophosphate.
5. The cyclic dinucleotide according to claim 4, wherein the 2-APMP is the first nucleoside monophosphate.
6. The cyclic dinucleotide according to claim any one of claims 1 to 5, having the following formula:
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wherein
when R1 is bound to P through a single bond, R1 is independently selected from the group consisting of O, S,
BH3 and CH3;
when R1 is bound to P through a double bond, R1 is independently selected from the group consisting of O, S
and NH;
wherein at least one R1 bound to each P is O;
R2 is independently selected from the group consisting of H, OH, methyl, amino-, methoxy-, fluoro-, methoxye-
thyl-, -O-propargyl and O-propylamine; and
R3 is O.
7. The cyclic dinucleotide according to any one of claims 1 to 6 having the following formula:
or
8. A method of measuring cGAS activity, the method comprising:
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(i) providing an aqueous solution comprising cGAS, cGAS-activating nucleic acid, a first nucleoside triphosphate,
a second nucleoside triphosphate, and one or more divalent cation, wherein at least one of the first and second
nucleoside triphosphates is a fluorescent nucleoside triphosphate, and wherein one of the first and second
nucleoside triphosphates has a free 2’ hydroxyl group and the other one has a free 3’ hydroxyl group; and
(ii) measuring the change of the fluorescence signal of the aqueous solution over time.
9. A method of identifying a substance having an ability to modulate the activity of cyclic GMP-AMP synthase (cGAS),
the method comprising:
(i) providing an aqueous solution comprising cGAS, cGAS-activating nucleic acid, a first nucleoside triphosphate,
a second nucleoside triphosphate, and one or more divalent cation, wherein at least one of the first and second
nucleoside triphosphates is a fluorescent nucleoside triphosphate, and wherein one of the first and second
nucleoside triphosphates has a free 2’ hydroxyl group and the other one has a free 3’ hydroxyl group;
(ii) measuring the fluorescence signal of the aqueous solution;
(iii) repeating steps (i) and (ii), wherein upon said repetition the aqueous solution further comprises the substance,
and wherein the fluorescence signal is measured under identical or substantially identical conditions following
the provision of the respective aqueous solution; and
(iv) comparing the fluorescence signal measured in the presence of the substance with the fluorescence signal
measured in the absence of the substance;
wherein a measured fluorescence signal which is higher in the presence of the substance than in the absence of
the substance indicates that the substance is a cGAS antagonist, while a measured fluorescence signal which is
lower in the presence of the substance than in the absence of the substance indicates that the substance is a cGAS
agonist.
10. A method of preparing a cyclic dinucleotide according to any one of claims 1 to 7, the method comprising:
(i) providing an aqueous solution comprising cGAS, cGAS activating nucleic acid, a first nucleoside triphosphate,
a second nucleoside triphosphate, and one or more divalent cation, wherein at least one of the first and second
nucleoside triphosphates is a fluorescent nucleoside triphosphate, and wherein one of the first and second
nucleoside triphosphates has a free 2’ hydroxyl group and the other one has a free 3’ hydroxyl group, thereby
preparing the cyclic dinucleotide; and optionally
(ii) purifying the cyclic dinucleotide.
11. The method according to any one of claims 8 to 10, wherein the fluorescent nucleoside triphosphate is 2-aminopurine
nucleoside triphosphate (2-APTP).
12. A method of identifying a substance having an ability to bind to stimulator of interferon genes (STING), the method
comprising:
(i) providing an aqueous solution comprising a cyclic dinucleotide and STING, wherein the cyclic dinucleotide
comprises a 3’-5’ phosphodiester linkage and a 2’-5’ phosphodiester linkage between a first nucleoside mono-
phosphate and a second nucleoside monophosphate, wherein at least one of the first and second nucleoside
monophosphates is a fluorescent nucleoside monophosphate;
(ii) measuring the fluorescence signal of the aqueous solution;
(iii) repeating steps (i) and (ii), wherein upon said repetition the aqueous solution further comprises the substance,
and wherein the fluorescence is measured under identical or substantially identical conditions following the
provision of the respective aqueous solution; and
(iv) comparing the fluorescence signal measured in the presence of the substance with the fluorescence signal
measured in the absence of the substance;
wherein a measured fluorescence signal which is higher in the presence of the substance than in the absence of
the substance indicates that the substance has an ability to bind to STING.
13. A method of identifying a substance having an ability to modulate the activity of a 2’-5’ phosphodiesterase, the
method comprising
(i) providing an aqueous solution comprising a cyclic dinucleotide and a 2’-5’ phosphodiesterase, wherein the
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cyclic dinucleotide comprises a 3’-5’ phosphodiester linkage and a 2’-5’ phosphodiester linkage between a first
nucleoside monophosphate and a second nucleoside monophosphate, wherein at least one of the first and
second nucleoside monophosphates is a fluorescent nucleoside monophosphate;
(ii) measuring the fluorescence signal of the aqueous solution;
(iii) repeating steps (i) and (ii), wherein upon said repetition the aqueous solution further comprises the substance,
and wherein the fluorescence is measured under identical or substantially identical conditions following the
provision of the respective aqueous solution; and
(iv) comparing the fluorescence signal measured in the presence of the substance with the fluorescence signal
measured in the absence of the substance;
wherein a measured fluorescence signal which is higher in the presence of the substance than in the absence of
the substance indicates that the substance is a 2’-5’ phosphodiesterase agonist, while a measured fluorescence
signal which is lower in the presence of the substance compared to the absence of the substance indicates that the
substance is a 2’-5’ phosphodiesterase antagonist.
14. The method according to claim 12 or 13, wherein the 3’-5’ phosphodiester linkage of the cyclic dinucleotide is
between the 3’-oxygen of the first nucleoside monophosphate and the 5’-oxygen of the second nucleoside mono-
phosphate, and
wherein the 2’-5’ phosphodiester linkage of the cyclic dinucleotide is between the 5’-oxygen of the first nucleoside
monophosphate and the 2’-oxygen of the second nucleoside monophosphate.
15. The method according to any one of claims 12 to 14, wherein the fluorescent nucleoside monophosphate is a
fluorescent purine nucleoside monophosphate.
16. The method according to any one of claims 13 to 15, wherein the first nucleoside monophosphate is 2-aminopurine
nucleoside monophosphate (2-APMP).
17. The method according to any one of claims 12 to 16, having the following formula:
wherein
when R1 is bound to P through a single bond, R1 is independently selected from the group consisting of O, S,
BH3 and CH3;
when R1 is bound to P through a double bond, R1 is independently selected from the group consisting of O, S
and NH;
wherein at least one R1 bound to each P is O;
R2 is independently selected from the group consisting of H, OH, methyl, amino-, methoxy-, fluoro-, methoxye-
thyl-, -O-propargyl and O-propylamine; and
R3 is O.
18. The method according to any one of claims 12 to 17, wherein the cyclic dinucleotide has the following formula:
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or
19. Use of a fluorescent nucleoside triphosphate for measuring cGAS activity or for identifying a substance having an
ability to modulate cGAS activity.
20. Use of a cyclic dinucleotide according to any one of claims 1 to 7 for identifying a substance with the ability to bind
to STING.
21. Use of a cyclic dinucleotide according to any one of claims 1 to 7 for labeling cGAS or STING.
22. A complex comprising STING and a cyclic dinucleotide according to any one of claims 1-7.
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This publication describes the synthesis of a 2′3′-cGAMP analogue with modified phosphodiester 
linkages. 2′3′-cGAMP is a signalling molecule in the cGAS-STING pathway, which is an 
important component of the innate immune system. As this pathway was discovered to have a 
high potential for immunotherapy, a great interest in drug discovery evolved. Cyclic dinucleotides 
represent suitable STING agonists but possess major issues in membrane crossing due to the 
negative charge. The compound from this publication has modified uncharged linkages to 
increase membrane permeability. It consists of one amide and one triazole linkage. The synthesis 
includes a CuI-catalyzed click reaction for the triazole incorporation and a macrolactamization for 
cyclization. 
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A Click-Chemistry Linked 2’3’-cGAMP Analogue
Clemens Reto Dialer,[a] Samuele Stazzoni,[a] David Jan Drexler,[b] Felix Moritz Meller,[a]
Simon Veth,[a] Alexander Pichler,[a] Hidenori Okamura,[a] Gregor Witte,[b] Karl-Peter Hopfner,[b]
and Thomas Carell*[a]
Abstract: 2’3’-cGAMP is an uncanonical cyclic dinucleotide
where one A and one G base are connected via a 3’-5’ and a
unique 2’-5’ linkage. The molecule is produced by the cy-
clase cGAS in response to cytosolic DNA binding. cGAMP ac-
tivates STING and hence one of the most powerful pathways
of innate immunity. cGAMP analogues with uncharged link-
ages that feature better cellular penetrability are currently
highly desired. Here, the synthesis of a cGAMP analogue
with one amide and one triazole linkage is reported. The
molecule is best prepared via a first CuI-catalyzed click reac-
tion, which establishes the triazole, while the cyclization is
achieved by macrolactamization.
Introduction
Cyclic dinucleotides (CDNs) are important cellular messenger
molecules in a variety of organisms.[1] The compounds play a
crucial role in a wide range of biological processes, such as
signal transduction, control of biofilm formation or quorum
sensing.[2] Bacteria produce molecules in which two purine
bases are linked via two 3’-5’ phosphate linkages to give sym-
metrical cyclophane structures.[3] One main example for such a
molecule is the c-di-GMP compound 1 shown in Figure 1.[4, 5]
Biochemically, the compound is generated from the corre-
sponding nucleotide-5’-triphosphates. Recently, an unsymmet-
rical cyclic dipurine molecule (cGAMP, 2) was discovered in
mammalian cells.[6,7] In this molecule, the two purines are con-
nected via one 3’-5’ and another 2’-5’ linkage.[8] The dinucleo-
tide 2 is assembled by the cyclase cGAS (cyclic GMP-AMP syn-
thase). cGAS is a cytosolic DNA sensor and part of the innate
immune system.[9,10] 2’3’-cGAMP (2) binds to the transmem-
brane receptor STING (stimulator of interferon genes) with
nanomolar affinity (kd=4.59 nm),
[11] which activates the type 1
interferon (IFN) pathway.[12–14] Subsequent degradation of
cGAMP 2 occurs by the specific cleavage of the 2’-5’ phospho-
diester bond by ENPP1 highlighting the importance of this un-
usual connection.[15,16]
There is currently tremendous interest to develop synthetic
routes towards analogues of cGAMP 2 as potential agonists or
antagonists for cGAS and STING.[17–19] The bisphosphorothioate
cGAMP derivative 3,[20,21] for example, is already in clinical
trials.[22,23] Alternative targeting of STING with small molecules
is also known.[24–26] Particularly, compounds which lack the neg-
atively charged phosphodiester linkages are discussed as new
immune-regulatory pharmaceuticals.[27] While such derivatives
are available for symmetric 3’-5’ dinucleotides,[28–32] to the best
of our knowledge, uncharged cGAMP 2 analogues do not
exist.
Figure 1. Depiction of the symmetrical microbial c-di-GMP 1, the unsymmet-
rical STING activator cGAMP 2, as well as the bisphosphorothioate analogue
3, together with the molecule 4 targeted here. AL = amide linked, TL = tria-
zole linked.
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In this article, we describe the modular synthesis of a neutral
cGAMP analogue 4 that features one triazole and one amide
linkage. The triazole was generated by a CuI catalyzed alkyne-
azide click reaction (CuAAC) that was found to be particularly
efficient on nucleotides and oligonucleotides.[33–35]
Results and Discussion
We decided to start our synthetic study by synthesizing the
cGAMP analogue 4, in which the 5’-G-3’-A linkage is replaced
by a triazole unit and the 2’-G-5’-A linkage is substituted by an
amide bond.
Molecular modeling (Figure 2) showed that the analogue 4
is able to adopt a conformation that is similar to the natural
ligand bound to STING.[11,36]
In both cases, the macrocycle is thought to force the bases
into a shifted parallel orientation with the imidazole part of
the nucleobases pointing towards each other. This requires
anti-conformations of both glycosidic bonds. The preferred
conformation of compound 4 will be governed by aromatic
the triazole unit. For the conformation of the amide we
assume a syn-conformation due to the small ring size.
Analysis of potential synthetic accesses of 4 shows that it
can be generated by CuI catalyzed azide alkyne reaction plus a
preceding or following lactamization. We developed the syn-
thesis based on the A-half 5 and the corresponding G-half 6 as
depicted in Figure 3. For the synthesis of the A-half 5
(Scheme 1), we started with the commercially available 1,2-ace-
tonide protected xylofuranoside 7 (two steps from d-xylose),
which we converted in three steps into the 5-TBS-1,2-aceto-
nide protected 3-methylene xylofuranoside 8.
After stereoselective hydroboration (BH3·DMS, dr: 9:1) of 8
and Swern oxidation, we obtained the carbonyl compound 9,
which we subjected to a Corey–Fuchs alkinylation (CBr4, BuLi).
TBS deprotection and conversion of the primary hydroxyl
group into the azide gave the key intermediate 10. X-ray anal-
ysis of the structure of 10 proved the right configuration of
the compound (recrystallisation from isohexanes/ethyl ace-
tate).
Subsequent cleavage of the isopropylidene group and
acetyl protection of the hydroxyl groups provided compound
11, which was the sugar building block for the following glyco-
Figure 2. 3D representation showing the potential conformational similarity
between compound 4 (left) and natural 2’3’-cGAMP (right, conformation of
2 bound to STING, PDB: 4LOH).
Figure 3. Synthetic strategy towards compound 4. dpc=diphenylcarbamoyl,
iBu= isobutyryl.
Scheme 1. Synthesis of the A-half 5 in 14 steps. a) TBSCl, Py, RT, 2 h, 97%;
b) (COCl)2, DMSO, NEt3, DCM, @60 8C, 3 h; c) CH3PPh3Br, BuLi, THF, RT, 6 h,
81% (over two steps) ; d) BH3·DMS, THF, RT, 12 h then 30% H2O2, 2n NaOH,
RT, 2 h, 76%; e) (COCl)2, DMSO, NEt3, DCM, @60 8C, 3 h, 93%; f) CBr4, PPh3,
DCM, 0 8C, 1 h then RT, 12 h, 85%; g) BuLi, THF, @78 8C, 1.5 h, 83%; h) TBAF,
THF, RT, 4 h, 95%; i) TsCl, Py, RT, 18 h, 87%; j) NaN3, DMF, 80 8C, 3 h, 94%;
k) HOAc/Ac2O, H2SO4 (cat.), RT, 5 h, 78%; l) 6-N-benzoyladenine, BSA,
TMSOTf, DCE, 80 8C, 4 h, 61%; m) PMe3, H2O, THF, 40 8C, then RT, 12 h, 66%;
n) Boc2O, NEt3, DCM, RT, 16 h, 64%. Overall yield starting from 7: 6%.
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sylation step. The Vorbreggen reaction to 12 was found to be
most efficient under BSA/TMSOTf conditions with a benzoyl
protected A-heterocycle (a/b : 1:12). Finally, we converted the
azide via a Staudinger reduction (PMe3 worked better than
PPh3) into the corresponding amine, which was Boc-protected
afterwards to give the A-half 5.
The desired G-half (Scheme 2) was synthesized starting from
d-arabinose (13). 1-O-Benzyl and 3,4-acetonide protection
yielded alcohol 14.
Subsequent Swern oxidation and Wittig homologation pro-
vided the intermediate 15 (E/Z : 4 :1). Employing the acetonide
protective group as a stereoselective directing group, com-
pound 16 was almost exclusively obtained in R-configuration
via a Raney-Ni-assisted hydrogenation (dr: 20:1).
Under these reduction conditions the 1-O-benzyl group re-
mained unaffected—keeping the sugar in its pyranoside con-
figuration. Removal of the protective groups and treatment
with catalytic amounts of acid furnished at 4 8C selectively the
ribofuranoside 17. This was followed by an in situ lactoniza-
tion. The resulting alcohol 17 was tosylated and reacted with
NaN3 to give azide 19. The absolute configuration of the com-
pounds was again proven with a crystal structure of 18 (Sup-
porting Information).
We subsequently opened the lactone ring to compound 20
via hydroxide-mediated benzyl protection and converted it
into its 1-O-acetyl derivative 21. The glycosylation reaction to
the G-half 6 was performed by a so far unreported Vorbreggen
pattern in high b-selectivity (a/b : 1:14) and good yields (79%).
The assembly of nucleoside building blocks A (5) and G (6)
was initiated by a CuAAC reaction. This reaction went smooth-
ly and provided the dinucleotide 22 in fair yield of 80%
(Scheme 3). We noticed that click-approaches with the Boc-de-
protected amine compound A gave rise of several side prod-
ucts as monitored by thin-layer chromatography (TLC).
TFA treatment of dinucleotide 22 resulted in the cleavage of
both the Boc and the diphenylcarbamoyl (dpc) group. Besides,
this was the last step of the consecutive synthesis where purifi-
cation could be easily conducted by flash column chromatog-
raphy (DCM/MeOH, 10:1) due to the increasing polarity of the
following compounds. A palladium catalyzed hydrogenation
reaction deprotected the benzyl ester by leaving the secondary
3’’’’-O-benzyl ether intact. Final macrolactamization with HATU
furnished the cyclized dinucleotide 24.
Deprotection of the 3’’’’-O-benzyl ether under BCl3/DCM con-
ditions (@40 8C) proved to be the best option even though sol-
ubility in organic solvents decreased with ongoing removal of
protective groups. Final ammonolysis revealed our target mol-
ecule 4 in 2% overall yield starting from the G-pathway (19
steps) and 1% starting from the A-pathway (20 steps), respec-
tively. Compounds 24, 25 and 4 were purified by RP-HPLC and
subjected to further NMR-studies.
Conformational Analysis and Conclusion
We performed detailed NOESY experiments in order to deter-
mine the conformation preferences of target compound 4 in
Scheme 2. Synthesis of the G-half 6 in 13 steps. a) AcCl, BnOH, 60 8C, 5 h,
80%; b) Me2C(OMe)2, Me2CO, p-TsOH (cat.), 60 8C, 2 h, 84%; c) (COCl)2, DMSO,
NEt3, DCM, @60 8C, 3 h; d) Ph3PCHCO2Et, DCM, RT, 12 h, 86% (over two
steps) ; e) H2, Raney-Ni, EtOH, RT, 20 h, 90%; f) H2, Pd/C, EtOH/THF, 36 h, 88%;
g) 80% HOAc, RT, 24 h; h) H2SO4 (cat.), MeOH, 4 8C, 3d, 72% (over two
steps) ; i) TsCl, Py, RT, 18 h, 76%; j) NaN3, DMF, 80 8C, 3 h, 75%; k) BnBr, KOH,
THF, reflux, 5 h, 91%; l) HOAc/Ac2O, H2SO4 (cat.), RT, 3 h, 85%; m) 6-O-(diphe-
nylcarbamoyl)-2-N-isobutyrylguanine (Gdpc/iBu), BSA, TMSOTf, DCE, 80 8C, 2 h,
72%. Overall yield starting from 13 : 10%.
Scheme 3. The assembly towards cyclic dinucleotide 4 in 6 steps. a) CuSO4,
Na-ascorbate, THF/tBuOH/H2O, RT, 24 h, 80%; b) TFA/DCM (1:1), 0 8C, 1 h,
81%; c) H2, Pd/C, EtOH, 36 h; d) HATU, DIPEA, DMF (1 mm), RT, 24 h, 52%
(over two steps) ; e) BCl3, DCM, @40 8C, 3d; f) NH3, H2O/MeOH, 50 8C, 20 h,
48% (over two steps). Overall yield starting from 5 and 6 : 16%.
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respect to potential STING binding. The spectrum is shown in
Figure 4. The most informative NOE contacts together with a
depiction of the modelling results of 4 in solution is shown in
Figure 5. The NMR data confirm the overall structure with two
b-configured glycosidic bonds both in anti-conformation. Most
interesting, however, is the large shielding of proton H-2’’’’,
which shifts from d(compound 23)=4.12 ppm to d(compound
4)=@0.47 ppm. This dramatic shift indicates that the proton is
positioned just on top of the aromatic triazole ring.
According to this low chemical shift, it is assumed that H-
2’’’’ points directly to the triazole ring within the cyclized struc-
tures of compounds 24, 25 and 4. Unraveling of the conforma-
tion just based on the NOE data shows that compound 4 likely
adopts a more open conformation in solution ([D6]DMSO) com-
pared to cGAMP 2, with the two heterocycles being not paral-
lel to each other.
Potential binding of compound 4 to STING was tested in
vitro by nanoDSF assays and analysis of thermal unfolding of
the STING constructs hSTING L139 (human STING AA139-379)
and mSTING L138 (mouse STING AA138-378). We used the
physiological ligand 2’3’-cGAMP and a ligand with lower affini-
ty, 3’3’-cGAMP, as positive controls. As expected after the con-
formational analysis of compound 4, binding to hSTING or
mSTING could not be detected. This result was confirmed with
ITC experiments (see supporting information). Based on the
more open structure of the here prepared compound 4, we
believe that interaction studies with cGAS or ENPP1 may be
more promising. Investigations in this direction are on the way.
In summary, we report the first synthesis of a 2’3’-cGAMP an-
alogue which features uncharged bridges that should provide
membrane crossing properties. The synthetic strategy involved
first linking of the two nucleotides by a CuI-catalyzed click reac-
tion followed by a macrolactamization to close the cycle. The
synthesis of medium size ring structures is always difficult. We
believe that the here described strategy will open the access
to a variety of derivatives of 4. This allows systematic scanning
of the conformational space of the two nucleobases relative to
each other regarding the binding to the involved proteins
STING, cGAS and ENPP1.
Experimental Section
Unless otherwise specified, all reactions were magnetically stirred
under an N2 atmosphere. Reaction vessels were dried under high
vacuum at 550 8C prior to use. Dry solvents and reagents were pur-
chased from commercial suppliers, such as Sigma–Aldrich, Acros
Organics, Carbosynth, TCI Europe, ABCR, VWR, stored under
septum over molecular sieves and used as received. The reaction
progress and fractions during column chromatography were moni-
tored by TLC on silica gel 60-F254 plates purchased from Merck and
visualized by irradiation with UV-light (254 nm or 366 nm) and p-
anisaldehyde staining solution (p-anisaldehyde (3.7 mL), EtOH
(135 mL), conc. H2SO4 (5 mL), conc. AcOH (1.5 mL)). Purification was
performed using flash column chromatography with silica gel
(Merck, particle size 0.063–0.200 mm). The eluents used were de-
termined by TLC. Purification of the crude dinucleotides 24, 25
and 4 was operated by Waters 2695 reversed phase high per-
formance liquid chromatography (RP-HPLC) using Nucleosil col-
umns (250/4 mm, C18ec, particle size 3 mm for analysis or 250/
10 mm, C18ec, 5 mm for purification) from Machery–Nagel with a
buffer-free H2O/MeCN eluent system. Water was purified by a Milli-
Q Plus system from Merck Millipore. NMR-spectra were measured
on a Bruker Ascend 400 or Bruker ARX 600 at room temperature op-
erating at 400 MHz or 600 MHz for 1H-nuclei and at 101 MHz or
151 MHz for 13C-nuclei. The chemical shift (d) in the NMR-spectra is
Figure 4. NOESY spectrum of the final compound 4 in [D6]DMSO.
Figure 5. Selected NOE contacts of compound 4 (in [D6]DMSO) and model-
ling of the preferred conformation based on the NOE data.
Chem. Eur. J. 2019, 25, 2089 – 2095 www.chemeurj.org T 2019 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim2092
Full Paper
239
reported in parts per million (ppm) and referenced by the residual
solvent signal. Measurements were performed in CDCl3 and
[D6]DMSO. The spectra were referenced to the residual protons
and carbons of the solvent (CHCl3 : d(
1H)=7.26 ppm, d(13C)=
77.16 ppm; [D6]DMSO: d(
1H)=2.50 ppm, d(13C)=39.52 ppm).
Proton-spectra also show the integral intensity, the multiplicity, ab-
breviated with s (singlet), d (doublet), t (triplet), q (quartet), m
(multiplet) and the coupling constant (J in Hz). Assignments of the
signals were performed using 2D-NMR techniques such as homo-
nuclear correlation spectroscopy (COSY), nuclear Overhauser effect
spectroscopy (NOESY), heteronuclear single quantum coherence
(HSQC) and heteronuclear multiple bond coherence (HMBC). All
spectra were analyzed with the software MestReNOVA 10.0 from
Mestrelab Research, S. L. Atom labelling and nomenclature are not
in correspondence with IUPAC. High resolution mass spectra
(HRMS) were measured on a Thermo Finnigan MAT 95 (EI) and a
Thermo Finnigan LTQ FTICR (ESI). IR-measurements were performed
on a PerkinElmer Spectrum BX FT-IR spectrometer with a diamond-
ATR (Attenuated Total Reflection) setup. Uncorrected melting
points were determined with an automated Stanford Research Sys-
tems EZ-Melt apparatus (digital image processing technology).
Samples were loaded in open capillary tubes. X-ray crystallography
of single crystals was performed on an Oxford XCalibur diffractome-
ter and further analysis by the software Ortep-3.[37] The structure of
the synthesized analogue 4 in Figure 2 was obtained using the ge-
ometry optimization tool of the open source software Avogadro
and visualized by PyMol.
Nano differential scanning fluorimetry (nanoDSF)
Thermal melting experiments of STING constructs were performed
using a Tycho NT.6 instrument (NanoTemper Technologies). In brief,
the samples were heated up in a glass capillary and while heating,
the internal fluorescence at 330 nm and 350 nm was recorded.
Data analysis, data smoothing, and calculation of derivatives was
done using the internal evaluation features of the NT.6 instrument.
All measurements were repeated to confirm robustness of the
assay.
Isothermal titration calorimetry
ITC experiments were performed using a Malvern PEAQ-ITC system
with 20 mm protein in ITC-buffer (20 mm HEPES pH 7.5, 150 mm
NaCl) in the cell. The positive controls of cGAMP ligands (Biolog)
were titrated in a concentration of 200 mm into the cell by 19 injec-
tions of 2 mL, spaced 150 s apart, at 25 8C. Compound 4 was used
in a concentration of 291 mm for titration. The results were ana-
lyzed using the MicroCal PEAQ-ITC analysis software provided with
the instrument. All titrations were repeated to confirm robustness
of the assay.
Cloning, expression and purification
Human STING AA139-379 and mouse STING AA138-378 constructs
were cloned according to previous studies.[38] The plasmids were
used to transform E. coli Rosetta (DE3) protein expression strain
cells (Novagen). The cells were grown in 1 L of Turbo BrothQ
media (Molecular Dimensions) supplemented with Kanamycin
(50 mgL@1) and Chloramphenicol (34 mgL@1) at 37 8C to an OD600=
1.3 and expression was induced by adding IPTG to a final concen-
tration of 0.2 mm. Purification of the STING constructs has been
performed as described previously.[38]
4-[6’-Benzoylamino-9’-(2’’-O-acetyl-5’’-amino-3’’,5’’-dideoxy-
b-d-ribofuranosyl)-9’H-purin-3’’-yl]-1-{9’’’-[3’’’’-O-benzyl-
2’’’’,5’’’’-dideoxy-2’’’’-C-carboxymethyl-b-d-ribofuranosyl]-2’’’-
N-isobutyrylguanin-5’’’’-yl}-2’’’’,5’’-lactame-1,2,3-triazole (24)
To a stirred solution of dinucleotide 22 (2.12 g, 1.61 mmol,
1.00 equiv.) in dry DCM (40 mL) was added TFA (20 mL) at 0 8C
under N2. The mixture was stirred for 1 h at this temperature and
then concentrated in vacuo. The brown residue was purified by
flash-column chromatography (silica gel, DCM/MeOH, 100:2!
100:5!5:1) to give amino compound 23 as a colorless solid
(1.33 g, 1.30 mmol, 81%). mp 128 8C (decomp.). Rf=0.39 (DCM/
MeOH=5:1). ESI-HRMS calcd for [C51H52N14O10+H]
+ : 1021.4064,
found: 1021.4038. ESI-HRMS calcd for [C51H52N14O10@H]@ :
1019.3918, found: 1019.3918.
To a solution of amino compound 23 (1.08 g, 1.06 mmol,
1.00 equiv.) in EtOH (50 mL) was added Pd/C (10 wt.%, 0.30 g)
under nitrogen stream at RT. The reaction vessel was evacuated
and flushed with hydrogen three times. The mixture was stirred
under hydrogen atmosphere for 36 h and then filtered through
celite. The solution was concentrated to dryness under reduced
pressure. The residue was used in the next step without further
purification. ESI-HRMS calcd for [C44H46N14O10+H]
+ : 931.3594,
found: 931.3594. ESI-HRMS calcd for [C44H46N14O10@H]@ : 929.3448,
found: 929.3450.
Finally, the title compound was prepared according to a modified
procedure of Horne et al.[45] and Kinzie et al.[46] To a yellow solution
of the hydrogenated compound 23 and HATU (0.60 g, 1.58 mmol,
1.50 equiv.) in dry DMF (1000 mL) was added DIPEA (0.72 mL,
0.54 g, 4.21 mmol, 4.00 equiv.) at RT. The solution turned orange
and was stirred at RT for 24 h. After addition of MeOH (5 mL), vola-
tile materials were removed under reduced pressure and the crude
product was purified by flash-column chromatography (silica gel,
DCM/MeOH, 100:2!100:5!5:1) to yield cyclized compound 24 as
a colorless solid (506 mg, 0.55 mmol, 52% over 2 steps). An analyti-
cal sample was provided by RP-HPLC. mp 185 8C (decomp.). Rf=
0.57 (DCM/MeOH=5:1). Rt=16.1 min (RP-HPLC, 15% to 80%
MeCN gradient elution). IR (ATR): v˜=3220, 1682, 1608, 1454, 1403,
1222, 1049, 797, 708 cm@1. 1H NMR, COSY, NOESY (600 MHz,
[D6]DMSO): d=12.06 (s, 1H, NH), 11.59 (s, 1H, NH), 11.27 (s, 1H,
NH), 8.83 (s, 1H, H-2’), 8.68 (s, 1H, H-8’), 8.54 (s, 1H, H-5), 8.35 (s,
1H, H-8’’’), 8.08–8.03 (m, 2H, Bz-o-CH), 8.06–8.03 (s, 1H,
CH2CONHCH2), 7.68–7.63 (m, 1H, Bz-p-CH), 7.59–7.53 (m, 2H, Bz-m-
CH), 7.52–7.49 (m, 2H, Bn-o-CH), 7.44–7.40 (m, 2H, Bn-m-CH), 7.38–
7.34 (m, 1H, Bn-p-CH), 6.46 (d, 3J=1.1 Hz, 1H, H-1’’), 5.92 (dd, 3J=
5.9 Hz, 3J=1.1 Hz, 1H, H-2’’), 5.66 (d, 3J=10.2 Hz, 1H, H-1’’’’), 4.85
(dd, 2J=15.0 Hz, 3J=3.3 Hz, 1H, Ha-5’’’’), 4.80–4.77 (m, 1H, Hb-5’’’’),
4.80 (d, 2J=10.9 Hz, 1H, OCH2Ph), 4.76 (dd,
3J=10.6 Hz, 3J=6.0 Hz,
1H, H-3’’), 4.68 (d, 2J=10.9 Hz, 1H, OCH2Ph), 4.68–4.66 (m, 1H, H-
4’’’’), 4.57 (td, 3J=10.5 Hz, 3J=4.1 Hz, 1H, H-4‘‘), 4.15 (d, 3J=3.4 Hz,
1H, H3’’’’), 3.87–3.81 (m, 1H, Ha-5’’), 2.91–2.83 (m, 1H, Hb-5’’), 2.67
(hept, 3J=6.9 Hz, 1H, CH(CH3)2), 2.11 (s, 3H, OCOCH3), 2.04 (t,
3J=
12.0 Hz, 1H, CH2CONH), 1.76–1.70 (m, 1H, CH2CONH), 1.07, (d,
3J=
6.9 Hz, 3H, CH(CH3)2), 1.06, (d,
3J=6.9 Hz, 3H, CH(CH3)2),
@0.19@0.26 (m, 1H, H-2’’’’) ppm. 13C NMR, HSQC, HMBC (151 MHz,
[D6]DMSO): d=180.1 (iBu-CONH), 170.8 (CH2CONHCH2), 169.1
(OCOCH3), 165.7 (N-CO-Ph), 154.8 (C-2’’’), 151.8 (C-2’), 151.5 (C-4’),
150.7 (C-6’), 149.1 (C-6’’’), 148.30 (C-4’’’), 144.0 (C-8’), 142.8 (C-4),
138.2 (OCH2Ph-C-1), 137.9 (C-8’’’), 133.3 (Bz-C-CO-N), 132.5 (Bz-p-
CH), 128.53 (Bz-o-CH), 128.49 (Bz-m-CH), 128.47 (Bn-m-CH), 128.3
(Bn-o-CH), 127.9 (Bn-p-CH), 126.8 (C-5), 126.2 (C-5’), 119.7 (C-5’’’),
89.3 (C-1’’), 83.3 (C-1’’’’), 81.2 (H-4’’), 79.9 (H-3’’’’), 79.8 (H-4’’’’), 77.5
(C-2’’), 72.0 (OCH2Ph), 53.0 (C-5’’’’), 46.9 (C-2’’’’), 44.5 (C-3’’), 42.4 (C-
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5’’), 34.7 (CH(CH3)2), 29.7 (CH2CONH), 20.7 (OCOCH3), 18.81
(CH(CH3)2), 18.79 (CH(CH3)2) ppm. ESI-HRMS calcd for [C44H44N14O9+
H]+ : 913.3489, found: 913.3495. ESI-HRMS calcd for
[C44H44N14O9@H]@ : 911.3343, found: 911.3348.
4-[6’-Benzoylamino-9’-(2’’-O-acetyl-5’’-amino-3’’,5’’-dideoxy-
b-d-ribofuranosyl)-9’H-purin-3’’-yl]-1-{9’’’-[2’’’’,5’’’’-dideoxy-
2’’’’-C-carboxymethyl-b-d-ribofuranosyl]-2’’’-N-isobutyrylgua-
nin-5’’’’-yl}-2’’’’,5’’-lactame-1,2,3-triazole (25)
To a solution of dinucleotide 24 (340 mg, 0.37 mmol, 1.00 equiv.) in
dry DCM (300 mL) was added BCl3 (5.96 mL, 5.96 mmol, 1m in
DCM, 16.0 equiv.) at @40 8C. The mixture was stirred for 3 days at
this temperature, quenched by addition of MeOH (5 mL) and ex-
tracted with saturated sodium bicarbonate (20 mL) and DCM (4V
50 mL). The combined organic layers were dried over anhydrous
MgSO4, filtered and concentrated in vacuo. The compound was
used in the next step without further purification. An analytical
sample was prepared by RP-HPLC to yield a colorless solid. mp
258 8C (decomp.). Rt=12.5 min (RP-HPLC, 15% to 80% MeCN gra-
dient elution). IR (ATR): v˜=3234, 1756, 1677, 1613, 1460, 1403,
1220, 1047, 796, 707 cm@1. 1H NMR, COSY, NOESY (600 MHz,
[D6]DMSO): d=12.07 (s, 1H, NH), 11.69 (s, 1H, NH), 11.26 (s, 1H,
NH), 8.82 (s, 1H, H-2’), 8.66 (s, 1H, H-8’), 8.43 (s, 1H, H-5), 8.33 (s,
1H, H-8’’’), 8.08–8.03 (m, 1H, Bz-o-CH), 7.93–7.87 (m, 1H,
CH2CONHCH2), 7.68–7.63 (m, 1H, Bz-p-CH), 7.59–7.53 (m, 2H, Bz-m-
CH), 6.42 (d, 3J=1.1 Hz, 1H, H-1’’), 5.88 (dd, 3J=5.9 Hz, 3J=1.1 Hz,
1H, H-2’’), 5.76 (d, J=10.2 Hz, 1H, H-1’’’’), 5.68 (d, J=3.4 Hz, 1H,
OH-3’’’’), 4.78 (dd, 2J=15.0 Hz, 3J=3.3 Hz, 1H, Ha-5’’’’), 4.71 (dd,
3J=
10.6 Hz, 3J=6.0 Hz, 1H, H-3’’), 4.68 (dd, 2J=15.0 Hz, 3J=1.8 Hz, 1H,
Hb-5’’’’), 4.50 (td,
3J=10.4 Hz, 3J=3.9 Hz, 1H, H-4’’), 4.32–4.29 (m,
1H, H-4’’’’), 4.17–4.13 (m, 1H, H3’’’’), 3.82–3.74 (m, 1H, Ha-5’’), 2.89–
2.79 (m, 1H, Hb-5’’), 2.73 (hept,
3J=6.8 Hz, 1H, CH(CH3)2), 2.09 (s,
3H, OCOCH3), 2.02 (t,
3J=12.0 Hz, 1H, CH2CONH), 1.67–1.60 (m,
1H, CH2CONH), 1.11, (d,
3J=6.8 Hz, 3H, CH(CH3)2), 1.10, (d,
3J=
6.8 Hz, 3H, CH(CH3)2), @0.39@0.49 (m, 1H, H-2’’’’) ppm. 13C NMR,
HSQC, HMBC (151 MHz, [D6]DMSO): d=180.1 (iBu-CONH), 171.0
(CH2CONHCH2), 169.2 (OCOCH3), 165.7 (N-CO-Ph), 154.8 (C-2’’’’),
151.8 (C-2’), 151.5 (C-4’), 150.7 (C-6’), 149.1 (C-6’’’), 148.30 (C-4’’’),
144.0 (C-8’), 142.6 (C-4), 138.2 (C-8’’’), 133.3 (Bz-C-CO-N), 132.5 (Bz-
p-CH), 128.52 (Bz-o-CH), 128.49 (Bz-m-CH), 126.6 (C-5), 126.2 (C-5’),
119.7 (C-5’’’), 89.3 (C-1’’), 83.2 (C-1’’’’),83.0 (C-4’’’’), 81.0 (C-4’’), 77.4
(C-2’’), 70.6 (C-3’’’’), 52.5 (C-5’’’’), 47.1 (C-2’’’’), 44.5 (C-3’’), 42.5 (C-
5’’), 34.8 (CH(CH3)2), 29.2 (CH2CONH), 20.6 (OCOCH3), 18.85
(CH(CH3)2), 18.83 (CH(CH3)2) ppm. ESI-HRMS calcd for [C37H38N14O9+
H]+ : 823.3019, found: 823.3015. ESI-HRMS calcd for
[C37H38N14O9@H]@ : 821.2873, found: 821.2873.
4-[6’-Amino-9’-(5’’-amino-3’’,5’’-dideoxy-b-d-ribofuranosyl)-
9’H-purin-3’’-yl]-1-{9’’’-[2’’’’,5’’’’-dideoxy-2’’’’-C-carboxymethyl-
b-d-ribofuranosyl]-guanin-5’’’’-yl}-2’’’’,5’’-lactame-1,2,3-tria-
zole (4)
The crude compound 25 was dissolved in MeOH (15 mL) and
aqueous ammonia (25%, 15 mL) in a sealed vessel at RT. The mix-
ture was stirred at 50 8C for 20 h. Volatile components were re-
moved under reduced pressure. The residue was purified by prepa-
rative RP-HPLC to provide the final compound 4 as a colorless
solid (109 mg, 0.18 mmol, 48% over 2 steps). mp 270 8C (decomp.).
Rt=7.8 min (RP-HPLC, 15% to 80% MeCN gradient elution). IR
(ATR): v˜=3338, 1639, 1599, 1477, 1419, 1209, 1089, 1047, 1005,
730 cm@1. 1H NMR, COSY, NOESY (600 MHz, [D6]DMSO): d=10.60 (s,
1H, Guanine-NH), 8.34 (s, 1H, H-8’), 8.19 (s, 1H, H-2’), 8.12 (s, 1H,
H-5), 8.07 (s, 1H, H-8’’’), 7.73–7.69 (m, 1H, CH2CONHCH2), 7.32 (s,
2H, A-NH2), 6.50 (s, 2H, G-NH2), 6.07 (d,
3J=1.1 Hz, 1H, H-1’’), 5.97
(d, 3J=5.1 Hz, 1H, H-2’’), 5.64 (d, J=10.3 Hz, 1H, H-1’’’’), 5.58 (d, J=
3.6 Hz, 1H, OH-3’’’’), 4.77 (dd, 2J=14.9 Hz, 3J=3.1 Hz, 1H, Ha-5’’’’),
4.65–4.62 (m, 1H, OH-2’’), 4.61 (dd, 2J=14.9 Hz, 3J=1.5 Hz, 1H, Hb-
5’’’’), 4.43 (td, 3J=10.5 Hz, 3J=4.1 Hz, 1H, H-4’’), 4.23–4.21 (m, 1H,
H-4’’’’), 4.23 (dd, 3J=10.6 Hz, 3J=5.6 Hz, 1H, H-3’’), 4.10–4.07 (m,
1H, H-3’’’’), 3.77–3.71 (m, 1H, Ha-5’’), 2.84–2.77 (m, 1H, Hb-5’’), 1.97
(m, 1H, CH2CONH), 1.56 (dd,
2J=12.0 Hz, 3J=2.2 Hz,1H, CH2CONH),
@0.44@0.41 (m, 1H, H-2’’’’) ppm. 13C NMR, HSQC, HMBC (151 MHz,
[D6]DMSO): d=170.9 (CH2CONHCH2), 156.8 (C-2’’’), 156.2 (C-6’),
153.8 (C-6’’’), 152.6 (C-2‘), 151.7 (C-4’’’), 148.7 (C-4’), 143.7 (C-4),
139.81 (C-8’), 136.0 (C-8’’’), 126.8 (C-5), 119.5 (C-5’), 116.1 (C-5’’’),
91.9 (C-1’’), 83.7 (C-4’’’’), 82.7 (C-1’’’’), 80.8 (C-4’’), 75.9 (C-2’’), 70.6
(C-3’’’’), 52.2 (C-5’’’’), 46.7 (C-2’’’’), 45.9 (C-3’’), 42.7 (C-5’’), 29.3
(CH2CONH) ppm. ESI-HRMS calcd for [C24H26N14O6+H]
+ : 607.2233,
found: 607.2231. ESI-HRMS calcd for [C24H26N14O6@H]@ : 605.2087,
found: 605.2090.
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1. Experimental procedures 
 
 
 
Synthesis of A-half 5. a) TBSCl, Py, RT, 2h, 97%; b) (COCl)2, DMSO, NEt3, DCM, -60°C, 3h; c) CH3PPh3Br, BuLi, 
THF, RT, 6h, 81% (over two steps); d) BH3·DMS, THF, RT, 12h then 30% H2O2, 2N NaOH, RT, 2h, 76%; e) (COCl)2, 
DMSO, NEt3, DCM, -60°C, 3h, 93%; f) CBr4, PPh3, DCM, 0°C, 1h then RT, 12h, 85%; g) BuLi, THF, -78°C, 1.5h, 
83%; h) TBAF, THF, RT, 4h, 95%; i) TsCl, Py, RT, 18h, 87%; j) NaN3, DMF, 80°C, 3h, 94%; k) HOAc/Ac2O, H2SO4 
(cat.), RT, 5h, 78%; l) 6-N-Benzoyladenine, BSA, TMSOTf, DCE, 80°C, 4h, 61%; m) PMe3, H2O, THF, 40 °C, then 
RT, 12h, 66%; n) Boc2O, NEt3, DCM, RT, 16h, 64%. Overall yield starting from 7: 6%. 
 
 
5-O-(tert-Butyldimethylsilyl)-3,3-deoxymethylene-1,2-O-isopropylidene-α-D-xylofuranose (8): 
The title compound was prepared according to a modified procedure of Betkekar et al.[1] To a solution of oxalyl 
chloride (12.3 mL, 17.9 g, 141 mmol, 1.10 eq.) in dry DCM (450 mL) was slowly added DMSO (20.0 mL, 22.0 g, 
282 mmol, 2.20 eq.) under N2 at -78 °C. The temperature was maintained below -60 °C and evolving gas was 
purged. After the mixture was stirred for 1 h at -60 °C, a solution of 5-O-(tert-butyldimethylsilyl)-1,2-O-
isopropylidene-α-D-xylofuranose[2] (39.0 g, 128 mmol, 1.00 eq.) in dry DCM (125 mL) was added to the reaction 
mixture over 5 min and stirred for 2 h. Triethylamine (53.6 mL, 38.9 g, 384 mmol, 3.00 eq.) was added and the 
suspension was stirred for a further hour at -60 °C. The reaction mixture was warmed to RT, quenched with 
saturated aqueous NaHCO3 (200 mL) and extracted with DCM (3x200 mL). The combined organic layers were 
dried over anhydrous MgSO4, filtered and concentrated in vacuo to obtain 5-O-(tert-butyldimethylsilyl)-3-oxo-1,2-
O-isopropylidene-α-D-xylofuranose[3] as a waxy yellow solid. The compound was used in the next step without 
further purification. 
Methyl triphenyl phosphonium bromide (86.2 g, 241 mmol, 2.00 eq.) was suspended in THF (360 mL) and cooled 
to -78 °C under N2. n-Butyl lithium (96.5 mL, 241 mmol, 2.5M in hexanes, 2.00 eq.) was carefully added dropwise 
and the resulting red suspension (LiBr precipitates) was stirred for 1 h at 0°C. Subsequent addition of a solution of 
the crude ketone (36.5 g, 121 mmol, 1.00 eq.) in THF (60 mL) over 10 min gave a slurry which was stirred at RT 
for 6h. The reaction mixture was quenched with saturated aqueous NH4Cl (50 mL) and then extracted with ethyl 
acetate (3 x 200 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated 
in vacuo. The crude product was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 9:1→4:1) 
to yield compound 8 as a colorless syrup (31.1 g, 104 mmol, 81% over 2 steps). Rf = 0.68 (silica, isohexanes/EtOAc 
= 4:1). IR (ATR): ṽ = 2930, 1463, 1372, 1252, 1071, 1018, 775 cm-1. 1H NMR, COSY (400 MHz, CDCl3): δ = 5.85 
(d, 3J = 4.1 Hz, 1H, H-1), 5.42 (dd, 4J = 2.2 Hz, 4J = 1.1 Hz, 1H, C=CHa), 5.26 (m, 1H, C=CHb), 4.88 (dd, 3J = 4.1 
Hz, 4J = 1.4 Hz, 1H, H-2), 4.75 (ddd, 3J = 4.2 Hz, 3J = 3.8 Hz, 4J = 2.2 Hz, 1H, H-4), 3.75 (dd, 2J = 10.6 Hz, 3J = 4.2 
Hz, 1H, Ha-5), 3.67 (dd, 2J = 10.6 Hz, 3J = 3.8 Hz, 1H, Hb-5), 1.49 (s, 3H, C(CH3)2), 1.38 (s, 3H, C(CH3)2), 0.87 (s, 
9H, SiC(CH3)3), 0.043 (s, 3H, Si(CH3)2), 0.040 (s, 3H, Si(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): 
δ = 147.7 (C-3),112.6 (C(CH3)2), 111.7 (C=CH2), 105.1 (C-1), 82.1 (C-2), 81.0 (C-4), 65.9 (C-5), 27.7 (C(CH3)2), 
27.5 (C(CH3)2), 26.0 (SiC(CH3)3), 18.4 (SiC(CH3)3), -5.24 (Si(CH3)2), -5.31 (Si(CH3)2) ppm. ESI-HRMS calcd. for 
[C15H28O4Si + NH4]+ 318.2095, found: 318.2098. 
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5-O-(tert-Butyldimethylsilyl)-3-deoxy-3-(hydroxymethyl)-1,2-O-isopropylidene-α-D-ribofuranose (9a): 
The title compound was prepared according to a modified procedure of Betkekar et al. [1] To a solution of vinyl 
compound 8 (29.5 g, 98.2 mmol, 1.00 eq.) in dry THF (300 mL) was added borane dimethyl sulfide complex 
(73.6 mL, 147 mmol, 2M in THF, 1.50 eq.) at 0 °C. After the solution was stirred for 12 h at RT, aqueous 2 N NaOH 
(225 mL) was carefully added under strong gas evolution at 0 °C to give a turbid suspension. The reaction mixture 
was treated slowly with 30% aqueous hydrogen peroxide (98.0 mL) at the same temperature to avoid heat 
development. The suspension was stirred for further 2 h at RT, quenched with saturated aqueous Na2S2O3 solution 
(200 mL) at 0 °C and finally extracted with EtOAc (3 x 300 mL). The combined organic layers were washed with 
brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude product was 
purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 4:1→2:1→1:1) to afford alcohol 9a (23.8 g, 
74.7 mmol, 76%) as a colorless oil. Rf = 0.76 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 3456, 2931, 1463, 1381, 
1253, 1105, 1019, 778 cm-1. 1H NMR, COSY (400 MHz, CDCl3): δ = 5.79 (d, 3J = 3.7 Hz, 1H, H-1), 4.75 (dd, 3J = 
4.9 Hz, 3J = 3.7 Hz, 1H, H-2), 4.08 (ddd, 3J = 9.9 Hz, 3J = 6.6 Hz, 3J = 3.5 Hz, 1H, H-4), 3.88 (dd, 2J = 10.6 Hz, 3J = 
3.5 Hz, 1H, Ha-5), 3.86 (d, 3J = 6.2 Hz, 2H, CH2OH), 3.66 (dd, 2J = 10.6 Hz, 3J = 6.6 Hz, 1H, Hb-5), 3.06 (s, 1H, 
OH), 2.19-2.09 (m, 1H, H-3), 1.52 (s, 3H, C(CH3)2), 1.32 (s, 3H, C(CH3)2), 0.90 (s, 9H, SiC(CH3)3), 0.091 (s, 3H, 
Si(CH3)2), 0.087 (s, 3H, Si(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 112.2 (C(CH3)2), 105.0 (C-
1), 82.6 (C-2), 80.7 (C-4), 64.0 (C-5), 59.6 (CH2OH), 50.0 (C-3), 26.9 (C(CH3)2), 26.4 (C(CH3)2), 26.0 (SiC(CH3)3), 
18.4 (SiC(CH3)3), -5.32 (Si(CH3)2) ppm. ESI-HRMS calcd. for [C15H30O5Si + NH4]+: 336.2201,  found: 336.2204. 
 
5-O-(tert-Butyldimethylsilyl)-3-deoxy-3-formyl-1,2-O-isopropylidene-α-D-ribofuranose (9): 
The title compound was prepared according to a modified procedure of Parr et al.[3] To a solution of oxalyl chloride 
(6.91 mL, 10.1 g, 79.6 mmol, 1.10 eq.) in dry DCM (380 mL) was slowly added DMSO (11.3 mL, 12.4 g, 159 mmol, 
2.20 eq.) under N2 at -78 °C. The temperature was maintained below -60 °C and evolving gas was purged. After 
the mixture was stirred for 1 h at -60 °C, a solution of alcohol 9a (23.0 g, 72.2 mmol, 1.00 eq.) in dry DCM (70 mL) 
was added to the reaction mixture over 5 min and stirred for 2 h. Triethylamine (30.2 mL, 21.9 g, 217 mmol, 
3.00 eq.) was added and the suspension was stirred for a further hour at -60 °C. The reaction mixture was warmed 
to RT, quenched with saturated aqueous NaHCO3 (150 mL) and extracted with DCM (3x150 mL). The combined 
organic layers were dried over anhydrous MgSO4, filtered and volatile components removed under reduced 
pressure. Purification of the crude product was performed by flash-column chromatography (silica gel, 
isohexanes/EtOAc, 9:1→4:1) to give aldehyde 9 (21.2 g 67.0 mmol, 93%) as a colorless oil. It was also possible to 
use the crude product in the next step without further purification. Rf = 0.61 (isohexanes/EtOAc = 4:1). IR (ATR): ṽ 
= 2931, 1726, 1472, 1382, 1253, 1100, 1019, 778 cm-1. 1H NMR, COSY (400 MHz, CDCl3): δ = 9.78 (d, 4J = 1.2 
Hz, 1H, CHO), 5.87 (d, 3J = 3.7 Hz, 1H, H-1), 5.03 (dd, 3J = 5.2 Hz, 3J = 3.7 Hz, 1H, H-2), 4.55 (ddd, 3J = 9.5 Hz, 3J 
= 3.6 Hz, 3J = 3.2 Hz, 1H, H-4), 3.86 (dd, 2J = 11.3 Hz, 3J = 3.6 Hz, 1H, Ha-5), 3.78 (dd, 2J = 11.3 Hz, 3J = 3.2 Hz, 
1H, Hb-5), 3.02 (dd, 3J = 9.5 Hz, 3J = 5.2 Hz, 4J = 1.2 Hz, 1H, H-3), 1.48 (s, 3H, C(CH3)2), 1.33 (s, 3H, C(CH3)2), 
0.86 (s, 9H, SiC(CH3)3), 0.04 (s, 3H, Si(CH3)2), 0.03 (s, 3H, Si(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, 
CDCl3): δ = 198.0 (CHO), 113.1 (C(CH3)2), 105.7 (C-1), 80.8 (C-2), 78.2 (C-4), 62.8 (C-5), 56.6 (C-3), 26.8 
(C(CH3)2), 26.6 (C(CH3)2), 26.0 (SiC(CH3)3), 18.5 (SiC(CH3)3), 5.31 (Si(CH3)2), -5.31 (Si(CH3)2) ppm. EI-HRMS 
calcd. for [C15H28O5Si - CH3]+: 301.1466, found: 301.1475. 
 
5-O-(tert-Butyldimethylsilyl)-3-deoxy-3-(2,2-dibromovinyl)-1,2-O-isopropylidene-α-D-ribofuranose (10a): 
The title compound was prepared according to a modified procedure of Betkekar et al. [1] A solution of 
tetrabromomethane (43.0 g, 130 mmol, 2.00 eq.) in DCM (350 mL) was mixed with triphenylphosphine (68.0, 
259 mmol, 4.00 eq.) under N2 at 0 °C and stirred for 1 h at this temperature. The resulting orange solution was 
treated with a solution of aldehyde 9 (20.5 g, 64.8 mmol, 1.00 eq.) in DCM (120 mL). The dark suspension was 
stirred at RT for 12 h. After removal of volatile materials, the crude product was purified by flash-column 
chromatography (silica gel, isohexanes/EtOAc, 9:1→4:1) to provide dibromo compound 10a (26.1 g, 55.3 mmol, 
85%) as a slightly yellow oil. Rf = 0.83 (isohexanes/EtOAc = 4:1). IR (ATR): ṽ = 2929, 1471, 1382, 1252, 1097, 
1020, 777 cm-1. 1H NMR, COSY (400 MHz, CDCl3): δ = 6.49 (d, 3J = 9.4 Hz, 1H, Br2CCH), 5.82 (d, 3J = 3.5 Hz, 1H, 
H-1), 4.68 (dd, 3J = 4.5 Hz, 3J = 3.5 Hz, 1H, H-2), 4.03 (ddd, 3J = 9.9 Hz, 3J = 3.6 Hz, 3J = 3.4 Hz, 1H, H-4), 3.81 
(dd, 2J = 11.5 Hz, 3J = 3.4 Hz, 1H, Ha-5), 3.66 (dd, 2J = 11.5 Hz, 3J = 3.6 Hz, 1H, Hb-5), 3.00 (td, 3J = 9.9 Hz, 3J = 
4.5 Hz, 1H, H-3), 1.53 (s, 3H, C(CH3)2), 1.32 (s, 3H, C(CH3)2), 0.89 (s, 9H, SiC(CH3)3), 0.06 (s, 6H, Si(CH3)2) ppm. 
13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 133.2 (Br2CCH), 112.2 (C(CH3)2), 105.2 (C-1), 91.8 (Br2CCH), 81.7 
(C-2), 80.9 (C-4), 62.3 (C-5), 49.2 (C-3), 26.9 (C(CH3)2), 26.4 (C(CH3)2), 26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), 5.16 
(Si(CH3)2), -5.22 (Si(CH3)2) ppm. EI-HRMS calcd. for [C16H28 Br2O4Si - CH3]+: 454.9884, found: 454.9882 
 
5-O-(tert-Butyldimethylsilyl)-3-deoxy-3-ethynyl-1,2-O-isopropylidene-α-D-ribofuranose (10b): 
The title compound was prepared according to a modified procedure of Betkekar et al.[1] Dibromo compound 10a 
(25.0 g, 52.9 mmol, 1.00 eq.) was dissolved in dry THF (270 mL) and cooled to -78 °C under N2. n-Butyl lithium 
(48.7 mL, 122 mmol, 2.5M in hexanes, 2.30 eq.) was added dropwise over a period of 10 min until a red solution 
was formed. After stirring for 1.5 h at this temperature, the reaction mixture was quenched with saturated aqueous 
NH4Cl (100 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were dried over anhydrous 
MgSO4, filtered and concentrated in vacuo. Purification of the residue was conducted by flash-column 
chromatography (silica gel, isohexane/EtOAc, 9:1→4:1) to afford ethynyl compound 10b (13.7 g 43.8 mmol, 83%) 
as a yellowish oil. Rf = 0.60 (isohexanes/EtOAc, 4:1). IR (ATR): ṽ = 3279, 2930, 1472, 1373, 1252, 1215, 1110, 
1017, 815, 777 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 5.81 (d, 3J = 3.6 Hz, 1H, H-1), 4.72 (dd, 3J = 4.1 Hz, 
3J = 3.6 Hz, 1H, H-2), 4.11 (ddd, 3J = 10.1 Hz, 3J = 2.9 Hz, 3J = 2.0 Hz, 1H, H-4), 3.97 (dd, 2J = 12.0, 3J = 2.0 Hz, 
1H, Ha-5), 3.79 (dd, 2J = 12.0, 3J = 2.9 Hz, 1H, Hb-5), 2.97 (ddd, 3J = 10.1 Hz, 3J = 4.1 Hz, 4J = 2.6 Hz, 1H, H-3), 
2.21 (d, 4J = 2.6 Hz, 1H, CCH), 1.57 (s, 3H, C(CH3)2), 1.36 (s, 3H, C(CH3)2), 0.89 (s, 9H, SiC(CH3)3), 0.08 (s, 3H, 
Si(CH3)2), 0.07 (s, 3H, Si(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 112.3 (C(CH3)2), 105.1 (C-
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1), 81.9 (C-4), 81.2 (C-2), 78.2 (CCH), 72.3 (CCH) , 61.1 (C-5), 36.3 (C-3), 26.8 (C(CH3)2), 26.5 (C(CH3)2), 26.1 
(SiC(CH3)3), 18.6 (SiC(CH3)3), -5.1 (Si(CH3)2), -5.2 (Si(CH3)2) ppm. ESI-HRMS calcd. for [C16H28O4Si + NH4]+: 
330.2095, found: 330.2098. 
 
3-Deoxy-3-ethynyl-1,2-O-isopropylidene-α-D-ribofuranose (10c): The title compound was prepared according 
to a modified procedure of Betkekar et al.[1] To a yellow solution of ethynyl compound 10b (13.3 g, 42.6 mmol, 
1.00 eq.) in THF (200 mL) was added TBAF (55.3 mL, 55.3 mmol, 1M in THF, 1.30 eq.) at RT. The resulting dark 
solution was stirred for 4 h at this temperature. The reaction mixture was quenched with silica and the solvent was 
concentrated under reduced pressure. The crude product was purified by flash-column chromatography (silica gel, 
isohexanes/EtOAc, 2:1→1:1→2:3) to yield alcohol 10c (8.03 g, 40.5 mmol, 95%) as colorless crystals. M.p. = 43 – 
45 °C. Rf = 0.38 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 3456, 3279, 2936, 1375, 1249, 1215, 1105, 1007, 871 
cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 5.83 (d, 3J = 3.5 Hz, 1H, H-1), 4.75 (dd, 3J = 4.1 Hz, 3J = 3.5 Hz, 1H, 
H-2), 4.17 (ddd, 3J = 10.3 Hz, 3J = 3.2 Hz, 3J = 3.0 Hz, 1H, H-4), (4.00 (dd, 2J = 12.2 Hz, 3J = 3.2 Hz, 1H, Ha-5), 
3.71 (ddd, 2J = 12.2 Hz, 3J = 8.8 Hz, 3J = 3.0 Hz, 1H, Hb-5), 2.96 (ddd, 3J = 10.3 Hz, 3J = 4.1 Hz, 4J = 2.5 Hz, 1H, 
H-3), 2.23 (d, 4J = 2.5 Hz, 1H, CCH), 1.84 (dd, 3J = 8.8 Hz, 4.2 Hz, 1H, OH), 1.58 (s, 3H, C(CH3)2), 1.37 (s, 3H, 
C(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 112.7 (C(CH3)2), 105.1 (C-1), 81.4 (C-4), 81.3 (C-
2), 77.6 (CCH), 72.6 (CCH), 60.6 (C-5), 36.3 (C-3), 26.7 (C(CH3)2), 26.5 (C(CH3)2) ppm. EI-HRMS calcd. for 
[C10H14O4 - CH3]+: 183.0652, found: 183.0652. 
 
3-Deoxy-3-ethynyl-1,2-O-isopropylidene-5-O-tosyl-α-D-ribofuranose (10d): p-Toluenesulfonyl chloride (15.5 g, 
56.8 mmol, 1.50 eq.) was dissolved in dry pyridine (50.0 mL) and added to a solution of alcohol 10c (7.5 g 
37.8 mmol, 1.00 eq.) in pyridine (150 mL) at 0 °C. The reaction mixture was stirred for 18 h at RT and finally 
quenched with MeOH (10 mL). After removal of volatile components, purification of the residue by flash-column 
chromatography (silica gel isohexanes/EtOAc, 2:1→1:1) gave tosyl compound 10d (11.7 g, 33.2 mmol, 87%) as 
colorless crystals. Crystallization from isohexanes/EtOAc (vapor diffusion) provided suitable single crystals for X-
ray characterization. M.p. = 113 – 114 °C. Rf = 0.73 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 3296, 2990, 1598, 
1450, 1360, 1176, 1097, 958, 813 665 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 7.80 (d, 3J = 8.2 Hz, 2H, aryl-
CH-CSO3), 7.34 (d, 3J = 8.2 Hz, 2H, aryl-CH-CCH3), 5.72 (d, 3J = 3.5 Hz, 1H, H-1), 4.68 (dd, 3J = 4.0 Hz, 3J = 3.5 
Hz, 1H, H-2),, 4.40 – 4.31 (m, 1H, Ha-5), 4.22 – 4.14 (m, 2H, H-4, Hb-5), 2.84 (ddd, 3J = 9.7 Hz, 3J = 4.0 Hz, 4J = 
2.4 Hz, 1H, H-3), 2.44 (s, 3H, aryl-CH3), 2.21 (d, 4J = 2.4 Hz, 1H, CCH), 1.52 (s, 3H, C(CH3)2), 1.34 (s, 3H, C(CH3)2) 
ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 145.1 (aryl-C-SO3), 132.7 (aryl-C-CH3), 130.0 (aryl-CH-
CCH3), 128.2 (aryl-CH-CSO3), 112.8 (C(CH3)2), 105.0 (C-1), 80.7 (C-2), 78.5 (C-4), 76.5 (CCH), 73.3 (CCH), 67.4 
(C-5), 37.0 (C-3), 26.7 (C(CH3)2), 26.4 (C(CH3)2), 21.8 (aryl-CH3) ppm. ESI-HRMS calcd. for [C17H20O6S + H]-: 
353.1054, found: 353.1057. ESI-HRMS calcd. for [C17H20O6S + NH4]+: 370.1319, found: 370.1317. 
 
5-Azido-3,5-dideoxy-3-ethynyl-1,2-O-isopropylidene-α-D-ribofuranose (10): A mixture of tosyl compound 10d 
(10.5 g, 29.8 mmol, 1.00 eq.) and sodium azide (8.86 g, 95.3 mmol, 3.20 eq.) was suspended in DMF (300 mL) and 
stirred under N2 at 80 °C for 3 h. The yellow suspension was diluted with brine (200 mL) and extracted with 
EtOAc (4 x 300 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. Purification of the crude product by flash-column chromatography (silica gel, isohexanes/EtOAc, 9:1→4:1) 
yielded azide compound 10 (6.25 g, 28.0 mmol, 94%) as a colorless oil. Rf = 0.67 (isohexanes/EtOAc = 2:1). IR 
(ATR): ṽ = 3280, 2989, 2100, 1375, 1216, 1166, 1105, 1012, 871 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 
5.86 (d, 3J = 3.6 Hz, 1H, H-1), 4.75 (dd, 3J = 4.1 Hz, 3J = 3.6 Hz, 1H, H-2), 4.24 (ddd, 3J = 10.2 Hz, 3J = 3.9 Hz, 3J 
= 2.7 Hz, 1H, H-4), 3.76 (dd, 2J = 13.6 Hz, 3J = 2.7 Hz, 1H, Ha-5), 3.37 (dd, 2J = 13.6 Hz, 3J = 3.9 Hz, 1H, Hb-5), 
2.88 (ddd, 3J = 10.2 Hz, 3J = 4.1 Hz, 4J = 2.5 Hz, 1H, H-3), 2.25 (d, 4J = 2.5 Hz, 1H, CCH), 1.57 (s, 3H, C(CH3)2), 
1.37 (s, 3H, C(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 112.8 (C(CH3)2), 105.1 (C-1), 81.0 (C-
2), 79.7 (C-4), 76.9 (CCH), 73.2 (CCH), 50.7 (C-5), 37.9 (C-3), 26.7 (C(CH3)2), 26.4 (C(CH3)2) ppm. EI-HRMS calcd. 
for [C10H13N3O3 - CH3]+: 208.0717, found: 208.0717. 
 
1,2-di-O-Acetyl-5-azido-3,5-dideoxy-3-ethynyl-D-ribofuranose (11): A stirred solution of azide compound 10 
(6.00 g, 26.9 mmol, 1.00 eq.) in acetic acid (100 mL) and acetic anhydride (50 mL) was treated with concentrated 
sulfuric acid (96%, 1.30 mL) at 0 °C. The reaction mixture turned dark and was stirred for 5 h at RT. After careful 
quenching with saturated aqueous NaHCO3 solution (200 mL) and solid NaHCO3 until CO2 evolution stopped, the 
reaction was extracted with DCM (4 x 200 mL). The organic phase was washed with brine (200 mL), dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash-column 
chromatography (silica gel, isohexanes/EtOAc, 9:1) to afford diacetate compound 11 (5.61 g, 21.0 mmol, 78%) as 
colorless crystals. α/β = 1:6. β anomer could be isolated for analysis. Crystallization from isohexanes/EtOAc (vapor 
diffusion) provided suitable single crystals of the β anomer for X-ray characterization. M.p. = 81 – 82 °C. Rf (α 
anomer) = 0.55 (isohexanes/EtOAc = 4:1). Rf (β anomer) = 0.46 (isohexanes/EtOAc, 4:1). IR (ATR, β anomer): ṽ = 
3281, 2934, 2099, 1743, 1438, 1371, 1205, 1097, 1024, 959, cm−1. Major β anomer: 1H NMR, COSY (400 MHz, 
CDCl3): δ = 6.12 (s, 1H, H-1), 5.37 (d, 3J = 4.5 Hz, 1H, H-2), 4.38 (ddd, 3J = 10.0 Hz, 3J = 3.2 Hz, 3J = 3.0 Hz, 1H, 
H-4), 3.75 (dd, 2J = 13.7 Hz, 3J = 3.0 Hz, 1H, Ha-5), 3.39 (ddd, 3J = 10.0 Hz, 3J = 4.5 Hz, 4J = 2.5 Hz, 1H, H-3), 3.24 
(dd, 2J = 13.7 Hz, 3J = 3.2 Hz, 1H, Hb-5), 2.16 (d, 4J = 2.5 Hz, 1H, CCH), 2.14 (s, 3H, C-2-OCOCH3), 2.08 (s, 3H, 
C-1-OCOCH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 169.5 (C-2-OCOCH3), 169.2 (C-1-OCOCH3), 
98.7 (C-1), 83.7 (C-4), 76.8 (C-2), 76.0 (CCH), 73.6 (CCH), 51.0 (C-5), 34.5 (C-3), 21.12 (C-1-OCOCH3), 20.73 (C-
2-OCOCH3) ppm. ESI-HRMS calcd. for [C11H13N3O5 + H]+: 268.0928, found: 268.0930. ESI-HRMS calcd. for 
[C11H13N3O5 + NH4]+: 285.1193, found: 285.1196. 
 
6-Benzoylamino-9-(2-O-acetyl-5-azido-3,5-dideoxy-3-ethynyl-β-D-ribofuranosyl)-9H-purine (12): N,O-
Bis(trimethylsilyl)acetamid (BSA) (3.66 mL, 3.05 g, 15.0 mmol, 4.00 eq.) was added under N2 to a stirred 
suspension of diacetate compound 11 (1.00 g, 3.74 mmol, 1.00 eq.) and 6-N-benzoyladenine (1.79 g, 7.48 mmol, 
247
EXPERIMENTAL PROCEDURES 
8 
2.00 eq.) in dichloroethane (40 mL) and heated to 80 °C for 1 h until a clear solution was obtained. The reaction 
mixture was brought to RT and treated with trimethylsilyl triflate (TMSOTf) (1.36 mL, 1.66 g, 7.48 mmol, 2.00 eq.). 
The dark red solution was stirred at 80 °C for 4 h and additional 8 h at RT. The reaction was quenched with saturated 
aqueous NaHCO3 (30 mL) and extracted with DCM (4 x 50 mL). The combined organic layers were dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The residue was purified by flash-column chromatography 
(silica gel, isohexanes/EtOAc, 2:1→1:1→1:2→EtOAc) to provide nucleoside 12 (1.02 g, 2.29 mmol, 61%) as a 
colorless foam. The reaction could also be performed on a 4 g scale of the diacetate starting material 11 (yield: 
50%). M.p. = 110 °C (decomp.). Rf = 0.20 (isohexanes/EtOAc = 1:2). Rf = 0.24 (DCM/MeOH, 100:5). IR (ATR): ṽ = 
3296, 3060, 2932, 2103, 1747, 1698, 1581, 1218, 1072, 797 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 9.27 (s, 
1H, NH), 8.74 (s, 1H, H-2), 8.16 (s, 1H, H-8), 7.98 (d, 3J = 7.7 Hz, 2H, aryl-o-CH), 7.58 – 7.53 (m, 1H, aryl-p-CH), 
7.46 (t, 3J = 7.7 Hz, 2H, aryl-m-CH), 6.09 (s, 1H, H-1’), 5.87 (d, 3J = 5.7 Hz, 1H, H-2’), 4.38 (ddd, 3J = 10.0 Hz, 3J = 
4.8 Hz, 4J = 2.7 Hz, 1H, H-4’), 4.07 (ddd, 3J = 10.0 Hz, 3J = 5.7 Hz, 4J = 2.4 Hz, 1H, H-3’), 3.79 (dd, 2J = 13.6 Hz, 
3J = 2.7 Hz, 1H, Ha-5’), 3.57 (dd, 2J = 13.6 Hz, 3J = 4.8 Hz, 1H, Hb-5’), 2.26 (d, 4J = 2.4 Hz, 1H, CCH), 2.18 (s, 3H, 
CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 169.6 (OCOCH3), 164.8 (N-CO-aryl), 152.8 (C-2), 151.2 
(C-4), 149.9 (C-6), 142.0 (C-8), 133.6 (aryl-C-CO-N), 132.9 (aryl-p-CH), 128.9 (aryl-m-CH), 128.0 (aryl-o-CH), 123.7 
(C-5), 89.7 (C-1’), 83.0 (C-4’), 76.9 (C-2’), 75.7 (CCH), 74.4 (CCH), 51.2 (C-5’), 36.2 (C-3’), 20.7 (OCOCH3) ppm. 
ESI-HRMS calcd. for [C21H18N8O4 + H]+: 447.1524, found: 447.1529. 
 
6-Benzoylamino-9-(2-O-acetyl-5-amino-3,5-dideoxy-3-ethynyl-β-D-ribofuranosyl)-9H-purine (5a): 
Trimethylphosphine (4.48 mL, 4.48 mmol, 1.0M in THF, 2.00 eq.) was added to a stirred solution of nucleoside 
12 (1.00 g, 2.24 mmol, 1.00 eq.) in THF (25 mL). After 5 min the reaction mixture turned turbid under N2 evolution 
and was heated to 40 °C for 1.5 h. The reaction mixture was treated with water (0.44 mL, 24.6 mmol, 11.0 eq.) and 
stirred for 10 h at RT. Volatile materials were removed under reduced pressure and the residue was purified by 
flash-column chromatography (silica gel, DCM/MeOH, 100:2→100:5) to give amino compound 5a (0.62 g, 
1.48 mmol, 66%) as a colorless foam. The reaction could also be performed on a 4 g scale of the azide starting 
material 12 (yield: 56%). Rf = 0.34 (DCM/MeOH = 5:1). IR (ATR): ṽ = 3366, 3275, 2918, 1747, 1640, 1422, 1296, 
1138, 943, 860 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 8.75 (s, 1H, H-2), 8.27 (s, 1H, H-8), 8.00 (d, 3J = 7.7 
Hz, 2H, aryl-o-CH), 7.61 – 7.55 (m, 1H, aryl-p-CH), 7.49 (t, 3J = 7.7 Hz, 2H, aryl-m-CH), 6.08 (s, 1H, H-1’), 5.81 (d, 
3J = 5.9 Hz, 1H, H-2’), 4.27 (ddd, 3J = 9.9 Hz, 3J = 4.8 Hz, 4J = 3.0 Hz, 1H, H-4’), 4.02 (ddd, 3J = 9.9 Hz, 3J = 5.9 
Hz, 4J = 2.4 Hz, 1H, H-3’), 3.24 (dd, 2J = 14.0 Hz, 3J = 3.0 Hz, 1H, Ha-5’), 3.01 (dd, 2J = 14.0 Hz, 3J = 4.8 Hz, 1H, 
Hb-5’), 2.23 (d, 4J = 2.4 Hz, 1H, CCH), 2.19 (s, 3H, CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 
169.8 (OCOCH3), 164.9 (N-CO-aryl), 152.8 (C-2), 151.3 (C-4), 149.9 (C-6), 142.2 (C-8), 133.6 (aryl-C-CO-N), 132.9 
(aryl-p-CH), 128.9 (aryl-m-CH), 128.0 (aryl-o-CH), 123.7 (C-5), 89.5 (C-1’), 85.4 (C-4’), 77.4 (C-2’), 76.7 (CCH), 
73.9 (CCH), 42.6 (C-5’), 35.8 (C-3’), 20.9 (OCOCH3) ppm. ESI-HRMS calcd. for [C21H20N6O4 + H]+: 421.1619, 
found: 421.1623. 
 
6-Benzoylamino-9-(2-O-acetyl-5-(tert-butoxycarbonyl)amino-3,5-dideoxy-3-ethynyl-β-D-ribofuranosyl)-9H-
purine (5): A mixture of amine compound 5a (2.00 g, 4.76 mmol, 1.00 eq.), triethylamine (1.99 mL, 1.44 g, 
14.3 mmol, 3.00 eq.) and di-tert-butyldicarbonate (1.53 mL, 1.56 g, 7.14 mmol, 1.50 eq.) in dry DCM (40 mL) was 
stirred at RT for 16 h. MeOH (3 mL) was added and volatile materials were removed in vacuo. The residue was 
purified by flash-column chromatography (silica gel, DCM/MeOH, 100:2→100:3) to give the title compound 5 as a 
colorless foam (1.59 g, 3.05 mmol, 64%). M.p. = 143 °C (decomp.). Rf = 0.20 (DCM/MeOH = 100:5). IR (ATR): ṽ = 
3265, 2977, 1749, 1699, 1610, 1516, 1455, 1248, 1227, 1086 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 9.15 
(s, 1H, NHBz), 8.79 (s, 1H, H-2), 8.03 (s, 1H, H-8), 8.01 (d, 3J = 7.7 Hz, 2H, aryl-o-CH), 7.63 – 7.56 (m, 1H, aryl-p-
CH), 7.49 (t, 3J = 7.7 Hz, 2H, aryl-m-CH), 6.26 (dd, 3J = 7.0 Hz, 4J = 3.7 Hz, 1H, NHBoc), 5.99 (d, 3J = 2.4 Hz, 1H, 
H-1’), 5.66 (dd, 3J = 6.6 Hz, 3J = 2.4 Hz, 1H, H-2’), 4.43 (ddd, 3J = 9.4 Hz, 3J = 3.7 Hz, 3J = 3.2 Hz, 1H, H-4’), 4.03 
(ddd, 3J = 9.4 Hz, 3J = 6.6 Hz, 4J = 2.4 Hz, 1H, H-3’), 3.67 (ddd, 2J = 14.5 Hz, 3J = 7.0 Hz, 3J = 3.7 Hz, 1H, Ha-5’), 
3.57 (ddd, 2J = 14.5 Hz, 3J = 7.0 Hz, 3J = 3.2 Hz, 1H, Hb-5’), 2.28 (d, 4J = 2.4 Hz, 1H, CCH), 2.18 (s, 3H, OCOCH3), 
1.46 (s, 9H, C(CH3)3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 170.0 (OCOCH3), 164.7 (N-CO-aryl), 
156.5 (N-CO-O), 152.9 (C-2), 151.1 (C-4), 150.2 (C-6), 142.4 (C-8), 133.5 (aryl-C-CO-N), 133.0 (aryl-p-CH), 129.0 
(aryl-m-CH), 128.1 (aryl-o-CH), 124.2 (C-5), 90.5 (C-1’), 83.5 (C-4’), 79.6 (C(CH3)3), 77.4 (C-2’), 76.4 (CCH), 74.4 
(CCH), 41.6 (C-5’), 35.8 (C-3’), 28.6 (C(CH3)3), 20.8 (OCOCH3) ppm. ESI-HRMS calcd. for [C26H28N6O6 + H]+: 
521.2143, found: 521.2150. 
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Synthesis of G-half 6. a) AcCl, BnOH, 60°C, 5h, 80%; b) Me2C(OMe)2, Me2CO, p-TsOH (cat.), 60°C, 2h, 84%; c) 
(COCl)2, DMSO, NEt3, DCM, -60°C, 3h; d) Ph3PCHCO2Et, DCM, RT, 12h, 86% (over two steps); e) H2, Raney-Ni, 
EtOH, RT, 20h, 90%; f) H2, Pd/C, EtOH/THF, 36h, 88%; g) 80% HOAc, RT, 24h; h) H2SO4 (cat.), MeOH, 4°C, 3d, 
72% (over two steps); i) TsCl, Py, RT, 18h, 76%; i) NaN3, DMF, 80°C, 3h, 75%; k) BnBr, KOH, THF, reflux, 5h, 
91%; l) HOAc/Ac2O, H2SO4 (cat.), RT, 3h, 85%; m) 6-O-(Diphenylcarbamoyl)-2-N-isobutyrylguanine (Gdpc/iBu), BSA, 
TMSOTf, DCE, 80°C, 2h, 72%. Overall yield starting from 13: 10%. 
 
 
Benzyl 3,4-O-isopropylidene-β-D-arabinopyranoside (14): 
The title compound was prepared according to a modified procedure of Shing et al.[4] Benzyl β-D-arabinopyranoside 
(48.0 g, 200 mmol, 1.00 eq.) was suspended in acetone (500 mL) and 2,2-dimethoxypropane (49.0 mL, 41.6 g; 
400 mmol, 2.00 eq.). After addition of p-toluenesulfonic acid monohydrate (1.14 g, 5.99 mmol, 0.03 eq.), the 
reaction mixture was stirred at 60 °C for 2 h to obtain a clear solution. The reaction was neutralized by treatment 
with triethylamine (0.84 mL, 0,61 g, 5.99 mmol, 1.00 eq.). Volatile components were removed in vacuo and the 
residue was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 2:1→3:2→1:1, gradient 
elution) to furnish the title compound 14 (46.8 g, 167 mmol, 84%) as a colorless oil. Rf = 0.54 (isohexanes/EtOAc = 
1:1). IR (ATR): ṽ = 3221, 2938, 1499, 1453, 1315, 1252, 1048, 1001, 848, 783, 701 cm−1. 1H NMR, COSY (400 MHz, 
CDCl3): δ = 7.42 – 7.28 (m, 5H, aryl-H), 4.94 (d, 3J = 3.6 Hz, 1H, H-1), 4.79 (d, 2J = 11.7 Hz, 1H, PhCH2O), 4.55 (d, 
2J = 11.7 Hz, 1H, PhCH2O), 4.24 (ddd, 3J = 6.2 Hz, 3J = 2.6 Hz, 3J = 1.2 Hz, 1H, H-4), 4.21 (q, 3J = 6.2 Hz, 1H, H-
3), 4.01 (dd, 2J = 13.2 Hz, 3J = 2.6 Hz, 1H, Ha-5), 3.93 (dd, 2J = 13.2 Hz, 3J = 1.2 Hz, 1H, Hb-5), 3.80 (dd, 3J = 6.2 
Hz, 3.6 Hz, 1H, H-2), 2.22 (br s, 1H, OH), 1.53 (s, 3H, CH3), 1.36 (s, 3H, CH3) ppm. 13C NMR, HSQC, HMBC (101 
MHz, CDCl3): δ = 137.1 (aryl-C-CH2), 128.7 (aryl-m-CH), 128.22 (aryl-p-CH), 128.15 (aryl-o-CH), 109.4 (C(CH3)2), 
97.0 (C-1), 76.1 (C-4), 73.1 (C-3), 70.1 (C-2), 69.9 (PhCH2O), 59.9 (C-5), 28.0 (CH3), 26.1 (CH3) ppm. ESI-HRMS 
calcd. for [C15H20O5 + NH4]+: 298.1649, found: 298.1651. EI-HRMS calcd. for [C15H20O5 - CH3]+: 265.1071, found: 
265.1084. 
 
Benzyl 2-deoxy-2-C-[(ethoxycarbonyl)methylene]-3,4-O-isopropylidene-β-D-arabinofuranoside (15): 
The title compound was prepared according to a modified procedure of Kaiya et al.[5] Oxalyl chloride (15.3 mL, 
22.4 g, 176 mmol, 1.15 eq.) was dissolved in dry DCM (600 mL). After cooling to −78 °C, dry DMSO (25.1 mL, 
27.6 g, 352 mmol, 2.30 eq.) was added dropwise and the mixture was stirred at −60 °C for 1 h until no further gas 
development was observed. Subsequently, a solution of acetonide compound 14 (43.0 g, 153 mmol, 1.00 eq.) in 
dry DCM (150 mL) was added slowly over 10 min and the mixture was stirred at -60 °C for 2 h. The reaction mixture 
was treated with triethylamine (64.1 mL, 46.6 g, 460 mmol, 3.00 eq.), stirred at -60 °C for 1 h, quenched upon 
addition of saturated aqueous NaHCO3 (300 mL) and extracted with DCM (3 x 300 mL). The combined organic 
layers were washed with brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. 
Ketone 15a was obtained as a waxy syrup which was used in the next step without further purification. EI-HRMS 
calcd. for [C15H18O5 - CH3]+: 263.0914, found: 263.0914. 
A mixture of crude ketone 15a (42.0 g, 151 mmol, 1.00 eq.) and (carbethoxymethylene)triphenylphosphorane[6] 
(68.3 g, 196 mmol, 1.30 eq.) in DCM (400 mL) was stirred at RT for 12 h. Volatile components were evaporated 
and the residue was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 4:1) to afford the title 
compound 15 as a colorless oil (46.0 g, 132 mmol, 86% over 2 steps). E/Z = 4:1 (inseparable mixture by fcc). Rf = 
0.84 (isohexanes/EtOAc = 2:1). IR (ATR, E/Z-mixture): ṽ = 2983, 1718, 1372, 1214, 1150, 1020, 853, 736, 699 
cm−1. Major E-Isomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 7.41 – 7.32 (m, 5H, aryl-H), 6.41 (d, 4J = 1.8 Hz, 1H, 
C=CH), 6.06 (d, 3J = 7.5 Hz, 1H, H-3), 5.44 (d, 4J = 1.8 Hz, 1H, H-1), 4.86 (d, 2J = 11.9 Hz, 1H, OCH2Ph), 4.62 (d, 
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2J = 11.9 Hz, 1H, OCH2Ph), 4.34 (dd, 3J = 7.5 Hz, 3J = 1.7 Hz, 1H, H-4), 4.20 (q, 3J = 7.1 Hz, 2H, OCH2CH3), 3.70 
(d, 3J = 1.7 Hz, 2H, H-5), 1.53 (s, 3H, C(CH3)2), 1.40 (s, 3H, C(CH3)2), 1.30 (t, 3J = 7.1 Hz, 3H, OCH2CH3) ppm. 13C 
NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 165.5 (C=O), 147.9 (C-2), 137.6 (aryl-C-CH2), 128.6 (aryl-m-CH), 128.1 
(aryl-p-CH), 128.0 (aryl-o-CH), 124.4 (C=CH), 110.6 (C(CH3)2), 95.8 (C-1), 75.2 (C-4), 69.5 (PhCH2O), 68. 6 (C-3), 
63.2 (C-5), 60.8 (OCH2CH3), 26.4 (C(CH3)2), 25.3 (C(CH3)2), 14.3 (OCH2CH3) ppm. ESI-HRMS calcd. for [C19H24O6 
+ NH4]+: 366.1911, found: 366.1911. 
 
Benzyl 2-deoxy-2-C-[(ethoxycarbonyl)methyl]-3,4-O-isopropylidene-β-D-ribopyranoside (16): 
The title compound was prepared according to a modified procedure of Kaiya et al.[5] Vinyl compound 15 (45.0 g, 
129 mmol, 1.00 eq.) was dissolved in EtOH (300 mL) and Raney-Ni (ca. 15 mL) was added to the solution at RT. 
The reaction vessel was evacuated and flushed with hydrogen three times. Subsequently, the mixture was stirred 
under hydrogen atmosphere for 20 h. Upon completion of the reaction as monitored by TLC, the reaction mixture 
was filtered through celite. Volatile materials were removed in vacuo and the residue was purified by flash-column 
chromatography (silica gel, isohexanes/EtOAc, 4:1) to yield reduced compound 16 (40.8 g, 116 mmol, 90%) as a 
colorless oil. dr = 13:1. Rf = 0.33 (isohexanes/EtOAc = 4:1). IR (ATR): ṽ = 2983, 1732, 1455, 1370, 1212, 1071, 
1021, 870, 738, 699 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 7.38 – 7.25 (m, 5H, aryl-H), 4.82 (d, 3J = 11.7 
Hz, 1H, OCH2Ph), 4.64 (d, 3J = 8.0 Hz, 1H, H-1), 4.49 (dd, 3J = 7.4 Hz, 3J = 2.8 Hz, 1H, H-3), 4.48 (d, 3J = 11.7 Hz, 
1H, OCH2Ph), 4.24 (ddd, 3J = 7.4 Hz, 3J = 2.6 Hz, 3J = 2.3 Hz, 1H, H-4), 4.10 (q, 3J = 7.2 Hz, 2H, OCH2CH3), 3.84 
(dd, 2J = 12.8 Hz, 3J = 2.6 Hz, 1H, Ha-5), 3.63 (dd, 2J = 12.8 Hz, 3J = 2.3 Hz, 1H, Hb-5), 2.60 – 2.55 (m, 2H, 
CH2COO), 2.28 (ddd, 3J = 8.0 Hz, 3J = 6.5 Hz, 3J = 2.8 Hz, 1H, H-2), 1.47 (s, 3H, C(CH3)2), 1.31 (s, 3H, C(CH3)2), 
1.22 (t, 3J = 7.2 Hz, 3H, OCH2CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 172.2 (C=O), 138.1 (aryl-
C-CH2), 128.5 (aryl-m-CH), 128.1 (aryl-p-CH), 127.8 (aryl-o-CH), 109.1 (C(CH3)2), 99.0 (C-1), 73.2 (C-4), 72.6 (C-
3), 69.7 (PhCH2O), 62.6 (C-5), 60.7 (OCH2CH3), 37.2 (C-2), 33.6 (CH2COO), 26.7 (C(CH3)2), 25.0 (C(CH3)2), 14.3 
(OCH2CH3) ppm. EI-HRMS calcd. for [C19H26O6 - CH3]+:335.1489, found: 335.1481. 
 
2-Deoxy-3,4-O-isopropylidene-2-C-[(ethoxycarbonyl)methyl]-D-ribopyranose (17a): To a stirred solution of 
ester compound 16 (38.0 g, 108 mmol, 1.00 eq.) in EtOH (250 mL) and THF (100 mL) was added Pd/C (10 wt.%, 
1.70 g) under N2 at RT. The reaction vessel was evacuated and flushed with hydrogen three times. The mixture 
was stirred under hydrogen atmosphere for 24 h and then filtered through celite. The solution was concentrated to 
dryness under reduced pressure and the residue was purified by flash-column chromatography (silica gel, 
isohexanes/EtOAc, 4:1→1:1) to furnish anomeric alcohol 17a as a colorless oil (24.8 g, 95.3 mmol, 88%). α/β = 1:9 
(inseparable mixture by fcc). Rf = 0.36 (isohexanes/EtOAc = 1:1). IR (ATR, α/β-mixture): ṽ = 2984, 1731, 1458, 
1371, 1213, 1109, 1056, 1020, 868 cm-1. Major β anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 4.88 (dd, 3J = 
8.3 Hz, 3J = 4.8 Hz, 1H, H-1), 4.44 (dd, 3J = 7.1 Hz, 3J = 2.9 Hz, 1H, H-3), 4.23 (ddd, 3J = 7.1 Hz, 3J = 3.7 Hz, 3J = 
3.4 Hz, 1H, H-4), 4.16 (q, 3J = 7.1 Hz, 2H, OCH2CH3), 3.88 (dd, 2J = 12.6 Hz, 3J = 3.4 Hz, 1H, Ha-5), 3.60 (dd, 2J = 
12.6, 3J = 3.7 Hz, 1H, Hb-5), 3.26 (d, 3J = 4.8 Hz, 1H, OH), 2.66 (dd, 2J = 16.9 Hz, 3J = 5.9 Hz, 1H, CH2COO), 2.59 
(dd, 3J = 16.9 Hz, 2J = 8.3 Hz, 1H, CH2COO), 2.20 (ddd, 3J = 8.3 Hz, 3J = 5.9 Hz, 3J = 2.9 Hz, 1H, H-2), 1.45 (s, 3H, 
(CH3)2), 1.30 (s, 3H, C(CH3)2), 1.26 (t, J = 7.1 Hz, 3H, OCH2CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): 
δ = 172.8 (C=O), 109.2 (C(CH3)2), 94.4 (C-1), 73.4 (C-3), 72.7 (C-4), 63.3 (C-5), 61.0 (OCH2CH3), 38.5 (C-2), 33.5 
(CH2COO), 27.0 (C(CH3)2), 25.27 (C(CH3)2), 14.3 (OCH2CH3) ppm. EI-HRMS calcd. for [C12H20O6 - CH3]+: 
245.1020, found: 245.1023. 
 
Methyl 2-C-carboxymethyl-2-deoxy-2,3-lactone-D-ribofuranoside (17): The title compound was prepared 
according to a modified procedure of Li et al.[7] Anomeric alcohol 17a (20.7 g, 79.5 mmol, 1.00 eq.) was dissolved 
in AcOH/H2O (v/v 4:1, 400 mL) and stirred at RT for 24 h. Tthe mixture was heated to 40 °C for additional 2 h. 
Volatile materials were evaporated and the crude product 17b was co-evaporated with toluene (3 x 300 mL) and 
used in the next step without further purification. Rf = 0.05 (isohexanes/EtOAc = 1:1). EI-HRMS calcd. for 
[C12H20O6 - 2 x H2O]+: 184.0730, found: 184.0726. 
Concentrated sulfuric acid (0.56 mL) was added to a stirred solution of triol compound 17b in dry methanol (450 mL) 
at 0 °C. The reaction mixture was stirred at 4 °C for 72 h and then neutralized by addition of solid sodium 
bicarbonate. The resulting suspension was filtered through celite and the filtrate was concentrated to dryness under 
reduced pressure. Purification by flash-column chromatography (silica gel, isohexanes/EtOAc, 2:1→1:1→1:3) 
yielded lactone 17 (10.8 g, 57.4 mmol, 72% over 2 steps) as colorless crystals. α/β = 2:3. β anomer could be isolated 
for analysis. M.p. = 45 – 47 °C. Rf (α anomer) = 0.44 (DCM/MeOH = 100:5). Rf (β anomer) = 0.30 (DCM/MeOH = 
100:5). IR (ATR, β anomer): ṽ = 3442, 2940, 1775, 1172, 1102, 1031, 1003, 932 cm−1. Major β anomer: 1H NMR, 
COSY (400 MHz, CDCl3): δ = 5.16 (dd, 3J = 7.0 Hz, 3J = 0.9 Hz, 1H, H-3), 4.90 (d, 3J = 1.4 Hz, 1H, H-1), 4.49 – 
4.44 (m, 1H, H-4), 3.73 (dd, 2J = 12.8 Hz, 3J = 2.9 Hz, 1H, Ha-5), 3.68 (dd, 2J = 12.8, 3J = 3.6 Hz, 1H, Hb-5), 3.41 
(s, 3H, OCH3), 3.13 – 3.05 (m, 1H, H-2), 2.87 (dd, 2J = 18.6 Hz, 3J = 11.0 Hz,1H, CH2COO), 2.55 (dd, 2J = 18.6 Hz, 
3J = 3.7 Hz, 1H, CH2COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 175.6 (C=O), 111.8 (C-1), 86.9 
(C-4), 84.8 (C-3), 63.7 (C-5), 55.8 (OCH3), 46.6 (C-2), 32.4 (CH2COO) ppm. EI-HRMS calcd. for [C8H12O5 - 
CH2OH]+: 157.0495, found: 157.0494. 
 
Methyl 2-C-carboxymethyl-2,5-dideoxy-2,3-lactone-5-tosyl-D-ribofuranoside (18): To a stirred solution of 
lactone compound 17 (10.0 g, 53.1 mmol, 1.00 eq.) in dry pyridine (300 mL) was added a solution of p-
toluenesulfonyl chloride (13.2 g, 69.1 mmol, 1.30 eq.) in pyridine (40 mL) at 0 °C. After stirring at RT for 18 h, the 
reaction was quenched by treatment with MeOH (20 mL). Solvents were removed in vacuo and the residue was 
purified by flash-column chromatography (silica gel, hexane/EtOAc, 3:2→1:1→1:3) to give tosyl compound 18 as 
colorless crystals (13.9 g, 40.6 mmol, 76%). α/β = 2:3 (inseparable mixture by fcc). Crystallization from 
isohexanes/EtOAc (vapor diffusion) provided suitable β single crystals for X-ray characterization. M.p. = 78 – 80 °C. 
Rf = 0.36 (isohexanes/EtOAc = 1:1). IR (ATR, α/β-mixture): ṽ = 2938, 1781, 1598, 1358, 1173, 1111, 979, 815, 665 
cm−1. β anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 7.82 – 7.75 (m, 2H, aryl H-2-2’), 7.40 – 7.32 (m, 2H, aryl 
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H-3,-3’), 4.98 (dd, 3J = 7.0 Hz, 3J = 0.9 Hz, 1H, H-3), 4.86 (d, 3J = 1.1 Hz, 1H, H-1), 4.41 – 4.34 (m, 1H, H-4), 4.10 
(dd, 2J = 10.3 Hz, 3J = 7.6 Hz, 1H, Ha-5), 4.06 (dd, 2J = 10.3 Hz, 3J = 6.4 Hz, 1H, Hb-5), 3.24 (s, 3H, OCH3), 3.13 – 
3.05 (m, 1H, H-2), 2.82 (dd, 3J = 18.6 Hz, 3J = 11.0 Hz, 1H, CH2COO), 2.56 – 2.47 (m, 1H, CH2COO), 2.45 (s, 3H, 
aryl CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 175.3 (C=O), 145.5 (aryl C-4), 132.5 (aryl C-1), 
130.13 (aryl C-3,-3’), 128.02 (aryl C-2,-2’), 111.6 (C-1), 83.9 (C-3), 82.2 (C-4), 68.3 (C-5), 55.5 (OCH3), 45.5 (C-2), 
31.6 (CH2COO), 21.8 (aryl CH3) ppm. α anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 7.82 – 7.75 (m, 2H, aryl 
H-2-2’), 7.40 – 7.32 (m, 2H, aryl H-3-3’), 4.99 (d, 3J = 3.8 Hz, 1H, H-1), 4.82 (dd, 3J = 7.6 Hz, 3J = 2.7 Hz, 1H, H-3), 
4.32 – 4.28 (m, 1H, H-4), 4.23 (dd, 2J = 11.0 Hz, 3J = 3.1 Hz, 1H, Ha-5), 4.20 (dd, 2J = 11.0 Hz, 3J = 3.4 Hz, 1H, Hb-
5), 3.31 (s, 3H, OCH3), 3.05 – 2.98 (m, 1H, H-2), 2.67 (dd, 3J = 17.7 Hz, 3J = 1.5 Hz, 1H, CH2COO), 2.56 – 2.47 (m, 
1H, CH2COO), 2.45 (s, 3H, aryl CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 176.2 (C=O), 145.4 
(aryl C-4), 132.4 (aryl C-1), 130.11 (aryl C-3,-3’), 128.03 (aryl C-2,-2’), 104.5 (C-1), 83.1 (C-3), 80.2 (C-4), 69.0 (C-
5), 55.4 (OCH3), 44.1 (C-2), 29.0 (CH2COO), 21.8 (aryl CH3) ppm. ESI-HRMS calcd. for [C12H20O6 + NH4]+: 
360.1111, found: 360.1109. 
 
Methyl 5-azido-2-C-carboxymethyl-2,5-dideoxy-2,3-lactone-D-ribofuranoside (19): A mixture of tosyl 
compound 18 (13.0 g, 38.0 mmol, 1.00 eq.) and sodium azide (14.1 g, 152 mmol, 4.00 eq.) was suspended in DMF 
(300 mL) and stirred under N2 at 80 °C for 3 h. The yellow suspension was diluted with brine (200 mL) and extracted 
with EtOAc (4x300 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 
4:1→2:1→1:1) to afford azide compound 19 (6.08 g, 28.5 mmol, 75%) as a colorless oil. α/β = 2:3 (inseparable 
mixture by fcc). Rf = 0.46 (isohexanes/EtOAc = 1:1). IR (ATR, α/β-mixture): ṽ = 2936, 2100, 1776, 1444, 1282, 
1160, 1110, 1031, 920 cm-1. β anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 4.95 (dd, 3J = 7.3 Hz, 3J = 1.3 Hz, 
1H, H-3), 4.92 (d, 3J = 1.3 Hz, 1H, H-1), 4.41 – 4.36 (m, 1H, H-4), 3.53 (dd, 2J = 12.7 Hz, 3J = 7.2 Hz, 1H, Ha-5), 
3.39 (s, 3H, OCH3), 3.38 (m, 1H, Hb-5), 3.18 – 3.11 (m, 1H, H-2), 2.86 (dd, 2J = 18.6 Hz, 3J = 10.9 Hz, 1H, CH2COO), 
2.56 (dd, 2J = 18.6 Hz, 3J = 4.7 Hz, 1H, CH2COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 175.3 
(C=O), 111.9 (C-1), 84.7 (C-3), 84.0 (C-4), 55.7 (OCH3), 53.1 (C-5), 45.8 (C-2), 31.8 (CH2COO) ppm. α anomer: 1H 
NMR, COSY (400 MHz, CDCl3): δ = 5.11 (d, 3J = 5.2 Hz, 1H, H-1), 4.81 (dd, 3J = 7.8 Hz, 3J = 2.9 Hz, 1H, H-3), 4.37 
– 4.33 (m, 1H, H-4), 3.68 (dd, 2J =  13.2 Hz, 3J = 3.4 Hz, 1H, Ha-5), 3.43 (dd, 2J = 13.2 Hz, 3J = 3.8 Hz, 1H, Hb-5), 
3.38 (s, 3H, OCH3), 3.12 – 3.05 (m, 1H, H-2), 2.73 (dd, 2J = 17.7 Hz, 3J = 1.6 Hz, 1H, CH2COO), 2.54 (dd, 2J = 17.7 
Hz, 3J = 9.1 Hz, 1H, CH2COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 176.3 (C=O), 104.4 (C-1), 
83.8 (C-3), 81.6 (C-4), 55.3 (OCH3), 52.1 (C-5), 44.4 (C-2), 29.0 (CH2COO) ppm. ESI-HRMS calcd. for [C8H11N3O4 
+ NH4]+: 231.1088, found: 231.1088. 
 
Methyl 5-azido-3-O-benzyl-2,5-dideoxy-2-C-[(benzyloxycarbonyl)methylene]-D-ribofuranoside (20): The title 
compound was prepared according to a modified procedure of Webber et al.[8] Azide compound 19 (5.05 g, 
23.7 mmol, 1.00 eq.) was mixed with KOH (10.6g, 190 mmol, 8.00 eq.) in THF (250 mL). The stirred suspension 
was treated with benzyl bromide (28.1 mL, 40.5 g, 237 mmol, 10.0 eq.) and refluxed for 5 h. After cooling to 0 °C, 
the reaction was diluted with water (250 mL) and extracted with EtOAc (3 x 300 mL). The combined organic layers 
were washed with brine (500 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude 
product was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 9:1→4:1→2:1) to furnish 
benzylated compound 20 as a colorless oil (8.89 g, 21.6 mmol, 91%). α/β = 2:3. β anomer could be isolated for 
analysis. Rf (α anomer) = 0.57 (isohexanes/EtOAc = 4:1). Rf (β anomer) = 0.48 (isohexanes/EtOAc = 4:1). IR (ATR, 
β anomer): ṽ = 2931, 2100, 1733, 1455, 1282, 1168, 1057, 910, 738, 698 cm−1. β anomer: 1H NMR, COSY 
(400 MHz, CDCl3): δ = 7.40 – 7.26 (m, 10H, aryl H), 5.11 (d, 2J = 12.3 Hz, 1H, COOCH2Ph), 5.06 (d, 2J = 12.3 Hz, 
1H, COOCH2Ph), 4.82 (d, 3J = 2.3 Hz, 1H, H-1), 4.43 (s, 2H, OCH2Ph), 4.16 – 4.11 (m, 1H, H-3), 4.14 – 4.08 (m, 
1H, H-4), 3.37 (s, 3H, OCH3), 3.32 (dd, 2J = 12.7 Hz, 3J = 6.2 Hz, 1H, Ha-5), 3.25 (dd, 2J = 12.7 Hz, 3J = 4.3 Hz, 1H, 
Hb-5), 2.86 – 2.79 (m, 1H, H-2), 2.74 (dd, 2J = 16.5 Hz, 3J = 7.6 Hz, 1H, CH2COO), 2.43 (dd, 2J = 16.5 Hz, 3J = 7.4 
Hz, 1H, CH2COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 172.2 (C=O), 137.5 (OCH2Ph-C-1), 135.9 
(COOCH2Ph-C-1), 128.7, 128.6, 128.41, 128.38, 128.08, 127.8 (aryl 10C), 109.4 (C-1), 81.4 (C-4), 80.3 (C-3), 72.6 
(OCH2Ph), 66.6 (COOCH2Ph), 55.8 (OCH3), 54.3 (C-5), 44.2 (C-2), 30.5 (CH2COO) ppm. ESI-HRMS calcd. for 
[C22H25N3O5 + NH4]+: 429.2132, found: 429.2138. 
 
Acetyl 5-azido-3-O-benzyl-2,5-dideoxy-2-C-[(benzyloxycarbonyl)methylene]-D-ribofuranoside (21): To a 
solution of benzylated compound 20 (8.02 g, 19.5 mmol, 1.00 eq.) in AcOH (70 mL) and Ac2O (70 mL), was added 
concentrated H2SO4 (0.20 mL) at 0 °C. The solution was warmed to RT and stirred for 3 h. After careful quenching 
with saturated NaHCO3 solution (150 mL) and solid NaHCO3 until CO2 evolution stopped, the reaction was extracted 
with DCM (4 x 200 mL), washed with brine (400 mL), dried over anhydrous MgSO4 and filtered. Volatile materials 
were removed in vacuo and the residue was co-evaporated with toluene (2 x 100 mL). The crude product was 
purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 9:1→4:1→2:1) to obtain acetylated 
compound 21 as a colorless oil (7.27 g, 16.5 mmol, 85%). α/β = 3:2 (inseparable mixture by fcc). Rf = 0.25 
(isohexanes/EtOAc = 4:1). IR (ATR): ṽ = 2101, 1733, 1455, 1366, 1230, 1170, 1007, 899, 738, 698 cm−1. β anomer: 
1H NMR, COSY (400 MHz, CDCl3): δ = 7.26 (s, 10H, aryl H), 6.09 (d, J = 2.4 Hz, 1H, H-1), 5.09 (d, 2J = 12.2 Hz, 
1H, COOCH2Ph), 5.04 (d, 2J = 12.2 Hz, 1H, COOCH2Ph), 4.45 (s, 2H, OCH2Ph), 4.28 – 4.24 (m, 1H, H-3), 4.16 
(ddd, 3J = 9.6 Hz, 3J = 5.0 Hz, 3J = 4.6 Hz, 1H, H-4), 3.43 (dd, 2J = 13.2 Hz, 3J = 4.6 Hz, 1H, Ha-5), 3.23 (dd, 2J = 
13.2 Hz, 3J = 5.0 Hz, 1H, Hb-5), 3.00 – 2.92 (m, 1H, H-2), 2.78 (dd, 2J = 16.9 Hz, 3J = 8.4 Hz, 1H, CH2COO), 2.61 
(dd, 2J = 16.9 Hz, 3J = 7.1 Hz, 1H, CH2COO), 2.07 (s, 3H, CH3COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, 
CDCl3): δ = 171.8 (COOBn), 170.1 (COOCH3), 137.3 (OCH2Ph-C-1), 135.7 (COOCH2Ph-C-1), 128.71, 128.64, 
128.51, 128.47, 128.20, 127.84 (aryl 10C), 101.3 (C-1), 82.2 (C-4), 78.9 (C-3), 72.8 (OCH2Ph), 66.8 (COOCH2Ph), 
52.5 (C-5), 43.7 (C-2), 30.3 (CH2COO), 21.3 (CH3COO) ppm. α anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 
7.41 – 7.22 (m, 10H, aryl H), 6.36 (d, 3J = 4.8 Hz, 1H, H-1), 5.10 (s, 2H, COOCH2Ph), 4.46 (d, 2J = 12.0 Hz, 1H, 
OCH2Ph), 4.42 (d, 2J = 12.0 Hz, 1H, OCH2Ph), 4.32 – 4.27 (m, 1H, H-4), 4.01 (dd, 3J = 7.0, 3J = 2.3 Hz, 1H, H-3), 
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3.35 (dd, 2J = 12.9 Hz, 3J = 5.1 Hz, 1H, Ha-5), 3.15 (dd, 2J = 12.9 Hz, 3J = 4.2 Hz, 1H, Hb-5), 2.89 – 2.82 (m, 1H, H-
2), 2.77 (dd, 2J = 16.7 Hz, 3J = 6.6 Hz, 1H, CH2COO), 2.61 (dd, 2J = 16.7 Hz, 3J = 5.8 Hz, 1H, CH2COO), 2.05 (s, 
3H, CH3COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 172.0 (COOBn), 170.5 (CH3COO), 137.8 
(OCH2Ph-C-1), 135.8 (COOCH2Ph-C-1), 128.74, 128.59, 128.52, 128.51, 128.05, 127.80 (aryl 10C), 98.2 (C-1), 
84.4 (C-4), 79.2 (C-3), 72.6 (OCH2Ph), 66.7 (COOCH2Ph), 52.7 (C-5), 43.1 (C-2), 28.5 (CH2COO) 21.3 (CH3COO) 
ppm. ESI-HRMS calcd. for [C23H25N3O6 + NH4]+: 457.2081, found: 457.2082. 
 
9-{5-Azido-3-O-benzyl-2,5-dideoxy-2-C-[(benzyloxycarbonyl)methylene]-β-D-ribofuranosyl}-6-O-
(diphenylcarbamoyl)-2-N-isobutyrylguanine (6): N,O-Bis(trimethylsilyl)acetamide (BSA) (2.23 mL, 1.85 g, 
9.10 mmol, 4.00 eq.) was added under N2 to a stirred suspension of compound 21 (1.00 g, 2.28 mmol, 1.00 eq.) 
and 6-O-(diphenylcarbamoyl)-2-N-isobutyrylguanine[9,10] (1.90 g, 4.55 mmol, 2.00 eq.) in dichloroethane (30 mL) 
and heated to 80 °C for 30 min until a clear solution was obtained. The reaction mixture was brought to RT and 
treated with trimethylsilyl triflate (TMSOTf) (1.07 mL, 1.32 g, 5.92 mmol, 2.60 eq.). The dark red solution was stirred 
at 80 °C for 2 h. The reaction was quenched with saturated aqueous NaHCO3 (30 mL) at RT and extracted with 
DCM (4 x 50 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 4:1→2:1→1:1) to 
give nucleoside 6 (1.31 g, 1.65 mmol, 72%) as a colorless foam. The reaction could also be performed on a 5 g 
scale of the starting material 21 (yield: 59%). Rf = 0.68 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 3321, 2933, 2102, 
1731, 1584, 1492, 1268, 1166, 1047, 694 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 7.99 (s, 1H, H-8), 7.92 (s, 
1H, NH), 7.47 – 7.18 (m, 20H, aryl-H), 6.00 (d, 3J = 8.2 Hz, 1H, H-1’), 4.94 (d, 2J = 12.3 Hz, 1H, COOCH2Ph), 4.88 
(d, 2J = 12.3 Hz, 1H, COOCH2Ph), 4.58 (d, 2J = 11.6 Hz, 1H, OCH2Ph), 4.443 (d, 2J = 11.6 Hz, 1H, OCH2Ph), 4.441 
(d, 3J = 5.8 Hz, 3J = 2.1 Hz, 1H, H-3’), 4.27 – 4.21 (m, 1H, H-4’), 3.80 (dd, 2J = 13.0 Hz, 3J = 6.3 Hz, 1H, Ha-5), 3.74 
– 3.63 (m, 1H, H-2’), 3.70 (dd, 2J = 13.0 Hz, 3J = 5.3 Hz, 1H, Hb-5), 2.85 (dd, 2J = 16.7 Hz, 3J = 8.3 Hz, 1H, CH2COO), 
2.80 – 2.70 (m, 1H, CH(CH3)2), 2.48 (dd, 2J = 16.7 Hz, 3J = 6.5 Hz, 1H, CH2COO), 1.26 (s, 3H, CH(CH3)2), 1.24 (s, 
3H, CH(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 174.7 (CONH), 171.3 (COOBn), 156.3 (C-2), 
154.6 (C-4), 151.9 (OCONPh2), 150.4 (C-6), 143.4 (C-8), 141.8 (OCON-Ph-C1), 137.4 (OCH2Ph-C-1), 135.5 
(COOCH2Ph-C-1), 129.3, 128.70, 128.67, 128.46, 128.41, 128.28, 128.17 (aryl 20C), 122.0 (C-5), 89.5 (C-1’), 82.8 
(C-4’), 80.1 (C-3’), 72.4 (OCH2Ph), 66.8 (COOCH2Ph), 52.6 (C-5’), 42.7 (C-2’), 36.5 (CH(CH3)2), 30.2 (CH2COO), 
19.5 (CH(CH3)2), 19.4 (CH(CH3)2) ppm. ESI-HRMS calcd. for [C43H41N9O7 + H]+: 796.3202, found: 796.3214. 
 
 
 
 
The assembly of dinucleotide 22. a) CuSO4, Na-Ascorbate, THF/tBuOH/H2O, RT, 24h, 80%. 
 
 
4-{6’-Benzoylamino-9’-[2’’-O-acetyl-5’’-(tert-butoxycarbonyl)amino-3’’,5’’-dideoxy-β-D-ribofuranosyl]-9’H-
purin-3’’-yl}-1-{9’’’-{3’’’’-O-benzyl-2’’’’,5’’’’-dideoxy-2’’’’-C-[(benzyloxycarbonyl)methylene]-β-D-
ribofuranosyl}-6’’’-O-(diphenylcarbamoyl)-2’’’-N-isobutyrylguanin-5’’’’-yl}-1,2,3-triazole (22): The title 
compound was prepared according to a modified procedure of Singh et al.[11] A-half 5 (1.30 g, 2.50 mmol, 1.00 eq.) 
and G-half 6 (2.39 g, 3.00 mmol, 1.20 eq.) were dissolved in THF/tert-BuOH/H2O (2:2:1, 80 mL) under N2 at RT. 
Subsequently, a solution of sodium ascorbate (0.41 g, 2.00 mmol, 0.80 eq.) in water (3 mL) and a solution of 
copper(II) sulfate (0.16 g, 1.00 mmol, 0.40 eq.) in water (2 mL) was added. The mixture was stirred at RT for 12 h. 
Volatile components were evaporated and the residue was purified by flash-column chromatography (silica gel, 
DCM/MeOH, 100:2→100:5→10:1) to provide dinucleotide 22 (2.62 g, 2.00 mmol, 80%) as a colorless foam. 
M.p. = 183 °C (decomp.). Rf = 0.46 (DCM/MeOH = 10:1). IR (ATR): ṽ = 3268, 2976, 2106, 1738, 1707, 1584, 1452, 
1216 1167, 732 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 9.14 (s, 1H, NHBz), 8.86 (s, 1H, H-2‘), 8.25 (s, 1H, 
NHiBu), 8.09 (s, 1H, H-8‘), 8.02 (d, 3J = 7.6 Hz, 1H, Bz-o-CH), 7.85 (s, 1H, H-8‘‘‘), 7.82 (s, 1H, H-5), 7.62 – 7.56 (m, 
1H, Bz-p-CH), 7.50 (t, 3J = 7.6 Hz, 2H, Bz-m-CH), 7.48 – 7.12 (m, 20H, aryl-H), 6.81 (dd, 3J = 7.3 Hz, 4J = 3.2 Hz, 
1H, NHBoc), 6.19 (d, 3J = 3.9 Hz, 1H, H-1‘‘), 5.95 (d, 3J = 8.2 Hz, 1H, H-1‘‘‘‘), 5.71 (dd, 3J = 7.3 Hz, 3J = 3.9 Hz, 1H, 
H-2‘‘), 5.15 (dd, 2J = 14.0 Hz, 3J = 6.5 Hz, 1H, Ha-5’’’’), 4.93 (dd, 2J = 14.0 Hz, 3J = 8.0 Hz, 1H, Hb-5’’’’), 4.88 (d, 2J 
= 12.3 Hz, 1H, COOCH2Ph), 4.87 – 4.83 (m, 1H, H-4’’’’), 4.83 – 4.78 (m, 1H, H-4‘‘), 4.79 (d, 2J = 12.3 Hz, 1H, 
COOCH2Ph), 4.61 (d, 2J = 11.6 Hz, 1H, OCH2Ph), 4.40 (d, 3J = 5.3 Hz, 1H, H-3’’’’), 4.37 – 4.32 (m, 1H, H-3’’), 4.32 
(d, 2J = 11.6 Hz, 1H, OCH2Ph), 4.15 – 4.04 (m, 1H, H-2’’’’), 3.61 – 3.51 (m, 1H, Ha-5’’), 3.53 – 3.44 (m, 1H, Hb-5’’), 
2.80 (dd, 2J = 16.6 Hz, 3J = 8.3 Hz, 1H, CH2COO), 2.59 (hept, 3J = 6.9 Hz, 1H, CH(CH3)2), 2.45 (dd, 2J = 16.7 Hz, 
3J = 7.1 Hz, 1H, CH2COO), 1.70 (s, 3H, OCOCH3), 1.45 (s, 9H, C(CH3)3), 1.25, (d, 3J = 6.9 Hz, 3H, CH(CH3)2), 1.21, 
(d, 3J = 6.9 Hz, 3H, CH(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 174.3 (iBu-CONH), 171.0 
(COOBn), 169.8 (OCOCH3), 164.7 (N-CO-Ph), 156.7 (N-CO-OC(CH3)3), 156.4 (C-2‘‘‘), 154.1 (C-4‘‘‘), 152.7 (C-2‘), 
151.6 (OCONPh2), 151.1 (C-4‘), 150.4 (C-6‘), 150.1 (C-6‘‘‘), 144.4 (C-8‘‘‘), 142.7 (C-8‘), 141.7 (OCON-Ph2-C1), 
140.7 (C-4), 137.1 (OCH2Ph-C-1), 135.4 (COOCH2Ph-C-1), 133.5 (Bz-C-CO-N), 133.0 (Bz-p-CH), 129.3, 129.0, 
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128.61, 128.55, 128.42, 128.25, 128.17, 128.03, 127.98 (aryl 25C), 125.2 (C-5), 124.2 (C-5‘), 122.8 (C-5‘‘‘), 90.9 
(C-1‘‘‘‘), 90.2 (C-1‘‘), 83.3 (C-4‘‘), 82.1 (C-4‘‘‘‘), 79.6 (C-3‘‘‘‘), 79.4 (C(CH3)3), 77.1 (C-2‘‘), 71.8 (OCH2Ph), 66.7 
(COOCH2Ph), 51.2 (C-5‘‘‘‘), 42.4 (C-5‘‘), 40.5 (C-2‘‘‘‘), 39.9 (C-3‘‘), 36.9 (CH(CH3)2), 30.3 (CH2COO), 28.6 
(C(CH3)3), 20.3 (OCOCH3), 19.5 (CH(CH3)2), 19.40 (CH(CH3)2) ppm. ESI-HRMS calcd. for [C69H69N15O13 + H]+: 
1316.5272, found: 1316.5330. ESI-HRMS calcd. for [C69H69N15O13 + Na]+: 1338.5091, found: 1338.5151. 
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2. NMR spectra of the synthesized compounds 
Compound 8 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 8 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 9a (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 9a (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 9 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 9 (13C-NMR, 101 MHz, Chloroform-d) 
 
256
1H-/13C-NMR SPECTRA OF THE SYNTHESIZED COMPOUNDS 
17 
Compound 10a (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 10a (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 10b (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 10b (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 10c (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 10c (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 10d (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 10d (13C-NMR, 100 MHz, Chloroform-d) 
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Compound 10 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 10 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 11 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 11 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 12 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 12 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 5a (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 5a (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 5 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 5 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 5 (COSY, 400 MHz, Chloroform-d) 
 
Compound 5 (HSQC, 400 MHz, Chloroform-d) 
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Compound 5 (HMBC, 400 MHz, Chloroform-d)  
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Compound 14 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 14 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 15 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 15 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 16 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 16 (13C-NMR, 101 MHz, Chloroform-d) 
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α-/β-anomer: 
Compound 17a (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 17a (13C-NMR, 101 MHz, Chloroform-d) 
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β-anomer: 
Compound 17 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 17 (13C-NMR, 101 MHz, Chloroform-d) 
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α-/β-anomer: 
Compound 18 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 18 (13C-NMR, 101 MHz, Chloroform-d) 
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α-/β-anomer: 
Compound 19 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 19 (13C-NMR, 101 MHz, Chloroform-d) 
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β-anomer: 
Compound 20 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 20 (13C-NMR, 101 MHz, Chloroform-d) 
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α-/β-anomer: 
Compound 21 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 21 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 6 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 6 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 6 (COSY, 400 MHz, Chloroform-d) 
 
Compound 6 (HSQC, 400 MHz, Chloroform-d) 
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Compound 6 (HMBC, 400 MHz, Chloroform-d)  
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Compound 22 (1H-NMR, 400 MHz, Chloroform-d) 
 
Compound 22 (13C-NMR, 101 MHz, Chloroform-d) 
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Compound 22 (COSY, 400 MHz, Chloroform-d) 
 
Compound 22 (HSQC, 400 MHz, Chloroform-d) 
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Compound 22 (HMBC, 400 MHz, Chloroform-d)  
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Compound 24 (1H-NMR, 600 MHz, DMSO-d6) 
 
Compound 24 (13C-NMR, 151 MHz, DMSO-d6) 
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Compound 24 (COSY, 600 MHz, DMSO-d6) 
 
Compound 24 (NOESY, 600 MHz, DMSO-d6) 
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Compound 24 (HSQC, 600 MHz, DMSO-d6)  
 
Compound 24 (HMBC, 600 MHz, DMSO-d6)  
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Compound 25 (1H-NMR, 600 MHz, DMSO-d6) 
 
Compound 25 (13C-NMR, 151 MHz, DMSO-d6) 
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Compound 25 (COSY, 600 MHz, DMSO-d6) 
 
Compound 25 (NOESY, 600 MHz, DMSO-d6) 
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Compound 25 (HSQC, 600 MHz, DMSO-d6)  
 
Compound 25 (HMBC, 600 MHz, DMSO-d6)  
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Compound 4 (1H-NMR, 600 MHz, DMSO-d6) 
 
Compound 4 (13C-NMR, 151 MHz, DMSO-d6) 
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Compound 4 (COSY, 600 MHz, DMSO-d6) 
 
Compound 4 (NOESY, 600 MHz, DMSO-d6) 
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Compound 4 (HSQC, 600 MHz, DMSO-d6)  
 
Compound 4 (HMBC, 600 MHz, DMSO-d6)  
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Selected NOE contacts for compound 4 
 
Temperature dependent 1H-NMR of compound 4 in DMSO-d6 
 
Chemical shift of H-2‘‘‘‘ 
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3. RP-HPLC 
The purification of compound 24, 25 and 4 was performed by reversed-phase HPLC. The crude 
products were dissolved in 30% MeCN, respectively. 
 
Preparative RP-HPLC (flow rate: 5 mL/min) 
T / min 0 15 17 22 24 30 
A (H2O) / % 85 80 20 20 85 85 
B (MeCN) / % 15 20 80 80 15 15 
 
Product fractions were collected from 23.0 – 25.0 min for 24, 11.5 – 13.5 min for 25 and 7.5 – 
9.5 min for 4, respectively. Solvents were evaporated and the compounds were lyophilized 
overnight to give colorless solids. 
 
Analytical RP-HPLC (flow rate: 0.5 mL/min) was conducted with a stronger gradient. 
T / min 0 15 17 22 24 30 
A (H2O) / % 85 20 20 20 85 85 
B (MeCN) / % 15 80 80 80 15 15 
 
Rt (compound 24) = 16.1 min 
Rt (compound 25) = 12.5 min 
Rt (compound 4) = 7.8 min 
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Analytical RP-HPLC (15% to 80% MeCN gradient elution) 
 
Compound 24: 
 
 
Compound 25: 
 
 
Compound 4: 
 
-0,20
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
1,60
0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 25 27.5 30
[A
.U
.]
[min]
-0,50
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 25 27.5 30
[A
.U
.]
[min]
-0,50
0,00
0,50
1,00
1,50
2,00
2,50
0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 25 27.5 30
[A
.U
.]
[min]
294
X-RAY CRYSTALLOGRAPHY   
55 
4. X-ray crystallography data 
 
Compound 10d: 
 
 
net formula C17H20O6S 
Mr/g mol−1 352.39 
crystal size/mm 0.080 × 0.050 × 0.030 
T/K 103.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorombic 
space group 'P 21 21 21' 
a/Å 5.5797(3) 
b/Å 16.2174(7) 
c/Å 18.6761(8) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1689.97(14) 
Z 4 
calc. density/g cm−3 1.385 
μ/mm−1 0.221 
absorption correction Multi-Scan 
transmission factor range 0.92–0.99 
refls. measured 17954 
Rint 0.0404 
mean σ(I)/I 0.0305 
θ range 3.327–27.090 
observed refls. 3480 
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x, y (weighting scheme) 0.0355, 0.4445 
hydrogen refinement constr 
Flack parameter −0.01(3) 
refls in refinement 3706 
parameters 220 
restraints 0 
R(Fobs) 0.0290 
Rw(F2) 0.0724 
S 1.041 
shift/errormax 0.001 
max electron density/e Å−3 0.236 
min electron density/e Å−3 −0.366 
 
 
Compound 11: 
 
 
net formula C11H13N3O5 
Mr/g mol−1 267.24 
crystal size/mm 0.080 × 0.050 × 0.030 
T/K 103.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21 1' 
a/Å 10.1530(7) 
b/Å 7.0554(5) 
c/Å 18.1171(13) 
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α/° 90 
β/° 101.769(2) 
γ/° 90 
V/Å3 1270.51(16) 
Z 4 
calc. density/g cm−3 1.397 
μ/mm−1 0.112 
absorption correction Multi-Scan 
transmission factor range 0.94–1.00 
refls. measured 13325 
Rint 0.0382 
mean σ(I)/I 0.0460 
θ range 3.376–26.363 
observed refls. 4785 
x, y (weighting scheme) 0.0337, 0.2537 
hydrogen refinement constr 
Flack parameter −0.6(5) 
refls in refinement 5174 
parameters 347 
restraints 1 
R(Fobs) 0.0344 
Rw(F2) 0.0821 
S 1.041 
shift/errormax 0.001 
max electron density/e Å−3 0.188 
min electron density/e Å−3 −0.183 
 
Correct structure derived from synthesis. 
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Compound 18: 
 
 
net formula C15H18O7S 
Mr/g mol−1 342.35 
crystal size/mm 0.444 × 0.148 × 0.141 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group 'P 21' 
a/Å 11.1971(7) 
b/Å 5.8612(3) 
c/Å 12.8844(8) 
α/° 90 
β/° 112.211(7) 
γ/° 90 
V/Å3 782.84(9) 
Z 2 
calc. density/g cm−3 1.452 
μ/mm−1 0.241 
absorption correction multi-scan 
transmission factor range 0.90050–1.00000 
refls. measured 4714 
Rint 0.0268 
mean σ(I)/I 0.0502 
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θ range 4.541–26.367 
observed refls. 2507 
x, y (weighting scheme) 0.0348, 0.1576 
hydrogen refinement constr 
Flack parameter −0.04(7) 
refls in refinement 2844 
parameters 210 
restraints 1 
R(Fobs) 0.0413 
Rw(F2) 0.0926 
S 1.029 
shift/errormax 0.001 
max electron density/e Å−3 0.249 
min electron density/e Å−3 −0.252 
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5. Binding evaluation of compound 4 to STING in vitro 
 
 
 
Figure S1: Compound 4 is not binding to STING in vitro. 
(A) DSF thermal shift first derivative of 5 µM hSTING_L139 (orange), 5 µM hSTING_L139 + 50 µM 2′3′-cGAMP 
(red), 3′3′-cGAMP (blue), 50 µM 4 (dark green) and 150 µM 4 (light green). 
(B) DSF thermal shift first derivative of 5 µM mSTING_L138 (orange), 5 µM mSTING_L139 + 50 µM 2′3′-cGAMP 
(red), 3′3′-cGAMP (blue), 50 µM 4 (dark green) and 150 µM 4 (light green). 
(C) ITC measurement raw data of 20 µM hSTING_L139 titrated with 291 µM 4. 
(D) ITC measurement raw data of 20 µM mSTING_L138 titrated with 291 µM 4. 
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 Discussion 
The degradation of second messengers is a crucial step to regulate their cellular level. In recent 
years, different PDEs have been identified to hydrolyze c-di-AMP in bacterial species. However, 
the precise degradation pathway and its regulation are not fully understood yet and many open 
questions remain. 
Two important enzyme classes in the degradation pathway of c-di-AMP are the two DHH-type 
PDEs, GdpP and DhhP [113,114]. Although both PDEs possess the same highly conserved 
catalytic DHH-DHHA1 domain, they exist in parallel in many species. A third PDE class is 
represented by the HD-domain PDE PgpH, which can be found in several species [94]. The set of 
these three PDE classes varies among bacteria, which raises several questions. Do all PDEs have 
the same function in one organism and for which purpose? Are there any differences in activity, 
substrate specificity or product formation? What are the precise molecular mechanisms to achieve 
specificity? These questions are discussed in the following chapters. 
1. Substrate specificity and product formation of DHH-type PDEs 
Studies in different organisms are consistent about substrate specificity and product formation of 
GdpP PDEs. GdpP hydrolyzes c-di-AMP exclusively to 5′-pApA, which represents an 
intermediate in the degradation pathway [32,63,65,67,113,123]. However, the substrate specificity 
of DhhP PDEs demonstrates significant interspecies differences. The DhhP homologues from 
M. pneumoniae, B. burgdorferi, M. tuberculosis (Rv2837c) and M. smegmatis (MsPDE or NrnA) 
were shown to accept c-di-AMP as a substrate [37,45,107,114]. In contrast, homologues from 
S. aureus, T. maritima (TmPDE), S. pneumoniae (SpPde2) and S. mutans demonstrate a clear 
preference for linear dinucleotides and are not able to hydrolyze c-di-AMP under physiological 
conditions [32,55,115,123]. 
The kinetic values for hydrolysis of 5′-pApA are comparable between M. tuberculosis Rv2837c 
(kcat = 0.87 ± 0.05 s-1, KM = 129.88 ± 12.95 µM), T. maritima TmPDE (kcat = 0.14 s-1, 
KM = 204 ± 10 µM), S. pneumoniae SpPde2 (KM = 97 ± 8 µM) and S. mutans Pde2 
(kcat = 36.5 ± 8.08 s-1, KM = 199 ± 65.4 µM) [32,107,115,123]. The hydrolysis of c-di-AMP could 
only be described kinetically for Rv2837c (kcat = 0.23 ± 0.02 s-1, KM = 30.89 ± 6.71 µM), MsPDE 
(kcat = 0.52 ± 0.03 s-1, KM = 6.80 ± 0.84 µM) and SpPde2 (KM = 16.75 ± 8.70 µM) [32,45,107]. 
The hydrolysis activity of SpPde2 was also analyzed within this work revealing a contradictory 
result [115]. According to our studies, SpPde2 and TmPDE have only weak activity for 
c-di-AMP, whereas 5′-pApA is hydrolyzed at high turnover rates [115]. This observation was also 
described for S. mutans Pde2 by Konno et al. [123]. The substrate specificity has been confirmed 
in the present work by binding analysis of the inactive TmPDE D80N D154N mutant. ITC and 
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SPR experiments revealed nanomolar affinities for 5′-pApA, whereas the c-di-AMP binding 
constant was calculated at 4.5 µM with a high error [115].  
Another difference in substrate specificity was observed for TmPDE compared to the homologue 
MsPDE [115]. MsPDE was shown to possess an exonuclease activity and act as a 
nanoRNase [118]. In contrast, nanoRNase activity was ruled out for TmPDE within this work. 
Almost no product formation was observed for 5′-pApApA, although a 10-fold higher enzyme 
concentration was used compared to the highly effective turnover of 5′-pApA [115]. This can also 
be explained based on structural analysis of TmPDE in complex with dinucleotide substrates. The 
base residues of the ligand are coordinated at the two access positions of the active site, while the 
ribose residues are covered in the core. Thus, an elongated RNA chain would not fit in the active 
site for hydrolysis. In conclusion, an RNase activity can be excluded as physiological role of 
TmPDE [115]. 
Apart from these observations, TmPDE was also shown to hydrolyze 5′-pApG and 5′-pGpG 
effectively [115]. Binding experiments of the TmPDE D80N D154N mutant confirmed this 
extended substrate specificity and demonstrated affinities in the following order 
5′-pApG < 5′-pGpG < 5′-pApA [115]. This is consistent with a previous study that describes a 
comparable hydrolysis of 5′-pGpG to 5′-pApA by Rv2837c [107]. As observed for c-di-AMP, 
TmPDE has no hydrolysis activity for c-di-AMP and Rv2837c converts c-di-GMP with much 
lower activity than c-di-AMP. At this, the conversion of c-di-GMP is catalyzed by EAL domains 
or HD-GYP domains [20]. Comparably to the first step of c-di-AMP degradation, EAL-domains 
hydrolyze c-di-GMP exclusively to 5′-pGpG. In contrast, HD-GYP domains catalyse the reaction 
of c-di-GMP to the final product GMP [20]. Species like M. tuberculosis do not possess HD-GYP 
domains, thus Rv2837c might have an important role for 5′-pGpG hydrolysis [107]. Although 
HD-GYP domains from T. maritima were shown to hydrolyze c-di-GMP to 5′-pGpG and GMP, 
TmPDE might still contribute to the hydrolysis of 5′-pGpG in the second step. Taken together, 
these findings indicate that the role of DhhP homologues is not limited to the c-di-AMP 
degradation pathway and might also be important for the second step in c-di-GMP degradation. 
The differences in substrate specificity and product formation have also been analyzed 
structurally. During this work, the crystal structure of TmPDE has been determined in complex 
with several ligands. The high-resolution structures of one ligand-free state, two substrate-bound 
states and three post-reaction states give a detailed insight in the reaction mechanism. The 
structures in complex with 5′-pApA and 5′-pApG represent the substrate-bound states and display 
their differences in binding affinity. In comparison to 5′-pApA, the guanosine base of 5′-pApG 
forms additional interactions from oxygen O6 to Arg 243 and nitrogen N2 to Asn 162. This is in 
good agreement with the higher binding affinity for 5′-pApG and 5′-pGpG compared to 
304
5′-pApA [115]. Notably, the overall structure of TmPDE in the substrate-bound states is highly 
similar to the structure of Rv2837c [107,115]. Therefore, it is difficult to depict a difference that 
explains why Rv2837c accepts c-di-AMP as a substrate, whereas TmPDE only accepts linear 
dinucleotides as substrates.  
In a recent study, the active site of Rv2837c was analyzed by mutational investigations in 
comparison with a separate DHH domain construct of S. aureus GdpP [116]. Here, the active site 
is divided into the three positions R, C and G. The hydrolysis of c-di-AMP by GdpP occurs in CG 
position. However, it is unclear if Rv2837c hydrolyzes c-di-AMP in the same position. In this 
study, a T180R mutant of Rv2837c was designed to reduce space in position G. This resulted in 
more than 50% diminished c-di-AMP hydrolysis, while the activity for 5′-pApA remained 
unaffected. It is assumed that the mutation prevents the access of c-di-AMP to position G, which 
supports the suggestion of c-di-AMP hydrolysis in CG position by Rv2837c [116]. Although 
position G from TmPDE is highly similar compared to Rv2837c (Figure 18B, C), TmPDE lacks 
hydrolysis activity for c-di-AMP. Thus, the difference in c-di-AMP specificity of TmPDE and 
Rv2837c remains unclear and is probably not dependent on the size of position G.  
The difference in substrate coordination can also explain exclusive product formation of 5′-pApA 
by GdpP. In Rv2837c, 5′-pApA can relocate into CR position, which is required for positioning 
the phosphodiester linkage in close proximity to the metal ions [116]. The bigger R site of 
Rv2837c is also present in the structure of TmPDE, which is in accordance with the ability to 
hydrolyze 5′-pApA (Figure 18A). GdpP has a smaller R site that is assumed to prevent access of 
5′-pApA. 
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 Figure 18: Binding site of TmPDE compared to binding site of Rv2837c. (A) Binding site of TmPDE (yellow) in 
complex with 5′-pApA (dark blue) (PDB: 5O4Z [115]) and binding site of Rv2837c (red) in complex with 5′-pApA 
(grey) and Mn2+ ions (purple) (PDB: 5JJU [107]). In both active sites 5′-pApA is coordinated in RC position. (B) G-site 
of TmPDE (yellow, PDB: 5O4Z [115]) and Rv2837c (red, PDB: 5JJU [107]) with modelled c-di-AMP from S. aureus 
GdpP (cyan, PDB: 5XSN [116]). (C) Surface view on G-site of TmPDE (yellow, PDB: 5O4Z [115]) and Rv2837c (red, 
PDB: 5JJU [107]) with modelled c-di-AMP from S. aureus GdpP (cyan, PDB: 5XSN [116]). 
The hydrolysis mechanism can be proposed based on the structures of TmPDE and Rv2837c and 
is consistent with a two metal ion hydrolysis for phosphodiester linkages [107,115]. Particularly, 
the different reaction states observed in the crystal structures of TmPDE within this work allow a 
detailed analysis of the reaction sequence. In one structure, 5′-pApA is present with a hydrolyzed 
phosphodiester linkage. In addition, one crystallization sample has been incubated with 5′-pGpG, 
which resulted in a structure of TmPDE bound to GMP. This indicates that the two resulting NMP 
molecules separately leave the active site after cleavage [115]. Another insight is obtained from 
the observation of a small conformational difference in the apo structure of TmPDE compared to 
the ligand-bound states. The active site of DHH-type PDEs is located between the DHH and the 
DHHA1 subunits, which are connected by a flexible linker. In the apo structure of TmPDE, one 
monomer has a larger distance between the two domains compared to the other monomer. This 
difference can be described as “open” and “closed” state. In contrast to the apo structure, all 
ligand-bound states of TmPDE have both active sites closed [115]. The different states can also be 
observed in structures of other DHH-type PDEs, like the nanoRNase NrnA from B. subtilis or the 
exonuclease RecJ from Thermus thermophilus [194–196] (Figure 19). This leads to the suggestion 
of an opening and closing mechanism of the DHH-DHHA1 domain during the reaction. It could 
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be possible that an open conformation is required for the substrate access to the active site. In 
order to bring the substrate in close proximity to the catalytic metal ions, the two subdomains 
have to close. After hydrolysis, the domains have to open for binding of the next substrate. In 
addition to the asymmetric open/closed dimer of apo TmPDE in the crystal structure, ITC 
experiments revealed a binding stoichiometry of n = 0.5 for 5′-pApA to TmPDE. Therefore, it is 
possible to speculate that the active site of only one monomer can be occupied at a time while the 
other monomer remains open. In contrast to this theory, all ligand-bound crystal structures have 
both active sites closed and occupied by ligands. For both observations in the TmPDE structures, 
an influence by crystallisation conditions and/or packing cannot be excluded for inducing a closed 
or open state of the active sites [115]. 
 
Figure 19: Open and closed conformations of the DHH-DHHA1 domain. Surface representation of the structures of 
TmPDE in apo state (upper left, PDB: 5O25 [115]) and in complex with 5′-pApA (lower left, PDB: 5O4Z [115]), 
B. subtilis NrnA in complex with pAp (middle upper and lower, PDB: 5IUF [194]) and T. thermophilus RecJ (upper 
right, PDB: 1IR6 [195], lower right, PDB: 2ZXP [196]). 
The proposed opening and closing mechanism might also be interesting in regard to the regulation 
of DHH domains in GdpP PDEs. The hydrolysis activity of GdpP was shown to be inhibited by 
heme-binding to the PAS domain [119]. Unfortunately, no full-length structure of GdpP could be 
determined to observe any conformational change induced by the additional domains. The 
structures of the separate DHH-DHHA1 domain of S. aureus GdpP are all present in the same 
state independent on ligand binding [116]. In comparison with the different conformations of 
TmPDE or NrnA, the GdpP DHH-DHHA1 is rather similar to the open active site of apo TmPDE. 
One suggestion for the inhibition of GdpP could be the opening or closing of the active site. 
Binding of heme could induce a closed conformation, which would reject the substrate access to 
the active site. However, this mechanism can also be proposed the other way round. Closing of 
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the active site is required for hydrolysis and heme binding would capture the domains in an open 
conformation. Although these theories are very speculative, they can be interesting in future 
studies in order to determine the mechanism of GdpP regulation. 
2. Degradation pathways of c-di-AMP 
Three different PDE types of the c-di-AMP degradation pathway have been discovered so far. 
The HD-type PgpH and the DHH-type GdpP are multidomain PDEs located at the membrane. 
Both are highly specific for the exclusive hydrolysis of c-di-AMP to the intermediate 5′-pApA in 
many species. The stand-alone DHH domain PDE DhhP has homologues with specificity for 
c-di-AMP or exclusively for 5′-pApA as discussed in the previous chapter (1. Substrate specificity 
and product formation of DHH-type PDEs). However, the current research status leads to the 
suggestion that most analyzed bacteria have different sets of these three PDE types for c-di-AMP 
degradation. For example, GdpP and DhhP homologues can be found in parallel in S. aureus, 
S. pneumoniae and S. mutans. Therefore, a two-step degradation pathway for c-di-AMP is 
proposed for these species with GdpP catalyzing the first step of c-di-AMP hydrolysis into 
5′-pApA, which is assumed to be regulated. To avoid accumulation of 5′-pApA, DhhP PDEs 
catalyze a fast conversion to the final product AMP in the second step. The activity analysis of 
GdpP and DhhP homologues from S. aureus, S. pneumoniae and S. mutans supports this 
model [32,55,123]. Other species, such as T. maritima do not contain a GdpP homologue but 
possess a set of PgpH and DhhP homologues. Particularly, the DhhP homologue TmPDE was 
identified within this work to catalyze the second step of c-di-AMP hydrolysis [115]. Although no 
information is available yet for the T. maritima PgpH homologue, the two-step degradation 
pathway is presumably performed by these two PDE types. Some species do contain all three 
PDE homologues, like L. monocytogenes or B. subtilis. In L. monocytogenes, the degradation of 
c-di-AMP to 5′-pApA is catalyzed predominantly by PgpH or PdeA (GdpP homologue) 
dependent on the cellular activity of [94]. Both homologues from B. subtilis were shown to 
hydrolyze c-di-AMP, with PgpH having a two-fold higher impact on c-di-AMP 
degradation [126]. The DhhP homologues from both species were not yet characterized with 
regard to c-di-AMP hydrolysis. The DHH-type nanoRNase NrnA from B. subtilis was shown to 
degrade 5′-pGpG and is therefore assumed to also accept 5′-pApA as a substrate [197]. 
Additionally, the DhhP homologue from L. monocytogenes was not found in pull down 
experiments of cell lysate on c-di-AMP beads, whereas PgpH and GdpP could be isolated. This 
leads to the suggestion that this DhhP homologue has no or minor interactions with c-di-AMP and 
is possibly responsible for the hydrolysis of 5′-pApA in L. monocytogenes [94]. In conclusion, 
these observations indicate that the two-step degradation pathway of c-di-AMP is also valid in 
L. monocytogenes and B. subtilis. 
308
From the three PDEs for c-di-AMP degradation, species, such as M. pneumoniae, B. burgdorferi, 
M. tuberculosis and M. smegmatis only contain one DhhP homologue, which was shown to 
hydrolyze c-di-AMP in several studies [37,45,107,114]. These studies indicate that the DhhP 
homologue is a single enzyme for the degradation of c-di-AMP in these species. Interestingly, all 
these species have an abnormal cell envelope compared to gram-positive bacteria. The cell wall of 
gram-positive bacteria consists of a thick layer of PG and LTA and is connected to a single 
membrane by diacylglycerol. In contrast, the cell wall of gram-negative bacteria does not contain 
LTA and has an additional outer membrane with a periplasmic space between each membrane and 
the PG layer. Lipopolysaccharides (LPS) are located on the extracellular part of the outer 
membrane [198]. The cell wall of B. burgdorferi has an atypical gram-negative envelope as it 
contains glycolipids instead of LPS in the outer membrane. In addition, the flagella are present in 
the periplasmic space [199]. Mycobacteria have a unique cell envelope among prokaryotes, which 
cannot be assigned by the gram stain. The cell wall consists of thin layers of PG and 
arabinogalactan and a thick layer of mycolic acids. Additionally, they possess a single inner 
membrane [198]. Mycoplasmas do not possess a cell wall in general [200]. As GdpP and PgpH 
PDEs are both membrane-coupled, a different cell envelope might be the reason for the lack of 
these PDEs. In contrast to this theory, the gram-negative bacterium T. maritima has a so far 
uncharacterized homologue of PgpH. However, the absence of GdpP and PgpH in some species 
raises the issue of regulation. The degradation of c-di-AMP is assumed to be regulated by the 
additional non-catalytic domains of GdpP and PgpH, whereas DhhP does not contain any 
additional domains. Thus, it remains unclear how the degradation of c-di-AMP is regulated in 
those species, which only contain a DhhP homologue as single c-di-AMP specific PDE. 
The proposed two-step degradation pathway for c-di-AMP raises another question. Why should 
bacteria possess an enzyme which catalyzes an incomplete hydrolysis of a second messenger and 
would therefore require a second enzyme for the final step? A possible explanation can be derived 
from the origin of DHH domains. They are also present in nanoRNases like NrnA. As these 
enzymes hydrolyze one phosphodiester linkage per base, they can catalyze the reaction with a 
single position in the active site. In contrast, c-di-AMP has two phosphodiester bonds for 
hydrolysis in opposite positions. The c-di-AMP specific PDEs could have evolved from 
nanoRNases and therefore contain a single hydrolysis site. Interestingly, all characterized PDEs 
for c-di-AMP degradation share the common two metal ion hydrolysis mechanism for 
phosphodiester linkages, which is only possible on one site. Thus, the substrate has to flip or leave 
the binding pocket and re-associate. Indeed, a flipping mechanism was proposed for the 
M. tuberculosis DhhP homologue Rv2837c by He et al. based on molecular docking and 
quantitative analysis [107]. However, this mechanism might be energetically less favoured 
compared to possessing a second enzyme for the final degradation step as it is observed in other 
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species. Another important aspect is the regulation of c-di-AMP hydrolysis. As the activity of 
GdpP and PgpH is most likely regulated by their additional domains, the substrate specificity of 
the catalytic domain is crucial. Accepting further substrates, such as 5′-pApA with high affinity in 
the same active site could interfere with a specific control of c-di-AMP levels. Since the second 
reaction step of degradation does not need to be regulated, it can be performed very effectively by 
DhhP PDEs. In addition, due to the phosphodiester linkages c-di-AMP adopts a more rigid 
conformation than the higher flexible 5′-pApA. Therefore, the active sites for these two molecules 
might require a different shape, as discussed in the previous chapter. 
PgpH, GdpP and DhhP represent the most important enzymes for c-di-AMP hydrolysis in many 
species. However, some c-di-AMP producing bacteria do not possess any homologues of these 
enzymes as observed for many species of the typus Actinobacteria. Whereas M. tuberculosis and 
M. smegmatis use a DhhP homologue as single c-di-AMP specific PDE [45,107], other 
Actinobacteria, such as Streptomyces do not contain any of the so far characterized c-di-AMP 
specific PDEs. Therefore, it is unclear how c-di-AMP is hydrolyzed in these species. A recent 
discovery of a novel and non-canonical PDE by our collaborators (Tschowri group) gives 
important insights into the degradation of c-di-AMP in S. venezuelae. This PDE is mainly present 
in Actinobacteria and therefore termed AtaC (actinobacterial PDE targeting c-di-AMP 
hydrolysis). The present work made a substantial contribution to the identification of AtaC as 
c-di-AMP specific PDE. AtaC was shown to hydrolyze c-di-AMP to AMP with a high activity 
under physiological conditions. In high substrate concentrations, the formation of the intermediate 
5′-pApA was observed. Notably, the turnover for 5′-pApA is ~2-fold higher than for c-di-AMP. 
Whereas DhhP homologues do not distinguish between adenosine and guanosine in linear 
dinucleotides [115], AtaC has only weak activity for c-di-GMP, 5′-pGpG or 5′-pApG. This 
indicates a high specificity for two adenosine residues in the active site. Unfortunately, no protein 
structure could be determined so far. Nevertheless, structural insights were derived from 
prediction models, SEC-RALS, SAXS analysis and mutational approaches. Based on an 
HHpred [201] analysis, the structural homologue with the highest similarity is predicted to be the 
phosphonoacetate hydrolase PhnA from Sinorhizobium meliloti [202]. Similar to PhnA, a 
monomeric structure was also indicated for AtaC by SEC-RALS experiments. In addition, an 
overall shape of AtaC obtained from SAXS analysis fits to the monomeric prediction model 
derived from HHpred [201]. AtaC was shown to bind Mn2+ ions, indicating a metal ion-dependent 
hydrolysis mechanism as common for c-di-AMP specific PDEs. Based on this observation in 
combination with the prediction model, conserved aspartate residues were suggested to be 
essential for Mn2+-coordination and hydrolysis activity. This was verified for aspartate D269 as a 
mutation to asparagine (D269N) results in abolished Mn2+-binding and activity. Similar to the 
TmPDE D80N D154N mutant, AtaC D269N is inactive but still able to bind c-di-AMP. A 
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monomeric structure with a single active site is also present in PDEs of the ENPP 
(Ecto-nucleotide pyrophosphatase phosphodiesterase) subfamily, which are predicted to be 
structurally similar to AtaC. Interestingly, one member of this subfamily, ENPP1, was shown to 
be important for degradation of 2′3′-cGAMP in mammalian cells [203]. Therefore, it can be 
suggested that AtaC and ENPP1 share a similar conserved active site, which is specific for cyclic 
dinucleotides.  
Within the work of our collaboration partner Andreas Latoscha (Tschowri group) the function of 
AtaC was also analzyed in vivo. Significantly increased levels of c-di-AMP in AtaC deletion 
strains of S. venezuelae confirm the important role of this PDE for c-di-AMP degradation. 
Furthermore, the analysis of the AtaC deletion strain on solid sporulation medium reveals 
sporulation and growth defects. This indicates a correlation of c-di-AMP levels on sporulation and 
growth in S. venezuelae. Homologues of AtaC can also be found in M. tuberculosis and 
M. smegmatis. In both species, only a single c-di-AMP specific PDE has been discovered so far, 
while most species possess at least two PDEs for c-di-AMP hydrolysis. Thus, it is possible that 
these AtaC homologues can also hydrolyze c-di-AMP specifically and contribute to the c-di-AMP 
degradation. In conclusion, AtaC represents a new identified and highly interesting PDE for the 
degradation of c-di-AMP but requires many more investigations to be fully understood. 
 
Figure 20: Proposed degradation pathways of c-di-AMP in different species. The membrane-coupled GdpP and PgpH 
PDEs hydrolyze c-di-AMP exclusively to 5′-pApA. The DhhP PDE has a preference for 5′-pApA hydrolysis, except for 
species that contain DhhP homologues as single c-di-AMP-degrading enzymes. AtaC is a non-canonical c-di-AMP 
specific PDE discovered in S. venezuelae. 
3. Applications of a fluorescent 2′3′-cGAMP analogue 
The cGAS-STING pathway is a key component of the mammalian innate immune system. It is 
crucial for the cytosolic recognition of different threats that derive from bacteria, viruses or 
defective cellular functions. Foreign DNA in the cytosol is detected by cGAS, which 
subsequently synthesizes 2′3′-cGAMP. Upon activation by 2′3′-cGAMP or bacterial CDNs, 
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STING induces a type I interferon response. Since an excessive activation of this pathway stands 
in correlation with autoimmune diseases, suitable inhibitors are of high interest in drug research. 
In recent years, the opposite modification, activation of cGAS or STING has become of particular 
relevance for potential cancer treatment approaches [157]. Therefore, assays to monitor the 
activity of both proteins are highly required. A very effective possibility to analyze protein 
interactions are fluorescence-based methods. Andreeva et al. developed a fluorescent high 
throughput screen to analyze the activity of cGAS [164]. This method replaces ATP by the 
fluorescent analogue 2-aminopurine riboside-5′-triphosphate (fATP). During the reaction, fATP is 
cyclized with GTP leading to a decrease in fluorescence, which can be measured [164]. However, 
the product of this reaction retains fluorescent properties. Within the present work, this molecule 
has been characterized as a fluorescent 2′3′-cGAMP analogue, termed fGAMP (Figure 21). Since 
fGAMP is highly similar to the physiological molecule, it is interesting for further applications in 
the cGAS-STING pathway. In particular, the analysis of STING interactions is relevant for drug 
development and therefore requires a high throughput screen. For an optimal set up of this type of 
assay, the following properties are important: The respective experiments have to be economical, 
fast in preparation and suitable for large-scale analysis. In addition, a simple readout without any 
modifications of the analyzed molecules ensures conditions close to the physiological situation. 
One commonly used method for STING interactions are thermal shift experiments by differential 
scanning fluorimetry (DSF) [181,184,190,192,204,205]. Ligand interaction has a significant 
influence on the stability of STING and thus results in a thermal shift proportional to the binding 
affinity. However, this method is limited in precision and cannot provide quantitative information. 
More precise protein interaction methods used for STING binding analysis, such as isothermal 
titration calorimetry (ITC) [178,180,206,207], are not suitable for large-scale applications. 
 
 
Figure 21: Structure of fGAMP compared to 2′3′-cGAMP. 
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The results of the present work indicate the potential of fGAMP in a fluorescence-based STING 
binding assay. In the desired model, STING binding to fGAMP results in fluorescence quenching. 
By adding a competitive ligand, the fluorescence is restored due to the release of fGAMP. 
Ligands with lower affinity do not show this effect unless applied in higher concentrations. 
Indeed, fGAMP was confirmed to be a suitable molecule regarding these properties. STING 
interacts with fGAMP, which leads to a decrease in fluorescence. The addition of increasing 
concentrations of 2′3′-cGAMP correlates with the fluorescence intensity. In contrast, c-di-GMP 
only induces a fluorescence increase when used at higher concentrations. This provides the 
possibility to monitor the binding event of STING by using a simple readout under different 
conditions. Moreover, transfection of fGAMP in HEK293T cells induces a type I interferon 
response, which indicates its similarity to the physiological pendant. Unfortunately, the 
experiments had to be performed without the possibility to calculate the concentration of fGAMP 
as the extinction coefficient was unknown. In addition, it has to be mentioned that the 
fluorescence quantum yield of fGAMP seems to be rather low and the molecule has to be applied 
in high amounts for detection. Subsequently, high concentrations of STING are necessary for the 
fluorescence quenching assays. Therefore, further investigations are required to optimize the 
set-up and establish a more sensitive assay based on the present results. However, a STING 
binding assay using fGAMP would have several advantages compared to common methods. It is 
highly similar to the physiological substrate and does not require further modifications of protein 
or ligand. Furthermore, the described assay has a simple readout suitable for large-scale 
applications. Collectively, this work provides the characterization of a novel 2′3′-cGAMP 
analogue with high potential for fluorescence-based STING applications. 
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